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Abstract
Human cytomegalovirus (HCMV) is a betaherpesvirus that establishes a lifelong infection
in hosts. In the majority of cases, the immune response to primary HCMV infection limits
viral replication and dissemination, such that overt clinical disease is prevented. However,
the immune system cannot prevent the virus establishing a latent infection, which enables
lifelong persistence. Historically, a long-standing view was that viral gene expression during
latency was largely absent, thus facilitating the avoidance of immune detection. However, it
has now been established that viral activity in latency is far from quiescent, and the expression
of a number of viral genes is known to occur. Therefore, an important question arises: are T
cells specific to these proteins generated, and, if so, why are HCMV latently infected cells
maintained in the face of these potential T cell responses? Previous work has shown that
two such viral gene products, UL138 and LUNA, are recognised by CD4+ T cells, with a
subpopulation of these cells secreting the immunosuppressive cytokines interleukin (IL)-10
and transforming growth factor beta (β ). However, little is known about the host immune
response to other key latency-associated viral proteins; US28, UL111A, and UL144.
Using overlapping peptide pools designed to cover the whole of the predicted amino acid
sequence of these HCMV proteins, in combination with fluorescent ELIspot (FluoroSpot),
ELISA, and intracellular cytokine staining, I have determined the frequency, cytokine
secretion profile, effector function, and memory phenotype of CD4+ and CD8+ T cells in a
large cohort of HCMV seropositive healthy donors. My results show that these viral gene
products are also recognised by CD4+ T cells and are composed of distinct cellular
populations secreting either IFNγ or IL-10. The high sensitivity of this assay has also
revealed previously uncharacterised CD8+ T cell responses to US28, UL111A, and UL144,
as well as responses to LUNA and UL138. Intriguingly, IL-10 secretion by a distinct
population of latency-specific CD8+ T cells was also observed. T cell responses to
latency-associated ORF products were found to be composed of greater proportions of IL-10
secreting cells compared to responses to the lytic ORFs pp65, IE1, and gB. The frequencies
of IL-10 secreting T cells specific to HCMV latency-associated proteins did not increase
xwith greater time of viral carriage, as measured indirectly by donor age. Although IFNγ
secreting T cells specific to latency-associated proteins were detected in kidney transplant
recipients immediately following primary HCMV infection, there were no such IL-10
secreting sub-populations, despite IL-10 T cell responses being detected to two lytic proteins,
US3 and pp71.
Given that latency-specific IL-10 secreting T cells were found to be a separate population
to those secreting IFNγ , it was hypothesised that depleting the IL-10 secreting cells could
improve the recognition and killing of latently infected cells by the specific but non-IL-10
producing T cell population. Classic regulatory T cells (Tregs) can be defined as
CD4+CD127loCD25hi, and depleting CD4+CD25hi cells was investigated as a means to
remove the latent-specific IL-10 secreting T cells. The results showed that this had a variable
effect, suggesting that HCMV-specific IL-10 secreting cells of this Treg phenotype represent
only a proportion of the IL-10 secreting CD4+ T cell population. As this strategy could not
provide a consistent method to remove IL-10 secreting CD4+ T cells, neutralising the effect
of IL-10 and TGFβ using anti-cytokine and anti-receptor antibodies was tested. My initial
data suggest that treatment of latently infected cells with these neutralising antibodies in the
presence of CD4+ and CD8+ T cells reduced latent viral carriage.
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Chapter 1
Introduction
1.1 Herpesviruses and HCMV
The Herpesviridae are a family of viruses all known to establish a lifelong latent infection
within their host. Herpesviruses are large double stranded DNA viruses with worldwide
seroprevalence that infect many animal species. The Herpesviridae can be grouped into
three subfamilies, the α-, β -, or γ-herpesviruses, which vary in host specificity, cell tropism,
rates of replication, and cytotoxicity [1]. Herpesviruses capable of infecting mammals are
present in each of the subfamilies. To date nine herpesviruses have been identified for which
humans are the primary host (Table 1.1). Human cytomegalovirus (HCMV) is a member of
the subfamily betaherpesvirinae and is the largest human herpesvirus [2].
Subfamily Herpesvirus Abbreviation
Alphaherpesvirinae
Herpes Simplex Virus 1 HSV-1 / HHV-1
Herpes Simplex Virus 2 HSV-2 / HHV-2
Varicella Zoster Virus VZV / HHV-3
Betaherpesvirinae
Human Cytomegalovirus HCMV / HHV-5
Human Herpesvirus 6A HHV-6A
Human Herpesvirus 6B HHV-6B
Human Herpesvirus 7 HHV-7
Gammaherpesvirinae
Epstein Barr Virus EBV / HHV-4
Kaposi’s sarcoma-associated
Herpesvirus KSHV / HHV-8
Table 1.1 Classification of the human herpesviruses, adapted from Crough (2009) [2, 3]
4 Introduction
1.1.1 HCMV seroprevalence and transmission
HCMV infection can be measured by the presence of anti-HCMV antibodies in the blood,
which informs the seroprevalence rates of the virus across populations. The proportion of
HCMV infected individuals varies throughout the world, and although its presence is globally
ubiquitous, prevalence is known to vary among different geographic regions. The highest
seroprevalence rates are found in less developed countries such as those in Africa, South
America, and Asia, where seroprevalence reaches 100%, and virus acquisition occurs from
early childhood [4–6]. This contrasts with the rates observed in more developed regions,
including certain areas of North America and Western Europe, where seroprevalence can be as
low as 30 to 40% [4], and are much lower in children and young adults [5, 6]. Seroprevalence
rates are inversely correlated with socio-economic status, with individuals of lower socio-
economic status being more likely to be seropositive [4]. In addition, seroprevalence is
directly correlated with age, reaching 60% or more in people over 50 [4]. Age can therefore
be a strong predictor of HCMV serostatus in areas where seroprevalence is moderate to low.
For example, in North America the seroprevalence of HCMV has been shown to rise steadily
between childhood and those over 60 years old [4], and it increases by around 2% per year
post-adolescence in North America and Northern Europe [7, 8]. A cross-sectional study
conducted in the USA found that HCMV seroprevalence rates within defined age groups
were fairly stable over time, indicating the age-related trends of rising seroprevalence rates
were not due to earlier cohorts having a higher rate of infection during early life [9].
Infectious virus is shed in blood, semen, urine, breast milk, saliva, cervical secretion, and
tears. It is thought that spread of the virus occurs naturally through close contact via saliva,
or sexual exposure for example, but can also iatrogenically following blood, stem cell, and
solid organ transplantation [2]. Additionally, vertical transmission can occur in utero, during
birth or postnatally through breastfeeding.
1.2 HCMV virology
1.2.1 HCMV genome and virion structure
HCMV is the largest human herpesvirus with a genome of approximately 235Kbp, thought
to encode between 175-750 open reading frames (ORFs) and at least 24 microRNAs [10–16].
The HCMV genome consists of two segments known as the unique long (UL) and the unique
short (US) sequences, which are separated by repeating sections. The UL region is flanked by
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terminal repeat long (TRL) and internal repeat long (IRL), whereas the US region is flanked
by internal repeat short (IRS) and terminal repeat short (TRL) regions. The order of the
HCMV genome is therefore TRL-UL-IRL-IRS-US-TRS.
The linear double stranded viral genome is packaged within an icosahedral capsid that
is enclosed within a protein complex called the viral tegument. The capsid and tegument
layers are composed of virally-encoded proteins in addition to the tegument layer containing
viral and cellular RNAs, which are incorporated during the generation of new virions [17–
19]. The viral tegument is composed of many proteins, the most abundant of which is the
phosphoprotein 65 (pp65) (UL83) [20, 21], which carry out a diverse array of functions
during initial infection and at the final stages of virion assembly. Surrounding the thick
viral tegument is a lipid bilayer envelope that is formed from the ER-Golgi intermediate
compartment or endosomal membranes and is modified by the insertion of viral-encoded
glycoproteins, many of which mediate entry into susceptible host cells. The viral envelope is
made up of both cellular proteins and virally-encoded glycoproteins, and is formed during
viral budding from the endoplasmic reticulum (ER) and Golgi apparatus [22–24].
1.2.2 HCMV cell tropism and viral entry
During primary HCMV infection, the virus is able to spread to the majority of tissues
throughout the host due to its ability to infect an extensive range of cells, including monocytes,
macrophages, dendritic cells (DCs), smooth muscle, neuronal, fibroblast, epithelial, and
endothelial cells [25–27]. The infection of such a diverse array of tissues underlies its
pathogenesis in immunocompromised hosts (see section 1.4.1 for more detail) and aids the
virus in its spread. For example, infection of epithelial cells will facilitate spread to new
hosts, whereas infection of endothelial and haematopoietic cells will promote systemic spread
within the host [28]. Furthermore, the tropism HCMV exhibits for such a wide range of
cells, demonstrates its utilisation of multiple cell-specific receptors and/or the use of cellular
receptors that are broadly expressed for entry. Indeed, HCMV has several different envelope
glycoprotein complexes that facilitate this broad cell tropism.
Infection is initiated by the tethering of HCMV virions to extracellular heparin sulphate
proteoglycans via one of the envelope glycoproteins, such as gB or the gM/gN complex,
which stabilises the virus at the cell surface and facilitates further receptor interactions
[29–31]. Subsequently, it is thought that more stable and specific interactions take place
between one of the gH/gL complexes, either the trimeric gH/gL/gO or the pentameric
gH/gL/UL128/130/131A envelope glycoprotein complex, with cellular entry receptors. A
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number of cellular receptors have been proposed to be important for viral entry including
the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor-α
(PDGFR-α), and integrins, which have all been shown to bind gB or gH, in addition to
PDGFR-α binding the trimeric gH/gL/gO complex [32–38]. Despite this, questions remain
over the role these receptors have in viral entry [39–41]. Following this stable interaction,
the gH/gL complex, together with gB, is thought to mediate fusion of the viral envelope with
the cellular membrane, most likely through integrin-mediated interactions, for entry into
fibroblasts [32, 42–45]. In contrast, entry into epithelial and endothelial cells is dependent
on the pentameric gH/gL/UL128/130/131A complex [46, 47].
The use of HCMV in cell culture has revealed its propensity to rapidly acquire mutations
during in vitro passage. Such mutations are known to occur in these glycoprotein complexes.
Mutants that are unable to form the gH/gL/UL128/130/131A pentamer lose their broad cell
tropism, rendering them unable to infect epithelial, endothelial, monocytic, and DCs in vitro,
but still retain the ability to infect fibroblasts [48–52]. Thus, as a consequence of passage
through fibroblasts, certain laboratory strains of HCMV, which have resulting mutations in
the ULb’ locus containing the UL128-131 genes, will be varied in their tropism for epithelial
and myeloid lineage cells [48, 49, 53]. Although propagation of HCMV in fibroblasts does
not select for viruses with endothelial tropism, passage through endothelial cells can maintain
the wide range cellular tropism [54, 55].
1.2.3 The lifecycle of HCMV
Following membrane fusion, the tegument is lost from the viral capsid. The liberated
tegument proteins then facilitate the microtubule-mediated trafficking of the capsid to the
nucleus, the release of the viral genome from the capsid, and the activation of viral gene
expression [56–60]. Genome replication can now take place. Lytic infection is characterised
by a temporal cascade of gene expression in three phases: the immediate early (IE) phase, the
early phase, and the late phase. During the IE phase, the most abundant gene transcription
occurs from the Major Immediate-Early promoter (MIEP). Alternative splicing of the UL123
and UL122 regions give rise to the IE72 (IE1) and IE86 (IE2) proteins respectively, which act
as transcriptional regulators by transactivating many HCMV genes and promoters, allowing
a progression into early and late phase [61–63]. IE2 is the main transcriptional activator of
HCMV early genes and has been shown to synergise with IE1 at low multiplicity of infection
(MOI) [61, 64–66]. Additionally, IE genes products can alter cell cycle progression [67]
and prevent expression of certain cellular antiviral genes [68–71]. Moreover, IE1 is able
1.3 HCMV latency 7
to disrupt ND10, also known as promyelocytic leukemia protein (PML) nuclear bodies to
counter cellular restriction factors [72–79]. During the early phase of lytic cycle genes which
are critical for successful viral replication are expressed, including those involved in DNA
synthesis and immune modulation [80]. Finally, from around 48 hours post infection, late
genes are expressed, the products of which are predominantly structural proteins of the virus
required for the assembly of infectious virions and egress from the cell [24].
Recent work utilising a temporal viromics approach, where mass spectrometry was
performed following the administration of protein synthesis or viral DNA synthesis inhibitors,
has extended the phases of viral gene expression into 5 temporal protein profiles, which map
well to the established phases of viral gene expression [81].
1.3 HCMV latency
1.3.1 Sites and establishment of HCMV latency
All herpesviruses can establish a latent infection, which enables the virus to persist for the
life of the host. Latency is defined as the maintenance of viral genome in an infected cell
without the production of infectious virions, but with the ability to reactivate given certain
stimuli into a full lytic infection. Lytic infection is then characterised by the expression of
all viral genes and the production of infectious virus. Herpesviruses have particular sites of
latency, which often differ between, and within, subfamilies [82–86].
Leukocytes were identified as one potential reservoir of HCMV infection as a result
of the link between unscreened blood donations and viral transmission, which then led to
findings showing such transmission is reduced when transfused blood has been leukocyte
depleted [87–90]. It was suspected that the carriage of virus in leukocytes was latent because
infectious virus could not be isolated from healthy donors [91]. However, attempts to detect
HCMV DNA, RNA, or protein were not reproducible, in part because the methods used
were not sensitive enough [92]. The advent of PCR enabled the amplification of specific
DNA sites, and thus partially overcame the problem of very low copy number of the virus
in peripheral blood, where during latency between every 100-5000 monocytes is infected,
therefore enabling the interrogation of the latent sites of HCMV infection [91–93].
The broad cell tropism of HCMV enables it to lytically infect a wide range of cells. Sites
of latent infection are more restricted however. The use of highly-sensitive DNA PCR has
revealed that one site of latent viral carriage is in cells of the early myeloid lineage, such as
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CD34+ progenitor cells and CD14+ monocytes, which in the peripheral blood is the principle
cell type carrying HCMV DNA [94–96]. Crucially, the presence of viral genomes in CD34+
cells and monocytes was shown to be in the absence of extensive lytic gene transcription, a
necessity for true sites of latency [95, 94, 97]. CD34+ cells are a self-renewing population of
stem cells present in the bone marrow, which are the progenitors of all blood cell lineages
[98]. CD34+ cells can differentiate down the myeloid lineage, to monoblasts followed by
promonocytes in the bone marrow, before entering the bloodstream where they lose their
CD34 cell-surface antigen and develop into monocytes [99]. The progress of this lineage
development is dependent on exposure to haematopoietic growth factors, in particular GM-
CSF and IL-3 [100]. Despite the ability of CD34+ cells to differentiate into lymphoid cells
and polymorphonuclear leukocytes, the viral genome has not been detected in these cells
[95, 101]. Similarly, CD34+ cells are able to differentiate into endothelial cells, and it has
been suggested these could also be a site of latency, especially given the HCMV-associated
pathologies observed in these cells [102–104]. Currently however, the evidence for this is
somewhat inconclusive. HCMV was not detected in endothelial cells isolated from saphenous
vein tissue of healthy seropositive individuals [105], but in vitro studies suggest that certain
subsets of endothelial cells, such as aortic, could potentially support a latent infection [106].
Unfortunately, carrying out this research is made difficult by the ethical issues of analysing
such tissues, in addition to the unsuitability of cadaverous tissue for study due to reactivation
of latent virus at death [107].
1.3.2 Reactivation from latency
The ability of HCMV to reactivate from sites of latency is crucial to its strategy of lifelong
persistence in the infected host, where subclinical reactivation events could enable the virus
to replenish the pool of latently infected cells [108]. It is thought that the key trigger for
viral reactivation from latency is cellular differentiation. Insights into this process came
from the observations that while monocytes were non-permissive to experimental infection,
differentiation of monocytes to macrophages led to a fully permissive phenotype [109, 110].
As a result, it was suggested that differentiation of myeloid lineage cells induces viral
reactivation. Data from ex vivo studies have shown that differentiation of monocytes to
macrophages leads to reactivation of viral IE gene expression [111] and production of
infectious virus [112]. Likewise, ex vivo differentiation of CD34+ cells to DCs leads to full
reactivation of infectious virus from naturally infected individuals [113]. Consistent with the
view that differentiated myeloid cells reactivate latent HCMV, in vivo differentiated alveolar
macrophages and DCs were found to express IE, whereas isolated monocytes that carried
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genome did not, in addition to recovering infectious virus from the alveolar macrophages
[114, 115].
1.3.3 The role of chromatin in latency and reactivation
Lytic HCMV infection is characterised by a temporal cascade of viral gene expression. The
initial genes expressed in this cascade, the IE genes, are under the control of the Major
Immediate Early Promoter (MIEP). During latency, the constraint on gene expression is
thought to be achieved in large part through the suppression of the MIEP, as repression of IE
genes will prevent E and L genes from being expressed. Repression of the MIEP is mediated
by a number of mechanisms, all functioning to keep the virus in latency. A shift in the balance
between repressive and activatory factors will subsequently lead to an active promoter state
on the MIEP, allowing lytic gene expression to occur. One such factor is the chromatin
structure of the MIEP, which is closely linked to the viral state within the infected host cell. In
early myeloid lineage cells (CD34+ progenitors and monocytes), the MIEP is associated with
repressive chromatin that suppresses lytic gene expression, and keeps the virus in latency.
Such repressive post-translational modifications of MIEP-associated histones found during
latent infection include trimethylation of histone H3 (lysine 9 and 27), the recruitment of
heterochromatin protein-1 (HP-1), and a lack of acetylation on histone H4 [116–118]. The
repressive chromatin structure however, is altered following the differentiation of myeloid
progenitor cells into terminally differentiated macrophages or DCs, allowing activation of
the MIEP and viral IE gene expression, with subsequent reactivation of lytic infection and
production of infectious virus [114, 116, 118, 119]. Thus, the differentiation dependent
presence of repressive or activatory chromatin marks around the MIEP is strongly related to
the latent or lytic phenotype of the virus. The chromatin-mediated suppression of lytic gene
expression has consequently been exploited to target latent HCMV. Inhibition of the enzyme
histone deacetylase (HDAC)-4 resulted in transient IE expression in latently infected cells
without full lytic reactivation, which then enabled these cells to be targeted by cytotoxic T
lymphocytes (CTLs) [120].
1.3.4 Gene expression during latency
The extent of HCMV activity during latency has been subject to much debate, but there
is growing evidence that the virus can carry out considerable cellular modifications in this
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state. Gene expression during latency is thought to function to maintain the carriage of viral
genomes, resist intrinsic cell death responses, and evade the host immune system [121–123].
During latent infection, it might be desirable for the virus to be in a completely quiescent
state, where viral proteins are not expressed, to prevent the processing and presentation of
viral proteins to the immune system and allow the virus to remain undetected by T cells.
Evidence now suggests that this is not the case for HCMV, and there is routine expression of
a several viral transcripts resulting in protein expression, as has been well established for
other herpesviruses such as EBV [124]. Gene expression during latency was thought to be
severely restricted in comparison to during lytic infection. A considerable body of work has
shown that only a small subset of viral genes are expressed, with an absence of expression
of the major lytic genes such as IE, caused by the repression of the MIEP [122]. The work
to identify these has resulted in the consistent detection of a handful of genes in naturally
latent cells, and include US28 [125], LUNA [126], UL111A [127], UL144 [125], and UL138
[128]. Although the full roles of the products of these genes are still to be elucidated, a
variety of functions for their gene products have been described, both during latent and
lytic infection. However, more recent work utilising highly sensitive RNA-sequencing
techniques has unbiasedly detected expression of a broader set of transcripts during natural
and experimental latency that posits a contrasting view on the level of transcriptional activity
during latent infection [129, 130]. The analysis of the transcriptome from single cells in this
manner revealed a gene expression profile during latency similar to that found during the late
stage of lytic viral infection, only with lower levels of expression [130].
UL138
The sequential knockout of genes in the ULb’ region of HCMV revealed the importance of
UL138 for the establishment of a latent infection [128], and subsequent work has shown that
UL138 contributes to the transcriptional repression of IE gene expression to achieve this
[131]. UL138 does this by inhibiting the recruitment of cellular lysine demethylases to the
MIEP, therefore preventing the removal of repressive histone methylation and subsequent
activation of viral IE gene expression [131]. Recently, UL138 was shown to be expressed as
two isoforms that have overlapping functions in IE repression and prevention of infectious
virion production, but might act at different time points during latency [132].
UL138 is also known to possess a number of other functions. UL138 encodes a
transmembrane protein that interacts with the tumour necrosis factor (TNF) receptor 1
(TNFR1), increasing and extending its expression on the cell surface [133, 134]. The
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upregulation of TNFR1 and resulting increase in sensitivity of latently infected cells to
TNFα , which has cell-death, as well as immunostimulatory and antiviral properties, might
seem to be counter-productive to the virus. However, it is hypothesised that this could be a
mechanism to aid in reactivation of the virus from latency given the ability of TNFα to
trigger monocytic differentiation, a known site of latency in vivo, into macrophages [135].
Additionally, TNFα can activate NFκB, and as the MIEP of HCMV is known to have
several NFκB target sites, TNFα could be directly stimulating IE expression, as has been
shown in vitro [136]. By increasing the sensitivity of a latently infected cell to TNFα , the
expression of UL138 during latency could therefore be acting at the level of the cell, by
promoting differentiation and therefore viral reactivation, and at the level of the virus, by
inducing MIEP activation and an associated switch to lytic infection. UL138 can also reduce
the surface expression of multidrug resistance-associated protein-1 (MRP1) by targeting it
for lysosomal degradation [137]. The loss of MRP1 reduces the infected cell’s ability to
export certain MRP1 specific substrates, and in the case of leukotriene C4, this might
function to prevent the migration of infected DCs to secondary lymphoid organs where
HCMV-specific immune responses would be generated [137].
UL144
The UL144 ORF encodes a transmembrane glycoprotein with structural homology to the
TNF receptor Herpesvirus Entry Mediator (HVEM/TNFRSF14) and is expressed early during
lytic infection [138]. There is considerable sequence variation in UL144 between clinical
isolates of HCMV [139], and polymorphisms within UL144 have been linked to worse
clinical outcomes following congenital HCMV infection [140, 141], although this link has
been disputed [142]. UL144 is responsible for the upregulation of CCL22 during lytic
infection, via potent NFκB activation [143, 144]. CCL22 acts as a chemoattractant for Th2
and regulatory cells T cells (Tregs) [145, 146], and this could be a mechanism employed
by the virus to dampen Th1-mediated responses. UL144 also acts by binding the B and T
lymphocyte attenuator (BTLA), and this could inhibit T cell proliferation [147].
Much less is known about the role of UL144 during latent HCMV infection. UL144
has been shown to be dispensable for the establishment and reactivation from latency, and
its expression during latency occurs in an isolate specific manner [125]. A comparison of
the promoter regions of UL144 from different viral isolates, both experimental strains and
those from natural infection, suggested this was partially due to the presence or absence of
GATA-2 binding sites [125].
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LUNA
The UL81-82 locus which encodes the tegument protein pp71 also gives rise to an antisense
transcript, predicted to code for a 133 amino acid long protein termed Latency Unique
Nuclear Antigen (LUNA) [148]. Experimental models of latency point to a role for LUNA
in latent viral carriage and virus reactivation. The promoter of LUNA contains functional
GATA-2 binding sites, similar to those found in the UL144 promoter, that enhance expression
of LUNA during latency, perhaps pointing to a common mechanism of gene regulation as
GATA-2 is upregulated during latent infection [125]. During lytic infection, LUNA was
found to be dispensable for virus replication, as a LUNA-deficient virus produced similar
levels of infectious particles to wild-type [149]. Furthermore, the expression kinetics and
levels of an IE gene UL123 (IE1) and a late gene UL82 (pp71) were comparable to wild-type
during lytic infection of fibroblasts.
The expression of LUNA was found to be required for the reactivation of HCMV from
latency, as infection of CD14+ monocytes with a LUNA-deficient virus resulted in an
inability to reactivate following differentiation, despite the maintenance of viral genomes
[149]. Additionally, there were considerable reductions in the expression levels of UL138
during latent infection of CD14+ monocytes and lytic infection of fibroblasts with the LUNA-
deficient virus [149]. Consistent with these findings, use of a virus that was mutated to
prevent LUNA expression had little impact on lytic replication or carriage of latent viral
genomes in CD34+ cells, and UL138 expression was also decreased on infection with this
LUNA-disrupted virus [125]. Similarly, there was a considerable defect in the reactivation of
virus from CD34+ cells latently infected with the LUNA-mutated virus [150]. Investigations
into the mechanisms by which LUNA facilitates viral reactivation uncovered the ability of
the LUNA encoded gene product to act as a deSUMOylase [150]. The formation of antiviral
ND10 bodies is dependent on PML SUMOylation [151], and LUNA was found to mediate
the dispersal of ND10 through its deSUMOylation of PML. In doing so, HCMV therefore
ensures that reactivating virus, which is re-entering lytic cycle, is not subject to the antiviral
effects of ND10 and can reactivate efficiently [150].
UL111A
Viruses capable of expressing homologues of immunomodulatory cellular cytokines can
use these to deflect immune responses and increase virus survival. IL-10 is one such
immunosuppressive cytokine that has been exploited by HCMV, in addition to other viruses,
such as EBV [152, 153], to subvert host immune responses. In HCMV, the UL111A gene
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encodes two homologues of human IL-10 (hIL-10) that have slightly different properties.
During lytic infection, the homologue expressed from UL111A is the 175-amino acid
protein cmvIL-10, which shares 27% sequence homology with hIL-10, and can to bind to,
and signal through, the hIL-10R to mediate many of the same immunomodulatory effects
as hIL-10 [154]. This includes suppression of proinflammatory cytokine production and
inhibition of PBMC proliferation [155], as well as downregulation of MHC class I and
II expression [155, 156] and stimulation of B cells [157]. cmvIL-10 can also upregulate
hIL-10 secretion from certain myeloid cells, giving it a mechanism to potentially amplify its
immunosuppressive effects [158].
During latent infection however, alternative splicing results in the expression of an
alternate transcript from UL111A, termed latency-associated cmvIL-10 (LAcmvIL-10).
LAcmvIL-10 is collinear with cmvIL-10 at the amino terminus, but a lack of splicing of
a second intron results in the coding of an in-frame stop codon, generating a predicted
139-amino acid protein that is truncated at its C terminus [127]. LAcmvIL-10 is expressed
during both lytic and latent infection, and is similar to cmvIL-10 in its ability to downregulate
MHC class II in latently infected granulocyte/macrophage progenitor cells [127, 156, 159].
Recently, an assay capable of detecting both cmvIL-10 and LAcmvIL-10, although unable to
distinguish between them, found both isoforms in the peripheral blood of healthy HCMV
seropositive donors [160]. Furthermore, LAcmvIL-10 also suppresses transcription of the
master regulator of MHC class II components, the class II transactivator (CIITA), indicating
that this downregulation of MHC class II occurs mainly at the level of mRNA transcription
[156]. The accumulation of MHC class II molecules in cytoplasmic vesicles in a small
percentage of monocytes treated with LAcmvIL-10 also hints at the ability of LAcmvIL-
10 to target MHC class II expression post-translationally [156]. Although the ability to
downregulate MHC class II expression on myeloid cells is shared between cmvIL-10 and
LAcmvIL-10, LAcmvIL-10 does not appear to exhibit the full range of functions that cmvIL-
10 possesses. For example, the inhibition of LPS-induced maturation of DCs treated with
cmvIL-10 [161, 162] cannot be replicated with LAcmvIL-10 [156]. Furthermore, unlike
hIL-10 and cmvIL-10, LAcmvIL-10 does not stimulate proliferation of B cells [157] or
increase FcRγ mediated phagocytosis by human monocytes [163]. It is unclear why the
differences between LAcmvIL-10 and cmvIL-10 functionality exist, but they could in part be
due to the differences in signalling induced upon receptor binding. The mechanism by which
LAcmvIL-10 signals through the human IL-10R is unknown, and it is thought it either does
not bind, or it engages the receptor in a different way to both cmvIL-10 and hIL-10 [157].
This would be in contrast to cmvIL-10, which mediates its immunomodulatory effects via
signalling through the hIL-10R. In this respect, cmvIL-10 induces the phosphorylation of
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Stat3, whereas LAcmvIL-10 does not, but still causes a down-regulation of MHC class II,
even in the presence of anti-human IL-10R antibodies [156].
UL111A has been shown to be important for the establishment of latency in CD14+
monocytes and CD34+ progenitor cells, most likely through enhancing infected cell survival
[164]. UL111A functions as an immunomodulatory agent during latency to evade CD4+ T
cell recognition by downregulating MHC class II on infected cells, therefore suppressing
the ability of these cells to present viral peptides [164, 165]. In addition to this, UL111A
can inhibit the production of proinflammatory cytokines such as TNFα and IL-1β from
latently infected CD34+ myeloid progenitor cells and to suppress their differentiation to
DCs [166]. Given that DCs are the most potent antigen presenting cells (APCs), preventing
differentiation of latently infected cells to DCs could be another mechanism to limit the
presentation of viral antigens to the immune system [166]. Moreover, LAcmvIL-10 has also
been shown to be involved in the regulation of cellular miRNA expression, which results
in changes to secreted cellular proteins. For example, LAcmvIL-10, via a decrease in the
cellular microRNA hsa-mir-92a, upregulates the expression of hIL-10 in CD14+ monocytes,
which could be a mechanism of amplifying the effects of LAcmvIL-10 [164]. A similar
effect of cmvIL-10 on hIL-10 expression has also been reported, although it is likely to act
via a different mechanism to LAcmvIL-10 [158].
In addition, the UL111A gene products can modulate myeloid cell differentiation.
Exposure of CD14+ monocytes to a combination of cmvIL-10 and LAcmvIL-10, or
supernatant from productively infected fibroblasts, induced polarisation to the
immunosuppressive M2c macrophage phenotype that reduced CD4+ T cells activation and
proliferation [167].
US28
US28 is a cell surface G protein-coupled receptor and viral chemokine receptor homologue
that can bind both CC (e.g., CCL2 [MCP-1], CCL5 [RANTES]), and CX3C (e.g. CX3CL1
[Fractalkine]) chemokines. US28 is expressed early during lytic infection [168, 169] and
is thought to be mainly localised to endocytic vesicles, with around 20% present on the
plasma membrane [170]. Ligand binding induces internalisation of US28, endocytosis, and
recycling from the cell surface [168, 171]. Following this, US28 is then recycled back to the
cell surface [168, 171]. Given the ability of US28 to bind and internalise multiple cytokines,
it has been proposed that this receptor acts as a chemokine sink, therefore reducing the local
concentration of inflammatory and chemotactic cytokines, which aids in immune evasion
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through the inhibition of antiviral immune responses. In support of this, HCMV infected
fibroblast have reduced production of cytokines CCL2 and CCL5, suggested to be caused by
US28 expression [171, 172]. This model of chemokine sequestration has been challenged
however, as the overexpression of US28 in endothelial cells was found to be insufficient to
prevent chemokine mediated adhesion of monocytes to endothelial monolayers, suggesting
that the local concentrations of cytokine are too high for US28 to have a significant effect
[173].
During lytic infection, US28 signals constitutively, resulting in the promotion of
proliferative signals such as NF-κB and MAP kinase (MAPK) which are known to
transactivate the MIEP. US28 is known to be expressed during latency [174, 121, 125], and
it has been shown that US28 is required for the establishment and maintenance of a latent
infection [175]. In this study, a US28 knockout virus was unable to establish latency in
CD34+ progenitor cells due to its inability to repress MIEP-driven transcription [175].
Although these roles of US28 contrast, where US28 activates the MIEP during lytic
infection, but inhibits the MIEP during latent infection, recent work has shown that US28
has divergent effects on cell signalling in undifferentiated compared to differentiated cells
[176]. In undifferentiated cells, where the virus establishes a latent infection, US28
attenuates NF-κB and MAPK signalling, which supports the epigenetic silencing of the
MIEP, thus preventing lytic infection. In differentiated cells however, US28 activates these
signalling pathways, to help drive IE gene expression and productive viral reactivation [176].
1.4 Pathogenesis and treatment of HCMV infection
1.4.1 HCMV infection and disease
Primary infection of an immunocompetent host with HCMV is generally asymptomatic or in
some cases results in a mononucleosis syndrome [2]. This is a result of the immune response
to HCMV which is capable of limiting lytic viral replication and preventing clinical disease in
the majority of cases. Although in a healthy host HCMV infection is typically asymptomatic,
it is of great clinical concern for those with an immature immune system, or an immune
system that is suppressed, either by drugs or by co-infection with another pathogen. It is in
these individuals, where the immune system is unable to control HCMV replication, either
during primary infection or during viral reactivation, where disease occurs [2]. The broad
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cell tropism of HCMV leads to a wide array of symptoms, which can culminate in organ
failure [28].
Congenital HCMV infection can lead to severe morbidity and mortality in newborns.
Of congenitally infected babies that are symptomatic at birth, there is a mortality rate of
around 30% in the most severely affect infants [177]. Surviving newborns can exhibit any of
a number of serious neurological, hearing, and developmental impairments [177]. Both the
risk and severity of symptomatic congenital HCMV infection are highest following primary
infection in a seronegative mother during the first trimester [178]. However, the reactivation
of latent HCMV, or infection with a different viral strain, during pregnancy can still lead
to symptomatic congenital infection [179, 180]. Around 85-90% of congenitally infected
babies are asymptomatic at birth [177], and 10-15% of these go on to develop one or more
long-term neurological sequelae, including sensorineural hearing loss [181].
The impairment of the adaptive immune system due to HIV infection can also lead to
HCMV disease. Prior to the introduction of highly active antiretroviral therapy (HAART) to
treat HIV, approximately 40% of HIV-infected patients with advanced stage disease suffered
from HCMV disease over their lifetime [182]. The use of HAART has led to a significant
decline in the incidence of HCMV disease in this group through its ability to suppress HIV
viraemia and reconstitute CD4+ T cell immunity [182]. Despite this being the case, there is
evidence suggesting that HCMV infection can accelerate the progression to AIDS and death
[183–186]. HCMV retinitis remains a problem in HIV-infected individuals despite a decline
of between 80 and 90% in the HAART era [182, 187], and the use of HAART has been
linked to a new clinical problem, "immune recovery uvitis" (IRU). IRU is characterised by an
increase in intraocular inflammation following HAART, thought to be due to the recovered
immune responses to accumulated HCMV antigens in the eye [188, 189].
Following transplantation, the requirement to suppress T cells capable of mediating graft
rejection has the undesired effect of inhibiting antiviral T cells. In solid organ transplantation
such as the kidney, the greatest risk of developing HCMV disease arises in seronegative
recipients (R-) transplanted with an organ from a seropositive donor (D+) [190]. In these
D+R- cases, the donor organ is highly likely to contain latent virus, which is then transplanted
into a recipient with no prior antiviral immunity. HCMV has also been linked to a greater
risk of graft rejection or long-term graft dysfunction, although this remains controversial in
the absence of causative evidence [191–195].
During haematopoietic stem cell transplantation (HSCT), the recipient immune system
is ablated and reconstituted with the donor immune system. As a result, the greatest risk
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for HCMV disease arises in situations where the donor is seronegative, but the recipient is
seropositive (D-R+). This is because the donor does not possess HCMV-specific T cells,
whereas the recipient harbours latent virus and is receiving immunosuppressive treatment
[196]. Primary infection or reactivation of latent virus can therefore lead to serious morbidity
and mortality, with viral reactivations in the seropositive recipient accounting for the majority
of HCMV infections [197–199].
1.4.2 Treatments for HCMV disease
Ganciclovir (GCV) is the current therapy of choice for HCMV infections, and is used
routinely for treatment, in addition to prophylactic and preemptive therapy [200]. GCV is a
nucleoside analogue that ultimately targets the HCMV DNA polymerase (encoded by the
UL54 gene), following a series of stepwise phosphorylations, to ganciclovir triphosphate.
The initial phosphorylation step is catalysed by the HCMV-encoded UL97 kinase followed
by subsequent phosphorylation steps mediated by cellular kinases [201–203]. Once
ganciclovir triphosphate is formed, it acts as a substrate for HCMV DNA polymerase,
competitively inhibiting viral DNA elongation [204, 205]. As the first phosphorylation event
is dependent on the viral kinase UL97, GCV is able to selectively target infected cells.
Resistance to GCV is observed following prolonged use and even after several months of
therapy, with characteristic mutations commonly arising in UL54 and UL97 [206–208].
Valganciclovir, a prodrug of GCV, is also used to treat HCMV, and was developed with a
greater oral bioavailability in comparison to GCV [209–211]. Second-line drug therapies
include foscarnet (FOS) and cidofivir (CDV), which also inhibit HCMV DNA polymerase
activity [212–214], although nephrotoxicity, and low oral bioavailability in the case of CDV,
limit their clinical utility, often to when resistance to GCV is suspected [200]. Treatment
with FOS and CDV can also lead to drug resistant HCMV infections [200]. Recently,
letermovir, which is an HCMV DNA terminase complex inhibitor, and therefore acts to
inhibit the packaging of DNA into the virion, was approved for use as a prophylactic in adult
seropositive recipients of allogeneic HSCT [215–217]. As the mechanism of action of
letermovir differs from GCV, CDV, and FOS, which are DNA polymerase inhibitors, its use
does not result in the development cross-resistance to these other drugs [216].
18 Introduction
1.4.3 Vaccines against HCMV
HCMV can cause severe morbidity, and even mortality, in the immunosuppressed and
immunonaive populations. Currently there are no licensed vaccines for HCMV, despite it
being ranked at the highest priority in a review by the Institute of Medicine in 1999, which
was based on the economic costs and prospective years of life and disability that would be
saved by a successful vaccine [218].
Initial efforts in the 1970s to develop a vaccine were focused on live attenuated viruses
derived from strains AD-169 and Towne [219, 220]. The Towne strain of HCMV was
generated following 125 passages in human diploid fibroblasts [220]. The Towne vaccine
was found to be immunogenic [221, 222], and reduced the severity of HCMV disease in
kidney transplant recipients, but did not reduce the rate of infection post-transplantation,
generated a limited neutralising antibody response compared to wild-type infection, and
also failed to prevent vaccinated mothers from acquiring HCMV [223–226]. In an effort to
improve the immunogenicity of Towne while maintaining its safety profile, recombinants
between Towne and the low passage Toledo isolate were constructed [227]. Four recombinant
virus vaccines have been tested, first in seropositive [228], and seronegative [229] subjects,
demonstrating safety and tolerability that warrant further trials. In HCMV seronegative
individuals, no viral shedding was observed in urine or saliva, and two chimeras showed
superior abilities to induce seroconversion [52]. CD4+ and CD8+ T cell responses were also
detected in a handful of vaccine recipients [52].
Development has also focused on recombinant vaccines utilising the highly immunogenic
viral antigen gB. Several trials of a gB subunit vaccine utilising recombinant gB in conjunction
with the oil in water adjuvant MF59 have been carried out at phase II [230–234]. The vaccine
showed 50% efficacy against primary HCMV infection in seronegative mothers [235, 231], a
45% efficacy in adolescent girls (although this did not reach significance) [232], and reduced
viraemia in kidney and liver transplant patients with a corresponding drop in GCV treatment
[233].
DNA vaccines are also in development, which have garnered interest for their potential
to elicit CD8+ T cell responses. These consist of plasmids containing immunogenic proteins
such as gB and pp65, and have been trialled with varying successes so far [236–238]. Other
potential vaccine candidates in earlier stages of development include RNA-based vaccines
utilising self-replicating RNA [239, 240], and vaccines based on dense bodies, which are
noninfectious enveloped particles that possess viral glycoproteins and tegument proteins but
no viral DNA, making them safer vaccine candidates [241–243].
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A successful vaccine against HCMV will likely need to induce robust cellular and
humoral responses to provide protection [244]. Given the observed ability of HCMV to
superinfect an already infected host [245], which can lead to a multi-strain infection [179],
such a development could be even more challenging, as vaccination would need to function to
elicit protective immunity in HCMV-naive individuals, and boost immunity in those already
infected to provide protection against superinfection and viral reactivation. Antivirals will
therefore continue to play an important role in treating HCMV infections, and deepening
our understandings of the mechanisms of HCMV persistence during latency could generate
novel targets against the virus.
1.5 The immune response to HCMV infection
1.5.1 The innate immune response to HCMV
The infection of host cells by HCMV triggers rapid intracellular immune responses which
attempt to establish an antiviral state in the infected and surrounding cells. Sensing of
HCMV is largely initiated by pattern recognition receptors (PRRs) detecting evolutionarily
conserved pathogen-associated molecular patterns (PAMPs) from HCMV. Toll-like receptor
(TLR) 2 expression at the plasma membrane has been shown to recognise the HCMV
glycoproteins gB and gH, resulting in the activation of the NF-κB pathway and subsequent
production of inflammatory cytokines including IL-6, IL-12, and interferon-(IFN)β [246–
248]. Intracellularly, multiple sensors are capable of recognising HCMV DNA including
cyclic GMP/AMP synthase (cGAS) and Z-DNA-binding protein 1 (ZBP1). Studies on
vascular endothelial cells and monocyte-derived DCs and macrophages have reported that
recognition of HCMV DNA in the cytosol by cGAS leads to the expression of type I IFNs
via the transcription factor IFN regulatory factor 3 (IRF3) [249, 250]. HCMV also activates
IRF3 following the sensing of cytoplasmic dsDNA by ZBP1, leading to the transcription
of IFN-stimulated genes (ISGs) and the expression of type I IFNs such as IFNβ [251, 252].
When secreted, IFNβ acts in an autocrine and paracrine manner to induce the expression
of ISGs. The proteins encoded by ISGs are broad acting and serve to impair intracellular
viral activities necessary for replication, and promote a general antiviral state. Such proteins
include protein kinase R (PKR) and 2’,5’-Oligoadenylate synthetases (OAS), which act by
blocking host and viral protein translation and causing the cleavage of mRNA and ribosomal
RNA respectively [253, 254].
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NK cells are innate lymphocytes and are important effector cells in the immune response
to HCMV. Their importance has been highlighted by cases of patients with a rare NK cell
deficiency resulting in enhanced susceptibility to HCMV infection [205, 255, 256], and by
a case describing a patient with T-B+NK+ Severe Combined Immune Deficiency (SCID)
who recovered from HCMV disease after an expansion of IFNγ producing NK cells without
antiviral therapy [257]. The reconstitution of NK cell responses in HSCT recipients was
also associated with protection against HCMV viraemia [258]. NK cells can rapidly respond
on encountering virally infected cells [259, 260] by carrying out effector functions such
as secreting antiviral cytokines including IFNγ and TNFα , and lysing infected cells [261–
265]. NK cell activity is regulated by the balance between multiple germ-line encoded
activatory and inhibitory receptors. Activatory receptors can recognise stress-induced ligands
on virus-infected cells while inhibitory receptors can bind self molecules such as MHC class
I [266]. HCMV infection is associated with the expansion and persistence of CD94/NKG2C
expressing NK cells capable of enhanced effector functions on re-exposure to HCMV [267–
273]. Additionally, in vitro experiments have highlighted the important role of IL-12 in the
expansion of CD94/NKG2C expressing NK cells [274], providing further evidence that this
subset could represent a type of memory NK cell [275].
1.5.2 The humoral response to HCMV
Although antibodies against HCMV are generated shortly after primary infection [276], their
protective capacity is debated. Antibodies to a diverse array of HCMV proteins have been
found in infected individuals, and many of these are specific for viral glycoproteins. Among
these are antibodies to gB, which constitute a large fraction of HCMV-neutralising
antibodies [277, 278] and gH which is part of the trimeric gH/gL/gO complex and
pentameric gH/gL/gO/UL128/UL131 complex [279, 280]. Antibodies generated against
other components of the gH-pentameric complex have potent neutralising ability as well
[281, 282], and many of these antibodies have been shown to neutralise HCMV in vitro
[281, 283].
Pre-existing antibodies in seropositive mothers are thought to be an important factor in
the prevention of congenital HCMV infection [284]. In a study following a large group
of 3000 women, the rate of congenital infection was three times higher in cases where the
mother was initially seronegative [285]. In addition, infants born prematurely and requiring
a blood transfusion were protected from transfusion-acquired infectious complications when
their mothers were seropositive [87]. Work on murine CMV (MCMV) has also shown that
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B cells, and therefore likely antibodies, are critical in preventing viral dissemination and
limiting disease severity [286].
1.5.3 The CD8+ T cell response to HCMV
The robust T cell response that is generated following primary HCMV infection is well
documented, with a high proportion of the total peripheral blood pool composed of CMV-
specific CD8+ T cells [287, 288]. In addition to the high frequencies of CD8+ T cells directed
against lytic antigens such as pp65 and IE [289, 290], the T cell responses to HCMV are
extensively diverse, with CD8+ and/or CD4+ T cells being directed to 70% of viral ORFs,
encompassing different replication stages and functions [288]. The T cell responses also
have considerable variation between individuals [288, 291]. Whereas this evidence points to
the effective ability of the immune system to limit viral replication during primary infection
and prevent serious disease, latency is always established and the virus is not eliminated.
HCMV-specific CD8+ T cells have a distinct phenotype, characterised by the expression
of markers associated with T cell maturation. The majority of HCMV-specific CD8+ T cells
in the blood during persistent phases of infection are phenotypically similar to terminally
differentiated effector memory T cells. Typically, HCMV-specific T cells downregulate
expression of the co-receptors CD27 and/or CD28, upregulate CD57 and killer cell lectin-like
receptor subfamily G member 1 (KLRG1), and express effector molecules such as perforin
and granzyme B [287, 292–295]. A large proportion of HCMV-specific CD8+ T cells
also re-express CD45RA, which is typically associated with naive T cells, from CD45RO,
which is associated with memory T cells [292, 293, 296–298]. Such cells are termed TEMRA
(effector memory expressing CD45RA) cells. Transcriptionally, features of mature effector
T cells are present from early following primary infection [299]. Furthermore, CD45RA+
HCMV-specific CD8+ T cells are also detectable soon after primary infection and persist into
the latent phase of infection, expanding with age [300–303]. It is possible that this phenotype
arises as a result of repeated antigenic stimulation [304–306]. However, unlike infections
with other chronic viruses including HIV-1 [307–314], HCMV-specific CD8+ T cells are not
exhausted and maintain functionality, as exemplified by their low expression of the inhibitory
receptor PD-1, their cytotoxic ability, and the secretion of antiviral cytokines such as IFNγ
and TNFα [287, 292–294, 299, 315, 316].
IFNγ is a proinflammatory cytokine with a range of direct and indirect antiviral functions
(such as upregulating MHC class I and II), in addition to its role in the activation and
differentiation of immune cells including macrophages, NK cells, and T cells [317–323].
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Similarly, the cytokine TNFα can act directly to induce inducing apoptosis in virally infected
cells, and indirectly to counter virus infection [317–319, 321, 324–327]. The emergence of
polyfunctional memory CD8+ T cells capable of carrying out multiple effector functions has
been associated with better control of HCMV [328–330]. Polyfunctional CMV-specific CD8+
T cells are able to secrete a combination of TNFα , IFNγ , CCL4 (MIP1β ), and upregulate
CD107a, an established marker of degranulation [287, 329, 331, 332].
The CD8+ T cell responses to HCMV remain highly stable over time, and deuterium-
labelled glucose experiments have demonstrated that CD45RA+ CD8+ memory T cells
have a long lifespan [315]. The clonal response against HCMV does not contract following
primary infection. Clones detected early after infection are maintained during the latent phase
and can be detected many years later, with hardly any new clones appearing [298, 333, 334].
Analysing the clonal composition of memory CD8+ T cells specific for pp65 and IE1
epitopes by T cell receptor (TCR) sequencing revealed a high degree of clonal focusing,
where in many donors CD8+ T cells specific to certain epitopes are dominated by a few
clones [294, 335–337]. Following the memory response to two different pp65 epitopes from
primary infection showed that, although the CD8+ TCR usage was diverse initially, there was
a rapid focusing as CD8+ T cells bearing certain TCR Vβ segments became undetectable
[333]. The cells selected into the memory phase were a subset of the CD8+ T cell responding
originally, and focusing occurred during the resolution of primary infection [333]. The
selection of particular CD8+ T cell clones during the course of HCMV infection may be
dependent on TCR avidity, which results in repertoire focusing on higher-avidity T cells
[298, 333, 336, 338]. Certain studies though, reported the opposite [339, 340], with proposed
antigen-independent expansion of low avidity clones occurring due to IL-15 [339].
HCMV-specific CD8+ T cells are detected at high frequencies in HCMV seropositive
donors [288], and it has been reported that these frequencies are higher in older individuals
[297, 341, 342]. It is presumed that longer term carriage of the virus is associated with the
expansion of the HCMV-specific CD8+ memory T cell pool because of repeated antigen
stimulation serving to boost T cell responses following viral reactivations. This phenomenon
was originally observed to occur in MCMV infection and has been termed ‘memory
inflation’ [343–346]. Despite the detected expansions in memory CD8+ T cells from HCMV
seropositive individuals, the majority of the evidence for memory inflation in humans comes
from cross-sectional age studies [302, 347], rather than longitudinal studies examining the
size of the HCMV-specific CD8+ T cell responses over a long period. It has been
hypothesised that the accumulation and maintenance of memory CD8+ T cells specific for
HCMV over time could reduce the pool of T cells needed for protection against other
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pathogens, which might explain the observations of increased all-cause mortality and
susceptibility to new infections in elderly HCMV seropositive individuals [348–352].
However, this hypothesis is disputed by numerous studies showing that poor responses to
vaccination in the elderly occur independently of HCMV seropositivity [353, 354], and that
HCMV infection does not impair the ability of older people to respond to new infections
[355, 356].
1.5.4 The CD4+ T cell response to HCMV
CD4+ T cells are composed of several functional subsets that can be grouped based on
cytokine secretion and transcription factor expression [357]. These subsets include: Th1
cells, which secrete the proinflammatory cytokine IFNγ , express the transcription factor T-bet,
and provide help to CD8+ T cells and macrophages; Th2 cells which express the transcription
factor GATA-3, secrete IL-4 and provide help to B cells; and Tregs, which will be discussed
below (Section 1.5.7) [357]. Naive CD4+ T cells become polarised toward an effector subtype
based on several factors including the signalling induced by exposure to certain cytokines,
the duration and strength of TCR signalling following antigen recognition, which can be
affected by the antigen dose and TCR affinity for the peptide-MHC class II complex, and
by the engagement of specific co-stimulatory molecules [357–360]. CD4+ T cells possess a
diverse array of antiviral effector functions. They exert their role in orchestrating immune
responses through the secretion of cytokines and via the expression of cell-surface markers
that regulate immune cell function, such as CD40L [361–365]. In this manner, CD4+ T cells
activate APCs, recruit other lymphoid cells, and help in CD8+ T cell priming as well as
the generation of high-affinity antibody responses [365]. Although these helper functions
are critical in protective immune responses, CD4+ T cells are also capable of more direct
antiviral functions such as cytotoxicity or secretion of antiviral cytokines [366–368].
CD4+ T cells play a diverse role in the immune response to HCMV. Their importance
in HCMV infection is evident from human studies and inferentially from experiments in
animal models. In mice, long-term depletion of CD4+ T cells is associated with persistent
replication of MCMV in the salivary gland [369]. Similar experiments, where CD8+ T cells
were depleted before infecting with MCMV, demonstrated that the remaining CD4+ T cells
could control virus in these mice with almost identical kinetics as immunocompetent mice
[370]. The secretion of IFNγ has also been demonstrated to be important in the control of
MCMV, where neutralisation of IFNγ reduced the antiviral activity of CD4+ T cells to a
level comparable with CD4+ cell depletion [371]. A more recent study also highlighted
24 Introduction
the necessity of CD4+ T cells secreting IFNγ to control MCMV replication in the salivary
gland, while showing the helper functions of CD4+ T cells for CD8+ T cells or B cells
to be dispensable [372]. In this study, IFNγR expression on non-haematopoietic cells was
required for the control of MCMV, pointing to the role of IFNγ secreted by CD4+ T cells
in signalling to infected non-hematopoietic cells, or bystander cells, to exert control of the
virus, rather than activating other immune cells [372]. Clinical data from transplant patients
also illustrates the importance of CD4+ T cells secreting IFNγ to control HCMV, with higher
levels of these cells correlating with increased viral control and better clinical prognosis
[373, 374]. Moreover, patients with a deficiency in IFNγR expression have an increased
susceptibility to HCMV and associated disease [375–377].
In renal transplant recipients, a delay in the generation of HCMV-specific CD4+ T
cell responses was associated with symptomatic infection and prolonged viral replication,
whereas asymptomatic infection was associated with the emergence of CD4+ T cells capable
of secreting IFNγ prior to the emergence of HCMV-specific CD8+ T cell responses [373].
Likewise, in healthy young children with primary HCMV infection, an impaired HCMV-
specific CD4+ T cell response was associated with prolonged viral shedding in urine and
saliva compared to adults with primary infection [378]. The presence of HCMV-specific
CD4+ T cells is also correlated with viral control and better clinical outcomes in several
other studies in the transplant setting [379–381], and the adoptive transfer of autologous ex
vivo expanded CD4+ T cells into stem cell transplant patients led to a significant decrease in
HCMV load associated with the reconstitution of their HCMV-specific CD4+ T cell response
[382].
Further evidence for the importance of CD4+ T cells in the control of HCMV infection
is provided by studies undertaken on HIV infected individuals. The reduction in CD4+ T
cell numbers caused by HIV infection is associated with a higher risk of developing HCMV-
related disease [383, 384]. Additionally, HIV infected individuals with quiescent end-organ
disease had unimpaired anti-HCMV CD4+ T cell responses, whereas those with active
CMV-associated end-organ disease correlated strongly with a loss of this HCMV-specific
CD4+ T cell response [385].
Much like CD8+ T cells, the CD4+ T cell responses to HCMV lytic ORFs, including pp65
and IE1, are widespread amongst seropositive individuals [386–389]. The use of peptide
libraries spanning the entire HCMV proteome has extended these findings and demonstrated
that CD4+ T cells from seropositive donors are capable of recognising a very broad array
of HCMV ORFs [288]. In this study on 33 seropositive subjects, the median number of
HCMV ORFs each donor had a CD4+ T cell response to was 12, and over half of donors
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had a response to pp65, IE, gB, UL86, and pp28 [288]. CD4+ T cells specific for HCMV
have also been estimated to reach up to 5% of peripheral blood CD4+ T cells [390], and have
been reported to even be as high as 10% [288]. The phenotypes of HCMV-specific CD4+
T cells have been investigated during both primary and chronic infection stages. The study
of healthy seropositive donors and renal transplant patients undergoing primary infection
indicated that during primary infection the HCMV-specific CD4+ T cell population expressed
CD38, both CD45RA and CD45RO, and a large proportion of cells maintained expression
of CD27 [391, 392]. Furthermore, CD4+ T cells obtained during both primary and latent
infection stages expressed CD11a, CD49d, CD40L, and were negative for CD62L and CCR7
[379, 391]. During latency, HCMV-specific CD4+ T cells lose expression of CD38, CD27,
and CD45RA, and the population becomes enriched for CD45RO expressing cells [379, 391–
395]. In seropositive individuals, a population of HCMV-specific CD4+ TEMRA cells, which
re-express CD45RA+ [393, 394, 396–399], and high frequencies of CD27-CD28- CD4+
T cells, which produce IFNγ and express granzyme B and perforin, can also be detected
[392, 400–403].
In addition to mediating antiviral effects by cytokine secretion, CD4+ T cells capable
of cytotoxicity have been documented in HCMV infection. The emergence of CD4+ T
cells from HCMV infected individuals that are able to express cytotoxic molecules, such
as granzyme B, is an indicator that these cells possess cytotoxic capacity [379]. These
populations of cells have been widely detailed. As mentioned previously, following primary
HCMV infection in renal transplant recipients, there was an emergence of a subpopulation of
CD4+ T cells that lost expression of CD28 and expressed granzyme B [400]. HCMV-specific
CD4+ T cells have also been shown to express the pore-forming protein perforin [401], and
show surface mobilisation of CD107a, a marker for degranulation [393, 404]. From the same
study, the expression of granzymes A and B, in addition to perforin, was elevated on highly
differentiated CD4+ T cells, which had lost expression of CD27 and gained expression of
CD57, giving weight to the idea that these CD4+ T cells develop cytotoxic capabilities with
increased maturation [404]. Further to this, a recent study confirmed that HCMV-specific
CD4+ T cells possessed a highly differentiated phenotype, and by utilising MHC class II
tetramers revealed these cells had a considerable cytotoxic profile, further supported by
microarray analysis revealing an upregulation of genes associated with cytotoxicity [405].
The ability of CD4+ T cells bearing these phenotypic markers for cytotoxicity have been
verified by in vitro killing assays where ex vivo isolated CD4+ T cells could lyse EBV-
transformed B lymphoblastoid cell lines loaded with HCMV antigens [404–407].
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The size of the HCMV-specific CD4+ T cell population has been observed to expand with
age, although to a lesser extent than CD8+ T cells [408, 409], and the documented expansion
of cells with phenotypes linked to terminal differentiation and dysfunctional responses
mentioned previously, has led to the hypothesis that dysfunctional CD4+ T cells accumulate
with age and may have negative consequences for the host [390, 410–412]. However, the
generation of polyfunctional CD4+ T cells capable of multiple simultaneous antiviral effector
functions, such as production of IL-2, TNFα , and IFNγ , has been reported for HCMV-
specific CD4+ T cells [393, 413, 414]. Polyfunctional CD4+ T cells have been shown to be
superior effector cells [316, 415], and are associated with better control of HCMV [374, 413].
Importantly, in older HCMV seropositive donors, polyfunctional HCMV-specific CD4+ T
cells are found, and can be detected within CD4+ T cell populations possessing highly
differentiated phenotypes [316, 394, 400, 401, 404, 416]. CD4+ T cells specific for HCMV
therefore do not appear to undergo functional exhaustion with age.
1.5.5 HCMV, the immune system, and ageing
It has been suggested that HCMV infection enhances the age-related decline in immune
function (immunosenescence). Several lines of evidence have been drawn on to support the
detrimental effects of HCMV carriage on immune ageing, including the above mentioned
phenomenon of memory T cell inflation, reported expansions of dysfunctional T cells in
old age, and impairment of responses newly encountered pathogens and vaccines [341, 350,
348, 417–419]. These observations have led to the hypothesis that HCMV could be the main
driver of immunosenescence, with long term viral carriage being linked to an increase in all
cause mortality.
This decrease in life expectancy associated with HCMV infection has been reported
alongside a number of other immune parameters to generate the ‘immune risk phenotype’
(IRP) [420]. In addition to HCMV seropositivity, the parameters in the IRP include reduced
B cell numbers, an inverted CD4+:CD8+ T cell ratio, an increased frequency of CD8+CD28-
T cells, and poor proliferative response to mitogen stimulation [348, 349, 351, 352, 421].
Further studies aiming to address the association between HCMV and increased mortality
have also been carried out, with some studies finding evidence supporting such a link
[422–426], and others not [427, 428].
As discussed previously, in HCMV seropositive individuals, there is an expansion of
highly differentiated HCMV-specific CD8+ T cells that re-express CD45RA, and gain
expression of CD57 as well as KLRG1, with a concurrent loss of expression of CD27 and/or
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CD28. It has been suggested that these T cells could be dysfunctional, with reports of a loss of
proliferative capacity and ability to secrete cytokines [341, 350, 429, 430]. However, separate
studies examining the ability of these cells to proliferate have found no evidence of a defect
when given appropriate co-stimulation [293, 315, 431, 432], and HCMV-specific T cells with
a highly differentiated phenotype have been shown to produce multiple antiviral cytokines
and possess cytotoxic potential [315, 433, 414]. Despite the presence of these functional
cells however, an age-related increase in HCMV DNA detected in the urine and blood
has been reported, suggesting a possible alteration in HCMV-specific responses with age
[434, 435]. Another potential reported manifestation of HCMV-enhanced immunosenescence
is a weakened response to immunisation. Several studies have shown an association between
HCMV seropositivity, or a high anti-HCMV IgG titre, with decreased antibody responses to
influenza vaccination in older age [419, 436–439], although numerous studies reported no
such effect, or even an enhanced response to vaccination in HCMV seropositive individuals
[351, 353, 354, 440–442]. Therefore, the evidence for a direct link between HCMV and
immunosenescence remains inconclusive.
1.5.6 Tissue-resident memory T cells
The view that memory T cells are grouped into either central memory (TCM) or effector
memory (TEM), with TCM cells circulating between the secondary lymphoid organs and the
blood, and TEM through the blood, lymphoid and non-lymphoid tissues, has recently been
expanded on to include a population of tissue-resident memory T cells (TRM) [443–445].
TRM cells have been identified in barrier tissues and secondary lymphoid organs where they
are maintained without recirculating into the blood and are not replenished by the circulating
memory T cell population [446–451]. Their localisation at sites of pathogen entry and
reactivation allows them to mount rapid immune responses and restrict infection to the tissue
site [448–455]. On antigen encounter, TRM cells are able to rapidly produce IFNγ and carry
out cytotoxicity against infected cells. The production of IFNγ along with cytokines such as
TNFα and IL-2 also acts to promote an antiviral state in the tissue by recruiting recirculating
CD4+ and CD8+ T cells, and B cells, as well as induce DC maturation, and NK cell activation
[448, 456–458].
Studies examining the development of TRM have demonstrated a level of tissue- and
context-dependency. For example, the induction of CD8+ TRM cells has been demonstrated to
occur independently of local antigen in the gut, skin, and female reproductive tract [455, 459–
462], whereas in the brain this has been shown to be dependent on antigen [451]. The surface
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markers CD103 and CD69 have commonly been used to identify TRM over other memory T
cells [451, 463–465], although there are reports of CD103- and/or CD69- TRM [466–468].
In a thorough examination of memory T cell distribution in the circulation and tissues from
deceased organ donors, memory T cell isolated from the lymphoid and mucosal tissue had
constitutive CD69 expression compared to circulating memory T cells which were mainly
negative for CD69 [465]. Furthermore, CD103 was shown to be exclusively expressed
on mucosal memory CD8+ T cells isolated from the colon and small intestine, with large
proportions of CD103+ memory CD8+ T cells also found in the lung and intestinal-draining
lymph node, whereas blood, spleen, and peripheral lymph node CD8+ memory T cells were
mainly CD103- [465].
In the context of herpesvirus infection, the presence of TRM cells at sites of latency and
viral entry could provide a rapid defence against reactivation and superinfection compared to
circulating memory T cells that might not have access to these tissue sites in non-inflammatory
conditions. Indeed, HSV-1 specific CD8+ TRM cells rapidly detect virus at neuronal sites of
latency and provide superior protection compared to circulating memory T cells [455, 469–
471]. CD4+ and CD8+ TRM cells have also been detected in response to MCMV infection
[460, 461]. Although CD8+ T cells are unable to control lytic MCMV replication during
primary infection in the salivary gland [369, 372], following re-infection, the population of
salivary gland CD8+ TRM can confer immediate protection due to the tropism of the virus
for cells that resist complete MHC class I downregulation [460]. In humans, CD103+ CD8+
T cells specific for EBV, and CD103+ CD4+ and CD8+ T cells specific for HSV-2, have
been detected in the tonsils and female genital mucosa, respectively [472–474], and a large
proportion of HCMV-specific CD8+ T cells in the lung and spleen were found expressing
CD69, indicative of a TRM phenotype [475].
1.5.7 HCMV and regulatory T cells
CD4+ regulatory T cells (Tregs) are an indispensable subset of cells with immunosuppressive
properties that negatively regulate immune-mediated inflammation. A deficiency of Tregs
results in spontaneous autoimmune disease, which in humans is fatal [476–478]. CD4+
Tregs are defined by their expression of the transcription factor forkhead box protein 3
(Foxp3) [479], which is required for their suppressor functions [480, 481], but they can
also be identified by a number of cell surface markers including the low expression of
CD127 and high expression of CD25 [482–484]. One population of Tregs is generated in
the thymus, termed natural Tregs (nTregs). The differentiation of nTregs is dependent on
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the high-avidity interaction between the TCR and peptide/MHC class II complexes in the
presence of IL-2 [485, 486]. Thus, nTregs are largely self-reactive and contribute to the
prevention of autoimmunity through tolerance to self antigens. Tregs can also differentiate in
the periphery, known as induced Tregs (iTregs), predominantly when naive T cells encounter
antigen under certain tolerogenic conditions. Factors that favour the generation of iTregs
include strong TCR signalling and suboptimal costimulation in the presence of high levels
of TGFβ and retinoic acid [485, 487, 488]. Differentiation of iTregs is therefore likely to
occur in response to non-self antigens, which iTregs can act on to restrict excessive immune
responses.
Tregs mediate their suppressive effects via several mechanisms such as the secretion of
immunosuppressive cytokines IL-10 and TGFβ [485, 489, 490]. Tregs also express surface
molecules involved in their suppressive functions, including CTLA-4, which may allow
Tregs to suppress DC-mediated activation of T cells by downregulating the co-stimulatory
molecules CD80 and CD86 [485, 491]. Additionally, the constitutively high expression of
CD25 (IL-2Rα chain), which binds IL-2, can act to reduce IL-2 availability for CD8+ T
cells, limiting their activation [492].
Although Tregs can mediate a protective effect against excessive inflammatory responses
during certain viral infections [493], they have also been demonstrated to interfere with
protective immune responses [494–500]. Multiple studies have reported the presence of
HCMV-specific Tregs [403, 494, 501–505] and demonstrated their ability to secrete IL-10 and
TGFβ , and to inhibit cytokine secretion and T cell proliferation [403, 502–504]. Attempts
to target these Tregs have found that depletion of CD25+ expressing cells can increase the
frequency of pp65- and IE-1-specific CD8+ T cells secreting IFNγ [494, 502]. There is also
evidence that the frequency of HCMV-specific iTregs is greater in older individuals [503].
In addition to FoxP3+ Tregs, a population of regulatory CD4+ T cells generated in the
periphery lacking expression of FoxP3 has been described, termed type 1 regulatory (Tr1)
cells. Tr1 cells were reported to be induced following the chronic activation of CD4+ T
cells by antigen in the presence of IL-10, and were able to suppress antigen-specific CD4+
T cell proliferation and prevent colitis in a mouse model of inflammatory bowel disease
[506]. Tr1 cells exert their suppressive effects mainly through elevated secretion of IL-10
and TGFβ , which can act to suppress T cell and DC function [506–509]. DCs modulated in
this manner, could upregulate tolerogenic surface molecules and inhibitory factors, and thus
indirectly suppress T cells [509]. Tr1 cells can also inhibit T cell responses by cell-to-cell
contact dependent mechanisms, metabolic disruption, and cytolysis, where Tr1 cells were
shown to express granzyme B and lyse myeloid APCs, representing another potential indirect
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mechanism to suppress T cells [509–511]. Tr1 cells have a distinct cytokine expression
profile and are defined by their secretion of IL-10, TGFβ , and IL-5, as well as low levels of
IFNγ and IL-2, in the absence of IL-4 [506–508]. In addition, several surface marker have
been associated with Tr1 cells such as inducible co-stimulatory molecule (ICOS), CD18,
CD49b, and the lymphocyte activation gene-3 (LAG-3) [512–515].
Various methods have been used to generate Tr1 cells in vitro. To do so, CD4+ T cells
have been stimulated with different subsets of APC, including plasmacytoid DCs, immature
DCs, or tolerogenic DCs [506, 516–520], as well as with different cytokines, such as IL-10,
IL-6, or IL-27 [521–524]. Furthermore, engagement of a range of co-stimulatory molecules
have been reported to be important for Tr1 cell generation such as CD46, CD55, ICOS, and
CD2 [521, 525–527]. It is unclear how representative these methods are of the complex
environment in vivo, and the different protocols employed to generate Tr1 cells has resulted in
a heterogeneous population of cells being described, making characterisation more difficult.
To date, no lineage defining transcription factor has been identified for Tr1 cells, and it has
not been conclusively demonstrated that they are a distinct cellular population [528].
1.5.8 The T cell responses during latent HCMV infection
Although the primary immune response to HCMV is usually effective at resolving primary
infection in immunocompetent hosts, HCMV is never cleared and can establish a latent
infection. During latency, the products of viral gene expression serve mainly to maintain
latency and assist in immune evasion. As the genes expressed during latency are also
expressed during lytic infection, it might be expected that T cells specific to latency-associated
gene products are also generated, potentially rendering latently infected cells vulnerable to T
cell detection and killing.
An early study examining T cell responses to 213 HCMV ORFs by peptide stimulation
and intracellular cytokine staining (ICS) found CD4+ T cell responses to UL138 in one
donor and to UL144 in four donors out of 33, but failed to detect responses to US28 or
UL111A [288]. Likewise, CD8+ T cell responses were only detected in one donor out
of 33 in response to UL138 and US28, and in none of the donors in response to UL144
and UL111A [288]. An additional study utilising ICS following peptide stimulation, did
not detect CD4+ T cell responses to LUNA and UL138, or LUNA-specific CD8+ T cell
responses, while only a CD8+ T cell response to one UL138-derived peptide presented on
HLA-B35 was reported [529]. A more recent study however, measured T cell responses to
viral proteins expressed during latency over a longer period of 48 hours by ELISpot [501]. T
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cell responses to UL138 and LUNA were detected, and these were primarily CD4+ T cell
mediated, with only low frequencies of CD8+ T cell responses detected if at all [501]. A
proportion of these CD4+ T cells specific for proteins expressed during latency secreted the
immunomodulatory cytokines IL-10 and TGFβ , which contrasted with CD4+ T cells specific
for lytic HCMV ORF products [501]. Furthermore, in CD4+ T cell lines specific for UL138
and LUNA, but not gB, a subset of cells was found to possess phenotypic characteristics of
Tregs, as they were CD4+CD25hiFoxP3+ [501]. The supernatant from UL138-stimulated
PBMC, but not gB-stimulated PBMC, was also able to inhibit the proliferation of CD4+ T
cells, and the use of neutralising antibodies against IL-10 and TGFβ confirmed they were the
mediators of this inhibition as proliferation was restored [501]. Based on these findings, it
was hypothesised that the secretion of IL-10 and TGFβ by latency-associated ORF specific
CD4+ T cells was contributing to the inhibition of antiviral IFNγ /TNFα secreting cytotoxic
Th1 cells during latency.
1.6 Immune evasion
There is a complex interplay between HCMV and the host immune system. HCMV has
evolved a variety of strategies to effectively modulate both innate and adaptive immune
responses. HCMV encodes an array of proteins that are capable of subverting immune
surveillance, and these often have overlapping and redundant functions [530, 531].
1.6.1 Immune evasion of the innate immune response
As the first line of defence against infection, innate immunity plays an important role in
preventing the establishment of viral infections and initiating antiviral immune responses.
HCMV disrupts the actions of PRRs in a number of ways. For example, the virus is able
to target the TLR2 pathway at late stages of infection with two microRNAs, miR-US5-1
and miR-UL112-3p [532, 533]. The expression of miR-UL112-3p downregulates TLR2
expression, and both of these microRNAs inhibit downstream NFκB signalling by inhibition
of IKKα and IKKβ , resulting in a decrease in proinflammatory cytokine secretion [532, 533].
HCMV encoded UL31 also interacts directly with cGAS and inhibits its enzymatic activity,
resulting in a decrease in cGAMP production [534]. Additionally, knockdown or knockout
of UL31 was found to increase production of type I IFNs and antiviral genes induced by
HCMV [534].
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IFNs play a key role in the defence against viruses, and HCMV employs several additional
mechanisms to evade IFN-dependent responses. UL83-encoded pp65 has a main role in the
inhibition of type I IFN responses, although the level at which it acts is still under debate [535–
538]. The tegument protein pp71 has been shown to interfere with stimulator of interferon
genes (STING) mediated signalling resulting in an inhibition of IFNβ transcription, amongst
other antiviral genes [539]. The viral glycoprotein US9 also interferes with STING-mediated
signalling pathways to block nuclear translocation of IRF3, resulting in an inhibition of the
IFNβ response [540], as does the IE2 protein IE86 by blocking NFκB binding to the IFNβ
promoter [68, 69, 541]. Furthermore, HCMV inhibits IFN signalling and ISG expression by
interfering with signalling components, such as Jak1, that are downstream of the stimulated
IFN-receptors [531]. In addition, HCMV impairs the induction of IFN-responses through
the secretion of a viral homologue of cmvIL-10 encoded by UL111A [154], and inhibits the
actions of PKR and OAS [531].
Cellular restriction factors represent a first line of defence against viruses by counteracting
viral replication. In defence against a nuclear DNA virus such as HCMV, the components
of ND10, which include hDaxx, Sp100, and PML, act as restriction factors and exert their
antiviral functions mainly by epigenetic mechanisms to repress HCMV IE gene expression
[542–547], with PML acting as a structural platform for the recruitment of other proteins
[548–550]. To replicate successfully, HCMV has evolved several mechanisms that help evade
these restriction factors. As mentioned previously (Section 1.2.3), IE1 disrupts ND10 by
preventing its SUMOylation and therefore its oligomerisation [73, 74, 76, 551]. Additionally,
the tegument protein pp71 can displace the chromatin-associated factor ATRX from ND10,
and cause the degradation of hDaxx by the proteasome, therefore relieving hDaxx-dependent
repression of the MIEP [552, 553, 544, 554].
As discussed subsequently HCMV downregulates MHC class I molecules on infected
cells to evade CD8+ T cell recognition (Section 1.6.2). Doing so however, should render
infected cells vulnerable to NK mediated lysis, which would normally receive inhibitory
signals from MHC class I molecules [266]. To prevent this, HCMV encodes multiple genes
dedicated to suppressing NK cell activation and cytotoxicity, the majority of which aim
to either prevent signalling from activating receptors, or trigger inhibitory signals [555].
HCMV attempts to maintain or increase inhibitory signals in a number of ways, including
the expression of MHC class I decoys, and selective retention or upregulation of MHC
class I molecules (such as the non-classical MHC molecule HLA-E) that are less adept at
stimulating extensive CD8+ T cell responses. HLA-E, for example, is restricted in its binding
of peptides, as its natural ligands are the leader sequences of HLA-A, -B, -C and -G alleles
1.6 Immune evasion 33
[556]. At the cell surface, HLA-E provides an inhibitory signal to NKG2A/CD94 on NK
cells [557]. HCMV takes advantage of this by expressing UL40 which contains a nonameric
peptide able to bind HLA-E and increase its cell surface expression in a TAP-independent
manner following processing in the ER [558–560]. HCMV also expresses a homologue of
MHC class I, UL18, which can bind the inhibitory NK receptor LIR-1 with greater affinity
than cellular MHC class I and inhibit LIR-1+ NK cells [560–563]. Additionally, the UL40
nonameric peptide is capable of upregulating UL18, in addition to HLA-E [560].
The potent activating receptor NKG2D, which is expressed on all human NK cells [564],
can bind ligands such as MICA, MICB, and ULBP1-3 and ULBP6 [555]. HCMV infection
results in an upregulation of these stress-induced ligands, which the virus can counteract
through binding of ULBP1, 2, and 6, and MICB, via its glycoprotein UL16, retaining them
intracellularly [555]. Downregulation of MICA and ULBP3 has been shown to be mediated
by the glycoprotein UL142, again via intracellular retention [565–567]. MICA can also be
targeted by the US12 gene family member US18 and US20, which promote MICA proteolysis
by lysosomal degradation [568]. A recent multiplex proteomic analysis followed these results
up to uncover additional member of the US12 family with roles in targeting activating NK
cell ligands, such as the contribution of US13 in downregulation of MICB [569]. An HCMV
encoded microRNA, miR-UL112-1, is also involved downregulating MICB by reducing
MICB mRNA translation [570].
1.6.2 Immune evasion of the adaptive immune response
HCMV can diminish the ability of CD4+ and CD8+ T cells to recognise viral antigens by
interfering with the MHC class I and II processing pathways. The viral US2-11 region is
integral to this. The immune evasion genes US2 and US11 code for proteins that
retrotranslocate newly synthesised MHC class I heavy chains from the ER to the cytosol,
where they are targeted for degradation by the proteasome [571–573]. Similarly US3 binds
to MHC class I peptide complexes and causes them to be retained in the ER [574–576],
whereas US6 prevents the transport of peptides from the cytosol into the ER by binding to
the cytosolic side of the transporter associated with antigen processing, thereby inhibiting
ATP binding [577–579]. US3 is expressed as an immediate-early protein, whereas US2 and
US11 as early proteins, and US6 is synthesised during both early and late times of infection
[580]. Antigen presentation via MHC class II is also interfered with by US2, which targets
HLA-DRα and HLA-DMα for proteasomal degradation [581, 582]. In addition, US3 can
bind MHC class II α /β complexes in the ER, and disrupt their association with the invariant
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chain [583]. This leads to inefficient sorting of MHC class II molecules into the peptide
loading compartment and a reduction in the loading of antigenic peptides onto MHC class II
[583]. Finally, viral pp65 can downregulate the expression of HLA-DR by mediating the
transport and accumulation of HLA class II molecules in lysosomes, resulting in the
degradation of the HLA-DRα chain [584].
Although MHC class II expression is usually restricted to professional APCs, such as
macrophages and dendritic cells, IFNγ stimulation can also induce expression of MHC class
II on non-professional APCs such as fibroblasts, endothelial, and epithelial cells [585, 586].
However, HCMV can target this IFNγ-mediated upregulation of MHC class II following
infection by interfering with the expression of the class II transactivator, CIITA, which is
essential for MHC class II transcription and expression [587]. The virus achieves this by
directly inhibiting the expression of CIITA mRNA, as has more recently been demonstrated
in a human dendritic cell subset [588, 589]. Moreover, HCMV interferes with IFNγ-mediated
signalling by inhibiting JAK expression, which results in reduced CIITA activation and MHC
class expression [590, 591]. These mechanisms serve to decrease the amount of viral peptides
presented to T cells, thereby reducing the potency of anti-viral T cell immunity.
The viral gene products of UL111A and UL144 can also interfere with T cell mediated
immune responses. As mentioned previously, the viral gene UL111A encodes two
homologues of hIL-10 which have immune evasion properties (Section 1.3.4). During lytic
infection these homologues (cmvIL-10 and LAcmvIL-10) can downregulate MHC class I
and II, inhibit the proliferation of PBMC, and suppress the production of proinflammatory
cytokines [127, 155, 156]. Furthermore, cmvIL-10 can upregulate the secretion of hIL-10
from certain myeloid cells, possibly amplifying its suppressive effects [160]. In addition,
expression of UL144 could also interfere with T cell responses, both through binding to
BTLA to inhibit T cell proliferation, and through its ability to induce expression of the Th2
chemoattractant CCL22 to dampen Th1 responses [143, 144, 147].
The use of microRNAs by HCMV is an effective way of avoiding immune surveillance
by T cells, given the lack of peptide component that could be presented on MHC molecules.
microRNAs implicated in the modulation of the host immune system during lytic infection
include miR-UL112-5p. miR-UL112-5p was shown to downregulate the aminopeptidase
ERAP1, which is required for peptide trimming prior to MHC class I presentation, and
reduce presentation of an immunodominant pp65 peptide to CD8+ T cells [592]. Finally,
miR-UL148D is responsible for the degradation of CCL5 mRNA, thereby impairing T cell
chemoattraction to infected cells [593].
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Despite the plethora of immune evasion functions encoded by HCMV, in the majority
of cases, the immune system is able to resolve primary infection. However, the immune
response to primary infection cannot prevent the establishment of latency, allowing the virus
to persist for the lifetime of the host. During primary infection, immune evasion mechanisms
targeting innate and intrinsic immunity could therefore be responsible for giving the virus
a window of opportunity where it can replicate and disseminate to cell types that support a
latent infection. As these events likely happen prior to the generation of the adaptive immune
response, immune evasion mechanisms targeting the components of adaptive immunity might
thus be more important in protecting the virus during reactivation to enable replication and
the production of infectious virions.
1.6.3 Immune evasion during latency
During latency, the known expression of a number of viral proteins should be expected to
result in the recognition of infected cells by HCMV-specific T cells. However, multiple
immune evasion mechanisms operate during latency to suppress T cell mediated responses.
The expression of non-immunogenic microRNAs during latency provide one such mechanism.
miR-UL148D targets the cellular receptor ACVR1B in latently infected monocytes, and
limits secretion of the proinflammatory cytokine IL-6 in response to activin A [594]. IL-6 has
several effects on T cells, including interference with the generation and suppressive effects
of Tregs [595–598]. Additionally, HCMV miR-UL112-1 was shown to target viral IE72
transcripts in latently infected cells to prevent IE RNA expression and subsequent recognition
by IE-72 specific CD8+ T cells [599].
HCMV is known to induce changes in the secreted proteins (secretome) of infected
cells during lytic infection. Such secreted proteins of both cellular and viral origin include
chemokines, cytokines, and growth factors [600–602]. HCMV also modulates the secretome
of latently infected cells. In this manner, HCMV can influence cellular migration, for
example by increasing the secretion of the monocyte-attracting cytokine CCL2 in latently
infected granulocyte macrophage progenitors, which was linked to the migration of CD14+
monocytes toward the site of latency [603]. Similarly, short-term latent infection of CD14+
monocytes resulted in the secretion of CCL2 and CCL8, which was linked to the recruitment
of both CD14+ monocytes and CD4+ T cells to latently infected cells [604]. In addition,
analysis of the supernatants from experimentally latent CD34+ cells revealed the secretion
of many cellular factors during latent infection [605]. Among these were chemokines
such as CCL2, CCL8, and CXCL12, but also the immunomodulatory cytokines IL-10 and
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TGFβ [605]. In this study, latently infected CD34+ cells were found to induce CD4+ T
cell migration, which was dependent on CCL8 binding to CCR3 and CCR5 receptors on
the T cells. The latent secretome was then able to inhibit the secretion of Th1 cytokines
(IFNγ , TNFα , and TNFβ ) from CD4+ T cells, as well as inhibit CD4+ T cell mediated
cytotoxicity. Furthermore, the latent secretome upregulated the secretion of IL-10 and
TGFβ from bystander CD34+ cells [605]. These results led to the hypothesis that latently
infected cells generate an immunosuppressive microenvironment that can inhibit CD4+ T cell
recognition and clearance of latently infected cells, even those recruited by CCL8 secretion
[605].
Alongside cellular protein secretion being regulated during latency, viral proteins are also
secreted. One such protein is an isoform of viral IL-10, LAcmvIL-10, which is capable of
downregulating MHC class II molecules on latently infected cells [127, 156]. LAcmvIL-
10 can also upregulate the transcription of cellular IL-10 via the downregulation of the
cellular microRNA hsa-mir-92a [164]. Thus, LAcmvIL-10 expression could additionally
impact the immunosuppressive microenvironment created by latently infected cells via
upregulation of cellular IL-10. Further to its function in immune evasion, IL-10 acts as a
survival factor for early myeloid lineage cells such as CD34+ progenitor cells and CD14+
monocytes by increasing resistance to apoptotic signals. IL-10 drives the expression of
anti-apoptotic proteins such as BCL-2 and PEA-15 [606–608]. PEA-15 was recently shown
to be upregulated following IL-10 signalling in CD34+ cells, which resisted extrinsic FAS-
mediated death [607]. Therefore, the increase in cellular IL-10 expression induced by
LAcmvIL-10 during latency could also act to prevent apoptosis by increasing the resistance
of latently infected cells to pro-death signals, thus helping to maintain viral genome carriage.
1.7 Aims for this thesis
It was hypothesised that T cells specific to HCMV latency-associated gene products could be
contributing to the maintenance of viral latency through the secretion of immunosuppressive
cytokines. In this manner, these T cells could be suppressing antiviral responses during
latency, enabling the virus to persist. To test this hypothesis, the following aims were set out
for this project:
• Determine if CD4+ and CD8+ T cells from HCMV seropositive donors respond to the
latency-associated ORFs UL138, LUNA, US28, UL111A, and UL144
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• Determine if T cells specific for latency-associated gene products produce IL-10
• Investigate the influence of age on the frequencies of cytokine secreting T cells specific
for latency-associated ORFs
• Characterise the phenotype and effector functions of latency-specific CD4+ T cells
• Characterise the phenotype and effector functions of latency-specific CD8+ T cells
• Improve recognition and clearance of latently infected cells by modulating
immunosuppressive cytokines

Chapter 2
Materials and Methods
2.1 Donors, Testing HCMV seropositivity, Data collection
Heparinised peripheral blood was collected from 104 healthy HCMV-seropositive donors, and
24 HCMV-seronegative donors (Appendix TableD.1). HCMV serostatus was verified from
serum by enzyme-linked immunosorbent assay (ELISA), using a commercial HCMV specific
IgG ELISA kit (Trinity Biotech) according to the manufacturer’s instructions. Donors were
recruited from the National Institute of Health Research (NIHR) Cambridge BioResource,
with ethical approval obtained from University of Cambridge Human Biology Research
Ethics Committee (HBREC.2014.07). Informed written consent was obtained from all
donors in accordance with the Declaration of Helsinki. The age range of seropositive donors
tested was 23 to 76 years, 60 donors were female and 44 donors were male. The age range
of seronegative donors was 38 to 78 years, 13 donors were female and 11 donors were
male. Full donor information is shown in Appendix D. Four donors were also HLA typed
by genotyping, which was carried out by the NHS Tissue Typing Service, Addenbrooke’s
Hospital, Cambridge.
The collection of FluoroSpot data from this large donor cohort, transplant recipients,
and bone marrow mononuclear cell donors (contained within Chapters 3, 4, and 5) was
carried out in collaboration with Dr Sarah Jackson, a Postdoctoral Research Associate whose
work focused on T cell responses to proteins expressed during lytic HCMV infection. The
collected raw data was then analysed independently
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2.2 Cell lines and culture media
All cell types were incubated at 37◦C in 5% CO2. Primary dermal fibroblasts were maintained
in 175cm2 flasks in Dulbecco modified Eagle medium (DMEM) (Gibco), supplemented with
20% inactivated foetal calf serum (FCS) (Gibco) and 5% penicillin/streptomycin (Sigma-
Aldrich). Human foreskin fibroblast cells (HFFs) were grown in DMEM supplemented with
10% inactivated FCS and 5% penicillin/streptomycin in 175cm2 flasks. Fibroblasts were split
at a 1:2 ratio, twice a week. Media was removed and the fibroblasts washed with phosphate-
buffered saline (PBS) before the addition of 5ml trypsin (Promega) for 5 minutes. The
enzymatic activity of trypsin was then stopped by the addition of DMEM supplemented with
FCS as appropriate. PBMC were maintained in RPMI-1640 (Sigma-Aldrich) supplemented
with 10% FCS and 5% penicillin/streptomycin, while T cells were maintained in X-VIVO
15 (Lonza) supplemented with 5% Human AB serum (Sigma-Aldrich).
2.3 Isolation of PBMC from whole blood
Fresh PBMC were isolated from venous blood obtained by venipuncture. Varying amounts
of blood was collected into 50ml tubes containing 2.5ml (100IU/ml) heparin sodium (Fannin)
diluted in PBS (Sigma-Aldrich). Blood was then diluted 1:2 in PBS before isolating PBMC
via Lymphoprep (Axis-shield) density gradient centrifugation. 12.5ml of Lymphoprep was
overlayed with 25ml of diluted blood then centrifuged at 500G for 25 minutes with the brake
off. The PBMC layer was extracted using a Pasteur pipette and resuspended in 50ml PBS
before being centrifuged at 500G for 5 minutes with the brake on. Finally, the supernatant
was poured off, and the PBMC resuspended in 50ml PBS and centrifuged at 300G for 10
minutes. PBMC numbers were then enumerated by hemocytometer counting of cells stained
with trypan blue (Sigma-Aldrich).
2.4 Cryopreservation and defrosting of cells
Cell lines and donor derived PBMCs that required storage in liquid nitrogen were
cryopreserved by washing in their constituent media and chilling the resulting cell pellet in
ice for 2 minutes before being resuspended at up to 4x107 cells per ml in chilled freezing
medium (10% dimethylsuphoxide, 90% foetal calf serum) and transferred to 1ml cryovials
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(Corning). Cryovials were placed in a freezing container (Thermo Fisher Scientific) at -80◦C
overnight before transfer to liquid nitrogen for long term storage the following day.
To defrost frozen cells, cryovials were removed from liquid nitrogen and hand warmed
until partially defrosted. Each 1 ml aliquot of cells in freezing media was then resuspended
in 10ml pre-warmed 37◦C serum-free RPMI-1640 made up with 10U/ml RNase free DNase
(Sigma-Aldrich). Cells were then centrifuged for 10 minutes at 300G before being
resuspended in 10ml RPMI-1640 with 10U/ml RNase free DNase and incubated for 1 hour
at 37◦C. Cells were then washed again, by centrifuging for 5 minutes at 500G, and
re-suspended in the appropriate media. Defrosted PBMC or T cells were rested overnight at
37◦C in media before use in assays.
2.5 Cell separations by Magnetic Associated Cell Sorting
(MACS)
2.5.1 Negative selection
To deplete an unwanted population(s) from PBMC and leave desired cells untouched,
negative selection using the MACS system was used. To isolate CD3+ T cells the Pan T cell
isolation kit was utilised (Miltenyi). PBMC were first washed twice in MACS buffer (PBS
without calcium and magnesium supplemented with EDTA (2nM) (Thermo Fisher Scientific)
and 0.5% FCS), and then resuspended in MACS buffer at the correct concentration as per the
manufacturer’s instructions, before the addition of direct beads against the cell population(s)
to be removed (Miltenyi). Cells were incubated for 15 minutes at 4◦C, washed in MACS
buffer once, before being resuspended in MACS buffer at desired concentration. Depletions
were then performed on LS columns (Miltenyi) or using automated cell separation with
autoMACS (Miltenyi) and autoMACS columns (Miltenyi) in accordance with the
manufacturer’s instructions.
2.5.2 Positive selection
Again, using the MACS system to obtain a pure population of cells where labelling the
cells of interest is not a concern, direct beads (Miltenyi) were used. For example, this was
used to isolate CD14+ monocytes from PBMC. Whole PBMC were first washed twice in
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MACS buffer, then resuspended in MACS buffer at the correct concentration according to
the manufacturer’s instructions. Direct beads (Miltenyi) against the target population were
then added and incubated for 15 minutes at 4◦C, washed in MACS buffer once, before being
resuspended in MACS buffer finally. Depletions were carried out on LS columns (Miltenyi)
and labelled cells eluted, or using automated cell separation with autoMACS (Miltenyi) and
autoMACS columns (Miltenyi) in accordance with the manufacturer’s instructions.
2.6 Peptides
Peptides obtained from Proimmune were constructed as sequential 15 amino acid peptides
that overlap by 10 amino acids, spanning UL55 (gB), UL123 (IE1), UL122 (IE2), UL83
(pp65), UL82 (pp71), US3, UL138, US28, UL81-82as (LUNA), UL111A (vIL-10), and
UL144. The sequences of all peptides are shown in Appendix B. Peptides were reconstituted
in 80% dimethylsulphoxide and stored according to the manufacturer’s instructions to a
concentration of 40 mg/ml. Each individual peptide was further diluted in RPMI-1640 to
give a stock of 1 mg/ml and a working concentration of 40µg/ml for each peptide. Peptides
were stored at -80◦C. Peptide pools spanning entire ORFs, or smaller regions of an ORF
were constructed from single peptides to a final concentration of 2µg/ml of each individual
peptide. To test T cell responses from patients undergoing kidney transplantation, peptide
pools were generated encompassing multiple ORFs, maintaining each peptide from each
pool at a concentration of 2µg/ml. Pools were made up from the peptides of UL138, LUNA,
US28, UL111A, and UL144, pp65 and UL144, IE1 and IE2, and pp71 and US3.
2.7 Flow Cytometry Analysis
2.7.1 Quantifying efficiency of cell depletions
PBMC alone, or PBMC subsets following cell separations by MACS, were stained to ensure
efficient separation had occurred. Cell suspensions were washed twice in MACS buffer
before being labelled with a mix of the relevant antibodies (Table 2.1) in MACS buffer for
45 minutes at 4◦C in the dark at the manufacturer’s recommended concentration.
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Target Species Clone Fluorophore Supplier
CD3 Mouse UCHT1 FITC BioLegend
CD4 Mouse RPA-T4 PE BioLegend
CD8 Mouse HIT8a PerCP/Cy5.5 BioLegend
CD14 Mouse HCD14 APC BioLegend
Table 2.1 Antibodies used for post separation purity analysis
2.7.2 Measuring T cell proliferation by flow cytometry
Freshly isolated PBMC were labelled with CellTrace violet proliferation kit, for flow
cytometry (Thermo Fisher Scientific), to a final dilution of dye at 1:2000 in PBS, according
to the manufacturer’s instructions. Labelled PBMC were then resuspended with supernatant
from CD4+ T cells stimulated for 48 hours with whole ORF US28 peptides (Section 2.13.1),
media alone, or 2ng/ml IL-10 (Peprotech) at a concentration of 1.0×105 cells per well of a
round bottom 96 well plate and incubate for one hour at 37◦C, 5% CO2. Post incubation
cells were stimulated with Dynabeads® Human T-Activator CD3/CD28/CD137 (Thermo
Fisher Scientific) at a bead to cell ratio of 1:100. Alternatively, cells were left unstimulated
or stimulated with 1ng/ml PHA (Sigma-Aldrich, U.K.) with 2ng/ml recombinant IL-2
(National Institute for Biological Standards and Control, Potters Bar, U.K.) as a proliferation
control. All wells were adjusted to 200µ l total volume and incubated for 5 days at 37◦C, 5%
CO2. Following the 5-day incubation, cells were stained with LIVE/DEAD® Fixable Green
Dead Cell Stain Kit (Thermo Fisher Scientific) at 1µl/test of a 1:10 stock dilution, along
with surface staining for CD4 and CD8. Cells were then acquired on the BD
LSR-FORTESSA and analysed with FlowJo software.
2.7.3 Identifying regulatory T cell populations
The antibodies used to phenotype regulatory T cells are shown in Table 2.2. Surface staining
was carried out in 100µl total volume of MACS buffer for 45 minutes at 4◦C. Staining of
CD25 was done using two different clones of antibody, both conjugated to PE, to provide
a brighter signal. A mix of CD25, CD4, CD3, CD8 and CD127 antibodies was made and
used to stain the cell surface before proceeding to intracellular staining. FoxP3 staining
was carried out using the FoxP3 Staining Buffer Set (Miltenyi) together with two different
clones of anti-FoxP3 antibody, or their isotype controls. The fixation/permeabilisation
solutions and permeabilisation buffer were freshly diluted before each experiment as per the
manufacturer’s instructions. Cells were incubated in fixation/permeabilisation buffer for 1
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hour at 4◦C followed by a wash with permeabilisation buffer before being resuspended in
permeabilisation buffer with anti-FoxP3 antibodies (5µ l/antibody/test) for an additional 1 hr.
Cells were then acquired on the BD LSR-FORTESSA and analysed with FlowJo software.
Target Species Clone Fluorophore Concentration Supplier
CD3 Mouse UCHT1 FITC 1:100 BioLegend
CD4 Mouse RPA-T4 PE/Cy7 BioLegend BioLegend
CD8 Mouse HIT8a APC BioLegend BioLegend
CD25 Mouse M-A251 PE BioLegend BioLegend
CD25 Mouse 2A3 PE BD Biosciences BD Biosciences
CD127 Mouse A019D5 Alexa Fluor 647 BioLegend BioLegend
FoxP3 Mouse PCH101 eFluor 450 eBioscience eBioscience
FoxP3 Mouse 259D/C7 V450 BioLegend BD Biosciences
IgG1 κ isotype Rat MOPC-21 Pacific Blue eBioscience BioLegend
IgG2a κ isotype Rat eBR2a eFluor 450 BioLegend eBioscience
Table 2.2 Antibodies used for regulatory T cell staining
2.7.4 Intracellular cytokine staining and cell phenotyping
Polyfunctional T cell responses to HCMV ORF peptides were determined by intracellular
cytokine staining. In addition, memory and effector phenotypes of HCMV specific T
cells was determined. The antibodies used are shown in Table 2.3. Between 2-3x106
PBMC were resuspended in 200µl X-VIVO 15 in individual polypropylene FACS tubes
(Falcon). 5µ l anti-CD107a antibody was added per tube and incubated at 37◦C for one hour.
245µl of either X-VIVO 15 only, positive control mixture (anti-CD3 antibody (Mabtech
AB), Staphylococcus enterotoxin B (SEB), phytohemagglutinin (PHA), pokeweed mitogen
(PWM), and lipopolysaccharide (LPS) (all from Sigma-Aldrich)), or the appropriate HCMV
ORF mixes were then added to the FACS tubes. Cells were then incubated overnight at
37◦C. 20 hours later, monensin (BioLegend) was added at a 1:1000 dilution to each tube and
incubated at 37◦C for four hours. Cells were then washed in MACS buffer and stained for
surface antigens (Table 2.3), in addition to a live cell discriminator (LIVE/DEADTM Fixable
Aqua Dead Stain Kit (Thermo Fisher Scientific)) at a 1:1000 dilution, for 20 minutes at 4◦C
before the addition of 100µl solution A (Nordic-MUbio) to fix the cells. Cells were then
washed in MACS buffer and resuspended in a mix of intracellular antibodies in solution B
(Nordic-MUbio) (Table 2.3) for up to 45 minutes at 4◦C. Cells were again washed in MACS
buffer before being resuspended at a final concentration of 2% PFA and acquired on the BD
LSR-FORTESSA and analysed with FlowJo software.
2.8 Quantifying cytokine secretion by flow cytometry 45
Target Species Clone Fluorophore Dilution Supplier
CD107a Mouse H4A3 AF647 1:200 BioLegend
CD14 Mouse M5E2 BV510 4:200 BioLegend
CD19 Mouse HIB19 BV510 3:200 BioLegend
CD45RA Mouse H1100 PECy7 1:200 BioLegend
CD3 Mouse OKT3 BV650 2.5:200 BioLegend
CD27 Mouse 0323 APC-Cy7 2:200 BioLegend
CD40L Mouse 24-31 PerCP-eFluor710 2.5:200 Thermo Fisher Scientific
CD69 Rat FN50 Pacific Blue 2:200 BioLegend
4-1BB Rat 4B4-1 PE/Cy5 3:200 BioLegend
IL-10 Mouse JES3-9D7 PE 5:200 BioLegend
IFNgamma Mouse 4S.B3 BV786 3:200 BioLegend
Granzyme A Rat CB9 FITC 3:200 BioLegend
Granzyme B Rat REA226 FITC 5:200 Miltenyi
Granzyme K Mouse SC-56125 FITC 3:200 Santa Cruz Biotech
CD4 Mouse 259D/C7 BV605 2.5:200 BD Biosciences
CD8 Rat MOPC-21 BV570 2.5:200 BioLegend
TNF Rat MAB 11 BUV395 5:200 BD Biosciences
Table 2.3 Antibodies used for intracellular cytokine staining and phenotyping of HCMV-
specific T cells. Antibodies used for surface staining are shaded in grey while those used for
intracellular staining are not shaded. AF = Alexa Fluor, BV = Brilliant Violet.
2.8 Quantifying cytokine secretion by flow cytometry
The quantitative detection of secreted cytokines was achieved through the use of the
LEGENDplexTM Human Anti-Virus Response Panel (BioLegend) which allowed for
multi-analyte detection from the same sample. This assay was utilised to quantify secretion
of IFNγ , TNFα , IL-10, and TGFβ by HCMV peptide stimulated T cells. TGFβ secretion
was analysed using the same system but as a single-plex assay however, as supernatants
required treatment with acidification solution as per the manufacturer’s instructions.
2.8.1 Cytokine secretion inhibition assay
The inhibitory effects of supernatant derived from latency-specific CD4+ T cells (Section
2.13.1), or exogenous IL-10 and TGFβ , on anti-viral cytokine secretion was determined in
this assay system. 1x105 PBMC were incubated for 24 hours with varying concentrations of
IL-10 (Peprotech) and TGFβ (Miltenyi), or 150µl CD4+ T cell supernatants, either neat or
diluted 1:2, at 37◦C in a total volume of 200µl in 96 well round bottom plates. In certain
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experiments, neutralising antibodies to IL-10 (R & D Systems) and TGFβ 1, 2, and 3 (R & D
Systems), were added at a concentration of 2µg/ml concurrently with the addition of IL-10
and TGFβ to block cytokine activity. Following this 18 hour incubation, a 1:250 dilution of
a 1:1 mix of anti-CD3 and anti-CD28 antibodies (Mabtech) was added to the PBMC. PBMC
were then incubated overnight at 37◦C with the anti-CD3 and anti-CD28 antibody mix. The
following day, the PBMC were centrifuged for 5 minutes at 500G and the supernatants
collected, either to be used fresh or frozen at -80◦C. Supernatants were then assessed in
duplicate on the LEGENDplexTM Human Anti-Virus Response Panel (BioLegend) according
to the manufacturer’s instructions for a combination of TNFα , IL-10, and IFNγ . Supernatants
were acquired on the BD Accuri C6 cytometer and analysed using the LEGENDplexTM Data
Analysis Software.
2.9 Virus Preparations
Virus preparations were carried out by myself, Georgina Brown, or Ian Groves. Virus stocks
were expanded in HFFs. Fibroblasts were infected when they reached 90% confluency in
175cm2 cell culture flasks (Corning). HFFs were infected at a multiplicity of infection (MOI)
of 0.1 and rocked for 30 minutes at room temperature before being incubated at 37◦C + 5%
CO2. The supernatants were removed when cytopathic effect (CPE) was apparent in 80% of
cells or infection determined by GFP expression by fluorescent microscopy if a GFP tagged
virus was used. Supernatants were removed every three days until the breakdown of the
cellular monolayer. Supernatants were frozen at -80◦C after each harvest. After the final
harvest, all frozen supernatants were defrosted and clarified by centrifugation (15 minutes at
1000G). Following this, the supernatants were centrifuged at 12000G for 2 hours to pellet the
virus. The virus was then resuspended in RPMI-1640 and stored in 100µl aliquots at -80◦C.
To determine the infectivity of viruses they were each titrated on HFFs and retinal pigmented
epithelial cells. The HCMV strains used were:
• TB40e, a gift from Christian Sinzger, University of Ulm [609]
• Merlin-UL32-GFP (RCMV 1172), a gift from Richard Stanton, University of Cardiff
[610]
• TB40e-UL32-GFP, a gift from Christian Sinzger, University of Ulm [611]
• TB40e-IE2-YFP (RV1164), a gift from Michael Winkler [612]
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For adherent cells such as HFFs, cell culture media was removed before the addition of
media containing virus diluted to the desired MOI with enough media to ensure cells are
well covered. The cells were then incubated for 3 hours at 37◦C before removing the virus
containing media, washing twice in PBS, and resuspending with the relevant fresh culture
media for the cell type.
For CD14+ monocytes in suspension, cells were centrifuged, and resuspended at 1ml per
1x106 cells with the desired virus at the desired MOI. Cells were then incubated for 3 hours
at 37◦C and shaken once an hour before removing the virus containing media, washing in
PBS, and resuspending with the relevant fresh culture media for the cell type.
Latent infection of CD14+ monocytes was carried out following their isolation by positive
selection from seropositive donors or apheresis cones (Section 2.5.2). Isolated monocytes
were resuspended in PBS with calcium and magnesium and plated at 2.5x106 per ml on
the desired size of flat well plates. Monocytes were then incubated for 1 hour 37◦C. The
PBS was then removed, the cells resuspended in X-VIVO 15 supplemented with 2.5mM
L-Glutamine and incubated overnight at 37◦C. The subsequent day, the desired virus type was
diluted to the appropriate MOI in X-VIVO 15. The media was removed from the monocytes
and replaced with virus-containing media before incubating at 37◦C for 3 hours. Monocytes
were then washed twice in PBS and incubated at 37◦C in X-VIVO 15 supplemented with
2.5mM L-Glutamine for between 4 and 7 days.
2.10 Latency-associated secretome generation
To generate latent secretomes, PBMC from an apheresis cone (designated CMV180308)
were first isolated. CD34+ cells were then positively selected, using CD34+ microbeads
(UltraPure) (Miltenyi), by MACS. The CD14+ cells were then obtained from the CD34+
cell negative fraction by MACS using CD14+ microbeads (Miltenyi). Isolated CD14+ and
CD34+ cells were plated in separate 24 well plates at a concentration of 1x106 in X-VIVO
15 supplemented with 2.5mM L-Glutamine in a total volume of 1ml, and incubated overnight
at 37◦C. The following day, cells were infected at with wild type TB40e at an MOI of 5 to
establish latency. Supernatants were harvested without disturbing the cellular monolayer on
day 14 post infection, pooled, and clarified by centrifugation at 1000G for 5 minutes and
then stored at -80◦C.
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2.11 Statistical Testing
Statistical testing was performed using GraphPad Prism. All statistical tests carried out were
non-parametric, having assessed that the data were not normally distributed by D’Agostino
and Pearson normality testing. The tests used are mentioned in the text. Where multiple
experimental replicates have been tested the spread of the data is measured by standard error
of the mean.
2.12 Detection of cytokine production by FluoroSpot assay
Pre-coated human IFNγ and IL-10, or IFNγ , IL-10, and TNFα FluoroSpot plates (Mabtech
AB) were used to simultaneously detect IFNγ and IL-10, or IFNγ , IL-10, and TNFα secretion
respectively following peptide stimulation. PBMC depleted of CD4+ or CD8+ T cells by
MACS using direct beads (Miltenyi) according to the manufacturer’s instructions were
plated in triplicate wells at a concentration of between 1x×105 and 2×105 cells per well
in X-VIVO 15 supplemented with 5% Human AB serum (Sigma-Aldrich), together with
peptide ORF mixes or individual peptides at a final concentration of 2µg/ml/peptide, to a
total volume of 150µl. Cells were tested for ability to produce cytokine by stimulating with
a polyclonal mix of mitogens (anti-CD3 antibody (Mabtech AB) PHA, PWM, SEB, LPS
(all Sigma-Aldrich)), at a concentration of 1µg/ml for each mitogen. Cells were also left
unstimulated by the addition of extra media. Plates were incubated for 48 hours at 37◦C
and 5% CO2 without motion. Following incubation, plates were developed according to the
manufacturer’s instructions and dried overnight before being read on the AID iSpot reader
(Autoimmun Diagnostika [AID] GmbH) and counted using EliSpot (version 7) software
(Autoimmun Diagnostika) to detect number of cytokine secreting cells. The efficiencies of
depletions were determined by surface staining cells with anti-CD4 or anti-CD8 antibodies
(Section 2.7.1), then analysed by flow cytometry.
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2.13 Cytokine Quantification by ELISA
2.13.1 FluoroSpot Validation and generation of CD4+ T cell
secretomes
To generate CD4+ T cell secretomes, PBMC were depleted of CD8+ T cells by MACS and
plated at 1×106 cells/ml in X-VIVO 15 in 48 well flat bottom plates. Peptides pools of each
HCMV ORF were added at a concentration of 2µg/ml/peptide, to a total volume of 500µl
per well. Cells were also left unstimulated and supplemented with extra media or stimulated
with a positive control mix of mitogens (PHA, PWM, SEB, LPS (all Sigma-Aldrich)) at
concentration of 1µg/ml for each mitogen. Cells were incubated for 48 hours at 37◦C. The
supernatants were then isolated, clarified by centrifuging at 1000G for 5 minutes, and frozen
at -80◦C or used immediately.
To validate the FluoroSpot results by ELISA, high binding 96 well flat bottom plates
(Greiner Bio-One) were coated 18 hours prior to use with anti-IFNγ or anti-IL-10 antibody
capture antibody, as per the manufacturer’s instructions (Mabtech AB), and incubated
overnight at 4◦C. Supernatant from stimulated cells was then added, and the ELISA plates
developed according to the manufacturer’s instructions before being read at 405nm. Results
were converted to pg/ml using a standard curve generated from known amounts of IL-10 or
IFNγ .
2.13.2 Inhibiting ORF-specific IFNγ secretion
PBMC depleted of CD8+ T cells were plated at 1×106 cells/ml in X-VIVO 15 in 48 well
flat bottom plates. Cells were either incubated with a range of IL-10 (Peprotech) and TGFβ
(Miltenyi) concentrations, or with 120µl of latency-associated secretome (Section 2.10),
for 2 hours prior to the addition of peptides. Alternatively, anti-IL-10 (R & D Systems),
anti-TGFβ 1, 2, 3 (R & D Systems), and anti-IL-10R antibodies (BioLegend), or IgG1 and
IgG2b isotype control antibodies (both R & D Systems), were added at a concentration of
5µg/ml, simultaneously with peptides. Peptides pools of HCMV ORFs were utilised at
a concentration of 2µg/ml/peptide, to a total volume of 300µl per well, or cells were left
unstimulated and supplemented with extra media. Cells were incubated for 48 hours at 37◦C.
The supernatants were then isolated and clarified by centrifuging at 1000G for 5 minutes,
then used immediately. High binding 96 well flat bottom plates (Greiner Bio-One) were
coated 18 hours prior to use with anti-IFNγ capture antibody, as per the manufacturer’s
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instructions (BioLegend IFNγ ELISA MAXTM Deluxe), and incubated overnight at 4◦C.
Supernatant from stimulated cells was then added, and the ELISA plates developed according
to the manufacturer’s instructions before being read at 450nm. Results were converted to
pg/ml using a standard curve generated from known amounts of IFNγ .
2.14 Viral dissemination assay
Primary, donor-derived, fibroblasts, isolated by skin punch biopsy, were plated in 96-well
flat bottom plates to 80% confluency and incubated at 37◦C overnight. The same day, donor-
matched PBMC were defrosted and incubated overnight at 37◦C. The following day, the
fibroblasts were infected with Merlin-UL32-GFP at a MOI of between 0.01 and 0.03 and
incubated at 37◦C overnight. The same day, CD8+ T cells were isolated from whole PBMC
by negative selection using the MACs system as above (Section 2.5.2). Desired numbers of
CD8+ T cells, for the appropriate effector to target ratios, were then incubated overnight in a
96 well plate with fresh media alone, IL-10 (Peprotech) and TGFβ (Miltenyi), or CD4+ T cell
supernatants (Section 2.13.1). The following day, to remove the CD4+ T cell supernatants,
the CD8+ T cells were washed twice by transferring to 96 well V-bottom plates before
being centrifuged and resuspended in PBS. CD8+ T cells were then resuspended in X-VIVO
15 and the desired numbers of T cells were transferred to the 96-well flat bottom plate
containing infected fibroblasts. CD8+ T cells incubated in media alone or IL-10 and TGFβ
were transferred without washing. Fibroblasts were then monitored daily by fluorescence
microscopy for the expression of GFP, and the experiment terminated between 9 and 12
days post infection. To test for the ability of CD4+ T cells supernatant alone to control virus
spread, these supernatants were added 24 hours post infection and viral spread monitored
over 9 to 12 days as above. Fibroblasts were then isolated for analysis. The media was
removed, and cells were washed twice in PBS without calcium and magnesium. Fibroblasts
were then detached by the addition of 75µl trypsin/EDTA per well. Cells were incubated
at 37◦C for 10 minutes or until the cells detached. The wells were then quenched by the
addition of 75µl DMEM containing 10% FCS. Cells were then acquired in the 96 well
plate using a BD Accuri C6 cytometer with automatic C-sampler. Data was then analysed
using FlowJo and the percentage of GFP positive fibroblasts in test wells was expressed as a
proportion of the GFP positive fibroblasts in infected only control wells.
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2.15 Reactivation of latent virus
2.15.1 Differentiation of monocytes to dendritic cells
CD14+ monocytes were differentiated to reactivate virus by one of two ways. Differentiation
to a dendritic cell (iDC) phenotype was carried out as previously described [613] [614].
Media was removed and replaced with X-VIVO15 supplemented with 2.5mM L-Glutamine
and 1000U/ml of GM-CSF (Peprotech) and 1000U/ml of IL-4 (Peprotech). Cells were then
incubated at 37◦C for five days and then matured by removing the media and replacing with
X-VIVO15 supplemented with 2.5mM L-Glutamine and 50ng/ml lipopolysaccharide (LPS)
(Sigma-Aldrich) for two days.
2.15.2 PMA treatment of monocytes
Alternatively, the media of latently infected monocytes was removed and replaced with
X-VIVO15 supplemented with 2.5mM L-Glutamine supplemented with 20ng/ml phorbol
12-myristate 13-acetate (PMA) to reactivate HCMV [615]. Infected cells were monitored
over a period of three days for the peak of virus reactivation.
2.16 Killing of latently infected monocytes
To attempt to improve T cell killing of latently infected cells by neutralising IL-10 and TGFβ ,
monocytes were first isolated from a seropositive donor by CD14+ positive MACS separation
(Section 2.5.2). CD14+ monocytes were plated onto 96 well flat bottom plates at a density of
1.25x105 cells per well and incubated at 37◦C overnight. Monocytes were then infected with
TB40E/UL32-GFP at an MOI of 1.25 and incubated at 37◦C for 3 hours before washing twice
with PBS and resuspending with media. Monocytes were then incubated at 37◦C overnight.
The following day, infected monocytes were washed to remove any anti-viral cytokines and
resuspended in media and incubated at 37◦C for an additional 6 days. On the penultimate
day, matched donor PBMC were defrosted (Section2.4) and incubated at 37◦C overnight.
The subsequent day, anti-TGFβ 1, 2, 3 (R & D Systems) and anti-IL-10 antibodies (R & D
Systems) or relevant isotype controls (IgG1, and IgG2b (both R & D Systems)) were added to
appropriate wells of infected monocytes at 5µg/ml/antibody and incubated for 1 hour at room
temperature. CD3+ T cells were then isolated from defrosted PBMC by MACS isolation and
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these pure T cells were added to appropriate wells of infected monocytes following IL-10
and TGFβ neutralisation. The cells were then incubated at 37◦C for three days, after which
the T cells were removed by aspirating off the media and washing twice with PBS. The
X-VIVO 15 media supplemented with 2.5mM L-Glutamine was replaced with or without
5µg/ml purified NA/LE mouse anti-Human HLA-DR, DP, DQ and 5µg/ml purified NA/LE
mouse anti-Human HLA-ABC antibodies (both BD Biosciences) to wells that had T cells
added. Latently infected monocytes were then differentiated to iDC (Section 2.15.1).
Chapter 3
Identifying Latency-specific CD4+ T cells
3.1 Introduction
Primary infection with HCMV induces antiviral immune responses that encompass both
the innate and adaptive arms of the immune system and lead to the generation of a high
frequency of antiviral T cells. [2, 616]. Despite these responses against HCMV, the virus is
not eliminated from the host, and a latent infection is established. CD4+ T cells are known to
play an important role during antiviral responses to HCMV, as has been shown in transplant
recipients and healthy young children [373, 378, 381, 382]. Additionally, it has been reported
that CD4+ T cells from seropositive individuals can recognise a median of 12 HCMV ORFs,
with responding CD4+ T cells making up on average 4% of the total peripheral CD4+ T cell
compartment [288].
The majority of studies on T cells have focused on lytic antigens such as pp65 and IE,
and therefore little is known about the T cell responses to proteins expressed during latent
HCMV infection, where gene expression is restricted. During latent infection, proteins
known to be expressed during latency include UL138, LUNA, US28, UL111A, and UL144
[125–128, 148, 149]. Recent work has also shown that viral gene expression during latency
might not be as highly restricted as previously thought [129, 130]. One study found no
evidence of highly restricted gene expression in an experimental latency model, with gene
expression resembling a late lytic profile with lower levels of gene expression [130]. A study
utilising intracellular cytokine staining (ICS) of T cells stimulated with overlapping peptide
pools found CD4+ T cell responses to UL138 in one donor and to UL144 in four of 33
donors tested, but did not find any responses in donors to US28, or UL111A, and did not test
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responses to LUNA [288]. However, a subsequent ELISpot-based study on a relatively small
number of donors did find CD4+ T cells specific for the latency-associated proteins UL138
and LUNA in seropositive individuals [501]. Whole PBMC were also stimulated with US28
and UL111A peptide pools to reveal responses to these ORFs, but whether CD4+ T cells
were the responding cells was not determined [501].
The presence of CD4+ T cells specific for proteins expressed during latency therefore
raises the question of why latency is maintained in the face of a potential anti-viral T cell
response specific these viral antigens. It is even more intriguing given that UL138- and
LUNA-specific CD4+ T cell responses were Th1-like, characterised by the secretion of
IFNγ and by the ability of UL138-specific CD4+ T cells to mediate MHC class II restricted
cytotoxicity against peptide-loaded target cells [501]. However, as well as secreting IFNγ ,
a proportion of these CD4+ T cells were also found to secrete the immunomodulatory
cytokines IL-10 and TGFβ , which together with the immunosuppressive microenvironment
generated by latently infected cells, could help explain why such antigen-specific T cells do
not eliminate latently infected cells [501, 605].
It is now recognised that UL138 and LUNA are only two of a number of latency-
associated proteins that are expressed during HCMV latency (as well as being expressed
during lytic infection), and these therefore could also be T cell targets. Consequently, I
initially set out to determine if CD4+ T cells specific for additional proteins known to be
expressed during latency, UL144, UL111A and US28 are also generated [125–128, 148, 149].
To accomplish this, I utilised Fluorescent ELISpot (FluoroSpot) to simultaneously detect
the secretion of IFNγ and IL-10 by CD4+ T cells isolated from seropositive donors in
response to HCMV proteins. The FluoroSpot provided a highly sensitive assay that could
capture responses over a long period (48 hours), and was therefore superior to the previously
utilised ELISpot assays. It was hoped that an examination of the T cell responses to proteins
expressed during latency could therefore yield important insights into the ability of the virus
to persist, and how these responses could then be modulated to clear a latent infection.
The large number of donors in our cohort also enabled an initial examination into the
effect age, as an indicator for time of latent carriage, might have on T cell responses to
HCMV. The normal age-related decline in T cell functions, characterised by a loss of CD28
expression and progressive accumulation of highly differentiated memory T cells, is thought
to be exacerbated by HCMV infection [408]. It has been suggested that long-term carriage
of the virus results in T cell dysfunction, with HCMV serostatus being linked to an increased
susceptibility to infection, poor responses to vaccines, and an increased risk of all-cause
mortality compared to seronegative individuals [351, 408, 410–412, 617]. I therefore wanted
3.2 Results 55
to test how T cell responses to the latency-associated proteins varied across a donor cohort of
23 to 74 years of age, and if age was an important factor in anti-viral responses.
The aims of this chapter were therefore to identify the presence of latency-specific CD4+
T cells and determine if they secrete the immunosuppressive cytokine IL-10, which could
be inhibiting anti-viral T cell responses during latency. In addition, I aimed to examine
the balance of IL-10 and IFNγ secreting cells to determine the extent IL-10 secreting cells
might dominate CD4+ T cell responses to latency-associated proteins. Finally, I wanted to
investigate the impact age and sex might have on these CD4+ T cell responses.
3.2 Results
3.2.1 Serostatus determination
Peripheral blood was taken from healthy donors for serological screening. CMV serostatus
was determined by the presence or absence of HCMV specific IgG antibodies as measured by
ELISA (Table D.1). Donors were grouped depending on their seropositivity and seronegative
donors used as controls for many of the analyses.
3.2.2 Detection of UL138- and LUNA-specific T cell responses by
FluoroSpot
Previous work has found that CD4+ T cells are able to recognise the latency-associated
proteins UL138 and LUNA [501]. In this previous study, the quantification of IFNγ and
IL-10 secreting cells was limited by the need to use separate ELISpot plates for the detection
of each cytokine. Data on the secretion of both of these cytokines from the same cell could
therefore not be collected. The FluoroSpot assay however allows for the detection of both
IFNγ and IL-10 secretion simultaneously on the same plate, and can thus detect dual secreting
CD4+ T cells. I therefore utilised the FluoroSpot assay to detect and quantify HCMV-specific
CD4+ T cells responses. To do this, ex vivo isolated CD4+ T cells from seropositive donors
were stimulated with overlapping peptide pools spanning HCMV ORFs and IFNγ and IL-10
secreting CD4+ T cells were quantified.
To confirm previous findings, CD4+ T cell responses were first tested to LUNA and
UL138. PBMC were isolated from four seropositive donors and depleted of CD8+ expressing
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cells by Magnetic-Activated Cell Sorting (MACS). The efficiencies of these depletions were
assessed by staining PBMC before and after depletion for expression of CD3, CD4, and
CD8. Representative plots and the gating strategies used are shown in Figure 3.1. Doublets
were excluded first, followed by gating for lymphocytes and CD3+ cells (Figure 3.1A), then
CD4+ and CD8+ cells, for PBMC pre-depletion (Figure 3.1B), post CD8+ cell depletion
(Figure 3.1C) or post CD4+ isolation (Figure 3.1D). The percentages of residual CD8+ T
cells following CD8+ cell depletion were calculated following gating on CD3+ cells. The
mean residual percentage of T cells that were CD8+ following CD8+ cell depletion was 1.8%
(standard deviation 1.36, n=57), leaving a mean percentage of 83.5% CD4+ T cells (standard
deviation 13.1, n=55) (Figure 3.1E). The CD8+ depleted PBMC was then incubated with the
overlapping peptide pools spanning the predicted ORFs of gB, IE1, pp65, UL138, and LUNA
for 48 hours on dual IFNγ/IL-10 FluoroSpot plates to assess the CD4+ T cell response to
these ORFs. The individual peptides in the pools were 15 amino acids long and overlapped
by 10 amino acids.
The T cell responses to proteins expressed during lytic infection have been extensively
studied. The lytically-expressed proteins gB, pp65, and IE1 were therefore included in the
analysis to provide a comparison between T cell responses to these ORFs and to latency-
associated proteins. Of the four seropositive donors tested, CD4+ T cells were found to
secrete IFNγ in response to at least two of these three lytic ORFs (Figure 3.2). CD4+ T cell
responses to UL138 were found in three of the four donors (75%), while positive responses
to LUNA were found in 2 of the four donors (50%) (Figure 3.2).
The same analysis was then carried out for IL-10 secreting cells. A relatively high
frequency of CD4+ T cells were found to secrete IL-10 in response to pp65 in three of the
four donors (75%), while low responses to gB were found in two donors (50%), and no
responders detected to IE1 (Figure 3.3). CD4+ T cells capable of secreting IL-10 in response
to UL138 were found in three of the four donors (75%) (Figure 3.3), while in only one of the
four donors (25%) was there a high frequency of CD4+ T cells that secreted IL-10 (Figure
3.3B).
The results from four HCMV seropositive donors therefore show that CD4+ T cells
secreting IFNγ and IL-10 in response to the latency-associated proteins UL138 and LUNA
can be detected, as previously reported [501].
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Fig. 3.1 Magnetic-activated Cell Sorting to deplete CD8+ cells, and to isolate untouched
CD4+ T cells, from PBMC. (A) Gating strategy to identify CD4+ and CD8+ T cells from
whole blood. Cells were gated to exclude doublets by forward scatter (FSC)-Height (FSC-
H) and FSC-Area (FSC-A), before gating for lymphocytes by FSC-A against side scatter
area (SSC-A). CD3+ cells were then gated to identify T cells by CD4 and CD8 expression.
Representative plots of (B) CD4+ and CD8+ T cells from whole PBMC, (C) CD8+ cell
depleted PBMC, and (D) CD4+ depleted PBMC. (E) Whole PBMC from 57 donors were
depleted of CD8+ cells using direct MACS CD8 microbeads or (F) used to isolate CD4+ T
cells untouched using an indirect MACS CD4+ isolation kit, and then stained for CD3, CD4,
and CD8 expression to determine the residual proportions of CD4+ and CD8+ T cells of
total CD3+ cells.
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Fig. 3.2 CD4+ T cells secrete IFNγ in response to UL138 and LUNA. PBMC from four
HCMV seropositive donors, (A) CMV324, (B) CMV319, (C) CMV323, and (D) CMV307,
were depleted of CD8+ expressing cells and stimulated with HCMV ORF peptides spanning
gB, p65, IE1, UL138, and LUNA, for 48 hours on dual IFNγ /IL-10 FluoroSpot plates. IFNγ
secretion was then stained for to give a number of positive spots that were counted, and
converted to spot forming units (SFU) per million cells. All samples were run in triplicate
and the frequencies of IFNγ positive cells was determined by subtracting values in all test
wells from the background number of positive cells in unstimulated well. The solid black
bars indicate proteins expressed during lytic HCMV infection, while the white bars show
proteins that are also expressed during latency.
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Fig. 3.3 CD4+ T cells secrete IL-10 in response to UL138 and LUNA. PBMC from four
HCMV seropositive donors, (A) CMV324, (B) CMV319, (C) CMV323, and (D) CMV307,
were depleted of CD8+ expressing cells and stimulated with HCMV ORF peptides spanning
gB, p65, IE1, UL138, and LUNA, for 48 hours on dual IFNγ /IL-10 FluoroSpot plates. IL-10
secretion was then stained for to give a number of positive spots that were counted, and
converted to spot forming units (SFU) per million cells. All samples were run in triplicate
and the frequencies of IL-10 positive cells was determined by subtracting values in all test
wells from the background number of positive cells in unstimulated well. The solid black
bars indicate proteins expressed during lytic HCMV infection, while the white bars show
proteins that are also expressed during latency.
60 Identifying Latency-specific CD4+ T cells
3.2.3 Validation of the FluoroSpot Assay
The confirmation of previous research showing CD4+ T cell responses to UL138 and LUNA
using the FluoroSpot assay was encouraging, although further work was required to ensure
that cytokine secreting cells detected in this manner were indeed valid. A number of assays
were therefore carried out to validate this system.
Cytokine secretion was assessed by ELISA, in parallel to FluoroSpot, on the supernatants
derived from stimulating PBMC depleted of CD8+ cells for 48 hours with HCMV ORF
peptides. The expectation was that greater frequencies of detected cytokine secreting cells
would also be apparent from increased cytokine concentration detected in the supernatants of
similarly stimulated cells. As expected, data from two seropositive donors showed that ELISA
results were highly comparable to the results obtained from the FluoroSpot assay. Individuals
with high frequencies of IFNγ (Figure 3.4A and B) or IL-10 (Figure 3.4C and D) positive
spots generally had elevated levels of IFNγ or IL-10 production following stimulation, and
vice versa where there were low frequencies of cytokine producing cells. This was not the
case for all responses however. The IL-10 responses to gB from donor CMV319 (Figure
3.4D) and the frequencies of cytokine positive cells detected by the FluoroSpot did not
correlate well with the cytokine secretion detected by ELISA.
In addition, the use of ELISA enabled the reliable quantification of cytokine secretion,
which could not be achieved by FluoroSpot alone. Two further donors were also analysed
for the secretion of IFNγ and IL-10 from their CD4+ T cells by ELISA. IFNγ and IL-10
secretion was detected in response to many of the ORF peptide pools (Figure 3.5), and
together with the ELISA data from two previous donors (Figure 3.4), show that secretion of
these cytokines from CD4+ T cells can be reliably quantified. This lends further support to
the validity of the results obtained via the FluoroSpot assay.
As a result of the experimental approach utilised with the FluoroSpot assay, the CD8+
depleted PBMC populations being stimulated with HCMV ORF peptides contained a very
small fraction of unwanted CD8+ T cells due to slight inefficiencies in the depletion (Figure
3.1E). To ensure that the cytokine responses being detected from PBMC depleted of CD8+
cells was indeed originating from CD4+ T cells, a modified approach to the FluoroSpot
assay was carried out. CD4+ T cells were isolated with high purity by MACS using a
CD4+ T cell isolation kit that removes all non-CD4+ cells (Figure 3.6A), and stimulated
with HCMV peptides ORFs for 48 hours in tandem with FluoroSpot utilising the depletion
protocol as before (where PBMC depleted of CD8+ cells were used) (Figure 3.6A). Using
this CD4+ T cell isolation method, the mean residual CD8+ T cell proportion of total CD3+
3.2 Results 61
gB US28 UL138 UL111A LUNA UL144
0
1000
2000
3000
4000
ORF
pg
/m
l
CMV324 IFNγ
gB US28 UL138 UL111A LUNA UL144
0
100
200
300
400
ORF
pg
/m
l
CMV319 IFNγA B
gB US28 UL138 UL111A LUNA UL144
0
20
40
60
CMV319 IL-10
ORF
pg
/m
l
gB US28 UL138 UL111A LUNA UL144
0
100
200
300
400
ORF
pg
/m
l
CMV324 IL-10C D
NC gB US28 UL138 UL111A LUNA UL144 NC gB US28 UL138 UL111A LUNA UL144
NC gB US28 UL138 UL111A LUNA UL144NC gB US28 UL138 UL111A LUNA UL144
Fig. 3.4 Validating FluoroSpot results for cytokine secretion from CD4+ T cells with
ELISA. PBMC isolated from two seropositive donors were depleted of CD8+ cells and
incubated for 48 hours with pools of overlapping 15 amino acid peptides spanning each
of the HCMV ORFs tested (gB, US28, UL138, UL111A, LUNA, and UL144). This was
simultaneously carried out on dual IFNγ/IL-10 FluroSpot plates, and on 48 well plates.
Following this stimulation, the supernatant was harvested and IFNγ and IL-10 secretion
was measured by ELISA (quantification was achieved using a standard curve of known
amounts of cytokine), and IFNγ captured on the FluoroSpot plates was stained to visualise
cytokine positive spots. All samples were run in triplicate with the mean value shown here.
CD4+ T cell IFNγ secretion was detected by ELISA from donors (A) CMV324, and (B)
CMV319, and IL-10 secretion from donors (C) CMV324, and (D) CMV319 and compared
to the images showing the frequencies of IFNγ positive spots obtained from the FluoroSpot
for each HCMV ORF peptide pool tested (NC = negative control).
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Fig. 3.5 Quantifying IFNγ and IL-10 secretion from CD4+ T cells by ELISA. PBMC
isolated from two seropositive donors (CMV320 and CMV323) were depleted of CD8+ cells
and incubated for 48 hours with overlapping peptide pools spanning each of the HCMV
ORFs tested (gB, US28, UL138, UL111A, LUNA, and UL144). Following this stimulation,
the supernatant was harvested and IFNγ and IL-10 secretion was measured by ELISA
(quantification was achieved using a standard curve of known amounts of cytokine). All
samples were run in triplicate with the mean value shown here.
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cells was 0.072% (standard deviation=0.12, n=19), while the mean proportion of CD3+
cells that were CD4+ T cells was 96.97% (standard deviation=2.71, n=19) following the
isolation (Figure 3.1F). The results show a high degree of similarity in the frequency of
detected IFNγ or IL-10 secreting cells between the two CD4 preparation methods (Figure
3.6B and C). The higher frequencies of cytokine secreting cells detected in the CD4+ T
cell isolation condition in response to many of the HCMV ORF peptide pools could be
explained by the higher proportion of CD4+ T cells present in each well. This results from
the higher purity of the isolation method and absence of other PBMC subsets in this condition,
such as monocytes. However, this effect was not seen with IL-10 secreting CD4+ T cells
responding to gB, although no differences were detected between the conditions (Figure
3.6C). I am therefore confident that the small frequency of unwanted CD8+ T cells present in
our depletion experiments does not have a large effect on the overall frequency of responding
cells detected, and neither does some other PBMC subset, such as monocytes or NK cells.
For further validation in a different assay system, I stimulated PBMC from 18 seropositive
donors with HCMV ORF peptides pools from each ORF for 24 hours and subsequently
carried out ICS on these cells. The typical gating strategy to define cytokine secreting cells is
shown in Figure 3.7 for the CD4+ T cell response to UL144 ORF peptides. Live cells were
first gated on, followed by the exclusion of doublets and gating of lymphocytes (Figure 3.6A).
CD3+ cells and CD4+ T cells were then defined, and, to detect cytokine secretion from
antigen-specific T cells only, cells positive for 4-1BB and/or CD40L were gated on, before
IFNγ and IL-10 gates were placed (Figure 3.6A). IFNγ and IL-10 production from CD4+
T cells was readily detected in response to all the HCMV ORF peptide pools tested with
variations in the proportions of cytokine positive cells responding to different ORFs (Figure
3.7). The ability to delineate cytokine secretion to defined cellular phenotypes, in this case
CD4+ T cells, also lends further support that the cytokine secretion detected in the FluoroSpot
assay is indeed originating from CD4+ T cells and not another PBMC subset. Given these
validation experiments, I continued using the FluoroSpot assay with this depletion protocol,
where PBMC were depleted of CD8+ cells to measure CD4+ T cell responses, as this proved
to be a relatively quick and effective method to achieve reliable results.
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Fig. 3.6 Comparison of the frequencies of cytokine secreting cells detected following
CD8+ cell depletion, or CD4+ T cell isolation, from PBMC using a negative selection
or isolation kit. In parallel, whole PBMC were either depleted of CD8+ cells by direct
MACS, or CD4+ T cells were isolated untouched using a CD4+ T cell isolation kit, before
being stimulated with HCMV ORF peptide pools for 48 hours on dual IFNγ /IL-10 FluoroSpot
plates. IFNγ and IL-10 secretion was then stained for to give a number of positive spots
that were counted and converted to spot forming units (SFU) per million cells. All wells
were tested in triplicate and the background number of cytokine secreting cells observed
in unstimulated wells was deducted from test wells. (A) The gating strategy to identify T
cells prior to, and following, MACS depletion and isolation. (B) IFNγ secretion from CD8+
depleted PBMC (shown with white bars) and isolated CD4+ T cells (shown with grey bars)
(C) IL-10 secretion from CD8+ depleted PBMC and isolated CD4+ T cells.
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Fig. 3.7 Intracellular cytokine staining of CD4+ T cells following HCMV ORF peptide
pool stimulation. Whole PBMC isolated from 18 seropositive donors were stimulated
overnight with HCMV peptide pools spanning the ORFs of gB, pp65, IE1, UL138, LUNA,
US28, UL111A, and UL144, in the presence of monensin. Stimulated PBMC were then
stained intracellularly. (A) The gating strategy to identify IFNγ and IL-10 secretion from
CD4+ T cells in response to the UL144 and US28 peptide pool is shown. Dead cells, CD14+
and CD19+ cells were first excluded, followed by doublets. Lymphocytes were then gated
on by FSCA and SSCA and CD3+ cells identified. CD4+ and CD8+ cells were then gated,
followed by activated CD4+ T cells, identified by gating for CD40L or 4-1BB positive cells,
and finally IFNγ and IL-10 positive cells. (B) CD4+ T cells positive for IFNγ and (C) CD4+
T cells positive for IL-10 are illustrated as proportions of CD3+CD4+ cells following the
gating shown in (A).
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3.2.4 The frequency of responding CD4+ T cells detected fluctuates
over time
Of total T cells, those present in the blood represent a low proportion, with one estimate
placing this figure at 2.5% for CD4+ T cells and 2.3% for CD8+ T cells [618]. I therefore
wanted to examine how sampling of PBMC at different time points might affect the T cell
responses detected. The small group of four seropositive donors used previously was tested
for their CD4+ T cell responses to HCMV ORF peptide pools multiple times over a period
of three years using the FluoroSpot assay. The sampling of donors was not uniform over
time, and certain donors were only sampled twice. The most comprehensive analysis was
undertaken on one donor (CMV324), with eight time points analysed for their CD4+ T cell
responses.
The CD4+ T cell responses to certain ORFs were very stable over the eight time points,
where positive responses were detected at all time points in response to gB, pp65, IE1, LUNA,
US28, and UL144 (Figure 3.8A). In contrast, responses to UL138 and UL111A fluctuated
over the eight time points. At certain sampling times there were effectively no CD4+ T
cells that secreted IFNγ in response to the latency-associated proteins UL138 and UL111A
(Figure 3.8A). The CD4+ T cell responses can therefore fluctuate to the extent that positive
responses are lost. In the case of UL138 responses for example, the first two time points
showed a considerably high number of IFNγ secreting CD4+ T cells, which was not seen
again over the next six time points (Figure 3.8A). This is in contrast to the UL111A-specific
CD4+ T cell responses, which were observed to oscillate between positive and no responses
over the sample period (Figure 3.8A). Furthermore, the frequency of IFNγ positive CD4+ T
cells was observed to vary considerably between certain time points (Figure 3.8A).
Overall, IL-10 responses were much less consistent than the IFNγ responses, and this
could partially be attributed to time points when the background IL-10 responses were too
high in the unstimulated wells, resulting in data that was not assessable. Positive responses to
US28 were the most frequently observed over the eight time points, while positive responses
to gB, pp65, and UL138, were the next most frequent, and UL111A, UL144, and IE1
responses the least frequent (Figure 3.8B). Of note, there were two time points months apart
which had considerably high US28 IL-10 responses that were much higher than any other
response at any time point (Figure 3.8B), and for which the IFNγ US28 responses were the
lowest of all the eight time points (Figure 3.8A).
As will be shown in Section 3.2.5, the threshold values for positive IFNγ and IL-10
responses were determined based on the number of cytokine positive spots detected from
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HCMV seronegative donors in response to HCMV ORF peptide pools. These values (100
SFU/106 for IFNγ secreting cells and above 50 SFU/106 for IL-10 secreting cells) provide
a threshold to identify responses as positive, in addition to the deduction of background
cytokine secreting cells from all test values. Based on these thresholds, examining how the
number of positive responses to HCMV ORFs changes over time in donor CMV324 revealed
that the number of ORFs responded to with IFNγ secretion oscillated between responding to
all eight, and to five, ORFs over the eight time points (Figure 3.9A). These fluctuations were
mainly in the responses to latency-associated proteins, where at all time points except for
one, all three lytically expressed proteins were responded to (Figure 3.9A).
Although the CD4+ IL-10 T cell responses were less frequent, they were still highly
variable. The number of positive CD4+ IL-10 T cell responses oscillated over time
considerably, from zero to three ORFs responded to, of eight total (Figure 3.9). There were
also two time points where there no CD4+ IL-10 T cell responses to any latency-associated
proteins were detected, highlighting the greater variation in sampling IL-10 responses
(Figure 3.9B) compared to IFNγ responses (Figure 3.9A).
Longitudinal data collected in the same way from different donors also illustrated the
fluctuations in T cell responses detected over time. As expected, the CD4+ IFNγ T cell
responses to the lytically expressed proteins were very consistent, where positive responses
were registered at nearly all sampling times (Figure 3.10A, 3.11A, and 3.12A). Interestingly,
the CD4+ IFNγ T cell responses to UL144 were the most consistent and often composed of
similar frequencies of IFNγ secreting cells at different time points (Figure 3.10A, 3.11A, and
3.12A). Responses to the latency-associated proteins were slightly more variable, although
it was still the case that if a donor made a response to an ORF, then they responded again
to that ORF at most time points. Donor CMV319, who was sampled across three time
points, possessed CD4+ IFNγ T cell responses at all time points to LUNA, US28, and
UL111A, while at two of three time points responded to UL138 (Figure 3.10A). On the
other hand, donor CMV323 had greater variability in responses over the three time points,
with responses to UL138 and LUNA only detected on two occasions, in addition to the
pronounced fluctuations in the frequencies of IFNγ secreting CD4+ T cells at different time
points (Figure 3.11A).
In these two donors the CD4+ IL-10 T cell responses were fairly consistent despite there
being fewer ORFs that were responded to, although there were ORFs that were responded
to at only one time point. Donor CMV319 had IL-10 responses at all three time points to
pp65 and UL138, and at two time points to LUNA, and US28, while only at one time point
to UL111A and UL144 (Figure 3.10B). Similarly donor CMV323 had IL-10 responses at
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two points to UL138 and US28, but only at one in response to pp65, gB, and LUNA (Figure
3.11B).
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Fig. 3.8 Longitudinal IFNγ and IL-10 CD4+ T cell responses to HCMV ORFs from
donor CMV324. CD4+ IFNγ and IL-10 T cell responses from donor CMV324 were tested at
eight separate time points over 35 months. PBMC were depleted of CD8+ expressing cells and
stimulated with overlapping peptide pools of HCMV peptides spanning gB, p65, IE1, UL138,
LUNA, US28, UL111A, and UL144, for 48 hours on dual IFNγ/IL-10 FluoroSpot plates.
(A) IFNγ and (B) IL-10 secretion was then stained for to give a number of positive spots
that were counted, and converted to spot forming units (SFU) per million cells. All samples
were run in triplicate and the frequencies of positive cells were determined by subtracting
values in all test wells from the background number of positive cells in unstimulated well.
Each different colour of bar indicates a different sampling time point. The thresholds for
positive responses of 100 SFU/106 cells for IFNγ and 50 SFU/106 for IL-10 are indicated by
the dotted line.
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Fig. 3.9 Longitudinal analysis of the number of positive CD4+ IFNγ and IL-10 T cell
responses in donor CMV324. (A) Positive IFNγ CD4+ T cell responses (responses over
100 SFU/106 cells) and (B) Positive CD4+ IL-10 T cell responses (threshold above 50 spot
forming units/106 cells) are shown at 8 time points over three years from one donor. The dates
of each time point are shown in the table. PBMC were depleted of CD8+ expressing cells and
stimulated with overlapping peptide pools of HCMV peptides spanning gB, p65, IE1, UL138,
LUNA, US28, UL111A, and UL144, for 48 hours on dual IFNγ/IL-10 FluoroSpot plates.
The number of IFNγ and IL-10 positive spots was determined and converted to SFU/106
cells. All samples were run in triplicate and the frequencies of positive cells were determined
by subtracting values in all test wells from the background number of positive cells in
unstimulated well. The black bars indicate responses to all 8 ORFs, both lytic and latency-
associated, the grey to lytic ORFs gB, pp65, and IE, and the white to latency-associated
ORFs UL138, LUNA, US28, UL111A, and UL144.
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Fig. 3.10 Long term IFNγ and IL-10 CD4+ T cell responses to HCMV ORFs from
donor CMV319. CD4+ IFNγ and IL-10 T cell responses from donor CMV319 were tested
at three separate time points. PBMC were depleted of CD8+ expressing cells and stimulated
with overlapping peptide pools of HCMV peptides spanning gB, p65, IE1, UL138, LUNA,
US28, UL111A, and UL144, for 48 hours on dual IFNγ/IL-10 FluoroSpot plates. (A) IFNγ
and (B) IL-10 secretion was then stained for to give a number of positive spots that were
counted, and converted to spot forming units (SFU) per million cells. All samples were run
in triplicate and the frequencies of positive cells were determined by subtracting values in all
test wells from the background number of positive cells in unstimulated well. Each different
colour of bar indicates a different sampling time point. The thresholds for positive responses
of 100 SFU/106 cells for IFNγ and 50 SFU/106 for IL-10 are indicated by the dotted line.
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Fig. 3.11 Long term IFNγ and IL-10 CD4+ T cell responses to HCMV ORFs from
donor CMV323. CD4+ IFNγ and IL-10 T cell responses from donor CMV323 were tested
at three separate time points. PBMC were depleted of CD8+ expressing cells and stimulated
with overlapping peptide pools of HCMV peptides spanning gB, p65, IE1, UL138, LUNA,
US28, UL111A, and UL144, for 48 hours on dual IFNγ/IL-10 FluoroSpot plates. (A) IFNγ
and (B) IL-10 secretion was then stained for to give a number of positive spots that were
counted, and converted to spot forming units (SFU) per million cells. All samples were run
in triplicate and the frequencies of positive cells were determined by subtracting values in all
test wells from the background number of positive cells in unstimulated well. Each different
colour of bar indicates a different sampling time point. The thresholds for positive responses
of 100 SFU/106 cells for IFNγ and 50 SFU/106 for IL-10 are indicated by the dotted line.
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Fig. 3.12 Long term IFNγ and IL-10 CD4+ T cell responses to HCMV ORFs from
donor CMV307. CD4+ IFNγ and IL-10 T cell responses from donor CMV307 were tested
at two separate time points. PBMC were depleted of CD8+ expressing cells and stimulated
with overlapping peptide pools of HCMV peptides spanning gB, p65, IE1, UL138, LUNA,
US28, UL111A, and UL144, for 48 hours on dual IFNγ/IL-10 FluoroSpot plates. (A) IFNγ
and (B) IL-10 secretion was then stained for to give a number of positive spots that were
counted, and converted to spot forming units (SFU) per million cells. All samples were run
in triplicate and the frequencies of positive cells were determined by subtracting values in all
test wells from the background number of positive cells in unstimulated well. Each different
colour of bar indicates a different sampling time point. The thresholds for positive responses
of 100 SFU/106 cells for IFNγ and 50 SFU/106 for IL-10 are indicated by the dotted line.
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3.2.5 CD4+ T cells can recognise and secrete IFNγ in response to US28,
UL111A, and UL144
Having tested a small group of seropositive donors for the ability of their CD4+ T cells
to respond to the latency-associated proteins UL138 and LUNA, the same methodology
was applied to a larger cohort to confirm these responses in the wider population, and to
investigate the CD4+ T cell responses to several other proteins known to be expressed during
HCMV latency, namely US28, UL111A, and UL144.
Once again, 15mer overlapping peptide pools spanning each ORF were utilised in
conjunction with the FluoroSpot assay to do this. All samples were run with unstimulated
control wells composed of the donor’s cells alone without any HCMV peptides. This
enabled the determination of the background level of cytokine secretion that each donors’
cells possessed and this value was subtracted from all test conditions. To ensure stringent
identification of positive cytokine responses, several quality control checks were put in place.
These were particularly important to assess IL-10 responses, as many donors possessed
high frequencies of background IL-10 secretion in their unstimulated samples. Donors with
responses in their background, unstimulated samples of above 1000 spots were excluded. For
IFNγ responses, the difference between the unstimulated samples and the positive control
samples had to be greater than 100 spots. For IL-10 responses, this difference was 50 spots,
given the relatively weaker ability of our positive control to elicit strong IL-10 secretion,
in addition to simultaneous IFNγ secretion. These imposed thresholds resulted in IL-10
response data from 33 donors being discarded, while for IFNγ responses, 10 donors were
excluded.
Positive responses from the FluoroSpot assay were counted as greater than 100 SFU/106
cells for IFNγ responses and greater than 50 SFU/106 cells for IL-10 responses. These
thresholds were chosen based on the non-specific responses obtained when stimulating cells
from seronegative donors with the HCMV ORF peptide pools (Figure 3.13 and 3.16) to
ensure the responses being observed in seropositive donors were specific to HCMV.
Alongside measuring the responses to the latency-associated proteins UL138, LUNA,
US28, UL111A, and UL144, I also tested ORF pools from the lytically expressed proteins
gB, pp65, and IE1 to allow for comparison between responses against proteins only expressed
during lytic infection and those also expressed during latency.
Of 91 donors tested that passed quality control, positive CD4+ T cell IFNγ responses were
detected against all ORFs and the number of responding donors varied according to ORF.
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Positive CD4+ T cell IFNγ responses were registered against UL138 (27 donors, 29.7%),
LUNA (26 donors, 28.6%), US28 (54 donors, 59.3%), UL111A (27 donors, 29.7%), and
UL144 (69 donors, 75.8%), in addition to responses against the lytically expressed gB (61
donors, 67%), IE1 (46 donors, 50.5%), and pp65 (78 donors, 85.7%) (Figure 3.13).
The results presented here confirm previously reported findings for the presence of UL138
and LUNA specific CD4+ T cells in seropositive individuals from a much larger donor cohort.
Additionally, these findings are extended to the latency-associated proteins US28, UL111A,
and UL144, where responses against all of these ORFs are reported here.
There were many individuals who have a high frequency of CD4+ T cells that secrete
IFNγ in response to the HCMV ORFs tested. Grouping these high responders as those who
have a T cell response greater than 250 SFU/106 cells reveals that of 91 donors, CD4+ T cell
responses to the lytically expressed proteins tested were made up of 47 high responders to
gB (51.6%), 68 to pp65 (74.7%), and 31 to IE1 (34.1%) (Figure 3.13). Of the CD4+ T cell
responses to the latency-associated proteins tested, the greatest number of high responders
were found to UL144 (55/91, 60.4%), and to US28 (34/91, 37.4%), whereas high responders
to LUNA (17/91 18.7%), UL111A (15/91, 16.5%), and UL138 (12/91, 13.2%) were much
less frequent (Figure 3.13).
These results demonstrate that T cell responses to the latency-associated proteins tested
are present, and in certain cases comparable to the frequencies of T cells responding to
lytically expressed proteins. There were clear differences in the CD4+ T cell responses to
each latency-associated protein, where UL144 and US28 were found to have the highest
number of donors with a positive CD4+ response, in addition to the highest frequency of
T cells responding to these proteins within individuals. Less common, were donors with a
positive IFNγ CD4+ T cell response to UL111A, LUNA, and UL138.
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Fig. 3.13 The frequency of CD4+ T cells from HCMV seropositive and seronegative
donors that recognise HCMV ORF pools. PBMC from 91 seropositive and eight
seronegative donors were depleted of CD8+ T cells and stimulated with HCMV ORF
peptide pools spanning gB, pp65, IE1, UL138, LUNA, US28, UL111A, and UL144 for
48 hours on dual IFNγ/IL-10 FluoroSpot plates. Each peptide pool was tested in triplicate
and the values from the number of background cells secreting cytokines in the unstimulated
wells was deducted from all test wells. Following stimulation, the number of IFNγ positive
spots was enumerated by the automated spot counter and converted to a spot forming unit
(SFU) value per million cells. The dotted line at 100 SFU/106 cells indicates the threshold
for positive responses, while the line at 250 SFU/106 cells shows the threshold for high
responding donors. Seropositive donors are shown with open circles (◦) while seronegative
donors are illustrated with filled black circles (•).
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3.2.6 The frequency of latency-specific IFNγ secreting CD4+ T cells
does not change with age
The large donor cohort used here enabled data to be obtained from a range of ages, which
could therefore give an indication of whether the strength of T cell responses to latency-
associated ORFs vary with age - given an assumed longer term carriage of the virus. Ideally,
a long-term study from the point of primary HCMV infection, with regular testing of T cell
responses, would be carried out, but this was not feasible. Consequently, the age of donors
was used as an indirect measure for time of HCMV carriage, where the use of a large donor
cohort was necessary to overcome the inability to determine time of primary infection.
Although the T cell responses to each latency-associated protein tested varied in
magnitude across all ages, Spearman rank correlation analysis yielded no significant
correlation between the strength of CD4+ T cell responses (SFU/106 cells) and the age of
donors for responses to any of the lytic or latency-associated proteins tested (Figure 3.14).
CD4+ T cell IFNγ responses were also not found to be affected by age when grouping the
donor cohort according to sex, with the exception of responses to US28 in male donors
which showed a weak negative correlation with donor age (rs = -0.3454, P = 0.0313)
(Appendix A.1)
Although the magnitude of responses to latency-associated proteins was not found to vary
with age, it could still be possible that age might affect the number of ORFs responded to, as
longer term carriage of the virus and resulting viral reactivations could be responsible for
the generation of responses to additional ORFs. However, when looking at the relationship
between the ages of donors and the number of latency-associated ORFs each individual
had a CD4+ T cell response to, there were no significant differences following a multiple
comparisons test (Kruskal-Wallis) (Figure 3.15).
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Fig. 3.14 Analysis of the magnitudes of CD4+ T cell IFNγ responses to 8 HCMV ORF
peptide pools correlated with donor age. CD8+ depleted PBMC from 91 seropositive
donors were stimulated with HCMV ORF peptide pools for 48 hours on dual IFNγ/IL-10
FluoroSpot plates and the frequencies of IFNγ positive spots within each seropositive donor
enumerated and converted to Spot Forming Units (SFU)/106 cells. The SFU/106 cells of
IFNγ secreting CD4+ T cells is shown against donor age for responses to (A) gB, (B) pp65,
(C) IE1, (D) UL138, (E) LUNA, (F) US28, (G) UL111A, and (H) UL144. The correlation
(Spearman rs valus and p values shown on each graph), and line of best fit are shown.
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Fig. 3.15 The number of latency-associated HCMV ORF peptide pools that CD4+ T
cells respond to with IFNγ secretion across donor age. CD8+ depleted PBMC were
stimulated with HCMV ORF peptide pools for 48 hours on dual IFNγ/IL-10 FluoroSpot
plates and the frequencies of CD4+ T cells secreting IFNγ enumerated and converted to Spot
Forming Units (SFU)/106 cells. The number of latency-associated ORFs out of the five tested
(UL138, LUNA, US28, UL111A, and UL144) that each donor responds to (considered a
positive response if above the threshold 100 SFU/106 cells) is shown against the age of donor.
There were no significant differences between the number of ORFs responded to by CD4+ T
cells and the ages of donors according to Kruskal-Wallis multiple comparisons test.
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3.2.7 CD4+ T cells can secrete the immunosuppressive cytokine IL-10
in response to HCMV latency-associated antigens
Having identified novel CD4+ T cell responses to the latency-associated HCMV proteins
US28, UL111A, and UL144 by IFNγ secretion, the ability of these T cells to secrete the
immunosuppressive cytokine IL-10 was assessed. Although CD4+ T cell responses to
lytically expressed HCMV proteins are characteristically Th1-like with high frequencies
secreting IFNγ , CD4+ T cells specific for latency-associated proteins have previously been
shown to secrete the immunosuppressive cytokine IL-10 [501]. Through the use of the
FluoroSpot assay, I was able to simultaneously examine the secretion of both IFNγ and
IL-10 in response to the HCMV ORF peptide pools. In this manner, the frequency of T cells
capable of secreting IL-10, in addition to those able to secrete both IL-10 together with IFNγ
was determined.
As previously, when utilising the FluoroSpot assay, depleting PBMC of CD8+ cells
enabled the examination of CD4+ T cell responses to HCMV ORF peptide pools. By doing
so, CD4+ T cells capable of secreting IL-10 in response to HCMV proteins were found to
be present in a proportion of seropositive donors, with positive responses counted as those
above 50 SFU/106 (Figure 3.16). In comparison to the number of donors with a positive
CD4+ T cell IFNγ response, there were considerably fewer donors with such CD4+ T cell
IL-10 responses, which can be partially attributed to the stringent selection criteria used that
excluded 33 donors. Although fewer donors had a CD4+ T cell IL-10 response, it is clear
that there were differences in the frequencies of CD4+ T cells secreting IL-10 in response
to different HCMV ORFs (Figure 3.16). Typically, from the 68 donors tested, there were
fewer CD4+ T cells secreting IL-10 in response to lytically-expressed proteins, especially
gB (10 donors, 14.7%) and IE1 (13 donors, 19.1%), although these were present, and in
response to pp65 relatively frequent (19 donors, 27.9%) (Figure 3.16). CD4+ T cell IL-10
responses were most frequently seen in response to US28 (30 donors, 44.1%), LUNA (29
donors, 42.6%), and UL138 (29 donors, 42.6%), followed by UL144 (17 donors, 25%) and
UL111A (13 donors, 19.1%), which were the least frequent (Figure 3.16).
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Fig. 3.16 The frequency of CD4+ T cells from HCMV seropositive and seronegative
donors secreting IL-10 in response to HCMV ORF pools. PBMC from 68 seropositive
and 6 seronegative donors were depleted of CD8+ T cells and stimulated with HCMV ORF
peptide pools spanning gB, pp65, IE1, UL138, LUNA, US28, UL111A, and UL144 for
48 hours on dual IFNγ/IL-10 FluoroSpot plates. Each peptide pool was tested in triplicate
and the values from the number of background cells secreting cytokines in the unstimulated
wells was deducted from all test wells. Following stimulation, the number of IL-10 positive
spots was enumerated by the automated spot counter and converted to a spot forming unit
(SFU) value per million cells. The dotted line at 50 SFU/106 cells indicates the threshold for
positive responses. Seropositive donors are shown with open circles (◦) while seronegative
donors are illustrated with filled black circles (•).
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3.2.8 The frequency of latency-specific IL-10 secreting CD4+ T cells
responding to IE1 and UL111A changes with donor age
Although the frequency of IFNγ secreting T cells within donors did not change with age in
response to any of the HCMV ORF pools tested (Figure 3.14), this might not be the case
for CD4+ T cells secreting IL-10. To investigate this, I examined how the frequencies of
IL-10 secreting T cells that had been stimulated with HCMV ORF overlapping peptide pools
changed with the age of seropositive donors (an indirect measure of time of viral carriage).
In response to the HCMV ORF peptide pools tested, I found CD4+ T cells secreting IL-10
across all ages, with varying magnitudes. Spearman rank correlation analysis was used to
test the correlation between the age and magnitude of CD4+ T cell IL-10 responses. There
were marginally significant decreases in the number of IL-10 secreting CD4+ T cells with
increasing donor age in response to IE1 (Spearman rs = -0.2427, P = 0.0461) (Figure 3.17C),
and to UL111A (Spearman rs = -0.2602, P = 0.0321) (Figure 3.17F), which were found to be
significant negative correlations in male rather than female donors when splitting the cohort
by sex (Appendix A.2). There were no significant changes in the frequencies of CD4+ T
cells secreting IL-10 in response to any of the ORFs tested with increasing age (Figure 3.17),
although a significant negative correlation was found in UL138 responses in male donors
only (Appendix A.2).
Long-term viral carriage could result in IL-10 secreting CD4+ T cells recognising an
increasing number of latency-associated ORFs, however no such increases were observed
across the ages tested (Kruskal- Wallis multiple comparisons test) (Figure 3.18). Although
the age of the donors was not related to the number of ORFs T cells secreted IL-10 in
response to, it cannot be ruled out that these results could change with an increase in the
number of donors that passed IL-10 selection criteria.
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Fig. 3.17 Analysis of the magnitudes of CD4+ T cell IL-10 responses to 8 HCMV ORF
peptide pools correlated with donor age. CD8+ depleted PBMC from 68 seropositive
donors were stimulated with HCMV ORF peptide pools for 48 hours on dual IFNγ/IL-
10 FluoroSpot plates and the frequencies of CD4+ T cells secreting IL-10 within each
seropositive donor enumerated and converted to Spot Forming Units (SFU)/106 cells. The
SFU/106 cells of IL-10 secreting CD4+ T cells is shown against donor age for responses to
(A) gB, (B) pp65, (C) IE1, (D) UL138, (E) LUNA, (F) US28, (G) UL111A, and (H) UL144.
The correlation (Spearman rs valus and p values are shown on each graph), and line of best
fit are shown.
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Fig. 3.18 The number of latency-associated HCMV ORF peptide pools that CD4+ T
cells respond to with IL-10 secretion across donor age. CD8+ depleted PBMC were
stimulated with HCMV ORF peptide pools for 48 hours on dual IFNγ/IL-10 FluoroSpot
plates and the frequencies of CD4+ T cells secreting IL-10 enumerated and converted to Spot
Forming Units (SFU)/106 cells. The number of latency-associated antigens out of the five
tested (UL138, LUNA, US28, UL111A, and UL144) that each donor responds to (considered
a positive response if above the threshold 50 SFU/106 cells) is shown against the age of
donor. There were no significant differences between the number of ORFs responded to by
CD4+ T cells and the ages of donors according to Kruskal-Wallis multiple comparisons test.
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3.2.9 CD4+ T cell response magnitudes to individual HCMV ORFs
vary depending on sex
In addition to age, the immune response to virus infection has been shown to be influenced
by the sex of the individual [619, 620]. The frequency of IFNγ and IL-10 secreting CD4+ T
cells in response to HCMV ORFs was compared between male and female donors. There
were significantly greater numbers of CD4+ T cells in male donors than female donors that
secreted IFNγ in response to UL144 (P = 0.0183, Kruskal-Wallis) (Figure 3.19A), in addition
to significantly greater frequencies of CD4+ T cells that secreted IL-10 in response to pp65
(P = 0.0171, Kruskal-Wallis) and US28 (P = 0.0330, Kruskal-Wallis) in male compared to
female donors (Figure 3.19B). There was also an appreciably greater frequency of CD4+
T cells secreting IFNγ in male donors in response to LUNA, although this did not reach
significance (Figure 3.19A).
Subsequently, the cumulative CD4+ T cell response to all HCMV ORFs within each
donor was compared between male and female donors. When taking into account all eight
HCMV ORFs tested (gB, pp65, IE1, UL138, LUNA, US28, UL111A, UL144), there were
significantly more cells secreting IFNγ (P = 0.0134, Mann-Whitney U) and IL-10 (P = 0.007,
Mann-Whitney U) in male compared to female donors (Figure 3.20A and B). The differences
in total response magnitudes was also apparent when considering only the three lytic ORFs
(gB, pp65, and IE1), where male donors had significantly greater number of IFNγ (P = 0.037,
Mann-Whitney U) and IL-10 (P = 0.0006, Mann-Whitney U) secreting cells compared to
female donors (Figure 3.20C and D). Additionally, total responses to latency-associated
proteins (UL138, LUNA, US28, UL111A, and UL144) were also significantly higher in
male compared to female donors for both IFNγ (P = 0.0111, Mann-Whitney U) and IL-10 (P
= 0.0.0272, Mann-Whitney U) secreting CD4+ T cells (Figure 3.20E and F). Thus, when
taking into account responses to all ORFs, male donors have higher frequencies of cytokine
secreting cells than female donors.
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Fig. 3.19 The frequency of CD4+ T cells secreting IFNγ or IL-10 in response to HCMV
ORF pools from HCMV seropositive donors grouped by sex. PBMC depleted of CD8+
T cells were stimulated with overlapping HCMV ORF peptide pools spanning each antigen
of interest for 48 hours on dual IFNγ /IL-10 FluoroSpot plates. Each peptide pool was tested
in triplicate and the values from all test wells were deducted from the number of background
cells secreting cytokines in the unstimulated wells. Following stimulation, the number of
cells secreting (A) IFNγ and (B) IL-10 was enumerated by the automated spot counter and
converted to a spot forming unit (SFU) value per million cells. Male responses are illustrated
with open circles (◦), and female responses with filled circles (•). Kruskal-Wallis multiple
comparisons test was carried out between male and female responses to each ORF.
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Fig. 3.20 A comparison of the total frequencies of CD4+ T cells within individual
donors that respond to HCMV ORFs when donors are grouped by sex. The total
frequency of CD4+ T cells responding with IFNγ or IL-10 secretion within individual donors
is shown in male and female donors. PBMC depleted of CD8+ T cells were stimulated with
overlapping HCMV ORF peptide pools spanning each HCMV ORF (gB, pp65, IE, UL138,
LUNA, US28, UL111A, UL144) for 48 hours on dual IFNγ/IL-10 FluoroSpot plates. Each
peptide pool was tested in triplicate and the values from all test wells were deducted from
the number of background cells secreting cytokines in the unstimulated wells. Following
stimulation, the number of cells secreting IFNγ and IL-10 was enumerated by the automated
spot counter and converted to a spot forming unit (SFU) value per million cells. Within in
each donor (A) the total number of CD4+ T cells secreting IFNγ or (B) IL-10 to all ORFs is
shown. Additionally, (C) the total number of CD4+ T cells secreting IFNγ or (D) IL-10 in
response to lytic ORFs only (gB, pp65, IE) and the total secreting (E) IFNγ and (F) IL-10 in
response to the latency-associated ORFs (UL138, LUNA, US28, UL111A, UL144) is shown.
Male responses are illustrated with open circles (◦), and female responses with filled circles
(•). Mann-Whitney U tests were utilised to compare between male and female responses to
ORFs.
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3.2.10 The secretion of IFNγ and IL-10 originates from distinct CD4+
T cell populations
Having shown that CD4+ T cells from seropositive donors responding to latency-associated
proteins are composed of IFNγ and IL-10 secreting cells, it was important to determine
to what extent responses within individuals were dominated by each cytokine secreting
population, and if overall responses to certain ORFs are composed of greater IFNγ or IL-10
secreting cells. Furthermore, the added benefit of the FluoroSpot assay, through its ability
to count cells that secrete both IFNγ and IL-10, enabled me to subsequently determine the
extent to which cytokine secretion from HCMV-specific T cells was originating from the
same population, or if these secreted cytokines separated cells into distinct populations.
To do this, the frequencies of each cytokine secreting population (CD4+ T cells secreting
IFNγ , IL-10, or both cytokines) was calculated as a proportion of the total number of
responding T cells within each donor. CD4+ T cell responses to the lytic proteins gB, pp65,
and IE1 were all composed of the highest percentages of IFNγ-secreting T cells, where the
majority of donors had CD4+ T cell responses dominated by IFNγ secretion (Figure 3.21A,
B, and C). I also observed several donors with CD4+ T cell IL-10 responses to these lytic
ORFs that were the dominant response, although these were much more infrequent than
dominant IFNγ responses. With the exception of the responses to UL144, CD4+ T cell
responses to the latency-associated proteins were composed of much higher proportions of
IL-10 secreting cells compared to the responses to the lytically-expressed proteins gB, pp65,
and IE1. Responses to UL144 had the lowest proportions of IL-10 secreting CD4+ T cells
of the responses to the latency-associated proteins, where the vast majority of individuals
had a dominant IFNγ response, resembling responses to gB, pp65, and IE1 (Figure 3.21D).
The CD4+ T cell responses to US28, UL111A, UL138, and LUNA were all composed of
much higher proportions of IL-10 secreting cells (Figure 3.21E, F, G, and H). To illustrate
these differences in the dominant cytokine responses, the proportion of donors with a given
dominant response to each ORF (where over 55% of all cytokine secreting CD4+ T cells
secrete IFNγ or IL-10) is shown (Figure 3.22). There is a clear hierarchy in dominant
cytokine responses to certain ORFs. As expected, over 85% of responding donors had a
dominant IFNγ response to the lytically expressed proteins gB (90.3%), pp65 (96.1%), or
IE1 (86.2%) (Figure 3.22). Responses to latency-associated proteins were more mixed and
highlight differences in dominant responses to different ORFs. The responses to UL144 for
example were IFNγ biased in 95.7% of all donors, which decreases steadily in response to
UL111A (74.3%), US28 (53.8%), LUNA (43.5%), and UL138 (40.5%) (Figure 3.22).
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Examining the CD4+ T cells that secreted both IL-10 and IFNγ in response to HCMV
ORFs revealed that these cells make up very small proportions of the total CD4+ T cell
response, indicating that cytokine secretion is originating from two separate populations
(Figure 3.21). This was the case for CD4+ T cell responses to all the HCMV proteins tested,
both lytically expressed and latency-associated, where very few donors possessed CD4+ T
cells secreting both cytokines, and in the donors that did have dual responders, these made
up very small proportions of the overall CD4+ T cell response (Figure 3.21).
The proportions of CD4+ T cells secreting IFNγ or IL-10 therefore varies in response
to different ORFs, but it could also be possible that these proportions were affected by the
age of the donor. Although no changes were observed in the frequencies of CD4+ T cells
secreting IFNγ in response to HCMV ORFs across the ages of donors (Figure 3.14), CD4+ T
cell IL-10 responses were less frequent in older ages in response to UL111A and IE1, which
might also be indicative of a change in the overall balance of cytokine secreting cells (Figure
3.17C and F). Donors were grouped into three age categories, young (18-39), middle (40-64),
and old (64+), and each individual’s corresponding dominant cytokine response analysed
across these age groups. Dominant responses were defined where over 50% of responding
CD4+ T cells secreted IFNγ or IL-10. As expected, in response to UL111A, the proportion of
CD4+ T cells secreting IFNγ compared to IL-10 increased across each age group from 62%
in the young, to 80% in the middle, and 91% in the old group (Figure 3.23D). While this was
by far the greatest change in proportion of cytokine secreting cells with age, CD4+ T cell
responses to LUNA decreased from 53% IFNγ biased, to 40% from young to old age (Figure
3.23B). The responses to US28 changed in the opposite direction, where the proportion of
donors with an IFNγ dominated response increased from 53 to 63% (Figure 3.23B). Rather
surprisingly, responses to UL138 and US28 had a characteristic shift in the middle age group
that did not follow the overall trend from young to old. CD4+ T cell responses to UL138
for example increased from 36% in the young to 56% in the middle, before reducing to 31%
IFNγ dominated in the old age group (Figure 3.23A). Similarly responses to US28 decreased
from 53% to 31% at middle age, before increasing to 63% IFNγ dominated in the old age
group (Figure 3.23C).
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Fig. 3.21 The proportions of CD4+ T cells secreting IL-10 and IFNγ in response to
latency-associated HCMV ORF pools from individual seropositive donors. PBMC from
91 seropositive donors were depleted of CD8+ cells and stimulated with overlapping peptide
pools from HCMV ORFs (A) gB, (B) pp65, (C) IE, (D) UL144, (E) US28, (F) UL111A, (G)
UL138, and (H) LUNA, for 48 hours. Following stimulation, IFNγ (black bars) and IL-10
(white bars) secretion was detected by FluoroSpot and enumerated to spot forming units
(SFU), where each cytokine response was calculated as a proportion of the total CD4+ T cell
response. The proportion of CD4+ T cells of total cytokine secreting cells that secreted both
IFNγ and IL-10 is also shown (blue bars). All samples were run in triplicate with the mean
value shown here. Donors without an IL-10 or IFNγ responses were omitted from each ORF
analysis.
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Fig. 3.22 The distribution of dominant CD4+ T cell IFNγ and IL-10 responses to
HCMV ORF peptide pools. PBMC from seropositive donors were depleted of CD8+
cells and stimulated with overlapping peptide pools from HCMV ORFs gB, pp65, IE, UL138,
LUNA, US28, UL111A, and UL144 for 48 hours. Following stimulation, IFNγ and IL-10
secretion was detected by dual IFNγ /IL-10 FluoroSpot and enumerated to spot forming units
(SFU), which allowed the proportion of each cytokine response to be calculated of the total
CD4+ T cell response. Dominant responses are classified when over 55% of the cytokine
secreting cells secreted (A) IFNγ (black bars), or (B) IL-10 (white bars). CD4+ T cell
responses where none of the cytokine secreting population was greater than 55% was classed
as equivocal (grey bars). Donors without an IL-10 or IFNγ responses were omitted from
each ORF analysis and the number of donors analysed for each antigen-specific response is
shown.
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Fig. 3.23 The distribution of dominant CD4+ T cell IFNγ and IL-10 responses to
HCMC ORF peptide pools across age groups. PBMC from seropositive donors were
depleted of CD8+ cells and stimulated with overlapping peptide pools from HCMV ORFs for
48 hours. Following stimulation, IFNγ and IL-10 secretion was detected by dual IFNγ /IL-10
FluoroSpot and enumerated to spot forming units (SFU), which allowed the proportion
of each cytokine response to be calculated of the total CD4+ T cell response. Dominant
responses are classed as such when over 50% of the cytokine secreting cells secreted IFNγ
(black bars), or IL-10 (white bars). The percentage of donors with dominant IFNγ and IL-10
responses to (A) UL138, (B) LUNA, (C) US28, (D) UL111A, and (E) UL144 is shown
for three age groups. Donors were separated into young (18-39), middle (40-64), and old
(64+) age groups. Donors without an IL-10 or IFNγ responses were omitted from each ORF
analysis and the number of donors analysed is shown.
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3.2.11 CD4+ T cells can also secrete TNFα in response to HCMV
latency-associated ORFs
FluoroSpot plates capable of detecting three cytokines simultaneously were then utilised to
examine the secretion of an additional antiviral cytokine, TNFα , together with IFNγ and
IL-10 secretion in response to HCMV ORFs. Eight seropositive donors were tested for their
CD4+ T cell TNFα responses. As previously, the frequency of responding CD4+ T cells
was measured by stimulating PBMC depleted of CD8+ cells with HCMV ORF peptides
for 48 hours. Again, to eliminate donors with high background TNFα secretion in their
unstimulated wells, data from donors was only used if the positive control elicited twice
the number of secreting cells as in unstimulated wells. Unfortunately due to high levels of
background TNFα secretion, five donors were excluded from the CD4+ T cell analysis.
Despite the exclusion of a large proportion of the donors tested, TNFα secretion by CD4+
T cells was observed in response to many of the HCMV ORFs tested. Although only three
donors were included for their CD4+ T cell responses, I did observe responses to gB (3
donors), pp65 (2 donors), LUNA (2 donors), UL138 (1 donor), and UL144 (1 donor), but
not to IE1, US28, and UL111A (Figure 3.24). Given the low number of donors, it is not
possible to determine if there are differences between responses to the lytically-expressed
proteins compared to the latency-associated proteins, however, it can be seen that all three
donors that passed the CD4+ T cell selection criteria had very high frequencies of CD4+ T
cell that secrete TNFα in response to gB, much higher than responses to the other ORFs
(Figure 3.24).
ICS for TNFα was also carried out on five donors to ensure the FluoroSpot results were
reproducible in a different assay system. PBMC stimulated overnight with HCMV ORF
peptides were stained intracellularly for TNFα in addition to IFNγ and IL-10. CD4+ T cell
TNFα responses were found to all ORFs tested, including IE1, US28, and UL111A, which
were not detected by FluoroSpot (Figure 3.24), and these responses were found in nearly
every donor (Figure 3.25). Overall, there was no major difference in the number of donors
with a positive TNFα response to lytically-expressed proteins compared to latency-associated
proteins (Figure 3.25). However IE1 and US28 were responded to with TNFα production in
all donors tested, and had the greatest percentages of CD4+ T cells positive for TNFα as
well (Figure 3.25).
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Fig. 3.24 The secretion of TNFα by CD4+ T cells from seropositive donors in response
to HCMV ORF peptide pools. PBMC from three seropositive donors were depleted of
CD8+ cells and stimulated with overlapping HCMV ORF peptide pools spanning gB, pp65,
IE1, UL138, LUNA, US28, UL111A, and UL144, for 48 hours on triple IFNγ /IL-10/TNFα
FluoroSpot plates. Each peptide pool was tested in triplicate and the values from all test wells
were deducted from the number of background cells secreting cytokines in the unstimulated
wells. Following stimulation, the number of cells secreting TNFα was enumerated by the
automated spot counter and converted to a spot forming unit (SFU) value per million cells.
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Fig. 3.25 Detection of TNFα production by CD4+ T cells in response to HCMV ORF
peptide pools by intracellular cytokine staining. PBMC depleted of CD8+ cells were
stimulated with overlapping HCMV peptide pools overnight spanning the ORFs of gB,
pp65, IE1, UL138, LUNA, US28, UL111A, and UL144. The following day, the PBMC
were incubated in monensin before staining intracellularly for TNFα . CD4+ T cells were
identified by gating on CD3+ and CD4+ cells, and ORF-specific T cells by expression of
4-1BB and/or CD40L. The data shown is from five seropositive donors where TNFα positive
cells are shown as a proportion of CD3+CD4+ cells.
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TNFα secreting CD4+ T cells are generally a separate population to those secreting
IFNγ or IL-10
Having established the ability of CD4+ T cells from seropositive donors to secrete TNFα
in response to HCMV ORFs, the secretion of IFNγ and IL-10 in combination with TNFα
secretion was then examined. The proportions of responding CD4+ T cells within donors that
secreted each cytokine alone, or secreted combinations of IFNγ or IL-10 together with TNFα
were determined from 3 HCMV seropositive donors. Donors with cytokine responses above
the background secretion from unstimulated samples were included in the analysis resulting
in the omission of several donor responses. All three TNFα/IFNγ responses to UL138, and
one such donor response to UL111A were not included. TNFα/IL-10 responses from one
donor were excluded to pp65, LUNA, and US28, while two of these responses were removed
from responses to UL138, UL111A, and UL144. CD4+ T cells that were dual TNFα/IFNγ
producers were detected mainly in one donor (Donor 181) but were never greater than 25%
of the total response (Figure 3.26). The only other donor with detected dual secretors were
from donor 310 in response to pp65, which made up nearly 12% of the total responding
CD4+ T cell population (Figure 3.26B). The dual secreting CD4+ T cells from donor 181
were found to be greater than 10% of the total response to gB (Figure 3.26A), pp65 (Figure
3.26B), LUNA (Figure 3.26D), and UL144 (Figure 3.26G). The dual TNFα/IFNγ CD4+ T
cells therefore do not appear to be a major population that is generated in response to these
HCMV ORFs, and are not generated preferentially in response to particular ORFs, although
these results could change with the further addition of donors.
CD4+ T cells that secreted both TNFα and IL-10 were even more infrequent, with almost
no T cells found to be such dual producers, with the exception of CD4+ T cell responses to
gB present in two of the three donors (Figure 3.27A).
Data from ICS of stimulated PBMC also corroborates these findings, where dual TNFα
secreting cells were most commonly found from CD4+ T cells co-producing IFNγ (Figure
3.28A). Here, individuals with dual TNFα /IFNγ producing CD4+ T cells were also found in
response to IE1, US28 and UL111A (Figure 3.28A) which were not seen in the FluoroSpot
assay (Figure 3.26). However, just as the results from the FluoroSpot, there were
comparatively few donors that possessed dual secreting TNFα/IFNγ CD4+ T cells (Figure
3.28A) compared to the number of donors with a TNFα response alone (Figure 3.25),
illustrating that these are mainly two separate populations. There were also very few donors
with CD4+ T cells that produced both TNFα and IL-10 (Figure 3.28B). Furthermore, there
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were no cells found to secrete all three cytokines in response to HCMV ORFs (data not
shown).
98 Identifying Latency-specific CD4+ T cells
18
1
31
0
00
1
0
25
50
75
100
CD4+ T cell gB
Donor
%
gB
 s
pe
ci
fic
 C
D
4 
T 
ce
lls
TNFα
IFNγ
Dual
18
1
31
0
00
1
0
25
50
75
100
CD4+ T cell US28
Donor
%
U
S2
8 
sp
ec
ifi
c 
C
D
4 
T 
ce
lls
TNFα
IFNγ
Dual
18
1
31
0
00
1
0
25
50
75
100
CD4+ T cell pp65
Donor
%
pp
65
 s
pe
ci
fic
 C
D
4 
T 
ce
lls
TNFα
IFNγ
Dual
18
1
31
0
00
1
0
25
50
75
100
CD4+ T cell LUNA
Donor
%
LU
N
A 
sp
ec
ifi
c 
C
D
4 
T 
ce
lls
TNFα
IFNγ
Dual
31
0
00
1
0
25
50
75
100
CD4+ T cell UL111A
Donor
%
U
L1
11
A 
sp
ec
ifi
c 
C
D
4 
T 
ce
lls
TNFα
IFNγ
Dual
18
1
31
0
00
1
0
25
50
75
100
CD4+ T cell IE1
Donor
%
IE
 s
pe
ci
fic
 C
D
4 
T 
ce
lls
TNFα
IFNγ
Dual
18
1
31
0
00
1
0
25
50
75
100
CD4+ T cell UL144
Donor
%
U
L1
44
 s
pe
ci
fic
 C
D
4 
T 
ce
lls
TNFα
IFNγ
Dual
A B
C D
E F
G
Fig. 3.26 Proportions of CD4+ T cells secreting TNFα and IFNγ in response to
latency-associated HCMV ORF peptide pools from seropositive donors. PBMC from 3
seropositive donors were depleted of CD8+ cells and stimulated with overlapping peptide
pools from HCMV ORFs (A) gB, (B) pp65, (C) IE, (D) LUNA, (E) US28, (F) UL111A, and
(G) UL144 for 48 hours. Following stimulation, IFNγ (black bars) and TNFα (grey bars)
secretion was detected by FluoroSpot and enumerated to spot forming units (SFU), where
each cytokine response was calculated as a proportion of the total CD4+ T cell response.
The proportion of CD4+ T cells of total cytokine secreting cells that secreted both IFNγ and
IL-10 is also shown (blue bars). All samples were run in triplicate and background spots
from unstimulated wells were deducted from the values obtained from test wells. The mean
value from each triplicate is shown here. Donors without an IL-10 or IFNγ responses were
omitted from each ORF analysis.
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Fig. 3.27 Proportions of CD4+ T cells secreting TNFα and IL-10 in response to
latency-associated HCMV ORF peptide pools from seropositive donors. PBMC from 3
seropositive donors were depleted of CD8+ cells and stimulated with overlapping peptide
pools from HCMV ORFs (A) gB, (B) pp65, (C) UL138, (D) LUNA, (E) US28, (F) UL111A,
and (G) UL144 for 48 hours. Following stimulation, IL-10 (white bars) and TNFα (grey bars)
secretion was detected by FluoroSpot and enumerated to spot forming units (SFU), where
each cytokine response was calculated as a proportion of the total CD4+ T cell response. The
proportion of CD4+ T cells of total cytokine secreting cells that secreted both TNFα and
IL-10 is also shown (blue bars). All samples were run in triplicate and background spots
from unstimulated wells were deducted from the values obtained from test wells. The mean
value from each triplicate is shown here. Donors without an IL-10 or TNFα responses were
omitted from each ORF analysis.
100 Identifying Latency-specific CD4+ T cells
gB pp65 IE UL138 LUNA US28 UL111A UL144
0.0
0.5
1.0
1.5
2.0
2.5
ORF
%
 IF
N
γ/T
N
Fα
 p
os
iti
ve
 c
el
ls
CD4+ T cell dual TNFα and IFNγ
gB pp65 IE UL138 LUNA US28 UL111A UL144
0.0
0.5
1.0
1.5
ORF
%
 T
N
Fα
/IL
-1
0 
po
si
tiv
e 
ce
lls
CD4+ T cell dual TNFα and IL-10
A
B
Fig. 3.28 Detection of CD4+ T cells capable of co-producing TNFα together with IFNγ
or IL-10 in response to HCMV ORF peptide pools by intracellular cytokine staining.
Whole PBMC isolated from 5 seropositive donors were stimulated overnight with HCMV
peptide pools spanning each ORF of interest (gB, pp65, IE, UL138, LUNA, US28, UL111A,
UL144), in the presence of monensin. Stimulated PBMC were then stained intracellularly for
IFNγ , IL-10 and TNFα production from CD4+ T cells. CD4+ T cells positive for both (A)
TNFα and IFNγ , and (B) TNFα and IL-10 are shown. T cells were identified after gating for
live and CD3+ cells, and ORF-specific T cells by expression of 4-1BB and/or CD40L.
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3.3 Discussion
The data presented in this chapter, which was mainly obtained from studies on a large donor
cohort, cover the CD4+ T cell responses to HCMV. In the interest of clarity, the analogous
data gathered simultaneously on CD8+ T cell responses is presented in the following chapter.
3.3.1 CD4+ T cell responses to latency-associated HCMV ORFs
Little is known about the T cell responses to proteins expressed during HCMV latency.
Therefore, one aim of this work was to determine if CD4+ T cells isolated from seropositive
donors could recognise latency-associated ORFs. Using an overlapping peptide pool approach
to stimulate CD4+ T cells ex vivo, cytokine secretion was determined by FluoroSpot assay.
The FluoroSpot assay was first validated to ensure the cytokine secretion being detected
was robust, reliable, and was originating from CD4+ T cells. An analysis of 91 HCMV
seropositive donors revealed CD4+ T cells recognised overlapping peptide pools from the
latency-associated ORFs UL138, LUNA, US28, UL111A, and UL144. The recognition of
UL138 and LUNA by CD4+ T cells has been reported previously [501], but responses to
US28, UL111A, and UL144 have not been reported at such prevalence before or from such a
large donor cohort [288].
Intriguingly, the frequencies of CD4+ T cells responding to UL144 and US28 were
comparable to those responding to the lytic ORFs gB, and IE1 respectively. While donors
with a positive CD4+ T cell response to UL138, LUNA, and UL111A were not as common,
these still represented a large minority of sampled individuals. In addition, 67% of donors
sampled were capable of responding to two or more of the five latency-associated ORFs
tested (data not shown). CD4+ T cells specific for proteins expressed during latency are
therefore widely present in HCMV seropositive donors. However, it is not clear why the
frequencies of CD4+ T cells secreting IFNγ in response to US28 and UL144 were more
prevalent, and of higher frequency, than those to UL138, LUNA, and UL111A.
The generation of CD4+ T cell responses to latency-associated ORFs is perhaps not
surprising given the expression of these proteins during the lytic infection cycle. However,
the extent to which HCMV seropositive donors have CD4+ T cells capable of recognising
viral proteins expressed during latency raises numerous questions regarding the ability of the
virus to persist in the face of such responses. One possible explanation could be that these
CD4+ T cells, or a subset of these cells, also secrete immunosuppressive factors that inhibit
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the anti-viral immune response during latency. One such factor is IL-10, which has been
shown to be produced by UL138- and LUNA-specific CD4+ T cells [501].
The capacity of CD4+ T cells from HCMV seropositive donors to secrete IL-10 in
response to proteins expressed during latency was examined. CD4+ T cells were capable of
secreting IL-10 in response to all ORFs tested, including UL138 and LUNA as previously
described [501]. Generally, IL-10 responses to the latency-associated ORFs, in particular
UL138, LUNA, and US28 were of a higher magnitude than those to the lytic ORFs gB,
IE1, and pp65. A higher frequency of CD4+ T cells secreting IL-10 in response to pp65
were however found compared to gB, IE1, and UL111A responses. The detection of IL-10
response to lytic ORFs might not be surprising as CD4+ T cells secreting IL-10 have been
previously reported to be generated in response to pp65, as well as gB [502, 621]. The
highest frequencies of IL-10 secreting cells were detected in response to US28, LUNA, and
UL138, followed by UL144 and UL111A. Of note, the frequencies of responding CD4+ T
cells secreting IL-10 were lower than those secreting IFNγ for all ORFs.
Examining the proportions of responding CD4+ T cells secreting IFNγ and IL-10 within
individuals revealed that a higher percentage of donors had dominant CD4+ T cell IL-10
responses to UL138 and LUNA than dominant IFNγ responses, while CD4+ T cell responses
to US28, UL111A, and UL144 were found to be dominated by IFNγ secreting cells. CD4+ T
cell responses to UL144 in particular resembled responses to the lytically expressed ORFs
gB, pp65, and IE1, in that the vast majority of CD4+ T cells responding to these ORFs
secreted IFNγ .
TNFα is a known pro-inflammatory and antiviral cytokine [622, 623]. In HCMV
infection, TNFα has been shown to repress viral IE expression in differentiated cells [624],
and to inhibit virus production [317, 625]. CD4+ T cell responses from a small number of
HCMV seropositive donors were tested for the secretion of TNFα by FluoroSpot and ICS in
response to overlapping HCMV peptide pools. TNFα secreting CD4+ T cells were found in
nearly all donors when measured by ICS, but these were not found reliably when measured
by FluoroSpot. One problem was the high background levels of TNFα secretion detected in
the unstimulated control wells which meant several donors had to be excluded from the
FluoroSpot analysis. It is not clear why the FluoroSpot and ICS results are not in alignment
for the TNFα secretion when those for IFNγ and IL-10 secretion are. The addition of further
donors to the FluoroSpot assessment and carrying out both ICS and FluoroSpot assays
simultaneously on the same donor will help rule out the small sample size and donor specific
effects. Examining the secretion of TNFα in combination with IFNγ and IL-10 by triple
FluoroSpot assays revealed that there was a small minority of cells that co-produced TNFα
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and IFNγ , but these were only highly prevalent in one donor, and otherwise were not widely
detected. Dual IFNγ/TNFα producing cells were also not detected by ICS, contrary to
several reports which carried out ICS following stimulation with CMV lysate, IE1, pp65, or
gB peptides [405, 414, 415]. IL-10/TNFα co-producers were even less common with almost
none detected. It appears that the majority of the CD4+ T cells responding to
latency-associated ORFs are therefore single producers from one of three sub-populations of
IL-10, IFNγ , or TNFα secreting cells. Furthermore, no cells secreting all three cytokines
were detected in any donor. More donors need to be tested for TNFα responses however
before these results can be verified.
The extensive CD4+ T cell IL-10 responses detected in response to all of the latency-
associated ORFs tested further lends weight to the hypothesis that these IL-10 producing T
cells are suppressing antiviral T cells, and therefore providing a mechanism that facilitates
the maintenance of viral latency. This hypothesis is further supported by the finding that
CD4+ T cells secreting IFNγ and those secreting IL-10 were separate cellular populations,
as has previously been reported for gB- and pp65-specific CD4+ T cells [621]. It could
therefore be possible that CD4+ T cells recognising proteins expressed during latency secrete
IL-10, and inhibit the population of IFNγ secreting CD4+ T cells, which might otherwise be
capable of eliminating latently infected cells.
Work carried out in mice on MCMV provides support that this could be the case. MCMV
is known to persistently replicate in the salivary glands of infected mice, and CD4+ T
cells secreting IL-10 have been observed to accumulate as a direct result of infection [626].
Blockade of IL-10R signalling results in a decrease in viral replication, and an increase of
IFNγ secreting CD4+ T cells known to be protective at this site [371, 626]. Furthermore, in
mice lacking CD4+ T cell IL-10 production, there was an increase in MCMV-specific CD4+
T cells secreting IFNγ in the salivary glands and periphery [621]. The resulting increase in
Th1 cells led to a reduction in replication and shedding of virus from the salivary gland [621].
Thus, during MCMV infection, IL-10 secreting CD4+ T cells act to limit the differentiation
of Th1 cells, which modulates anti-viral immune responses. Similarly, IL-10 derived from
CD4+ T cells contributed to restricting the expansion of MCMV-specific memory T cells, and
reducing the production of antiviral cytokines [627]. MCMV infection of IL-10 knockout
mice or IL-10R blockade during latent infection resulted in a reduction in viral load [627].
The exploitation of the IL-10 pathway to evade host immune responses is not unique to
HCMV. IL-10 secreting CD4+ T cells are also generated in response to a latent protein from
EBV. CD4+ T cells specific to EBV latent membrane protein 1 were shown to secrete IL-10
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and suppress T cell proliferation and IFNγ secretion, which could contribute to the evasion
of antiviral immune responses during latency [628].
In addition to IL-10 production by a subset of latency-associated ORF specific CD4+ T
cells, HCMV has further mechanisms that could act together to suppress anti-viral T cell
responses during latent infection. During latency, HCMV induces a number of modifications
to the infected cell that result in a reduction of T cell recognition and activation. The
expression of the UL111A gene product LAcmvIL-10, which is a cellular IL-10 homologue,
can downregulate the expression of MHC class II on granulocyte macrophage progenitor
cells and monocytes [156]. Furthermore, the ability of CD4+ T cells to recognise latently
infected myeloid progenitor cells was enhanced upon infection with a UL111A deletion virus,
in line with the resulting increase in MHC class II expression [165]. Therefore, UL111A acts
to modulate the presentation of viral peptides via MHC class II, in an attempt to limit CD4+
T cell recognition of latently infected cells.
UL111A could also be contributing to the evasion of T cell immunity through its ability
to affect the differentiation of myeloid progenitor cells. Latent infection of myeloid
progenitor cells with a UL111A deletion virus results in the higher production of
pro-inflammatory cytokines, and the differentiation of a greater proportion of myeloid DCs
compared to infection with wild-type virus [166]. As DCs are the most potent antigen
presenting cell, restricting their differentiation from myeloid progenitor cells could act to
limit the presentation of latency-associated viral peptides to virus-specific T cells,
contributing to the evasion of immune detection by latently infected cells.
Latent infection with HCMV is also associated with changes to the cellular secretome that
contribute to the evasion of T cell immunity. Latently infected CD34+ progenitor cells secrete
both IL-10 and TGFβ , and upregulate CCL8 expression, a chemokine that induces migration
of CD4+ T cells [605]. These factors then act in combination to modulate the effector
functions of CD4+ T cells attracted to sites of latent infection, resulting in a decrease in CD4+
T cell mediated cytotoxicity and in the production of inflammatory Th1 cytokines [605]. This
upregulation of CCL8 and IL-10 is at least in part caused by the expression of LAcmvIL-10,
which acts by suppressing cellular hsa-miR-92a [164]. In addition, the secretome from
latently infected CD34+ cells induces the expression of IL-10 from uninfected bystander
cells [605]. Thus, the virus is able to create an immunosuppressive microenvironment capable
of preventing T cell mediated effector functions that might otherwise act to eliminate latently
infected cells.
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The effects of the latent secretome on anti-viral T cell responses could therefore be
compounded by the secretion of IL-10 from both uninfected bystander cells and from
latency-specific CD4+ T cells entering the microenvironment of latently infected cells.
By suppressing anti-viral T cell responses, such concerted action could act to prevent the
elimination of latently infected cells. The inhibition of T cells by secreted immunosuppressive
factors is also known to occur during cancer. The secretion of IL-10 and TGFβ into the
tumour microenvironment by tumour cells or tumour-associated macrophages has been shown
to contribute to the suppression of tumour-specific T cell responses [629–637]. Crucially, it
has been demonstrated that in certain cases interference with these factors results in improved
T cell immune responses against cancer cells [638–641].
It is unclear why CD4+ T cell responses to lytically-expressed proteins are dominated by
IFNγ secreting cells while responses to the proteins expressed during latency are composed
of much greater proportions of IL-10 secreting cells. In the case of responses to UL138 and
LUNA for example, more donors had dominant CD4+ T cell IL-10 responses than IFNγ
responses. Interestingly, UL144, which is hypervariable [139], was not found to be expressed
in all donors during natural latency [125]. However, whether this influences the highly IFNγ
biased CD4+ T cell response to UL144 remains to be determined.
It could be possible that chronic activation of CD4+ T cells recognising cognate antigen
in the presence of the latent cell microenvironment, which contains the immunosuppressive
cytokines IL-10 and TGFβ , results in the generation of latency-specific CD4+ T cells that
secrete immunosuppressive cytokines themselves [506]. As lytic proteins are not expressed
to the same extent during latency, this could lead to the generation of a greater number
of IL-10 secreting CD4+ T cells specific to latency-associated ORFs in comparison. It is
therefore important to determine whether IL-10 secreting CD4+ T cells arise shortly after
primary infection, or are generated following the establishment of latency. Preliminary work
to address this question will be presented in a later chapter.
3.3.2 Fluctuations in the CD4+ T cell responses detected over time
The frequencies of CD4+ T cells secreting IFNγ and IL-10 in response to HCMV ORFs
were found to fluctuate across independent sampling points over a three year period in the
same individuals. The extent of these fluctuations was in part ORF-dependent. Responses
to the lytically expressed proteins and to UL144 were the most consistent across all time
points, while the T cell responses to latency-associated ORF products had a greater degree of
variability. However, because only one donor was sampled on more than three occasions,
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it is not possible to ascertain if responses to latency-associated ORFs do indeed vary to a
greater extent than responses to lytically-expressed proteins. The detection of CD4+ T cell
IL-10 responses was also more inconsistent than IFNγ responses, and there were time points
where no IL-10 secreting cells were detected to any of the latency-associated ORFs tested. It
is also not possible to determine if the variation in detected cytokine secreting CD4+ T cells
over time is more common in certain donors over others, given the limited sampling points
from three of the four donors.
Fluctuations in CD4+ T cell responses to lytic HCMV proteins have been reported
previously, although over a much shorter 9- to 25-week period with frequent sampling
[642]. The observed fluctuations in the frequencies of cytokine secreting CD4+ T cells
over time could be a direct result of isolating CD4+ T cells from peripheral blood. The
peripheral blood compartment contains a small proportion of an individual’s total T cells and
given its dynamic and transient nature, this could lead to differences in the frequencies of
cytokine secreting cells detected between sampling time points [618, 643, 644]. Furthermore,
CD4+ T cell numbers in peripheral blood could be drastically affected by active immune
responses. HCMV reactivation events that might drive more CD4+ T cells into the blood
could result in an over-representation of responses at that time point, or if immune responses
to other pathogens were occurring, this might result in a lymphocytosis, and resulting dilution
of HCMV-specific CD4+ T cells in the peripheral blood. As total lymphocyte counts in
combination with CD3+/CD4+ phenotyping were not carried out, which would provide
an absolute value for CD4+ T cells numbers at different time points, the possibility that
fluctuations in HCMV-specific CD4+ T cells were caused by overall fluctuations in CD4+
T cells in the peripheral blood cannot be excluded. It is interesting to note that there are
certain time points where responses to many of the ORFs were much higher than other time
points, which could point to such a change in the overall blood compartment. Furthermore,
ORF-specific CD4+ T cell responses of low frequency might be disproportionately affected
by such fluctuations in peripheral blood CD4+ T cells composition. Large differences in the
number of IFNγ secreting cells in response to UL144 for example, never resulted in a time
point where positive cells could not be detected. These relatively high frequency responses,
such as to UL144, might therefore remain detectable when the peripheral blood compartment
changes, whereas lower frequency responses might drop to below positive.
Another contributing factor to the observed fluctuations in CD4+ T cell responses over
time could be incomplete binding of released cytokines by the capture antibodies of the
FluoroSpot assay. Following peptide pool stimulation, ORF-specific CD4+ T cells secreting
IFNγ might therefore be capable of inhibiting the release of IL-10, and vice versa. There
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are certain time points from the longitudinal sampling of within donor responses where
ORF-specific IL-10 secretion is high but IFNγ secretion is low, as well as the reverse being
observed. Further work could assay the supernatant for IFNγ and IL-10 by ELISA following
the completion of the assay to determine levels of free cytokines, as well as introducing
neutralising IL-10 antibodies concurrently with peptide pool stimulation to determine if this
increases IFNγ secretion.
3.3.3 CD4+ T cell responses and age
A number of studies have drawn a link between lifelong carriage of HCMV and an age-
related decline in immune functions, such as an increased susceptibility to infections and
poor responses to vaccinations [419, 645], although many studies have also found no such
associations [353, 355]. Older HCMV infected individuals seem to retain the ability to
control HCMV to the extent that they do not suffer from overt clinical disease from viral
reactivations or re-infection [434]. There does however appear to be an age-related increase
in the levels of viral DNA detected in the blood [434] and urine [435]. The immune responses
of older individuals might therefore undergo changes with age, which could be caused by
lifelong viral carriage. In this manner, HCMV might directly or indirectly modulate anti-
HCMV immune responses to the extent that there is reduced control of reactivating virus. As
IL-10 possesses inhibitory properties, it could be possible that long-term viral carriage results
in a skewing of CD4+ T cell responses from pro-inflammatory, IFNγ secreting, to IL-10
secreting cells. Such immunosuppressive cells might then reduce the ability to control lytic
HCMV replication and account for the apparent decreases in anti-HCMV immune responses
with age. The breadth (number of ORFs donors responded to), and frequencies of CD4+ T
cell responses were examined in relation to donor age using a cross-sectional methodology
on donors ranging from 23 to 74 years of age. ORF-specific responses were compared across
donor ages for both IFNγ and IL-10 secreting CD4+ T cells.
No association between the frequencies of IFNγ secreting CD4+ T cells and donor age
was found when taking into account our cohort as a whole and interestingly, marginally
significant decreases were detected in the frequencies of CD4+ T cells secreting IL-10
in response to IE1 and UL111A with increasing donor age. Additionally, the breadth of
responses did not seem to be affected by the age of donor either, where it might be predicted
that longer viral carriage and resulting increase in reactivation events might be expected to
drive immune responses to additional ORFs. Therefore when considering the donor cohort
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as a whole, it seems unlikely that potential declines in anti-HCMV immunity with age are
caused by increases in HCMV-specific IL-10 secreting CD4+ T cells.
The unchanging number of ORFs responded to by CD4+ T cells with increasing donor
age could indicate that primary infection is responsible for generating ORF-specific T cell
responses against HCMV. Latent viral carriage and periodic reactivations into productive
infection might then serve to stimulate existing T cells rather than generate responses to new
antigens. Indirect evidence for this arises from the observations that CD4+ T cell clonal
diversity contracts and becomes severely restricted in the persistent stages of infection
compared to the acute phase [406]. As the donors used here have not been followed from
primary infection, and it is not known when this occurred, it cannot be determined how the
number of ORF-specific responses changes immediately following acute infection.
Furthermore, questions still remain over the kinetics of IL-10 secreting CD4+ T cell
generation, as these could arise immediately following primary infection, or could be
induced during the latent phase. Work seeking to address this by utilising multiple samples
from transplant recipients before and after primary infection will be presented in a
subsequent chapter.
An important caveat to the results from the longitudinal studies, and those measuring
responses at different ages, is that antigen-specific T cell response frequencies are being
detected by IFNγ/IL-10 FluoroSpot assays, which rely on antigen-specific cells possessing
these functions. As such, changes in antigen-specific T cell frequencies with age or over time
could be due to changes in the proportions of T cells which possess these functions, rather
than in the absolute sizes of these populations.
3.3.4 CD4+ T cell responses and sex
When grouping the donor cohort based on sex, differences in CD4+ T cell responses were
found when comparing the frequencies of cytokine secreting cells responding to individual
ORFs. CD4+ T cell IFNγ responses to UL144 were found to be of higher magnitude in male
compared to female donors. Likewise male CD4+ T cell IL-10 responses to pp65 and US28
were significantly higher than female CD4+ T cell responses to these ORFs. Furthermore,
when considering the total CD4+ T cell responses within individuals to either all ORFs,
latency-associated ORFs only, or lytic ORFs only, male donors exhibit greater frequencies of
both IFNγ and IL-10 secreting cells than female donors.
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It is not clear why certain ORF-specific CD4+ T cell response frequencies differ between
sexes. Sex has been shown to have an influence on a number of aspects of adaptive immunity
[619]. In humans, females have higher numbers of CD4+ T cells and higher CD4/CD8 T cell
ratios than age-matched males [619]. Additionally, females have greater antibody responses
than males and higher numbers of B cells [619]. Differences in cytokine production between
sexes has also been observed for CD4+ T cells. Naive CD4+ T cells isolated from the
peripheral blood of female donors were found to proliferate to a greater extent in response
to anti-CD3 and anti-CD28 stimulation than those isolated from men [646]. Female CD4+
T cells also produced more IFNγ , while male CD4+ T cells had a bias towards IL-17A
production following stimulation [646].
There is currently a lack of evidence on the sex-specific immune responses to HCMV.
However, seroprevalence is known to be higher among females than males [9, 647], with
higher reported HCMV IgG titres in elderly females [423], although this might not be the
case for middle aged individuals, where in a separate study no sex-specific difference was
found [648]. Middle aged male HCMV infected individuals were also shown to have lower
absolute numbers of CD4+ T cells than females [648], while a study assessing the frequency
of CD4+ T cells within the T cell compartment found no difference between men and women
in old and young HCMV positive seropositive donors [649]. Further work could assess the
CD4+ T cell compartment sizes in males and females by absolute counts in conjunction
with FluoroSpot response data for CD4+ T cells. This could assess whether differences in
HCMV-specific CD4+ T cell numbers are proportional to any differences in the overall CD4+
T cell compartment between male and female donors. Interestingly, the absolute numbers of
CD8+ T cells have been found to be relatively unaffected by HCMV infection and sex [648],
and the data from CD8+ T cells presented in the subsequent chapter, found no differences in
total donor CD8+ T cell responses to either all ORFs, latency-associated ORFs only, or lytic
ORFs only, between sexes (Section 4.2.8).
A major limitation of these experiments is that they only take into account CD4+ T cells
isolated from the peripheral blood compartment. As fewer than 2.5% of all T cells have been
estimated to reside in the peripheral blood [618], the results obtained here ideally need to be
paired with responses from CD4+ T cells isolated from other tissue sites. This will enable
a more complete picture of CD4+ T cell responses to proteins expressed during latency
to be generated. In this manner, any differences in CD4+ T cell antigen-specificities and
effector-functions between tissue-sites and the peripheral blood could be determined. One
such site to investigate could be the bone marrow, where resident CD34+ progenitor cells
are known to harbour latent HCMV [94]. Polyfunctional pp65-specific CD4+ T cells have
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been found to be considerably enriched in the bone marrow compared to peripheral blood
[650], and carrying out a paired comparison with peripheral blood CD4+ T cell responses to
latency-associated ORFs would be highly beneficial. Examining the CD4+ T cell responses
to HCMV from tissues such as bone marrow could also provide a means to reduce the
fluctuations in the frequencies of detected cytokine secreting cells when sampling from the
peripheral blood. The characterisation of CD4+ T cell responses from bone marrow derived
T cells will be elaborated on in a subsequent chapter.
Chapter 4
Identifying Latency-specific CD8+ T cells
4.1 Introduction
CD8+ T cell responses to HCMV can reach a large proportion of total T cells in the peripheral
blood compartment, especially to highly immunogenic antigens such as pp65 and IE1
[297, 288]. An extensive analysis utilising overlapping peptide pools spanning 213 predicted
HCMV ORFs revealed that three ORFs (UL48, pp65, and IE1) were recognised by over half
of the 33 donors tested, where recognition was determined by IFNγ production via ICS [288].
Furthermore, CD8+ T cells from donors recognised a median of 8 ORFs, although this was
highly heterogeneous between individuals [288]. Subsequent work has since highlighted the
considerable variability in the size of these responses between individuals, the reasons for
which are not fully understood [291].
Studies examining CD8+ T cell responses have failed to detect high frequencies of CD8+
T cells specific for latency-associated ORFs. Out of 33 HCMV seropositive donors, responses
to US28 and UL138 were found in one donor, while no responses to UL144 and UL111A
were detected by ICS [288]. Work examining CD8+ T cell responses to the latency-associated
HCMV ORFs UL138 and LUNA by ELISpot did find low frequencies of responding cells,
but these were below the set positive threshold [501]. The relative simplicity of the depletion
system used to test CD4+ T cell responses, and the ease of the FluoroSpot assay, which
allowed for both CD4+ and CD8+ T cell responses to be tested on the same plate, provided
the rationale to test the CD8+ T cell responses to proteins expressed during latency.
As both CD4+ and CD8+ T cell responses to HCMV ORFs were being tested from a
large donor cohort, this gave the opportunity to assess the effects, if any, of age on CD8+ T
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cell responses to HCMV. As with the effect of HCMV on CD4+ T cells, HCMV has been
observed to be associated with age-related alterations in the CD8+ T cell compartment, and
thought to be a driver of immunosenescence [651]. These include the expansion of CD8+
T cells with a proposed highly differentiated phenotype (loss of CD28 expression, gain of
CD57 expression), and diminished replicative ability, which many report to be dysfunctional
[352, 417, 652–654]. As such, it has been suggested that the accumulation of these highly
differentiated T cells during HCMV infection could have negative consequences for responses
to vaccination, responses to other pathogens, and on mortality [348, 418, 655, 656]. Utilising
the FluoroSpot assay, I therefore wanted to assess the effect of age on the magnitudes of
CD8+ T cell responses to HCMV proteins.
This chapter therefore aimed to determine whether CD8+ T cells specific for latency-
associated ORFs US28, UL111A, and UL144 are present in seropositive individuals, if there
was any association in the frequencies of HCMV-specific CD8+ T cells and the age of donor,
and to examine the cytokines secreted by HCMV-specific CD8+ T cells.
4.2 Results
4.2.1 CD8+ T cells can recognise proteins expressed during HCMV
latency
A FluoroSpot based approach was utilised to examine the CD8+ T cell responses to proteins
expressed during latency. Overlapping peptide pools spanning HCMV ORFs were used to
stimulate CD8+ T cells from HCMV seropositive donors, and the frequency of cytokine
secreting cells determined by FluoroSpot. To obtain a dominant CD8+ T cell population,
CD4+ cells were depleted from PBMC by MACS, which resulted in a mean residual CD4+
T cell proportion of 5.42% (standard deviation=3.77, n=47) of all CD3+ cells (Figure 4.1A).
Consequently, the mean CD8+ T cell proportion of CD3+ cells following CD4+ cell depletion
was 68.22% (standard deviation=14.39, n=47) (Figure 4.1A).
Previous work carried out by Mason et al. [501] using ELISpot assays did not find
donors with CD8+ T cell responses to UL138 and LUNA greater than 100 SFU/106 cells.
In the experiments here, the FluoroSpot assay was employed in part because of its greater
sensitivity compared to the ELISpot. To validate this increase in sensitivity, CD8+ T cells
were polyclonally stimulated and the frequencies of IFNγ secreting cells were compared
between FluoroSpot and ELISpot. Substantially higher frequencies of CD8+ T cells secreting
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IFNγ were detected by FluoroSpot compared to ELISpot in three donors (Figure 4.2),
illustrating the greater sensitivity of the FluoroSpot assay.
The FluoroSpot was then utilised to test CD8+ T cell responses to latency-associated
ORF products in a large donor cohort. To do this, PBMC depleted of CD4+ cells by MACS
were stimulated with overlapping peptide pools spanning the HCMV ORFs of gB, pp65,
IE1, UL138, LUNA, US28, UL111A, and UL144 on dual IFNγ/IL-10 FluoroSpot plates.
Following this, the frequencies of cytokine secreting CD8+ T cells were determined. As
previously, selection criteria were put in place to exclude potentially erroneous results.
Initially, donors were excluded if the background responses in the unstimulated control wells
were greater than 1000 spots. Subsequently, positive IFNγ responses were only considered if
the difference between the unstimulated samples and positive control samples was greater
than 100 spots. These selection criteria resulted in 11 donors being excluded from the IFNγ
secretion analysis.
Examining the secretion of IFNγ from 90 seropositive donors revealed previously
uncharacterised CD8+ T cell responses against all latency-associated ORFs tested. As with
the data from CD4+ T cells, the number of donors with above threshold CD8+ T cell IFNγ
responses (>100 SFU/106 cells as determined by HCMV seronegative donor responses), was
found to vary in response to different ORFs. CD8+ T cells from a number of donors had
positive IFNγ responses to UL138 (27 donors, 30%), LUNA (29 donors, 32.2%), US28 (66
donors, 73.3%), UL111A (41 donors, 45.6%), and UL144 (70 donors, 77.8%) (Figure 4.3).
CD8+ T cell responses to lytically-expressed proteins were expectedly frequent, with the
majority of all donors possessing a positive response to each of gB (62 donors, 68.9%), IE1
(62 donors, 68.9%), and pp65 (82 donors, 91.1%) (Figure 4.3).
Out of 90 donors, there were 43 CD8+ T cell high responders (with above 250 SFU/106
responding cells) to gB (47.8%), 74 to pp65 (82.2%), and 49 to IE1 (54.4%) (Figure 4.3).
Interestingly, CD8+ T cell responses to the latency-associated ORFs were composed of a
similar number of donors who were high responders compared to CD4+ T cell responses
(Figure 3.13). There were CD8+ T cell high responding donors most frequently found to
UL144 (56/90, 62.2%) and US28 (44/90, 48.9%), and least frequently to UL138 (12/90,
13.3%), LUNA (14/90, 15.6%), and UL111A (14/90, 15.6%) (Figure 4.3).
Similarities were also found between the number of donors with a positive CD4+ or CD8+
T cell response to certain latency-associated proteins. UL144 and US28 had the highest
number of donors with a positive CD4+ or CD8+ T cell response, in addition to the highest
frequencies of T cells responding to these ORFs within individuals (Figures 3.13 and 4.3).
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Fig. 4.1 Magnetic-activated Cell Sorting to deplete CD4+ cells from PBMC and to
isolate untouched CD8+ T cells from PBMC. Whole PBMC from 47 donors were depleted
of CD4+ cells using direct MACS CD4+ microbeads and stained for CD3, CD4, and CD8
expression to determine the residual proportions of CD4+ and CD8+ T cells of total CD3+
cells.
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Fig. 4.2 Comparison of the detected frequencies of CD8+ T cells secreting IFNγ
between FluoroSpot and ELISpot assays. PBMC from three donors (ARIA145, ARIA146,
and ARIA147) were depleted of CD4+ cells by MACS to obtain a dominant CD8+ T cell
population. The CD4+ cell depleted PBMC were then stimulated with a mix of anti-CD3
and anti-CD28 monoclonal antibodies for 48 hours and the secretion of IFNγ assessed by
FluoroSpot (grey bars) and ELISpot (white bars) concurrently. The frequency of IFNγ
positive spots was counted and converted to spot forming units (SFU) per million cells.
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Likewise, the lowest number of donors with a positive IFNγ T cell response was found to
UL111A, LUNA, and UL138 in both CD4+ and CD8+ T cells.
To ensure the detected IFNγ secretion was mediated specifically by CD8+ T cells and the
responses detected by the FluoroSpot were reproducible, these responses were also examined
by ICS. PBMC from 18 donors were stimulated with HCMV ORF overlapping peptide pools
overnight, and the secretion of IFNγ identified from CD8+ T cells. IFNγ production was
readily detected in the majority of donors in response to the lytically-expressed proteins gB,
pp65, and IE1, whereas responses to the latency-associated proteins were more variable,
both in the number of donors with positive responses, and in the proportions of CD8+ T
cells secreting IFNγ within donors (Figure 4.4). The proportion of donors with CD8+ T cell
responses detected by ICS were similar to those obtained by the FluoroSpot, with positive
responses to UL138 and UL111A the least common, while those to US28 and UL144 were
the most common (Figure 4.4). Interestingly, responses to LUNA were more frequently
detected by ICS (72% of donors) (Figure 4.4) than by FluoroSpot (31.9% of donors) (Figure
4.3). The results from the ICS assay are therefore in agreement with the cytokine secretion
detected by the FluoroSpot assay and show the responses are CD8+ T cell specific.
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Fig. 4.3 The frequency of CD8+ T cell responses from HCMV seropositive and
seronegative donors stimulated with HCMV ORF pools. PBMC from 90 seropositive
and seven seronegative donors were depleted of CD4+ T cells and stimulated with HCMV
ORF peptide pools spanning gB, pp65, IE1, UL138, LUNA, US28, UL111A, and UL144 for
48 hours on dual IFNγ/IL-10 FluoroSpot plates. Each peptide pool was tested in triplicate
and the values from the number of background cells secreting cytokines in the unstimulated
wells was deducted from all test wells. Following stimulation, the number of IFNγ positive
spots was enumerated by the automated spot counter and converted to a spot forming unit
(SFU) value per million cells. The dotted line at 100 SFU/106 cells indicates the threshold
for positive responses, while the line at 250 SFU/106 cells shows the threshold for high
responding donors. Seropositive donors are shown with open circles (◦) while seronegative
donors are illustrated with filled black circles (•).
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Fig. 4.4 Intracellular cytokine staining for IFNγ production from CD8+ T cells
following HCMV ORF peptide pool stimulation. Whole PBMC isolated from 18
seropositive donors were stimulated overnight with overlapping HCMV peptide pools
spanning the ORFs of gB, pp65, IE1, UL138, LUNA, US28, UL111A, and UL144, in
the presence of monensin. Stimulated PBMC were then stained intracellularly for IFNγ from
CD8+ T cells. T cells were identified after gating for live and CD3+ cells, and ORF-specific
T cells by expression of 4-1BB and/or CD69.
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4.2.2 The frequency of IFNγ secreting CD8+ T cells detected fluctuates
over time
The CD4+ T cell responses to latency-associated HCMV ORFs within four donors were
found to vary across independent sampling points taken over a three year period (Section
3.3.2). In parallel, the CD8+ T cell responses to HCMV ORFs were examined from the same
four donors at various time points over three years using the FluoroSpot assay. The most
extensive analysis was carried out on one donor (CMV324), who had CD8+ T cell responses
measured on seven occasions over three years. Similar to the CD4+ T cell responses, there
were responses to certain ORFs that were relatively consistent over time, such as to the
lytically-expressed proteins gB, pp65, and IE1, which were composed of a high frequency
IFNγ secreting cells at nearly all times points (Figure 4.5). Likewise, consistently elevated
CD8+ T cell responses were observed to US28 and UL144 at all seven time points (Figure
4.5). Although subject to greater variation, CD8+ T cell responses to LUNA were also above
background at all time points (Figure 4.5). The responses to UL138 and UL111A were
the most inconsistent, with responses fluctuating from positive to no response at various
time points (Figure 4.5), much like the CD4+ IFNγ T cell responses over time in this donor
(Figure 3.8A). Even for the most consistent above-threshold ORF-specific responses, there
were often substantial fluctuations in the frequencies of IFNγ secreting CD8+ T cells detected
between time points (Figure 4.5). Examining the number of ORFs responded to across these
time points (responses greater than 100 SFU/106 T cells) highlighted the greater degree of
fluctuations in response to the latency-associated ORFs compared to the lytic ORFs. At all
but one time point all three lytic ORFs were responded to by CD8+ T cells, while the number
of positive responses to latency-associated ORFs varied from five to two across the sampling
times (Figure 4.6).
Three additional donors were also examined on more than one occasion for their CD8+
T cell responses over time. Donor CMV319 had their CD8+ T cell responses tested at four
time points, and again the results obtained highlighted that responses to certain ORFs were
more consistent than others. High frequency IFNγ secreting CD8+ T cells were present in
response to the lytically-expressed proteins gB, pp65, and IE1 at each time point, as were
responses to US28, UL111A, and UL144 (Figure 4.7). CD8+ T cell responses to UL138
and LUNA were the least consistent, where positive responses were registered at the first
two time points but these were not observed again (Figure 4.7). Additionally, frequencies of
detected IFNγ positive CD8+ T cells were relatively similar across all time points for which
a positive response was registered for this donor (Figure 4.7).
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Although donor CMV323 was only sampled at two time points, there was also variation
in their CD8+ T cell IFNγ responses. Donor CMV323 had inconsistent IFNγ responses to
pp65 and US28 across the two time points, and there were considerable differences in the
frequencies of IFNγ secreting cells between sampling times in response to all ORFs, with
the exception of UL138 (Figure 4.8).
Donor CMV307 was also only sampled on two occasions and had relatively consistent
responses between these time points, although the frequencies of CD8+ T cells secreting
IFNγ did vary in response to gB (Figure 4.9).
Therefore, the CD8+ T cell responses tended to vary over time, often considerably, in the
frequencies of IFNγ secreting cells detected. The detection of positive responses to particular
ORFs, such as UL138 and LUNA were found to fluctuate across the sampling times to a
greater extent than responses lytically-expressed proteins such as gB. Furthermore, these
results are comparable to the fluctuations observed in CD4+ T cell responses to HCMV
ORFs.
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Fig. 4.5 Longitudinal CD8+ T cell IFNγ responses to HCMV ORF peptide pools from
donor CMV324. CD8+ T cells from one donor were tested at seven separate time points over
three years. PBMC were depleted of CD4+ expressing cells and stimulated with overlapping
peptide pools of HCMV peptides spanning gB, p65, IE1, UL138, LUNA, US28, UL111A,
and UL144, for 48 hours on dual IFNγ/IL-10 FluoroSpot plates. IFNγ secreting CD8+ T
cells were then stained for, counted, and converted to spot forming units (SFU) per million
cells. All samples were run in triplicate and the frequencies of positive cells was determined
by subtracting values in all test wells from the background number of positive cells in
unstimulated well. Each different colour of bar indicates a different sampling time point.
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Fig. 4.6 Longitudinal analysis of the number of positive CD8+ T cell responses in donor
CMV324. Positive IFNγ CD8+ T cell responses (responses over 100 SFU/106 cells) are
shown at 7 time points over three years from one donor. The dates of each time point are
shown in the table. PBMC were depleted of CD4+ expressing cells and stimulated with
overlapping peptide pools of HCMV peptides spanning gB, p65, IE1, UL138, LUNA, US28,
UL111A, and UL144, for 48 hours on dual IFNγ/IL-10 FluoroSpot plates. The number of
IFNγ positive CD8+ T cells was determined and converted to SFU/106 cells. All samples
were run in triplicate and the frequencies of positive cells was determined by subtracting
values in all test wells from the background number of positive cells in unstimulated well.
The black bars indicate responses to all 8 ORFs, both lytic and latency-associated, the grey to
lytic antigens gB, pp65, and IE, and the white to latency-associated antigens UL138, LUNA,
US28, UL111A, and UL144.
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Fig. 4.7 Longitudinal CD8+ T cell IFNγ responses to HCMV ORF peptide pools from
donor CMV319. CD8+ T cell responses from one donor were tested at four separate time
points over three years. PBMC were depleted of CD4+ expressing cells and stimulated with
overlapping peptide pools of HCMV peptides spanning gB, p65, IE1, UL138, LUNA, US28,
UL111A, and UL144, for 48 hours on dual IFNγ/IL-10 FluoroSpot plates. IFNγ secreting
CD8+ T cells were then stained for, counted, and converted to spot forming units (SFU) per
million cells. All samples were run in triplicate and the frequencies of positive cells was
determined by subtracting values in all test wells from the background number of positive
cells in unstimulated well. Each different colour of bar indicates a different sampling time
point.
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Fig. 4.8 Longitudinal CD8+ T cell IFNγ responses to HCMV ORF peptide pools from
donor CMV323. CD8+ T cell responses from one donor were tested at two separate time
points over three years. PBMC were depleted of CD4+ expressing cells and stimulated with
overlapping peptide pools of HCMV peptides spanning gB, p65, IE1, UL138, LUNA, US28,
UL111A, and UL144, for 48 hours on dual IFNγ/IL-10 FluoroSpot plates. IFNγ secreting
CD8+ T cells were then stained for, counted, and converted to spot forming units (SFU) per
million cells. All samples were run in triplicate and the frequencies of positive cells was
determined by subtracting values in all test wells from the background number of positive
cells in unstimulated well. Each different colour of bar indicates a different sampling time
point.
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Fig. 4.9 Longitudinal CD8+ T cell IFNγ responses to HCMV ORF peptide pools from
donor CMV307. CD8+ T cell responses from one donor were tested at two separate time
points over three years. PBMC were depleted of CD4+ expressing cells and stimulated with
overlapping peptide pools of HCMV peptides spanning gB, p65, IE1, UL138, LUNA, US28,
UL111A, and UL144, for 48 hours on dual IFNγ/IL-10 FluoroSpot plates. IFNγ secreting
CD8+ T cells were then stained for, counted, and converted to spot forming units (SFU) per
million cells. All samples were run in triplicate and the frequencies of positive cells was
determined by subtracting values in all test wells from the background number of positive
cells in unstimulated well. Each different colour of bar indicates a different sampling time
point.
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4.2.3 The frequency of latency-specific IFNγ secreting CD8+ T cells
does not change with age
Age could be in an important factor affecting the magnitude of CD8+ T cell responses
to HCMV, as age provides an indirect measure for the time of latent viral carriage. The
frequencies of CD8+ T cells that secreted IFNγ in response to each HCMV ORF was
therefore examined in relation to donor age in the cohort of 90 individuals. CD8+ T cell
responses were found to vary in magnitude across all ages but there was no significant
correlation (Spearman rank correlation analysis) between the frequency of IFNγ secreting
CD8+ T cells and the age of donor for responses to any of the latency-associated ORFs tested
(Figure 4.10). However, there was a significant negative correlation between CD8+ T cell
IFNγ responses to UL138 and the age of donor in males when the donor cohort was grouped
by sex (Spearman rs = -0.3805, P = 0.0169) (Appendix A.3). The frequency of CD8+ T cells
responding to the lytically-expressed proteins gB, pp65, and IE1 with IFNγ secretion also
did not change with increasing donor age (Figure 4.10).
Although the frequencies of IFNγ secreting CD8+ T cells did not vary with increasing
donor age, older donors might be expected to respond to a greater number of HCMV ORFs.
This would be the case given a presumed longer time of viral carriage, and therefore exposure
to more viral reactivation events, which could serve to generate new responses. The number
of latency-associated HCMV ORFs each donor responded to out of the five tested were
compared to the ages of donors. In agreement with data from CD4+ T cells (Figure 3.15),
there was no change in the number of ORFs responded to with increasing donor age following
a Kruskal-Wallis multiple comparisons test, and there was a relatively consistent distribution
of ages responding to each number of ORFs (Figure 4.11).
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Fig. 4.10 Analysis of the magnitudes of CD8+ T cell IFNγ responses to 8 HCMV ORF
peptide pools correlated with donor age. CD4+ depleted PBMC from 90 seropositive
donors were stimulated with HCMV ORF peptide pools for 48 hours on dual IFNγ/IL-
10 FluoroSpot plates and the frequencies of CD8+ T cells secreting IFNγ within each
seropositive donor enumerated and converted to Spot Forming Units (SFU)/106 cells. The
SFU/106 cells of IFNγ secreting CD8+ T cells is shown against donor age for responses to
(A) gB, (B) pp65, (C) IE1, (D) UL138, (E) LUNA, (F) US28, (G) UL111A, and (H) UL144.
The correlation (Spearman rs values and p values shown on each graph), and line of best fit
are shown.
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Fig. 4.11 The number of latency-associated HCMV ORF peptide pools that CD8+ T
cells respond to with IFNγ secretion across donor age. CD4+ depleted PBMC were
stimulated with HCMV ORF peptide pools for 48 hours on dual IFNγ/IL-10 FluoroSpot
plates and the frequencies of CD8+ T cells secreting IFNγ enumerated and converted to Spot
Forming Units (SFU)/106 cells. The number of latency-associated ORFs out of the five tested
(UL138, LUNA, US28, UL111A, and UL144) that each donor responds to (considered a
positive response if above the threshold 100 SFU/106 cells) is shown against the age of donor.
There were no significant differences between the number of ORFs responded to by CD8+ T
cells and the ages of donors according to Kruskal-Wallis multiple comparisons test.
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4.2.4 CD8+ T cells can secrete the immunosuppressive cytokine IL-10
in response to HCMV latency-associated ORFs
CD8+ T cells secreting IL-10 in response to latency-associated HCMV ORFs have not been
reported previously. IL-10 has several immunosuppressive effects and could therefore be an
important factor contributing to the evasion of host immune responses. As the FluoroSpot
plates capture both IFNγ and IL-10 secretion simultaneously, IL-10 secretion from CD8+
T cells following HCMV ORF peptide pool stimulation was also assessed from the large
donor cohort. As previously, PBMC from 45 seropositive donors were depleted of CD4+
cells and stimulated with overlapping peptide pools spanning HCMV ORFs for 48 hours
then analysed for IL-10 secretion by FluoroSpot assay. CD8+ T cell responses to gB, pp65,
IE1, UL138, LUNA, US28, UL111A, and UL144 were tested. Unexpectedly, the use of this
highly sensitive FluoroSpot assay has revealed previously uncharacterised IL-10 responses to
HCMV, as CD8+ T cells were found to respond with IL-10 secretion to all latency-associated
ORFs tested (Figure 4.12). As with the detected CD4+ IL-10 T cell responses (Figure 3.16),
the frequencies of IL-10 secreting CD8+ T cells varied in response to different ORFs (Figure
4.12).
Applying the selection criteria for positive IL-10 responses resulted in the inclusion of
data from only 45 donors. Responses were excluded if the background frequency of IL-10
positive spots in the unstimulated wells was greater than 1000 or the difference between
the unstimulated samples and the positive control samples was less than 50 spots. Using
these selection criteria, 56 donors were excluded. Of these donors, responses to the lytically-
expressed proteins were typically the least frequent, as they were only detected in 11 donors
in response to gB (24.4%) and 9 donors in response to IE1 (20%). However, similar to
CD4+ T cell IL-10 responses (Figure 3.16), CD8+ T cell IL-10 responses were found quite
frequently to pp65, in 21 of 45 donors (46.7%) (Figure 4.12). CD8+ T cell IL-10 responses
to the latency-associated proteins tested were most frequently found in response to US28
(30 donors, 66.7%), followed by LUNA (21 donors, 46.7%), and UL138 (20 donors, 44.4%),
with the least frequent responses detected against UL144 (16 donors, 35.6%), and UL111A
(14 donors, 31.1%) (Figure 4.12).
To ensure the CD8+ T cell IL-10 responses to latency-associated ORFs detected by
FluoroSpot were reproducible, ICS was also carried out as previously. PBMC from 16
seropositive donors were stimulated with overlapping HCMV ORF peptide pools for 18
hours before staining for IL-10. CD8+ T cells capable of producing IL-10 were detected
consistently by ICS. CD8+ T cells producing IL-10 were detected in a number of donors
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(Figure 4.13), although these were generally less frequent and were a lower proportion of total
CD8+ T cells compared to those secreting IFNγ (Figure 4.4). These data are in agreement
with the data obtained from the FluoroSpot assay, where IL-10 responding CD8+ T cells
were not found as often, and were of lower frequency than those secreting IFNγ . The ability
to detect IL-10 secretion from CD8+ T cells by ICS therefore validates the data obtained by
FluoroSpot, and confirms that IL-10 secretion was CD8+ T cell specific and not other PBMC
subsets.
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Fig. 4.12 The frequency of CD8+ T cells from HCMV seropositive and seronegative
donors secreting IL-10 in response to HCMV ORF pools. PBMC from 45 HCMV
seropositive and 6 seronegative donors were depleted of CD4+ T cells and stimulated
with HCMV ORF peptide pools spanning gB, pp65, IE1, UL138, LUNA, US28, UL111A,
and UL144 for 48 hours on dual IFNγ /IL-10 FluoroSpot plates. Each peptide pool was tested
in triplicate and the values from the number of background cells secreting cytokines in the
unstimulated wells was deducted from all test wells. Following stimulation, the number of
IL-10 positive spots was enumerated by the automated spot counter and converted to a spot
forming unit (SFU) value per million cells. The dotted line at 50 SFU/106 cells indicates the
threshold for positive responses. Seropositive donors are shown with open circles (◦) while
seronegative donors are illustrated with filled black circles (•).
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Fig. 4.13 Intracellular cytokine staining of CD8+ T cells for IL-10 following HCMV
ORF peptide pool stimulation. Whole PBMC isolated from 16 seropositive donors were
stimulated overnight with HCMV peptide pools spanning the ORFs of gB, pp65, IE1, UL138,
LUNA, US28, UL111A, and UL144, in the presence of monensin. Stimulated PBMC were
then surface stained for CD3, CD4, and CD8, and intracellularly stained for IL-10. T cells
were identified after gating for live cell, CD3+ cells, CD8+ cells, and ORF-specific T cells
by expression of 4-1BB and/or CD69.
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4.2.5 The frequency of IL-10 secreting CD8+ T cells detected fluctuates
over time
A longitudinal analysis to assess the stability of CD8+ T cell IL-10 responses to HCMV ORFs
was carried out in four seropositive donors. Donor CMV324 was sampled at seven time points
over three years. PBMC depleted of CD4+ T cells were stimulated with overlapping peptide
pools spanning the ORFs of gB, pp65, IE1, UL138, LUNA, US28, UL111A, and UL144
and analysed for IL-10 secretion by FluoroSpot assay. There was very little consistency in
the positive CD4+ T cells responses over time to certain ORFs, for example clear positive
responses to gB, pp65, and US28 were present at the same three of the seven sampled time
points, but were absent at the other four time points (Figure 4.14). IL-10 responses to UL138,
LUNA, UL111A, and UL144 were consistently negative, although there was one time point
(10.5.17), with positive responses to these ORFs. An additional response was also observed
to UL138, although this was absent for the further five time points. (Figure 4.14). This time
point was also one that was positive for responses to gB, pp65, and US28 (Figure 4.14).
The fluctuations in CD8+ T cell IL-10 responses can be further illustrated by the changes
in the number of positive responses (those over 50 SFU/106) across the seven sample time
points. Taking into account responses to all 8 ORFs, the number of positive responses varied
from one to seven (Figure 4.15). Although there were positive responses to two of the three
lytic ORFs at only three of the seven time points, there was at least one positive response to
the latency-associated ORFs at every time point, although these varied from one to all five
(Figure 4.15).
Donor CMV319 was sampled four times over a two and half year period. There was no
consistent detection of ORF-specific responses over the four sampling points to any ORF
(Figure 4.16). Of the responses detected at two or more time points, there were often large
differences in the frequencies of IL-10 secreting CD8+ T cells detected between sampling
times. This was especially true of pp65, UL138, and US28 responses (Figure 4.16). There
was also a high frequency gB response that was detected on only one of the four time points
(Figure 4.16).
Two donors were tested at two time points for their CD8+ T cell IL-10 responses.
Differences in the ORF-specific responses and the frequencies of IL-10 secreting cells were
detected between the two time points. For donor CMV323, clear responses to LUNA and
UL138 were detected on both occasions, while clear responses to IE1, US28, and UL111A
were only detected on one occasion (Figure 4.17). Large differences in the frequencies of
IL-10 positive cells were also observed from the first to the second time point in this donor
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(Figure 4.17). Likewise donor CMV307 exhibited extensive variation in the frequencies of
IL-10 positive CD8+ T cells responding to gB, pp65, and US28 between the two sampling
points (Figure 4.18).
HCMV ORF-specific CD8+ T cell responses were therefore observed to vary considerably
over time in four donors. This variation in the frequencies of IL-10 secreting CD8+ T cells
between time points often resulted in fluctuations above or below the positive response
threshold for ORF-specific responses.
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Fig. 4.14 Longitudinal CD8+ T cell IL-10 responses to HCMV ORFs from donor
CMV324. CD8+ T cell responses from one donor were tested at seven separate time
points over three years. PBMC were depleted of CD4+ expressing cells and stimulated with
overlapping peptide pools of HCMV peptides spanning gB, p65, IE1, UL138, LUNA, US28,
UL111A, and UL144, for 48 hours on dual IFNγ/IL-10 FluoroSpot plates. IL-10 secreting
CD8+ T cells were then stained for, counted, and converted to spot forming units (SFU) per
million cells. All samples were run in triplicate and the frequencies of positive cells was
determined by subtracting values in all test wells from the background number of positive
cells in unstimulated well. Each different colour of bar indicates a different sampling time
point.
4.2 Results 135
1 2 3 4 5 6 7 1 2 3 4 5 6 7 1 2 3 4 5 6 7
0
1
2
3
4
5
6
7
8
Time pointN
um
be
r o
f O
RF
s 
CD
8 
+ 
T 
ce
lls
 re
co
gn
is
e 
(>
50
 S
FU
/1
06
 T
 c
el
ls
) CMV324 CD8+ T cell IL-10 responses
All ORFs
Lytic ORFs
Latency-associated ORFs
Lytic ORFs (gB, 
pp65, IE1)
Latency-associated ORFs 
(UL138, LUNA, US28, 
UL111A, UL144)
All ORFs
Time point Date
1 9-Jan-2015
2 5-May-2015
3 2-Jun-2015
4 22-Feb-2016
5 10-May-2017
6 25-Jul-2017
7 16-Sep-2017
Fig. 4.15 Longitudinal analysis of the number of positive CD8+ T cell responses in
donor CMV324. Positive IL-10 CD8+ T cell responses (responses over 50 SFU/106 cells)
are shown at 7 time points over three years from one donor. The dates of each time point
are shown in the table. PBMC were depleted of CD4+ expressing cells and stimulated with
overlapping peptide pools of HCMV peptides spanning gB, p65, IE1, UL138, LUNA, US28,
UL111A, and UL144, for 48 hours on dual IFNγ/IL-10 FluoroSpot plates. The number of
IL-10 positive CD8+ T cells was determined and converted to SFU/106 cells. All samples
were run in triplicate and the frequencies of positive cells was determined by subtracting
values in all test wells from the background number of positive cells in unstimulated well.
The black bars indicate responses to all 8 ORFs, both lytic and latency-associated, the grey to
lytic antigens gB, pp65, and IE, and the white to latency-associated antigens UL138, LUNA,
US28, UL111A, and UL144.
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Fig. 4.16 Longitudinal CD8+ T cell IL-10 responses to HCMV ORFs from donor
CMV319. CD8+ T cell responses from one donor were tested at four separate time points
over 30 months. PBMC were depleted of CD4+ expressing cells and stimulated with
overlapping peptide pools of HCMV peptides spanning gB, p65, IE1, UL138, LUNA, US28,
UL111A, and UL144, for 48 hours on dual IFNγ/IL-10 FluoroSpot plates. IL-10 secreting
CD8+ T cells were then stained for, counted, and converted to spot forming units (SFU) per
million cells. All samples were run in triplicate and the frequencies of positive cells was
determined by subtracting values in all test wells from the background number of positive
cells in unstimulated well. Each different colour of bar indicates a different sampling time
point.
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Fig. 4.17 Longitudinal CD8+ T cell IL-10 responses to HCMV ORFs from donor
CMV323. CD8+ T cell responses from one donor were tested at two separate time points.
PBMC were depleted of CD4+ expressing cells and stimulated with overlapping peptide pools
of HCMV peptides spanning gB, p65, IE1, UL138, LUNA, US28, UL111A, and UL144, for
48 hours on dual IFNγ/IL-10 FluoroSpot plates. IL-10 secreting CD8+ T cells were then
stained for, counted, and converted to spot forming units (SFU) per million cells. All samples
were run in triplicate and the frequencies of positive cells was determined by subtracting
values in all test wells from the background number of positive cells in unstimulated well.
Each different colour of bar indicates a different sampling time point.
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Fig. 4.18 Longitudinal CD8+ T cell IL-10 responses to HCMV ORFs from donor
CMV307. CD8+ T cell responses from one donor were tested at two separate time points.
PBMC were depleted of CD4+ expressing cells and stimulated with overlapping peptide pools
of HCMV peptides spanning gB, p65, IE1, UL138, LUNA, US28, UL111A, and UL144, for
48 hours on dual IFNγ/IL-10 FluoroSpot plates. IL-10 secreting CD8+ T cells were then
stained for, counted, and converted to spot forming units (SFU) per million cells. All samples
were run in triplicate and the frequencies of positive cells was determined by subtracting
values in all test wells from the background number of positive cells in unstimulated well.
Each different colour of bar indicates a different sampling time point.
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4.2.6 The frequency of latency-specific IL-10 secreting CD8+ T cells
does not change with age
The frequencies of detected IL-10 secreting CD8+ T cells could change with increasing
donor age given an assumed longer time of viral carriage. CD8+ T cells secreting IL-10 were
therefore examined across a large donor cohort in relation to the age of donor. CD4+ depleted
PBMC from 45 HCMV seropositive donors ranging in age from 23 to 74 were stimulated
with overlapping peptide pools spanning the ORFs of gB, pp65, IE1, UL138, LUNA, US28,
UL111A, and UL144 and analysed for IL-10 secretion by FluoroSpot assay. CD8+ T cells
secreting IL-10 were found across all ages tested and were of varying magnitudes. There
was no significant correlation between the frequency of IL-10 secreting CD8+ T cells and
the age of donors, according to Spearman rank correlation analysis, in response to any of
the HCMV ORFs tested. However, grouping donors by sex did reveal a significant negative
correlation in males between the frequency of IL-10 secreting CD8+ T cells and increasing
donor age in response to pp65 (Spearman rs = -0.5288, P = 0.0055) (Figure A.4B)
The number of latency-associated ORFs each donor had a positive IL-10 response to
(those greater than 50 SFU/106) was then examined in relation to the age of donors. It could
be expected that older donors, assuming they have been infected for longer periods of time,
might have generated responses to a greater number of ORFs than younger donors. However,
there was no significant difference in the number of ORFs responded to across donor ages
following a Kruskal-Wallis multiple comparisons test, although it is possible that with more
donors these results could change (Figure 4.20).
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Fig. 4.19 Analysis of the magnitudes of CD8+ T cell IL-10 responses to 8 HCMV ORF
peptide pools correlated with donor age. CD4+ depleted PBMC from 45 seropositive
donors were stimulated with HCMV ORF peptide pools for 48 hours on dual IFNγ/IL-
10 FluoroSpot plates and the frequencies of CD8+ T cells secreting IFNγ within each
seropositive donor enumerated and converted to Spot Forming Units (SFU)/106 cells. The
SFU/106 cells of IFNγ secreting CD8+ T cells is shown against donor age for responses to
(A) gB, (B) pp65, (C) IE1, (D) UL138, (E) LUNA, (F) US28, (G) UL111A, and (H) UL144.
The correlation (Spearman rs values and p values shown on each graph), and line of best fit
are shown.
4.2 Results 141
0 1 2 3 4 5
0
10
20
30
40
50
60
70
80
CD8+ T cell IL-10 responses vs age
ORFs responded to
A
ge
Fig. 4.20 The number of latency-associated HCMV ORF peptide pools that CD8+ T
cells respond to with IL-10 secretion across donor age. CD4+ depleted PBMC were
stimulated with HCMV ORF peptide pools for 48 hours on dual IFNγ/IL-10 FluoroSpot
plates and the frequencies of CD8+ T cells secreting IL-10 enumerated and converted to Spot
Forming Units (SFU)/106 cells. The number of latency-associated ORFs out of the five tested
(UL138, LUNA, US28, UL111A, and UL144) that each donor responds to (considered a
positive response if above the threshold 50 SFU/106 cells) is shown against the age of donor.
There were no significant differences between the number of ORFs responded to by CD8+ T
cells and the ages of donors according to Kruskal-Wallis multiple comparisons test.
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4.2.7 The secretion of IL-10 and IFNγ is from distinct CD8+ T cell
populations
CD8+ T cells from HCMV seropositive donors can secrete IFNγ and IL-10 in response
to HCMV ORFs, but whether these were two distinct cellular populations, as was shown
with CD4+ T cells, remained to be determined. By utilising the ability of the FluoroSpot
assay to detect both IFNγ and IL-10 secretion from HCMV specific cells, the frequencies of
such dual cytokine producing CD8+ T cells responding to HCMV ORFs were investigated.
Additionally, this enabled the distribution between IFNγ and IL-10 secreting CD8+ T cells
within individuals to be determined. Of the total responding CD8+ T cells within donors,
there were only low proportions of cells that secreted IL-10 in response to the lytically-
expressed proteins gB, pp65, and IE1, with the majority of donors possessing a dominant
IFNγ response to these ORFs (Figure 4.21A, B, and C). However, CD8+ T cell responses to
the latency-associated ORFs were composed of higher proportions of IL-10 secreting cells
(Figure 4.21 D, E, F, G), with the exception of responses to UL144 which were composed
predominantly of IFNγ secreting cells (Figure 4.21H).
To quantify these differences in the distribution of cytokine responses within individuals,
the dominant cytokine response to each ORF (where over 55% of all cytokine secreting
CD8+ T cells secrete IFNγ or IL-10) was calculated for every donor. The proportions of
donors with an IFNγ or IL-10 dominant response was then plotted for responses to each ORF
(Figure 4.22). Using this analysis, a clear hierarchy in dominant cytokine responses to the
different ORFs was revealed. IFNγ dominant CD8+ T cell responses were most common
to the lytically-expressed proteins, where over 84% of responding donors had a dominant
CD8+ T cell IFNγ response to gB (84.2%), pp65 (88.1%), or IE1 (87%) (Figure 4.22).
Responses to latency-associated proteins were more variable and highlighted differences in
dominant responses to different ORFs. The responses to UL144 for example were similar to
those against the lytically-expressed proteins, where IFNγ dominant responses were very
prevalent, and observed in 86% of all donors (Figure 4.22). Compared to UL144, no other
latency-associated ORF elicited such a high percentage of donors with a dominant IFNγ
response. The proportion of donors with a dominant IFNγ response to US28 and UL111A
was considerably lower, with 67% and 57% of donors respectively (Figure 4.22). Donors
responding to UL138 and LUNA however were much more likely to have a dominant IL-10
CD8+ T cell response, where the proportions of donors with an IFNγ dominant response
were 36% and 27% respectively, the lowest of all responses to latency-associated ORFs
(Figure 4.22). This is also in agreement with the data obtained from CD4+ T cell responses
(Figure 3.22), where UL138- and LUNA-specific responses were the most IL-10 dominant.
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Proportionally, of all the CD8+ T cells that secreted IFNγ or IL-10, there were very few
that secreted both of these cytokines, and this was the case for responses to all the ORFs
tested (Figure 4.21). In the small number of individuals that did have dual responding CD8+
T cells, these cells were a very small proportion of the total CD8+ T cell response (Figure
4.21). Similar to the CD4+ T cell responses, the CD8+ T cells that secreted IFNγ and those
that secreted IL-10 therefore appear to be separate cellular populations.
Long-term carriage of HCMV is associated with changes in the CD8+ T cell compartment,
a number of which are linked to immune dysfunction [340, 348, 350, 656]. It might therefore
be expected that long-term infection with HCMV could result in a shift in the balance
between IFNγ and IL-10 secreting CD8+ T cells, with either a decrease in IFNγ secreting
cells occurring concurrently with an increase in IL-10 secreting cells, or either of these
occurring in isolation. Age can provide a surrogate measure for the duration of HCMV
carriage. To determine if there was a shift towards an IL-10 CD8+ T cell responses with
age, the balance between dominant IL-10 and IFNγ ORF-specific CD8+ T cell responses
were stratified by age group. Each donor’s dominant cytokine response, where over 50%
of all responding CD8+ T cells secreted IFNγ or IL-10, was grouped by age as young
(18-39), middle (40-64), and old (64+). The proportions of IL-10 dominant CD8+ T cell
responses detected in response to UL138 (Figure 4.23A) and US28 (Figure 4.23C) showed
small increasing shifts with age, while responses to UL111A (Figure 4.23D) and UL144
(Figure 4.23E) showed the reverse, with small shifts towards IFNγ bias with age. CD8+ T
cell responses to LUNA showed a decreasing trend with increasing age. The proportions of
donors with an IL-10 dominant CD8+ T cell responses decreased from 50% in the young
age group, to 80% in the middle age group, to 90% in the old age group (Figure 4.23B).
Therefore, taking into account CD8+ T cell responses to all latency-associated proteins, large
shifts in dominant cytokine responses do not seem to occur with increasing age.
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Fig. 4.21 Proportions of CD8+ T cells secreting IL-10 and IFNγ in response to latent
HCMV antigens from individual seropositive donors. PBMC from seropositive donors
were depleted of CD4+ cells and stimulated with overlapping peptide pools from HCMV
ORFs (A) gB, (B) pp65, (C) IE, (D) UL144, (E) US28, (F) UL111A, (G) UL138, and
(H) LUNA, for 48 hours. Following stimulation, IFNγ (black bars) and IL-10 (white bars)
secretion was detected by FluoroSpot and enumerated to spot forming units (SFU), where
each cytokine response was calculated as a proportion of the total number of responding
CD8+ T cells. The proportion of CD8+ T cells of total cytokine secreting cells that secreted
both IFNγ and IL-10 is also shown (blue bars). All samples were run in triplicate with the
mean value shown here. Donors without an IL-10 or IFNγ responses were omitted from each
ORF analysis.
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Fig. 4.22 The distribution of dominant CD8+ T cell IFNγ and IL-10 responses to
HCMV ORF peptide pools. PBMC from seropositive donors were depleted of CD4+
cells and stimulated with overlapping peptide pools from HCMV ORFs gB, pp65, IE, UL138,
LUNA, US28, UL111A, and UL144 for 48 hours. Following stimulation, IFNγ and IL-10
secretion was detected by dual IFNγ/IL-10 FluoroSpot and enumerated to spot forming
units (SFU), which allowed the proportion of each cytokine response to be calculated of the
total CD4+ T cell response. Dominant responses are classed as such when over 55% of the
cytokine secreting cells secreted (A) IFNγ (black bars), or (B) IL-10 (white bars). CD4+ T
cell responses where none of the cytokine secreting population was greater than 55% was
classed as equivocal (grey bars). Donors without an IL-10 or IFNγ responses were omitted
from each ORF analysis and the number of donors analysed for each ORF-specific response
is shown.
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Fig. 4.23 The distribution of dominant CD8+ T cell IFNγ and IL-10 responses to
HCMV ORF peptide pools across age groups. PBMC from seropositive donors were
depleted of CD4+ cells and stimulated with overlapping peptide pools from HCMV ORFs for
48 hours. Following stimulation, IFNγ and IL-10 secretion was detected by dual IFNγ /IL-10
FluoroSpot and enumerated to spot forming units (SFU), which allowed the proportion
of each cytokine response to be calculated of the total CD4+ T cell response. Dominant
responses are classed as such when over 50% of the cytokine secreting cells secreted IFNγ
(black bars), or IL-10 (white bars). The percentage of donors with dominant IFNγ and IL-10
responses to (A) UL138, (B) LUNA, (C) US28, (D) UL111A, and (E) UL144 is shown
for three age groups. Donors were separated into Young (18-39), Middle (40-64), and Old
(64+) age groups. Donors without an IL-10 or IFNγ responses were omitted from each ORF
analysis and the number of donors analysed is shown.
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4.2.8 CD8+ T cell response magnitudes to individual HCMV ORFs
vary depending on sex
The frequencies of IFNγ and IL-10 secreting CD8+ T cells in response to HCMV ORFs was
compared with donor age between males and females, as sex has been shown to be a factor
affecting the immune response to virus infection [619, 620]. The frequencies of CD8+ T cells
secreting IFNγ and IL-10 in response to HCMV ORF peptide pools was grouped according to
sex. CD8+ T cells secreting IFNγ in response to gB were found to be of higher frequency in
male compared to female donors (P = 0.0003, Kruskal-Wallis, Dunn’s multiple comparisons)
(Figure 4.24A). No other significant differences between male and female donors were found
for ORF-specific CD8+ T cell IFNγ responses. Examining IL-10 responses however showed
CD8+ T cells secreting IL-10 in response to LUNA to be of higher frequency in female
donors compared to male donors (P = 0.0376, Kruskal-Wallis, Dunn’s multiple comparisons)
(Figure 4.24B). No other differences in IL-10 response magnitudes were found.
The total within-donor CD8+ T cell response to HCMV ORFs was then compared
between males and females. For each donor, the frequencies of CD8+ T cells that secreted
IFNγ or IL-10 in response to each HCMV ORF was summed and then compared between
males and females. No differences were found in the total IFNγ or IL-10 CD8+ T cell
responses to all eight HCMV ORFs tested (gB, pp65, IE1, UL138, LUNA, US28, UL111A,
and UL144) (Figure 4.25A and B), the lytic ORFs only (gB, pp65, IE1) (Figure 4.25 C and
D), or the latency-associated ORFs (UL138, LUNA, US28, UL111A, and UL144) (Figure
4.25 E and F).
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Fig. 4.24 The frequency of CD8+ T cells secreting IFNγ or IL-10 in response to HCMV
ORF pools from HCMV seropositive donors grouped by sex. PBMC depleted of CD4+
T cells were stimulated with overlapping HCMV ORF peptide pools spanning each antigen
of interest for 48 hours on dual IFNγ /IL-10 FluoroSpot plates. Each peptide pool was tested
in triplicate and the values from all test wells were deducted from the number of background
cells secreting cytokines in the unstimulated wells. Following stimulation, the number of cells
secreting (A) IFNγ from 90 HCMV seropositive donors and (B) the number of cells secreting
IL-10 from 45 HCMV seropositive donors was enumerated by the automated spot counter
and converted to a spot forming unit (SFU) value per million cells. Male responses are
illustrated with open circles (◦), and female responses with filled circles (•). Kruskal-Wallis
multiple comparisons test was carried out between male and female responses to each ORF
and the standard error of the mean shown for each response.
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Fig. 4.25 A comparison of the total frequencies of CD8+ T cells within individual
donors that respond to HCMV ORFs when donors are grouped by sex. The total
frequency of CD8+ T cells responding with IFNγ or IL-10 secretion within individual donors
is shown in male and female donors. PBMC depleted of CD4+ T cells were stimulated with
overlapping HCMV ORF peptide pools spanning each HCMV ORF (gB, pp65, IE, UL138,
LUNA, US28, UL111A, UL144) for 48 hours on dual IFNγ/IL-10 FluoroSpot plates. Each
peptide pool was tested in triplicate and the values from all test wells were deducted from
the number of background cells secreting cytokines in the unstimulated wells. Following
stimulation, the number of cells secreting IFNγ from 90 HCMV seropositive donors and
the number secrering IL-10 from 45 HCMV seropositive donors was enumerated by the
automated spot counter and converted to a spot forming unit (SFU) value per million cells.
Within in each donor (A) the total number of CD8+ T cells secreting IFNγ or (B) IL-10 to all
ORFs is shown. Additionally, (C) the total number of CD4+ T cells secreting IFNγ or (D)
IL-10 in response to lytic ORFs only (gB, pp65, IE) and the total secreting (E) IFNγ and (F)
IL-10 in response to the latency-associated ORFs (UL138, LUNA, US28, UL111A, UL144)
is shown. Male responses are illustrated with open circles (◦), and female responses with
filled circles (•). Mann-Whitney U tests were utilised to compare between male and female
responses to ORFs.
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4.2.9 CD8+ T cells can also secrete TNFα in response to HCMV
latency-associated antigens
Having examined the secretion of IFNγ and IL-10 from CD8+ T cells in response to HCMV
ORF peptide pools, the analysis was extended to include TNFα production. CD8+ T cells
can secrete TNFα in response to lytic HCMV ORF products, but such responses have not
been tested to latency-associated proteins [316, 414, 657]. Using FluoroSpot plates capable
of detecting IFNγ , IL-10, and TNFα secretion simultaneously, the CD8+ T cell responses to
HCMV ORF peptide pools were investigated. CD4+ cell depleted PBMC were stimulated
with overlapping peptide pools spanning the ORFs of gB, pp65, IE1, UL138, LUNA, US28,
UL111A, and UL144, on FluoroSpot plates for 48 hours before assessing the number of
cytokine positive spots. Donors with high background TNFα secretion in their unstimulated
wells were excluded from the data if their positive control did not elicit above twice the
number of TNFα secreting cells than in unstimulated wells. Due to high levels of background
TNFα secretion, eight donors were excluded, leaving five donors for the analysis.
Despite the exclusion of a large proportion of sampled donors, TNFα secretion from
CD8+ T cells was found in response to all of the HCMV ORFs tested. Of the five donors,
responses to gB (5 donors), IE1 (2 donors), pp65 (3 donors), UL138 (2 donors), LUNA (
1 donor), US28 (5 donors), UL111A (2 donors), UL144 (3 donors) were observed (Figure
4.26). CD8+ T cell responses to gB were composed of the highest frequencies of cytokine
secreting cells (Figure 4.26). Responses to the latency-associated ORFs were variable in the
number of cytokine positive cells detected. UL138 and LUNA responses were composed of
the lowest frequencies of TNFα positive CD8+ T cells, compared to UL111A and UL144
responses which were intermediate, and to US28 which were the highest (Figure 4.26).
ICS was also carried out to detect TNFα production from CD8+ T cells. PBMC from
five HCMV seropositive donors were stimulated with viral ORF peptide pools overnight and
stained for TNFα . CD8+ T cells producing TNFα were only detected at high proportions
in one donor, who had positive responses to all the ORFs tested excluding gB and LUNA
(Figure 4.27 illustrated with black filled circles). Low level TNFα responses that were
detectable by ICS were also found in one donor in response to pp65 and UL144, and in
another to IE1 (Figure 4.27). The results obtained by ICS were therefore not consistent with
those obtained by the FluoroSpot assay.
4.2 Results 151
gB IE pp65 UL138 LUNA US28 UL111A UL144
0
500
1000
1500
2000
2500
2500
3750
5000
ORF
SF
U
/M
ill
io
n 
T 
ce
lls
CD8+ TNFα responses
gB IE pp65 UL138 LUNA US28 UL111A UL144
0
500
1000
1500
2000
2000
3000
4000
4500
6000
ORF
SF
U
/M
ill
io
n 
T 
ce
lls
CD8+ T cell responses
TNFα
IFNγ
IL-10
Fig. 4.26 The secretion of TNFα by CD8+ T cells from seropositive donors in response
to HCMV ORF peptide pools. PBMC from five seropositive donors were depleted of CD4+
cells and stimulated with overlapping HCMV ORF peptide pools spanning gB, pp65, IE1,
UL138, LUNA, US28, UL111A, and UL144, for 48 hours on triple IFNγ/IL-10/TNFα
FluoroSpot plates. Each peptide pool was tested in triplicate and the values from all test wells
were deducted from the number of background cells secreting cytokines in the unstimulated
wells. Following stimulation, the number of cells secreting TNFα , IFNγ , and IL-10 was
enumerated by the automated spot counter and converted to a spot forming unit (SFU) value
per million cells.
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Fig. 4.27 Detection of TNFα production by CD8+ T cells in response to HCMV ORF
peptide pools by intracellular cytokine staining. PBMC depleted of CD4+ cells were
stimulated with HCMV ORF peptide pools overnight. The following day, cells were
incubated in monensin before staining intracellularly for TNFα . CD8+ T cells were identified
by gating on CD3+CD8+ cells, and ORF-specific T cells by expression of 4-1BB and/or
CD69. TNFα positive cells are shown as a proportion of these CD3+CD8+ cells. The
data shown are from five seropositive donors and the filled black circles (•) represent the
proportions of TNFα CD8+ T cells from donor, CMV310.
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TNFα secreting CD8+ T cells are generally a separate population to those secreting
IFNγ or IL-10
Having detected CD8+ T cells secreting IFNγ , IL-10, and TNFα in response to HCMV ORF
peptide pools, it remained to be established if CD8+ T cells could secrete these cytokines in
combination. The data obtained from the stimulation of CD8+ T cells from five seropositive
donors with overlapping HCMV ORF peptide pools on triple FluoroSpot plates enabled this
analysis. Following this, the proportions of responding CD8+ T cells within donors that
secreted one cytokine, or combinations of IFNγ /IL-10 together with TNFα were established.
Only donors with cytokine responses above the background frequencies observed in the
unstimulated samples were included in the analysis, which resulted in the omission of several
donor responses. Two donor TNFα/IFNγ responses to UL138 were excluded, while two
donor TNFα/IL-10 responses to IE1 and UL138, and three such responses to LUNA and
UL111A were not included.
CD8+ T cells that secreted both IFNγ and TNFα were only found in two of the five donors
tested (donors 181 and 321) and were never greater than 5% of all cytokine secreting CD8+
T cells (Figure 4.28). There were also no ORF-specific responses that had characteristically
higher frequencies of such dual cytokine secreting cells. Of note, there were no dual secreting
cells detected in response to IE1, UL138, or LUNA (Figure 4.28C, D, G).
Similarly, there were almost no CD8+ T cells that secreted both TNFα and IL-10 in
response to HCMV ORFs, with the exception of responses to gB and pp65 (Figure 4.29A and
B). CD8+ T cells secreting both TNFα and IL-10 in response to gB accounted were found in
three donors (Figure 4.29A). In two of these donors, dual TNFα/IL-10 secreting CD8+ T
cells accounted for approximately 11% of all cytokine secreting cells (Figure 4.29A). This
was also the case for responses to pp65, which were found in three of the five donors tested,
two of which had between 5-10% dual TNFα /IL-10 secreting CD8+ T cells (Figure 4.29B).
Although dual TNFα /IL-10 secreting CD8+ T cells were found in response to UL144 in two
donors, these cells were less than 3% of total UL144-specific cytokine secreting population
(Figure 4.29H).
Dual cytokine secreting CD8+ T cells were also assessed by ICS following HCMV ORF
peptide stimulation. IFNγ/TNFα secreting cells could only be detected in two donors in
response to LUNA and UL144, and these were a very small proportion of responding CD8+
T cells (Figure 4.30A). Only one donor was found to possess a dual IL-10/TNFα response to
IE1 (Figure 4.30B).
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The FluoroSpot and ICS methods utilised were therefore not able to find significant
populations of CD8+ T cells secreting combinations of IL-10, IFNγ , and TNFα , although
firm conclusions cannot be drawn from this limited set of five donors.
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Fig. 4.28 Proportions of CD8+ T cells secreting TNFα and IFNγ in response to latency-
associated HCMV ORF peptide pools from seropositive donors. PBMC from three
HCMV seropositive donors were depleted of CD4+ cells and stimulated with overlapping
peptide pools from HCMV ORFs (A) gB, (B) pp65, (C) IE, (D) LUNA, (E) US28, (F)
UL111A, and (G) UL144 for 48 hours. Following stimulation, IFNγ (black bars) and TNFα
(grey bars) secretion was detected by FluoroSpot and enumerated to spot forming units
(SFU), where each cytokine response was calculated as a proportion of the total CD8+ T cell
response. The proportion of CD8+ T cells of total cytokine secreting cells that secreted both
IFNγ and IL-10 is also shown (blue bars). All samples were run in triplicate and background
spots from unstimulated wells were deducted from the values obtained from test wells. The
mean value from each triplicate is shown here. Donors without an IL-10 or IFNγ responses
were omitted from each ORF analysis.
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Fig. 4.29 Proportions of CD8+ T cells secreting TNFα and IL-10 in response to latency-
associated HCMV ORF peptide pools from seropositive donors. PBMC from three
HCMV seropositive donors were depleted of CD4+ cells and stimulated with overlapping
peptide pools from HCMV ORFs (A) gB, (B) pp65, (C) UL138, (D) LUNA, (E) US28,
(F) UL111A, and (G) UL144 for 48 hours. Following stimulation, IL-10 (white bars) and
TNFα (grey bars) secretion was detected by FluoroSpot and enumerated to spot forming
units (SFU), where each cytokine response was calculated as a proportion of the total CD8+
T cell response. The proportion of CD8+ T cells of total cytokine secreting cells that secreted
both TNFα and IL-10 is also shown (blue bars). All samples were run in triplicate and
background spots from unstimulated wells were deducted from the values obtained from test
wells. The mean value from each triplicate is shown here. Donors without an IL-10 or TNFα
responses were omitted from each ORF analysis.
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Fig. 4.30 Detection of CD8+ T cells capable of co-producing TNFα together with IFNγ
or IL-10 in response to HCMV ORF peptide pools by intracellular cytokine staining.
Whole PBMC isolated from five HCMV seropositive donors were stimulated overnight
with HCMV peptide pools spanning each ORF of interest (gB, pp65, IE, UL138, LUNA,
US28, UL111A, UL144), in the presence of monensin. Stimulated PBMC were then stained
intracellularly for IFNγ , IL-10 and TNFα production from CD4+ T cells. CD4+ T cells
positive for both (A) TNFα and IFNγ , and (B) TNFα and IL-10 are shown. T cells were
identified after gating for live and CD3+ cells.
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4.3 Discussion
4.3.1 CD8+ T cell responses to latency-associated HCMV ORFs
Previous work examining CD8+ T cell responses to latency-associated ORF products have
either been unable to detect responses, or have detected CD8+ T cell responses at frequencies
below a set positive threshold [288, 501]. While low frequency CD8+ T cell responses to
UL138 and LUNA were detected [501], US28, UL111A, and UL144 responses were not
tested directly. The CD4+ and CD8+ T cell responses to these additional latency-associated
ORFs were therefore examined in parallel using the highly sensitive FluoroSpot assay. The
Fluorospot plates used were dual IFNγ/IL-10, chosen to be able to test the IL-10 secretion
from CD4+ T cells simultaneously to IFNγ . The use of these plates however also generated
data for IL-10 secreting CD8+ T cells, which was assessed across the large donor cohort
of 90 individuals ranging in ages from 23 to 74. Donors were assessed by stimulating
CD4+ depleted PBMC with overlapping peptide pools spanning the ORFs of gB, pp65, IE1,
US28, LUNA, UL138, UL111A, and UL144 on dual IFNγ/IL-10 FluoroSpot plates and the
frequencies of cytokine secreting cells were then determined. The threshold for positive
responses in these experiments was set based on the frequencies of cytokine secreting cells
detected following whole peptide ORF stimulation of CD8+ T cells from HCMV seronegative
donors, which was not done previously [501]. Several of these seronegative donors were
found to possess relatively high responses to peptide pool stimulation however, and while it
is entirely plausible that these responses were non-HCMV specific, perhaps due to T cell
cross-reactivity [658], HCMV-specific T cell responses have been observed from individuals
deemed to be seronegative, which could also explain these responses [659, 660].
Unexpectedly, CD8+ T cell responses to all the HCMV ORFs tested were detected, and
this can be largely attributed to the highly sensitive nature of the FluoroSpot assay. There
were differences in the number of donors responding to each ORF, and in the frequencies of
IFNγ secreting CD8+ T cells specific for each ORF. Of the 90 donors tested for CD8+ T cell
responses, the vast majority recognised US28 and UL144, and these responses were more
prevalent than responses to the lytic ORFs gB and IE1. Additionally, responses to these ORFs
were composed of the highest frequencies of IFNγ secreting CD8+ T cells. Around a third of
donors recognised UL138 and LUNA, while nearly half recognised UL111A. Two-thirds of
donors were also capable of responding to two or more of the five latency-associated ORFs
tested (data not shown), making these responses widespread amongst the cohort. The extent
to which these CD8+ T cell responses were present was surprising given the lack of such
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responses reported in the literature. Given the potent antiviral effectors functions of CD8+ T
cells, such widespread recognition of proteins expressed during latency without subsequent
elimination of the virus raises further questions regarding the ability of HCMV to persist
when latent.
The ability of the FluoroSpot to detect both IFNγ and IL-10 secretion simultaneously
enabled an analysis of IL-10 secretion from CD8+ T cells recognising latency-associated
ORF products. Surprisingly, this has uncovered the presence of widespread CD8+ T cell
IL-10 responses. Of the donors that passed the selection criteria, 80% were found to have
an IL-10 response to at least one of the five latency-associated ORF products, and 56% to
at least two (data not shown). These CD8+ T cells were a separate population from those
secreting IFNγ , in the same way HCMV-specific CD4+ T cells were found to be, and were
most frequently found in response to US28, where 67% of donors had a positive IL-10
response. CD8+ T cell IL-10 responses to UL138 and LUNA were also observed relatively
frequently, with a response detected in around 45% of donors. IL-10 responses to UL144 and
UL111A were the least frequently detected of the latency-associated ORFs. In general there
were low responses to the lytic ORFs compared to the latency-associated ORFs, although
pp65 was the exception to this. The ability of pp65-specific CD8+ T cells to produce IL-10
has been reported previously in a study comparing the effects of ageing on the balance
between proinflammatory and anti-inflammatory cytokine secretion [350]. In young HCMV
seropositive donors, pp65-specific CD8+ T cells that secreted IL-10 following in vitro peptide
stimulation made up an average of 2.77% of the pp65-specific CD8+ T cell population, while
this figure was 0.82% in the old group.
It should be noted that in the donor cohort analysed, a large number of participants (56)
had to be excluded from the IL-10 FluoroSpot analysis because they did not pass the selection
criteria, usually due to the levels of background IL-10 secretion being too high. The high
level of IL-10 positive spots in unstimulated control wells could be the result of non-antigen
specific IL-10 secretion and was considerably higher than that observed for IFNγ secretion.
Examining the distribution of IFNγ and IL-10 secretion by CD8+ T cells in response
to HCMV ORFs within individuals revealed similarities with the CD4+ T cell responses.
The responses to the lytic ORFs gB, pp65, and IE1 were dominated by IFNγ secreting
CD8+ T cells, while responses to latency-associated ORFs were composed of much higher
proportions of IL-10 secreting CD8+ T cells, with the exception of UL144 responses. This
IL-10 bias was particular for responses to UL138 and LUNA, where the majority of donors
possessed a dominant CD8+ T cell IL-10 response to these ORFs. Thus, the subset of CD8+
T cells capable of secreting IL-10 on recognition of proteins expressed during latency could
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be aiding virus persistence through the inhibition of antiviral T cell responses, including the
CD8+ T cells capable of secreting IFNγ detected here.
IL-10 secreting CD8+ T cells have been shown to be generated in response to infection
with various acute and chronic viruses. These CD8+ T cells secreting IL-10 have been
described as both regulatory CD8+ T cells, expressing FoxP3 and CD25, in EBV- and
Human immunodeficiency virus (HIV)-infected individuals for example [661–664], as well
as FoxP3-negative effector CD8+ T cells, expressing the transcription factor T-bet and
effector molecules such as granzyme B, CD107a, and TNFα , in animal models of influenza,
respiratory syncitial virus (RSV), and vaccinia virus [665–668]. Several studies have also
demonstrated that IL-10 secreting effector CD8+ T cells were generated transiently and their
decline coincided with viral control [665, 669–671].
During acute virus infection, CD8+ T cells secreting IL-10 are thought to act in a
regulatory capacity by contributing to the prevention of excess inflammation and
immunopathology. This has been demonstrated using mouse models of influenza virus and
RSV where IL-10 secreting CD8+ T cells were found in the airways and/or lungs of infected
animals [665, 666, 672, 673]. These cells acted to regulate the levels of inflammation and
inflammatory cell infiltrate, as demonstrated by the blockade of the IL-10R in infected mice
[665, 666, 672, 673]. While IL-10R blockade resulted in increased pulmonary inflammation
and morbidity it did not have an effect on viral clearance [665, 666, 672]. A protective role
of IL-10 produced by CD8+ T cells has also been demonstrated in a mouse coronavirus
model where these cells reduced the severity of coronavirus-induced acute encepahilitis
[669]. In these studies showing a protective role for IL-10 secreting CD8+ T cells during
viral infection, the phenotypes of the CD8+ T cells were either not examined or possessed
markers of effector T cells. Interestingly, one report identifying regulatory FoxP3-positive
CD8+ T cells that secreted IL-10 in response to influenza infection found that these cells
were responsible for the suppression of CD8+ T cell effector responses and increased the
mortality of infected mice [662]. The researchers also found a population of FoxP3-negative
IL-10 secreting CD8+ T cells that were induced but did not test if these acted to control lung
inflammation and improve mouse morbidity and mortality [662].
CD8+ T cells that secrete IL-10 in response to chronic viruses such as HIV and Hepatitis
C virus have also been described [674–680]. In HIV-1 infected individuals who were
antiretroviral naive, the presence of IL-10 secreting CD8+ T cells, as detected by ICS
following Gag peptide pool stimulation, was associated with a lower CD4+ T cell count,
higher levels of HIV-1 plasma RNA, and a decreased frequency of Gag-specific CD107a/b-
positive CD8+ T cells [674]. HIV Gag- and Nef-specific CD8+ T cells that secreted IL-10
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did not express FoxP3 and removal of these cells resulted in an increase in the frequency of
HIV-specific CD8+ T cells expressing CD107a/b and IL-2 [675, 676]. A further study also
found the majority of the IL-10 secreting CD8+ T cells specific for HIV-1 to be negative for
FoxP3 [678].
During chronic viral infection, the immunosuppressive functions of IL-10 that act to
prevent immunopathology from chronic inflammation could also aid the persistence of the
virus. During HIV-1 infection, the IL-10 produced by CD8+ T cells is thought to contribute
to the avoidance of the host’s immune system as evidenced by their ability to suppress
HIV-specific CD8+ T cell mediated cytolysis [674, 675]. However, it has also been shown
that patients with greater proportions of CD8+ T cells positive for IL-10 and negative for
IFNγ had better control of viraemia compared to those with more dual producing CD8+ T
cells. This suggests that these cells arise as a protective response to inflammation resulting
from chronic antigenic stimulation [678]. Similarly, there is evidence that during chronic
HCV infection virus-specific CD8+ T cells secreting IL-10 are involved in reducing liver
immunopathology [680] by protecting against hepatocellular necrosis and liver fibrosis
caused by chronic inflammation [679]. However, a recent report claims that IL-10 producing
CD8+ T cells contribute to liver immunopathology by preventing the antigen-dependent
apoptosis of IFNγ secreting effector CD8+ T cells [681].
Few investigations have focused on IL-10 secreting CD8+ T cells during HCMV infection.
From one such report, carried out on donors co-infected with HIV [678], it was not clear
what role these cells have during infection and if they are generated protectively and/or by
the virus to aid persistence [678]. Ten donors were tested for HCMV responses and eight
of these possessed a CD8+ T cell IL-10 response. Of these individuals, dual IFNγ/IL-10
secreting cells, detected by flow cytometry following enrichment of cytokine secreting cells
stimulated with pp65 peptides, made up the majority of responding CD8+ T cells in most
donors [678]. In a number of previous studies carried out on a range of viruses, CD8+ T
cells secreting IL-10 have also mainly been reported as dual producers of IL-10 and IFNγ ,
where IFNγ was also examined [665, 669, 670, 672, 673, 678]. These studies run contrary
to the work presented here, where very low proportions of dual IL-10/IFNγ secreting CD8+
T cells were detected in response to HCMV. However, one important difference between
the previously published work and the results presented here is that the previous studies
were carried out in mouse models, or in HIV/HCMV co-infected individuals. Data from
humans do report the presence of CD8+ T cells from HIV and HCV infected individuals
that secreted IL-10 without IFNγ [677–680], which supports the findings that single IL-10
producing CD8+ T cells can be generated from virus infection.
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Carrying out in depth phenotypic and functional analyses of IL-10 secreting CD8+ T
cells in response to HCMV will determine if these cells express markers of regulatory or
effector T cells, whether these cells are capable of anti-viral effector functions, and advance
our understanding of the role these cells have during infection. Furthermore, the conditions
which lead to the generation of these cells should be investigated. It has been demonstrated
that IL-10 expression from CD8+ T cells can been induced by IL-4 alone [682] or together
with IL-12 [683], by blockade of TNFα [684], and by IL-27 [668, 673, 685, 686]. The
role of IL-27 in promoting IL-10 expression from CD8+ T cells has also been studied in
the context of viral infection. In a mouse model of influenza, optimal IL-10 expression
from CD8+ T cells required the synergy of CD4+ T cell derived IL-2 with IL-27, and
CD8+ T cells that expressed IL-10 also expressed high levels of the transcription factor
Blimp-1 [673]. Although IL-27 was shown to be required for CD8+ T cell IL-10 expression
in response to acute virus infection of the lung [668, 673], memory CD8+ T cells upon
rechallenge were found to be unresponsive to IL-27 and were unable to produce IL-10 due
to the downregulation of surface gp130 [668]. It could therefore be possible that during
primary HCMV infection, IL-27 is involved in the initial generation of IL-10 secreting CD8+
T cells, which arise as a protective response against immunopathology. These cells might
then be maintained by the virus following the establishment of the immunosuppressive latent
microenvironment. To begin to answer these questions, initial work on the generation of
HCMV-specific IL-10 secreting T cells following primary infection will be presented in the
following chapter.
CD8+ T cells were also tested for their ability to secrete the anti-viral cytokine TNFα
in response to HCMV ORF peptide pools by FluoroSpot. TNFα responses to all ORFs
tested were observed from CD8+ T cells but due to high background TNFα secretion the
majority of donors had to be excluded from the analysis. The highest frequency responses
were detected in response to gB and US28 while the lowest in response to UL138 and LUNA.
ICS was also utilised to validate these TNFα responses but robust responses were found
from only one of the five donors. TNFα secretion by HCMV-specific CD8+ T cells has been
detected by ICS by many others [287, 414, 687], and the failure to detect them here could be
partly due to the ICS protocol used. Better optimisation might therefore be required in order
to capture TNFα secretion.
Of the limited number of donors analysed for TNFα , IL-10, and IFNγ simultaneously
by FluoroSpot, none were found to possess cells that secreted all three cytokines, and very
few had CD8+ T cells secreting both IL-10 and TNFα , or IFNγ and TNFα . Although
this preliminary work might indicate these are three distinct cellular populations within the
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HCMV-specific CD8+ T cell pool, several investigations have found polyfunctional HCMV-
specific dual secreting IFNγ and TNFα CD8+ T cells by ICS [316, 414, 657]. Such dual
secreting CD8+ T cells were only found in two of five donors tested by ICS here, and none
were found responding to lytic ORFs such as pp65 and IE1, as previous research has shown
[316, 414, 657]. The absence of these dual secreting cells as measured by FluoroSpot or ICS
here could be due to the very small donor cohort and problems associated with background
TNFα secretion in the FluoroSpot, in addition to sub-optimal staining protocols for ICS,
especially as dual TNFα/IFNγ secreting cells were also not detected in positive control
(CD3/CD28 MAb mix) treated cells (data not shown), although they were in the FluoroSpot
assay.
The finding that IFNγ secreting CD8+ T cells were a separate population to those
secreting IL-10, and possibly TNFα , raises the question of whether epitope-specific CD8+
T cells from each of these populations originate from the same parent cell or are distinct T
cell lineages. The experiments conducted here used peptides derived from whole ORFs to
stimulate cells. However, individual peptides could be used to map CD8+ T cell responses,
where it might be expected that CD8+ T cells secreting IFNγ or IL-10 in response to a single
peptide would be the same T cell clonotype. Doing so could therefore give an indication
of whether T cell clones diverge from their parent cell into two distinct cytokine secreting
populations specific for the same peptide; this is addressed in a subsequent chapter.
4.3.2 Fluctuations in the frequency of CD8+ T cell responses over time
The CD8+ T cell responses to individual HCMV ORFs were found to vary across independent
sampling points spanning a three year period, with responses to certain ORFs found to be
more variable than others. CD8+ T cell IFNγ responses were highly consistent across time
points in response to the lytically-expressed proteins gB, pp65, and IE1, and to the latency-
associated proteins US28 and UL144. Greater variation across time points was observed in
responses to UL138, LUNA, and UL111A. The CD8+ T cell IL-10 responses displayed much
greater variability across the sampled time points with the frequencies of IL-10 secreting cells
detected fluctuating below and above the seronegative threshold point frequently, resulting in
the respective loss or gain of positive responses. There were no ORFs that were consistently
responded to at all time points and these fluctuations often resulted in very large differences
in the frequencies of IL-10 secreting CD8+ T cells detected between time points.
As only two donors could be sampled on more than three instances it is not possible
to generalise these differences in ORF-specific fluctuations to the broader population. It is
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however clear that there were differences in the magnitudes of IFNγ and IL-10 secreting
CD8+ T cells in response to HCMV ORFs when the same donors were re-challenged multiple
times, and these differences were considerably greater for IL-10 secreting CD8+ T cells.
Fluctuations in the CD8+ T cell response to HCMV over time have been reported
previously in studies utilising ELISpot assays [291, 642]. One of these, using IFNγ ELISpot,
examined the CD8+ T cell responses to HCMV ORFs, including IE1 and pp65, at multiple
time points over a 40 month period, and also found variation in the donor specific response
frequencies over time [291]. A number of factors could be driving these fluctuations in
detected cytokine secreting CD8+ T cell frequencies, such as periodic reactivations of
HCMV from latency serving to expand certain antigen-specific CD8+ T cells. Exercise
has also been shown to affect the peripheral blood CD8+ T cell compartment, and it was
demonstrated that the mobilisation of effector memory CD8+ T cells was greatest in HCMV
seropositive individuals, compared to seronegative participants, during a one hour period
of exercise [688]. It is also possible that such fluctuations were observed because of the
nature of sampling CD8+ T cells from the peripheral blood compartment. As the peripheral
blood contains a small percentage of total T cells, and is more prone to fluctuations in T
cell composition, caused for example by active infections and environmental perturbations,
it is more likely to lead to differences in HCMV ORF-specific responses detected across
many time points [618, 643, 644]. Furthermore it has been suggested that the blood could
act as a repository for newly activated CD8+ T cells generated in response to infection [398],
such as observed following yellow fever virus and smallpox vaccination [689]. From the
experiments carried out here, there were particular time points where high frequency IFNγ or
IL-10 responses to many HCMV ORFs were detected, which could be indicative of a greater
infiltration of HCMV-specific CD8+ T cells into the blood or a decrease in non-HCMV
specific CD8+ T cells in the blood. To investigate this possibility, total lymphocyte counts in
combination with CD3+/CD8+ phenotyping could be carried out which would also allow
for changes in the size of the CD8+ T cell compartment to be taken into account over time.
The extent of the fluctuations in T cell responses observed also raises the question of how
reproducible the data are from studies that take a snapshot approach of T cell responses.
This might especially be a problem for studies using smaller donor cohorts as such sampling
dependent variations would be amplified, particularly those looking for correlations, as the
fluctuations in frequencies of responding T cells can be very high across time points.
4.3 Discussion 165
4.3.3 CD8+ T cell responses and age
Previous investigations into the effects of long-term HCMV carriage on age-related
immunosenescence have reported a number of changes in the CD8+ T cell compartment.
Relatively early following HCMV infection, the CD8+ memory T cell pool increases
[297, 690]. Characteristic of HCMV infection, an expansion of CD8+ T cells considered to
be highly differentiated occurs. These cells exhibit features such as a loss of CD27 and
CD28 expression, upregulated expression of CD57 and killer cell lectin-like receptor
subfamily G member 1 (KLRG1), and the re-expression of CD45RA [292, 300, 304]. Such
T cells could potentially be dysfunctional as they often lose the ability to secrete cytokines
such as IFNγ , and display limited proliferative capacity [340, 341, 348, 350, 429, 656]. The
expansion of highly differentiated CD8+ T cells with age, and subsequent loss of naive
CD8+ T cells, has been linked to mortality [351, 352, 617], however such highly
differentiated CD8+ T cells have also been found amongst young HCMV-positive
individuals [301], and were shown to be proliferative given correct co-stimulation [432, 433].
Additionally, despite viral reactivation occurring more frequently in older HCMV infected
individuals, these did not result in overt clinical disease, which could indicate a retained
ability to control HCMV in the aged [434]. However, the increase in HCMV DNA detected
in urine and blood of elderly individuals [434, 435] could be indicative of a reduced ability
to control reactivating virus, perhaps caused by the effects of the lifelong carriage of HCMV
on the immune system.
HCMV possesses a multitude of immune evasion strategies to facilitate viral persistence.
The secretion of immunosuppressive cytokines by latently infected cells, bystander cells, and
HCMV-specific CD4+ T cells could all contribute to this immune evasion by suppressing T
cell function [501, 605]. It might be expected that longer carriage of HCMV could result
in more pronounced effects of such immunomodulatory cytokines on antiviral CD8+ T
cell responses and lead to immune dysfunction. One manifestation of immune dysfunction
could be a decrease in HCMV-specific IFNγ secreting CD8+ T cells. Given the difficulty in
following individuals from the time of primary infection, the effects of age on IFNγ secreting
CD8+ T cells was examined as an indirect measure for time of viral carriage. The use of the
dual IFNγ/IL-10 FluoroSpot plates to do this also enabled the examination of changes in
IL-10 secreting CD8+ T cells with increasing age, which could be predicted to increase. The
breadth and magnitude of HCMV ORF-specific CD8+ T cell responses in relation to donor
age were thus studied by a cross-sectional approach on donors ranging from 23 to 74 years
of age.
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No significant association between the frequency of CD8+ T cells secreting IFNγ or
IL-10 and age was found for any of the ORF-specific responses examined to gB, pp65, IE1,
UL138, LUNA, US28, UL111A, or UL144. Age also did not have an affect on the breadth
of CD8+ T cell IFNγ or IL-10 responses to HCMV ORFs as might be expected from a
presumed longer time of virus carriage. Previous work from our group on a smaller subset
of donors also found the breadth of CD8+ T cell IFNγ responses to be independent of age
[291].
The balance between IFNγ and IL-10 secretion within individuals was largely unaffected
by age. Small changes in the proportion of donors with dominant CD8+ T cell IL-10
responses were observed for UL138 and US28, which went up with age, and UL111A and
UL144, which went down with age, while a large shift in the balance towards IL-10 producing
LUNA-specific CD8+ cells was observed with increasing age. It is unclear whether such
shifts have any impact on immune response to HCMV, especially given the persistence of
detectable IFNγ responses into old age, particularly for US28, UL111A, and UL144. Any
potential immune dysfunction caused by HCMV with increasing age therefore does not
seem to affect the frequencies of HCMV-specific CD8+ T cells secreting IFNγ or IL-10.
One possible explanation for not finding a decline in IFNγ secreting CD8+ T cells as has
been reported previously [350] is due to the whole ORF approach that was utilised here. By
stimulating T cells with peptide pools spanning the entire predicted ORFs, this has likely
captured a broader set of HCMV ORF-specific CD8+ T cell responses compared to the single
peptide tetramer-based approach used in this study [350].
4.3.4 CD8+ T cell responses and sex
The ORF-specific CD8+ T cell responses were also examined according to sex. Widespread
differences between male and female donors were not observed, however the frequency of
IFNγ secreting CD8+ T cells was significantly higher in male compared to female donors
in response to gB, and CD8+ T cell IL-10 responses were found to be significantly higher
in female donors in response to LUNA. Furthermore, no differences were found between
males and females when total individual responses to all ORFs, lytic ORFs only, or latency-
associated ORFs only were compared. This contrasts with CD4+ T cell responses where
male donors had greater frequencies of IFNγ and IL-10 secreting cells when taking into
account total responses to all ORFs, lytic ORFs only, or latency-associated ORFs only.
Chapter 5
The Generation of HCMV-specific IL-10
Secreting T cells
5.1 Introduction
In previous chapters I have demonstrated that T cells specific to a number of HCMV ORFs
can secrete IL-10 [350, 501]. Of the HCMV-specific T cell responses identified, IL-10
secreting T cells were most commonly found in response to latency-associated proteins of
HCMV. This IL-10 secretion, in addition to the secretion of TGFβ , could be suppressing
antiviral T cell responses during latency and therefore aiding viral persistence. It is possible
that these T cells are being generated as a result of lifelong viral carriage which could be
driving T cell differentiation towards an IL-10 phenotype. However, in a large donor cohort,
no differences were observed in the magnitudes of peripheral blood derived CD4+ or CD8+
T cell IL-10 responses with increasing age, demonstrating that IL-10 secreting T cells do not
accumulate with longer viral carriage during the latent phase of infection (Chapter 3 and 4)
[691].
Whether responses to latency-associated proteins are detectable during primary infection
remains to be established, as prior studies have mainly focused on responses to lytic ORF
products such as pp65 [333, 373]. IL-10 secreting T cells could therefore be generated during
the primary immune response to HCMV infection, as latency-associated proteins are also
expressed during lytic infection. A well established model of primary immune responses
using seronegative renal transplant patients receiving a seropositive kidney was used to
investigate these T cell responses [373, 400]. This work was carried out with material from
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Dr Ester Remmerswaal and Professors Ineke ten Berge and Rene Van Lier (Academisch
Medisch Centrum, AMC Amsterdam) who provided the blood samples from transplant
recipients and data for viral loads.
5.2 Results
5.2.1 T cell responses to pp71 and US3
The donor cohort used to investigate CD4+ and CD8+ T cell responses to latency-associated
HCMV ORFs was also tested for their ability to respond to the lytic ORFs US3 and pp71.
US3 and pp71 (UL82) were found to be in the top 15 most recognised ORFs by T cells in
a whole HCMV ORF screen [288], warranting their further study. US3 is expressed at IE
time points and has a role in immune evasion, while the tegument protein pp71 is expressed
at late time points [574, 692, 693]. PBMC were depleted of either CD4+ or CD8+ cells
then stimulated with overlapping peptide pools spanning the ORFs of pp71 and US3 on
dual IFNγ /IL-10 FluoroSpot plates. After 48 hours the frequencies of cytokine positive cells
were then determined. Extensive CD4+ and CD8+ T cell IFNγ responses were observed in
response to US3 (CD4+ T cell responses in 51/91 donors [56%], CD8+ T cell responses in
60/91 donors [66%]), and pp71 (CD4+ T cell responses in 57/91 donors [63%], CD8+ T cell
responses in 66/91 donors [73%]) (Figure 5.1A and 5.2A). However, high background levels
of non-specific IFNγ secretion in response to pp71 was observed in HCMV seronegative
individuals in both CD4+ and CD8+ T cells, which could indicate that the threshold for
positive responses to pp71 is greater than 100 SFU/106 T cells. Examining the number of
donors with high frequency T cell responses, using a threshold of 250 SFU/106 T cells as
previously, revealed CD4+ T cell high responders to US3 in 26/91 donors (29%) (Figure
5.1A), and in 42/91 donors (46%) for CD8+ T cell responses (Figure 5.2A). High frequency
responses to pp71 were detected in 28/91 donors (31%) for CD4+ T cell responses (Figure
5.1A), and in 40/91 donors (44%) for CD8+ T cell responses (Figure 5.2A). The responses
from all HCMV seronegative donors fell below this threshold for high frequency responses.
Surprisingly, a large proportion of seropositive donors possessed IL-10 secreting T cells
in response to US3 (CD4+ T cell responses in 27/67 donors [40%], CD8+ T cell responses in
26/46 donors [57%]), and pp71 (CD4+ T cell responses in 28/67 donors [42%], CD8+ T cell
responses in 30/46 donors [65%]) (Figure 5.1B and 5.2B). These IL-10 responses were the
most commonly detected in comparison with responses to the other lytic ORFs gB, pp65,
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and IE1 (Figure 3.16 and 4.12), with the exception of CD8+ T cell IL-10 responses to pp65
which were more prevalent than those to pp71.
The relative proportions of IFNγ and IL-10 secreting T cells within individuals was
then determined using the ability of the FluoroSpot to count dual secreting cells. CD4+
T cell responses to US3 and pp71 were composed of high proportions of IL-10 secreting
cells with many individuals possessing a dominant IL-10 response to these ORFs (Figure
5.3). Comparatively, CD4+ T cell responses to other lytic ORFs gB, pp65, and IE1 were
composed of considerably lower propotions of IL-10 secreting cells and were dominated by
IFNγ secreting cells (Figure 3.21). Similarly, a large number of donors possessed CD8+ T
cell responses to US3 and pp71 that were predominantly composed of IL-10 secreting cells
(Figure 5.4), which is in contrast to the corresponding responses to gB, pp65, and IE1 (Figure
4.21). Low proportions of dual IFNγ and IL-10 secreting T cells were found in response to
US3 and pp71, with the highest proportions reaching around 10% of total responses to US3
(Figure 5.3A and 5.4A), although these were not observed in all donors (Figure 5.3 and 5.4).
The T cells responding to US3 and pp71 therefore also seem to be separate IFNγ and IL-10
secreting populations.
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Fig. 5.1 The frequency of CD4+ T cells from HCMV seropositive and seronegative
donors that secrete IFNγ or IL-10 in response to US3 and pp71. PBMC were depleted of
CD8+ T cells and stimulated with HCMV peptide pools spanning the ORFs of US3 and pp71
for 48 hours on dual IFNγ /IL-10 FluoroSpot plates. Each peptide pool was tested in triplicate
and the values from the number of background cells secreting cytokines in the unstimulated
wells was deducted from all test wells. Following stimulation, the number of (A) IFNγ or
(B) IL-10 positive spots was enumerated by the automated cell counter and converted to
a spot forming unit (SFU) value per million cells. Results from 91 seropositive and eight
seronegative donors displayed for IFNγ responses while results from 67 seropositive and
three seronegative donors displayed for IL-10 responses. The dotted line at 100 SFU/106
cells indicates the threshold for positive responses. Seropositive donors are shown with open
circles (◦) while seronegative donors are illustrated with filled black circles (•).
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Fig. 5.2 The frequency of CD8+ T cells from HCMV seropositive and seronegative
donors that secrete IFNγ or IL-10 in response to US3 and pp71. PBMC were depleted of
CD4+ T cells and stimulated with HCMV peptide pools spanning the ORFs of US3 and pp71
for 48 hours on dual IFNγ /IL-10 FluoroSpot plates. Each peptide pool was tested in triplicate
and the values from the number of background cells secreting cytokines in the unstimulated
wells was deducted from all test wells. Following stimulation, the number of (A) IFNγ or
(B) IL-10 positive spots was enumerated by the automated cell counter and converted to
a spot forming unit (SFU) value per million cells. Results from 91 seropositive and eight
seronegative donors displayed for IFNγ responses while results from 46 seropositive and
three seronegative donors displayed for IL-10 responses. The dotted line at 100 SFU/106
cells indicates the threshold for positive responses. Seropositive donors are shown with open
circles (◦) while seronegative donors are illustrated with filled black circles (•).
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Fig. 5.3 The proportions of CD4+ T cells secreting IL-10 and IFNγ in response to US3
and pp71 from individual seropositive donors. PBMC seropositive donors were depleted
of CD8+ cells and stimulated with overlapping peptide pools from HCMV ORFs (A) US3,
and (B) pp71, for 48 hours. Following stimulation, IFNγ (black bars) and IL-10 (white bars)
secretion was detected by FluoroSpot and enumerated to spot forming units (SFU), where
each cytokine response was calculated as a proportion of the total CD4+ T cell response.
The proportion of CD4+ T cells of total cytokine secreting cells that secreted both IFNγ and
IL-10 is also shown (blue bars). All samples were run in triplicate with the mean value shown
here. Donors without an IL-10 or IFNγ response were omitted from each ORF analysis.
5.2 Results 173
C
M
V
32
4
C
M
V
32
3
A
R
IA
03
2
C
M
V
32
8
A
R
IA
14
5
A
R
IA
13
3
A
R
IA
04
3
C
M
V
32
1
A
R
IA
05
5
A
R
IA
04
5
A
R
IA
12
6
A
R
IA
13
1
A
R
IA
06
3
A
R
IA
07
2
A
R
IA
14
8
A
R
IA
14
6
A
R
IA
14
7
A
R
IA
06
6
C
M
V
31
9
A
R
IA
04
7
A
R
IA
05
2
A
R
IA
04
6
C
M
V
30
7
A
R
IA
06
2
A
R
IA
07
6
A
R
IA
08
0
A
R
IA
04
4
A
R
IA
06
9
A
R
IA
01
0
A
R
IA
07
8
C
M
V
32
7
A
R
IA
06
1
A
R
IA
13
7
C
M
V
32
0
A
R
IA
15
8
C
M
V
30
1
A
R
IA
04
8
A
R
IA
02
2
A
R
IA
08
5
A
R
IA
02
4
A
R
IA
06
4
A
R
IA
03
1
A
R
IA
01
4
A
R
IA
03
4
A
R
IA
01
9
A
R
IA
01
6
A
R
IA
03
3
A
R
IA
06
7
A
R
IA
00
2
A
R
IA
01
3
A
R
IA
05
4
A
R
IA
02
8
A
R
IA
07
9
A
R
IA
12
7
A
R
IA
07
1
A
R
IA
12
4
A
R
IA
12
3
A
R
IA
13
8
A
R
IA
14
3
A
R
IA
12
1
A
R
IA
13
6
A
R
IA
05
1
A
R
IA
12
8
A
R
IA
12
0
A
R
IA
14
0
0
25
50
75
100
Donor
%
 U
S3
 s
pe
ci
fic
 C
D
8+
 T
 c
el
l 
IFNγ
IL-10
Dual
CD8+ T cell US3
n=65
C
M
V
32
4
C
M
V
32
3
A
R
IA
01
7
A
R
IA
03
2
C
M
V
32
8
A
R
IA
14
5
A
R
IA
13
3
A
R
IA
04
3
A
R
IA
05
5
A
R
IA
04
5
A
R
IA
12
6
A
R
IA
13
1
A
R
IA
06
3
A
R
IA
14
8
A
R
IA
14
6
A
R
IA
14
7
A
R
IA
06
6
A
R
IA
08
1
C
M
V
31
9
A
R
IA
13
4
A
R
IA
04
7
A
R
IA
05
2
A
R
IA
04
6
C
M
V
30
7
A
R
IA
06
2
A
R
IA
07
6
A
R
IA
02
6
A
R
IA
08
0
A
R
IA
04
4
A
R
IA
06
9
A
R
IA
02
1
A
R
IA
01
0
A
R
IA
02
9
A
R
IA
07
8
C
M
V
32
7
A
R
IA
06
1
A
R
IA
01
5
A
R
IA
13
7
C
M
V
32
0
A
R
IA
15
8
A
R
IA
02
2
A
R
IA
06
4
A
R
IA
03
1
A
R
IA
01
4
A
R
IA
03
4
A
R
IA
01
9
A
R
IA
01
6
A
R
IA
03
3
A
R
IA
06
7
A
R
IA
07
3
A
R
IA
01
3
A
R
IA
02
8
A
R
IA
12
7
A
R
IA
07
1
A
R
IA
01
2
A
R
IA
12
4
A
R
IA
13
9
A
R
IA
01
1
A
R
IA
12
3
A
R
IA
13
8
A
R
IA
14
3
A
R
IA
12
1
A
R
IA
13
6
A
R
IA
05
1
A
R
IA
12
8
A
R
IA
12
0
A
R
IA
07
0
A
R
IA
14
0
0
25
50
75
100
Donor
%
 p
p7
1 
sp
ec
ifi
c 
C
D
8+
 T
 c
el
l 
IFNγ
IL-10
Dual
CD8+ T cell pp71
n=68
A
B
Fig. 5.4 The proportions of CD8+ T cells secreting IL-10 and IFNγ in response to US3
and pp71 from individual seropositive donors. PBMC seropositive donors were depleted
of CD4+ cells and stimulated with overlapping peptide pools from HCMV ORFs (A) US3,
and (B) pp71, for 48 hours. Following stimulation, IFNγ (black bars) and IL-10 (white bars)
secretion was detected by FluoroSpot and enumerated to spot forming units (SFU), where
each cytokine response was calculated as a proportion of the total CD4+ T cell response.
The proportion of CD4+ T cells of total cytokine secreting cells that secreted both IFNγ and
IL-10 is also shown (blue bars). All samples were run in triplicate with the mean value shown
here. Donors without an IL-10 or IFNγ response were omitted from each ORF analysis.
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5.2.2 T cell responses to HCMV following primary infection
The identification of IL-10 secreting CD4+ and CD8+ T cells responding to HCMV ORFs
in a large donor cohort led to the question of when in the course of infection these cells
are generated. The secretion of immunosuppressive IL-10 could be further aiding HCMV
persistence during latency, and it remains to be determined if T cells secreting IL-10 are
generated early during primary infection or during longer term carriage of the virus. The
sampling of responses from a large donor cohort of varying ages did not find any significant
differences in IL-10 secreting T cell frequencies with age, but as these experiments were
cross-sectional, even donors in the youngest age groups could have been infected for over
20 years if infection occurred in early life. Therefore, there was a lack of data from primary
infection and the weeks following from this.
To investigate the generation of IFNγ and IL-10 secreting HCMV-specific T cells
following primary infection, peripheral blood samples from seven individuals who
underwent kidney transplantation were analysed. Prior to transplantation, the recipients were
seronegative for HCMV, but were longitudinally studied after receiving kidneys from
seropositive donors, as the likelihood of primary HCMV infection is very high in these
situations [373, 400]. Blood samples were collected at multiple time points beginning from
between one day prior, to two days post, transplantation, with subsequent samples collected
at varying times points up to a maximum time point of 158 weeks post-transplantation. The
patient details, including their immunosuppressive drug regimes, are summarised in Table
5.1.
Patient
Number
Age
at Tx
Immunosuppressive
Drugs
Peak Viraemia
(weeks post Tx)
HCMV Seroconversion
(weeks post Tx)
133 66 P, CSA, MMF 12.14 15.71
136 31 P, CSA, MMF 8.57 10.57
197 31 P, MMF, FK, CD25MAb 14.00 14.00
352 26 P, CSA, MMF, CD25MAb 7.14 7.14
365 54 P, CSA, MMF, CD25MAb 6.86 8.57
439 21 P, MMF, FK, CD25MAb 9.00 10.00
574 50 P, MMF, FK, CD25MAb 6.29 25.43
Table 5.1 Transplant recipient information. Tx = transplantation, immunosuppressive drugs
P = prednisolone, CSA = cyclosporin A, MMF = mycophenolate mofetil, FK = Tacrolimus,
CD25MAb = anti-CD25 monoclonal antibodies
Due to the limited lymphocyte numbers available from the clinical samples, HCMV
responses were investigated by combining particular ORF peptide pools together instead
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of testing each ORF individually. Similarly, whole PBMC were stimulated instead of
CD4+ or CD8+ T cell depleted populations. The background cytokine secretion from
unstimulated PBMC was deducted from peptide stimulated samples. To control for variation
in lymphocyte numbers over time, the frequencies of spot forming units detected were
expressed as a proportion of the total CD3+ cell population, as determined by lymphocyte
absolute count data and flow cytometry. In this way the number of CD4+ and CD8+ T cells
responding to HCMV ORF peptide pools together was determined. Pools composed of
UL138, LUNA, US28, and UL111A peptides were made to determine the T cell responses to
latency-associated ORFs without the highly IFNγ biased responses to UL144. UL144 and
pp65 ORF pools were combined, as were IE1 and IE2, while the gB pool was used in isolation.
Additionally, as widespread CD4+ and CD8+ T cell IL-10 responses to US3 and pp71 were
detected, these ORF pools were combined and tested together. PBMC were defrosted in
batches at each time point and stimulated with these ORF pools on FluoroSpot plates capable
of detecting IFNγ and IL-10 for 48 hours before the frequencies of cytokine positive cells
were determined. Representative individual wells obtained from the FluoroSpot assay of
patient 133 show IFNγ responses for each time point and highlight the low background
secretion of IFNγ observed in unstimulated T cells (Figure 5.5). Data for HCMV DNAemia
at each time point was provided by our collaborators to give a measure of viral load.
Across the seven donors, detectable IFNγ responses arose immediately following
transplantation in response to nearly all ORF pools. Individual patient IFNγ secretion
followed one of a number of patterns in their immune response in the weeks following
transplantation. In contrast to IFNγ responses, IL-10 secreting T cells were detected much
less frequently and were of lower magnitudes in response to most of the ORF pools tested.
The most consistent IL-10 T cell responses were found to the US3 and pp71 pool, as well as
to gB. Each patient’s results are presented individually below.
Patient 133
The viral load of patient 133 was first detected at week 6, and peaked at week 13, following
transplantation (Figure 5.6). Viral load remained elevated until week 35, following which
virus was not detected in the peripheral blood again (Figure 5.6). Seroconversion was detected
at week 16 post transplantation (Figure 5.6). Patient 133 had very early rising IFNγ secreting
T cells which were maintained at a relatively stable frequency over the regular sampling
period, remaining relatively unaffected by peak viral load (Figure 5.6) and a decrease in total
peripheral blood lymphocytes at weeks 5 and 15 post transplantation (Figure 5.6F). This
176 The Generation of HCMV-specific IL-10 Secreting T cells
U
ns
tim
ul
at
ed
La
te
nt
 P
ep
tid
es
W
ee
ks
 p
os
t 
tra
ns
pl
an
t
3.1
Patient 133 IFNγ FluoroSpot
5.3 11.7 14.7 18.7 25.7 123.3
Fig. 5.5 The individual FluoroSpot wells showing the frequencies of T cells secreting
IFNγ following primary infection in response to HCMV latency-associated peptides
Blood samples were collected at several time points from seronegative transplant patient
133 following the transplantation of a seropositive kidney. These samples were analysed
for T cell secretion of IFNγ in response to HCMV latency-associated ORFs. PBMC were
incubated for 48 hours with an ORF peptide mix composed of UL138, LUNA, US28, and
UL111A (latent peptides), or with media only (unstimulated), on FluoroSpot plates capable
of detecting IFNγ . Each ORF peptide pool was tested in triplicate and one well of each
triplicate is represented here for each time point.
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pattern was the same for responses to all five ORF pools tested, although the frequencies of
cytokine secreting cells detected did differ. IL-10 T cell responses on the other hand were
not observed to all ORF pools. T cells secreting IL-10 in response to gB were found to
fluctuate. Immediately following transplantation IL-10 secreting cells were detected, but
these preceded to drop below the positive threshold just after the peak of viral load, before
increasing again and dropping below threshold again by the last time point (Figure 5.6B).
IL-10 secreting cells were only found at one time point in response to pp65 and UL144,
coincidental with peak viral load (Figure 5.6C). T cell IL-10 responses to US3 and pp71
showed a similar oscillating pattern as those responding to gB, although the frequencies of
IL-10 positive cells detected were higher at each time point and there was only one drop
below the positive threshold, following peak viral load (Figure 5.6D).
Patient 439
Patient 439 had detectable viral load from week 7 post transplantation, which peaked at week
9 and gradually decreased to undetectable levels at week 14 (Figure 5.7). Seroconversion
in patient 439 was detected at week 10 post transplantation (Figure 5.7). Patient 439 T cell
responses to ORF pools could also be detected immediately after transplantation and these
responses exhibited a peak in the frequencies of IFNγ secreting T cells coinciding with the
the peak of viral load (Figure 5.7) and drop in total lymphocyte numbers (Figure 5.7F). The
frequencies of IFNγ secreting T cells then decreased, most dramatically in response to gB
which fell below the positive threshold (Figure 5.7B), before stabilising to around the same
levels as before the peak by week 17 (Figure 5.7). Positive IL-10 T cell responses were
first detected in response to gB (Figure 5.7B), pp65 and UL144 (Figure 5.7C), and UL138,
LUNA, US28, and UL111A (Figure 5.7E) 7 weeks post transplantation, concurrent with the
rise in virus load and decrease in total lymphocyte numbers (Figure 5.7F). These responses
then dropped below threshold and either rebounded for responses to gB and the pp65 and
UL144 pool, or remained below threshold. T cell IL-10 responses to US3 and pp71 were
detected immediately post transplantation and then began decreasing from 7 weeks post
transplant as virus load increased (Figure 5.7D).
Patient 574
Virus present in the peripheral blood of patient 574 was first detected 7 weeks post
transplantation and remained detectable until week 16 (Figure 5.8). Viraemia then recurred
at week 21 and lasted until week 35, with seroconversion detected in week 25 (Figure 5.8).
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Fig. 5.6 The frequencies of HCMV-specific T cells secreting IFNγ or IL-10 following
primary infection Blood samples were collected at various time points from seronegative
transplant patient 133 following the transplantation of a seropositive kidney. These samples
were analysed for T cell secretion of IFNγ and IL-10 in response to HCMV ORF peptide
pools. PBMC were incubated for 48 hours with ORF peptide mixes composed of (A) IE1
and IE2, (B) gB, (C) pp65 and UL144, (D) US3 and pp71, and (E) UL138, LUNA, US28,
and UL111A on FluoroSpot plates capable of detecting IFNγ and IL-10 secretion. Each ORF
peptide pool was tested in triplicate and the values from the number of background cells
secreting cytokines in the unstimulated wells was deducted from all test wells. Following
stimulation, the number of cytokine positive spots was enumerated by the automated cell
counter and converted to a spot forming unit (SFU) value per million cells. PBMC were also
analysed for their composition of CD3+, CD4+, and CD8+ cells by flow cytometry, and the
values for cytokine secreting cells adjusted as a proportion of CD3+ T cells per donor. Virus
load expressed as viral copies/ml of blood. The black vertical dotted lines indicate the time
points sampled for serum anti-HCMV IgG, the outcome of which is denoted above the line
as negative (-) or positive (+) for the time of seroconversion. The horizontal dotted red line
indicates the 50 SFU/106 cell threshold for positive IL-10 responses, while the green dotted
line at 100 SFU/106 illustrated the threshold for positive IFNγ responses. (F) Total leukocyte
counts per litre of blood were also carried out over a range of time points.
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Fig. 5.7 The frequencies of HCMV-specific T cells secreting IFNγ or IL-10 following
primary infection Blood samples were collected at various time points from seronegative
transplant patient 439 following the transplantation of a seropositive kidney. These samples
were analysed for T cell secretion of IFNγ and IL-10 in response to HCMV ORF peptide
pools. PBMC were incubated for 48 hours with ORF peptide mixes composed of (A) IE1
and IE2, (B) gB, (C) pp65 and UL144, (D) US3 and pp71, and (E) UL138, LUNA, US28,
and UL111A on FluoroSpot plates capable of detecting IFNγ and IL-10 secretion. Each ORF
peptide pool was tested in triplicate and the values from the number of background cells
secreting cytokines in the unstimulated wells was deducted from all test wells. Following
stimulation, the number of cytokine positive spots was enumerated by the automated cell
counter and converted to a spot forming unit (SFU) value per million cells. PBMC were also
analysed for their composition of CD3+, CD4+, and CD8+ cells by flow cytometry, and the
values for cytokine secreting cells adjusted as a proportion of CD3+ T cells per donor. Virus
load expressed as viral copies/ml of blood. The black vertical dotted lines indicate the time
points sampled for serum anti-HCMV IgG, the outcome of which is denoted above the line
as negative (-) or positive (+) for the time of seroconversion. The horizontal dotted red line
indicates the 50 SFU/106 cell threshold for positive IL-10 responses, while the green dotted
line at 100 SFU/106 illustrated the threshold for positive IFNγ responses. (F) Total leukocyte
counts per litre of blood were also carried out over a range of time points.
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At the first sample time point, one day prior to transplantation, although patient 574 was
negative for HCMV according to serology, positive IFNγ T cell responses were detected to
all ORF pools (Figure 5.8). The IFNγ secreting T cells were then observed to decrease
following transplantation before increasing contemporaneously with viral load (Figure 5.8).
Although the magnitude of T cell IFNγ responses to all ORF pools remained elevated, the
virus was not being controlled, as evidenced by the elevated viral load across the majority of
time points (Figure 5.8). T cells secreting IL-10 were found to exhibit a similar response
pattern as those secreting IFNγ in response to gB (Figure 5.8B ) and to the US3 and pp71
pool (Figure 5.8D). These high frequency IL-10 responses were detected immediately post
transplant and peaked coincidentally with the peak virus load. HCMV-specific IFNγ and
IL-10 secreting T cell frequencies were unaffected by the fluctuations in total lymphocyte
number (Figure 5.8F).
Patient 352
Patient 352 exhibited a similar inability to control viral replication with periodic spikes of
high virus load detected in these post transplantation blood samples which persisted over
the majority of the sampled time points (Figure 5.9). Seroconversion was detected in week
7 post transplantation (Figure 5.9). IFNγ secreting T cells were detected in response to all
ORF pools from the first post transplant sample, and these increased to a peak just after the
peak of virus load at 11 weeks post transplantation (Figure 5.9), despite a decrease in total
lymphocyte numbers at this point (Figure 5.9F). IFNγ positive T cells were maintained at
a high level but showed oscillations over the remaining sample points (Figure 5.9). IL-10
T cell responses were only detected to gB, and to US3 and pp71. IL-10 responses to gB
were present at the first two time points within 5 weeks post transplantation but then no
positive response was observed again until week 54 and week 97 (Figure 5.9B). T cell IL-10
responses to US3 and pp71 on the other hand were detectable at all time points and followed
a similar pattern and frequency of positive cells as those secreting IFNγ (Figure 5.9D).
Patient 197
The virus load of patient 197 showed one peak at week 14 and remained detectable until
week 22, with seroconversion also detected at week 14 (Figure 5.10). T cell responses
from patient 197 showed two different patterns over the sampling period. Responses to gB
(Figure 5.10B), pp65 and UL144 (Figure 5.10C), and UL138, LUNA, US28, and UL111A
(Figure 5.10E) all displayed a high frequency of IFNγ positive T cells immediately following
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Fig. 5.8 The frequencies of HCMV-specific T cells secreting IFNγ or IL-10 following
primary infection Blood samples were collected at various time points from seronegative
transplant patient 574 following the transplantation of a seropositive kidney. These samples
were analysed for T cell secretion of IFNγ and IL-10 in response to HCMV ORF peptide
pools. PBMC were incubated for 48 hours with ORF peptide mixes composed of (A) IE1
and IE2, (B) gB, (C) pp65 and UL144, (D) US3 and pp71, and (E) UL138, LUNA, US28,
and UL111A on FluoroSpot plates capable of detecting IFNγ and IL-10 secretion. Each ORF
peptide pool was tested in triplicate and the values from the number of background cells
secreting cytokines in the unstimulated wells was deducted from all test wells. Following
stimulation, the number of cytokine positive spots was enumerated by the automated cell
counter and converted to a spot forming unit (SFU) value per million cells. PBMC were also
analysed for their composition of CD3+, CD4+, and CD8+ cells by flow cytometry, and the
values for cytokine secreting cells adjusted as a proportion of CD3+ T cells per donor. Virus
load expressed as viral copies/ml of blood. The black vertical dotted lines indicate the time
points sampled for serum anti-HCMV IgG, the outcome of which is denoted above the line
as negative (-) or positive (+) for the time of seroconversion. The horizontal dotted red line
indicates the 50 SFU/106 cell threshold for positive IL-10 responses, while the green dotted
line at 100 SFU/106 illustrated the threshold for positive IFNγ responses. (F) Total leukocyte
counts per litre of blood were also carried out over a range of time points.
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Fig. 5.9 The frequencies of HCMV-specific T cells secreting IFNγ or IL-10 following
primary infection Blood samples were collected at various time points from seronegative
transplant patient 352 following the transplantation of a seropositive kidney. These samples
were analysed for T cell secretion of IFNγ and IL-10 in response to HCMV ORF peptide
pools. PBMC were incubated for 48 hours with ORF peptide mixes composed of (A) IE1
and IE2, (B) gB, (C) pp65 and UL144, (D) US3 and pp71, and (E) UL138, LUNA, US28,
and UL111A on FluoroSpot plates capable of detecting IFNγ and IL-10 secretion. Each ORF
peptide pool was tested in triplicate and the values from the number of background cells
secreting cytokines in the unstimulated wells was deducted from all test wells. Following
stimulation, the number of cytokine positive spots was enumerated by the automated cell
counter and converted to a spot forming unit (SFU) value per million cells. PBMC were also
analysed for their composition of CD3+, CD4+, and CD8+ cells by flow cytometry, and the
values for cytokine secreting cells adjusted as a proportion of CD3+ T cells per donor. Virus
load expressed as viral copies/ml of blood. The black vertical dotted lines indicate the time
points sampled for serum anti-HCMV IgG, the outcome of which is denoted above the line
as negative (-) or positive (+) for the time of seroconversion. The horizontal dotted red line
indicates the 50 SFU/106 cell threshold for positive IL-10 responses, while the green dotted
line at 100 SFU/106 illustrated the threshold for positive IFNγ responses. (F) Total leukocyte
counts per litre of blood were also carried out over a range of time points.
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transplantation but subsequently declined and settled at a lower level than the initial response.
T cell IFNγ responses to IE1 and IE2 (Figure 5.10A), and US3 and pp71 (Figure 5.10D) were
also detected from the initial time point, but these gradually increased and peaked at over
100 weeks post transplantation. T cells secreting IL-10 were only detected in response to
pp65 and UL144 (Figure 5.10C), and UL138, LUNA, US28, and UL111A (Figure 5.10E) at
the final time point (157 weeks post transplantation), while IL-10 responses to gB fluctuated,
with responses above threshold at two time points (50 and 115 weeks post transplant) (Figure
5.10B). IL-10 T cell responses to US3 and pp71 were detected early post transplantation
and showed a gradual increase to 115 weeks post transplant before declining slightly (Figure
5.10D). Despite initial decreases in total lymphocyte numbers, the frequencies of cytokine
secreting HCMV-specific T cells were not affected (Figure 5.10F).
Patient 136
The viral load of patient 136 was first detected at week 7, peaked at week 9, and remained
elevated until week 15 post transplantation (Figure 5.11). At week 51, virus was again
detected in the peripheral blood but was not present at any later time point (Figure 5.11).
Seroconversion was measured at 11 weeks post transplantation (Figure 5.11). Unfortunately,
PBMC samples from patient 136 were only obtained from 7 weeks post transplantation so
T cell responses prior to this are unknown. T cell IFNγ responses to IE1 and IE2 (Figure
5.11A), and pp65 and UL144 (Figure 5.11C) were found to be relatively constant over the
first 36 weeks, with a slight decrease in the IE1 and IE2 pool response magnitude, but after 36
weeks the frequency of IFNγ positive cells was found to increase into the 80 week time point.
T cell IFNγ responses to gB (Figure 5.11B), US3 and pp71 (Figure 5.11D), and UL138,
LUNA, US28, and UL111A (Figure 5.11E) pools decreased following the peak of viral load,
but where response magnitudes to gB, and UL138, LUNA, US28, and UL111A increased to
around the initial post transplant levels, response to US3 and pp71 stabilised to below their
initial level. Positive T cell IL-10 responses were sporadically found in this patient. Several
relatively low frequency responses to gB observed (Figure 5.11B) and responses to US3
and pp71 were found to decline from initially positive responses to below threshold before
increasing again to positive responses consistently after 50 weeks post transplantation (Figure
5.11D). T cell responses were again maintained despite decreased lymphocyte numbers from
four weeks post transplantation (Figure 5.11F).
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Fig. 5.10 The frequencies of HCMV-specific T cells secreting IFNγ or IL-10 following
primary infection Blood samples were collected at various time points from seronegative
transplant patient 197 following the transplantation of a seropositive kidney. These samples
were analysed for T cell secretion of IFNγ and IL-10 in response to HCMV ORF peptide
pools. PBMC were incubated for 48 hours with ORF peptide mixes composed of (A) IE1
and IE2, (B) gB, (C) pp65 and UL144, (D) US3 and pp71, and (E) UL138, LUNA, US28,
and UL111A on FluoroSpot plates capable of detecting IFNγ and IL-10 secretion. Each ORF
peptide pool was tested in triplicate and the values from the number of background cells
secreting cytokines in the unstimulated wells was deducted from all test wells. Following
stimulation, the number of cytokine positive spots was enumerated by the automated cell
counter and converted to a spot forming unit (SFU) value per million cells. PBMC were also
analysed for their composition of CD3+, CD4+, and CD8+ cells by flow cytometry, and the
values for cytokine secreting cells adjusted as a proportion of CD3+ T cells per donor. Virus
load expressed as viral copies/ml of blood. The black vertical dotted lines indicate the time
points sampled for serum anti-HCMV IgG, the outcome of which is denoted above the line
as negative (-) or positive (+) for the time of seroconversion. The horizontal dotted red line
indicates the 50 SFU/106 cell threshold for positive IL-10 responses, while the green dotted
line at 100 SFU/106 illustrated the threshold for positive IFNγ responses. (F) Total leukocyte
counts per litre of blood were also carried out over a range of time points.
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Fig. 5.11 The frequencies of HCMV-specific T cells secreting IFNγ or IL-10 following
primary infection Blood samples were collected at various time points from seronegative
transplant patient 136 following the transplantation of a seropositive kidney. These samples
were analysed for T cell secretion of IFNγ and IL-10 in response to HCMV ORF peptide
pools. PBMC were incubated for 48 hours with ORF peptide mixes composed of (A) IE1
and IE2, (B) gB, (C) pp65 and UL144, (D) US3 and pp71, and (E) UL138, LUNA, US28,
and UL111A on FluoroSpot plates capable of detecting IFNγ and IL-10 secretion. Each ORF
peptide pool was tested in triplicate and the values from the number of background cells
secreting cytokines in the unstimulated wells was deducted from all test wells. Following
stimulation, the number of cytokine positive spots was enumerated by the automated cell
counter and converted to a spot forming unit (SFU) value per million cells. PBMC were also
analysed for their composition of CD3+, CD4+, and CD8+ cells by flow cytometry, and the
values for cytokine secreting cells adjusted as a proportion of CD3+ T cells per donor. Virus
load expressed as viral copies/ml of blood. The black vertical dotted lines indicate the time
points sampled for serum anti-HCMV IgG, the outcome of which is denoted above the line
as negative (-) or positive (+) for the time of seroconversion. The horizontal dotted red line
indicates the 50 SFU/106 cell threshold for positive IL-10 responses, while the green dotted
line at 100 SFU/106 illustrated the threshold for positive IFNγ responses. (F) Total leukocyte
counts per litre of blood were also carried out over a range of time points.
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Patient 365
Peak viraemia in patient 365 occurred at week 7 post transplantation with virus remaining
detectable in the peripheral blood until week 12 (Figure 5.12). Seroconversion was measured
at week 9 post transplantation (Figure 5.12). Initially, T cell IFNγ secretion was detected in
response to all ORFs, although the frequencies of IFNγ positive cells then decreased to below
the positive threshold following peak viral load (Figure 5.12). This was most dramatically
seen in T cell responses to IE1 and IE2 (Figure 5.12A), gB (Figure 5.12B), and US3 and
pp71 (Figure 5.12D). IFNγ secreting T cells then rebounded and increased in frequency to a
peak at 28 or 40 weeks post transplantation before contracting (Figure 5.12). IL-10 T cell
responses to gB (Figure 5.12B), and US3 and pp71 (Figure 5.12D), were similar to IFNγ
responses in that a decline in IL-10 secreting cells to below threshold was observed after peak
viral load which then rebounded by week 27 to positive. There was then a decline in IL-10
positive cells. IL-10 responses to pp65 and UL144 also showed a similar pattern but lower
frequencies of cytokine secreting cells were detected (Figure 5.12C). The decline in cytokine
secreting T cells following peak viral load at week 7 was also coincidental with a decrease in
total lymphocyte numbers (Figure 5.12F). Furthermore, the increase in cytokine secreting
cells from week 16 parallels the increase in total lymphocytes present in the peripheral blood
from this time point (Figure 5.12F).
In summary, IFNγ T cell responses to lytic and latency-associated proteins were
detectable immediately post transplantation and these were generally maintained throughout
the sampling period with some fluctuations. These T cell responses were also detectable
prior to viraemia and in one case prior to transplantation, despite the donor being
HCMV-negative when tested by serology. IL-10 T cell responses to latency-associated
proteins were inconsistently seen or were of low frequency in this time period. Likewise no
T cell IL-10 responses were observed to IE1 and IE2. T cells secreting IL-10 were however
consistently found in response to US3 and pp71, and these were maintained across the time
period tested in most donors.
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Fig. 5.12 The frequencies of HCMV-specific T cells secreting IFNγ or IL-10 following
primary infection Blood samples were collected at various time points from seronegative
transplant patient 365 following the transplantation of a seropositive kidney. These samples
were analysed for T cell secretion of IFNγ and IL-10 in response to HCMV ORF peptide
pools. PBMC were incubated for 48 hours with ORF peptide mixes composed of (A) IE1
and IE2, (B) gB, (C) pp65 and UL144, (D) US3 and pp71, and (E) UL138, LUNA, US28,
and UL111A on FluoroSpot plates capable of detecting IFNγ and IL-10 secretion. Each ORF
peptide pool was tested in triplicate and the values from the number of background cells
secreting cytokines in the unstimulated wells was deducted from all test wells. Following
stimulation, the number of cytokine positive spots was enumerated by the automated cell
counter and converted to a spot forming unit (SFU) value per million cells. PBMC were also
analysed for their composition of CD3+, CD4+, and CD8+ cells by flow cytometry, and the
values for cytokine secreting cells adjusted as a proportion of CD3+ T cells per donor. Virus
load expressed as viral copies/ml of blood. The black vertical dotted lines indicate the time
points sampled for serum anti-HCMV IgG, the outcome of which is denoted above the line
as negative (-) or positive (+) for the time of seroconversion. The horizontal dotted red line
indicates the 50 SFU/106 cell threshold for positive IL-10 responses, while the green dotted
line at 100 SFU/106 illustrated the threshold for positive IFNγ responses. (F) Total leukocyte
counts per litre of blood were also carried out over a range of time points.
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5.2.3 Detection of IL-10 responses to latency-associated proteins from
tissue resident T cells
It is possible that IL-10 secreting T cells specific for HCMV latency-associated proteins were
not detected following primary infection because these T cells were confined to tissue sites
and had not yet entered the peripheral blood. To investigate the presence of HCMV-specific
T cells in tissue sites, preliminary work was carried out using bone marrow samples obtained
from two HCMV positive donors.
Bone marrow derived mononuclear cells (BMMNC) were tested for IFNγ and IL-10
secretion by FluoroSpot assay. BMMNC were incubated with HCMV ORF peptide pool
mixes for 48 hours on FluoroSpot plates and the frequencies of IFNγ and IL-10 positive
cells determined. BMMNC were also stained for CD3 to determine the proportion of T
cells present. The frequencies of cytokine secreting cells detected was then expressed as a
proportion of all T cells. An initial screen was carried out with BMMNC from one donor
to test if responses to HCMV ORF products were present. IFNγ or IL-10 secreting T cells
were detected to all of the HCMV ORFs tested (Figure 5.13). The frequencies of cytokine
secreting T cells in response to certain ORFs were very low, such as to UL138 (Figure 5.13).
As it was not possible to test bone marrow T cell responses from HCMV seronegative donors,
a threshold for positive responses could not be determined. It is therefore possible that these
low frequency responses were due to non-HCMV specific T cell activation. However, as the
background frequencies of cytokine secreting cells in unstimulated cells were exceptionally
low, these responses were likely not due to a general activation of the donor’s T cells.
Having demonstrated that bone marrow derived T cells could respond to HCMV ORFs,
paired bone marrow and blood mononuclear cell samples were obtained from one donor to
test if these different compartments possessed ORF-specific T cells of different frequencies.
BMMNC and PBMC samples were depleted of CD4+ or CD8+ cells by MACS, to test CD8+
and CD4+ T cell responses respectively, and then analysed in parallel on the FluoroSpot.
Doing so enabled the frequencies of IFNγ and IL-10 secreting T cells specific to HCMV
ORF products to be determined.
Considerable differences in the frequencies of T cells secreting IFNγ or IL-10 were found
between bone marrow and peripheral blood derived mononuclear cells. High frequencies
of ORF-specific IFNγ secreting CD4+ T cells were detected in both the bone marrow and
peripheral blood. However, greater frequencies of IFNγ secreting CD4+ T cells were detected
in the bone marrow compared to the peripheral blood for the majority of responses, with
the exception of responses to LUNA, which were only detected in the blood (Figure 5.14A).
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Fig. 5.13 Bone marrow resident T cell responses to HCMV ORF peptide pools Bone
marrow mononuclear cells (BMMNC) from donor 10435 were incubated for 48 hours
with HCMV ORF peptide pools on FluoroSpot plates capable of detecting IFNγ and IL-10
secreting cells. Peptide pools composed of HCMV ORFs gB, pp65, IE1, IE2, US3, pp71,
UL138, LUNA, US28, UL111A, and UL144 were tested. Each ORF peptide pool was tested
in triplicate and the values from the number of background cells secreting cytokines in the
unstimulated wells was deducted from all test wells. Following stimulation, the number of
IFNγ (green bars) and IL-10 (red bars) positive spots was enumerated by the automated cell
counter and converted to a spot forming unit (SFU) value per million cells. BMMNC were
also analysed for their composition of CD3+ cells by flow cytometry, and the values for
cytokine secreting cells adjusted as a proportion of CD3+ T cells.
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IFNγ responses to IE1 and UL138 were also only detected in the bone marrow (Figure
5.14A). Of the ORF-specific responses detected in both compartments (excluding LUNA),
the proportions of peripheral blood CD4+ T cells secreting IFNγ was reduced by up to 80%
compared to bone marrow derived CD4+ T cells (Figure 5.16A). High frequency US3 and
pp71 IL-10 T cell responses were detected in both the bone marrow and blood, although
these were of greater frequency in the bone marrow by around 25% and 35% respectively
(Figure 5.14B and 5.16B). IL-10 responses were also greater in the bone marrow in response
to UL111A and IE1, where they were not detected in the blood, as well as to LUNA (Figure
5.14B). Conversely, IL-10 secreting CD4+ T cells responding to gB, pp65, and UL138 were
only detected in the peripheral blood (Figure 5.14B).
Although the bone marrow harboured mostly greater frequencies of IFNγ secreting CD4+
T cells compared to the peripheral blood, differences in the CD8+ T cell responses to HCMV
were more varied between the two compartments (Figure 5.16C). Greater frequencies of IFNγ
secreting CD8+ T cells responding to gB, pp65, IE2, UL111A, and UL144 were detected in
the peripheral blood compared to the bone marrow, while the reverse was true for responses
to IE1, US3, pp71, and US28 (Figure 5.15A). CD8+ T cell IFNγ responses were also only
detected to UL138 and LUNA in the peripheral blood (Figure 5.15A). In contrast, greater
frequencies of CD8+ T cells secreting IL-10 were generally found in the bone marrow as
evidenced by responses to IE1, IE2, and US28, which were absent from the peripheral blood,
and to pp65, US3, pp71, UL138, LUNA, UL111A, which were nearly twofold higher on
average in the bone marrow (Figure 5.15B and 5.16D).
In summary, this preliminary data has highlighted differences in the frequencies of CD4+
and CD8+ T cells responding to HCMV ORFs between T cells derived from the bone marrow
and peripheral blood. In particular, in CD4+ T cells secreting IFNγ and CD8+ T cells
secreting IL-10, seemed to be retained in the bone marrow in higher frequencies compared to
the peripheral blood.
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Fig. 5.14 Bone marrow and peripheral blood derived CD4+ T cell responses to HCMV
ORF peptide pools Bone marrow mononuclear cells (BMMNC) and peripheral blood
mononuclear cells (PBMC) from donor 9788 were depleted of CD8+ cells and incubated for
48 hours with HCMV ORF peptide pools on FluoroSpot plates capable of detecting IFNγ
and IL-10 secreting cells. Peptide pools composed of HCMV ORFs gB, pp65, IE1, IE2, US3,
pp71, UL138, LUNA, US28, UL111A, and UL144 were tested. Each ORF peptide pool was
tested in triplicate and the values from the number of background cells secreting cytokines in
the unstimulated wells was deducted from all test wells. Following stimulation, the number
of (A) IFNγ positive spots from BMMNC (solid green bars) and PBMC (patterned green
bars) and (B) IL-10 positive spots from BMMNC (solid red bars) and PBMC (patterned red
bars) was enumerated by the automated cell counter and converted to a spot forming unit
(SFU) value per million cells. BMMNC were also analysed for their composition of CD3+
cells by flow cytometry, and the values for cytokine secreting cells adjusted as a proportion
of CD3+ T cells.
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Fig. 5.15 Bone marrow and peripheral blood derived CD8+ T cell responses to HCMV
ORF peptide pools Bone marrow mononuclear cells (BMMNC) and peripheral blood
mononuclear cells (PBMC) from donor 9788 were depleted of CD4+ cells and incubated for
48 hours with HCMV ORF peptide pools on FluoroSpot plates capable of detecting IFNγ
and IL-10 secreting cells. Peptide pools composed of HCMV ORFs gB, pp65, IE1, IE2, US3,
pp71, UL138, LUNA, US28, UL111A, and UL144 were tested. Each ORF peptide pool was
tested in triplicate and the values from the number of background cells secreting cytokines in
the unstimulated wells was deducted from all test wells. Following stimulation, the number
of (A) IFNγ positive spots from BMMNC (solid green bars) and PBMC (patterned green
bars) and (B) IL-10 positive spots from BMMNC (solid red bars) and PBMC (patterned red
bars) was enumerated by the automated cell counter and converted to a spot forming unit
(SFU) value per million cells. BMMNC were also analysed for their composition of CD3+
cells by flow cytometry, and the values for cytokine secreting cells adjusted as a proportion
of CD3+ T cells.
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Fig. 5.16 Proportions of bone marrow and peripheral blood derived CD4+ and CD8+
T cells secreting IFNγ in response to HCMV ORF peptides pools Paired bone marrow
mononuclear cell (BM) and peripheral blood mononuclear cell (PB) samples from donor
9788 were depleted of CD8+ or CD4+ cells, to test (A and B) CD4+ and (C and D) CD8+
T cell responses respectively, and incubated for 48 hours with HCMV ORF peptide pools
on FluoroSpot plates capable of detecting IFNγ and IL-10 secreting cells. Peptide pools
composed of HCMV ORFs gB, pp65, IE1, IE2, US3, pp71, UL138, LUNA, US28, UL111A,
and UL144 were tested, and the responses to each ORF are represented as individual points.
Each ORF peptide pool was tested in triplicate and the values from the number of background
cells secreting cytokines in the unstimulated wells was deducted from all test wells. Following
stimulation, the number of cytokine positive cells was enumerated by the automated cell
counter. Samples were analysed for their composition of CD3+ cells by flow cytometry, and
the values for cytokine secreting cells adjusted as a proportion of CD3+ T cells.
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5.3 Discussion
The generation of IL-10 secreting T cells specific for HCMV latency-associated proteins
following primary infection was investigated using blood samples collected from patients
undergoing kidney transplantation (D+R-). Blood samples from seven initially seronegative
transplant recipients were obtained over a period of several weeks post transplantation. T
cell IFNγ and IL-10 responses to HCMV ORF pools were analysed by FluoroSpot assay
and the frequencies of cytokine secreting T cells determined. IFNγ responses were deemed
positive if they exceeded a 100 SFU/106 T cell threshold, while this was set at 50 SFU/106 T
cells for IL-10 responses. However, this threshold was set using data from healthy HCMV
seronegative donors for each ORF peptide mix, and to CD4+ and CD8+ T cells separately. It
is therefore possible that the threshold values used here are not appropriate, and future work
should test seronegative D-R- transplant patients with these peptide mixes to determine the
frequencies of CD4+ and CD8+ T cells secreting IFNγ and IL-10 non-specifically. Doing
so is also important to determine if the transplant process has an effect on the background
cytokine secretion from T cells. In several transplant patients studied here, at the initial time
points following transplantation, IFNγ secreting T cells could be detected in response to
peptide stimulation, weeks before detectable viral load. The frequencies of IFNγ secreting
cells at these first time points were often between 0.1% and 1% of all T cells, or even
higher for patients 197 and 352. In some cases these cells decreased in the subsequent
weeks, before increasing again after, or in line with, peak viral load. These initial responses
therefore seem erroneous given how quickly after transplantation many of these have been
detected, especially as several previous studies examining T cell responses to primary
HCMV infection found virus specific T cells to emerge only after viral load was detectable
[333, 373, 381, 391, 392, 400, 406, 694]. Although low background cytokine secretion was
detected from unstimulated T cells, indicating T cells were not spontaneously producing
IFNγ , it could be possible that T cells isolated at such early time points post transplantation
non-specifically produce IFNγ in response to peptide stimulation.
The presence of T cell responses one day prior to transplantation in one donor (574)
was also surprising, given their negative HCMV infection status as measured by serology.
No additional patient information is available so it is not known what the health status of
this individual was, which could influence non-specific T cell activity. However, recent
work has revealed HCMV-specific T cell responses in HCMV seronegative individuals
[659, 660]. One such study reported the presence of HCMV-specific CD4+ and CD8+ T cells
capable of secreting IFNγ in seronegative pretransplant patients [660]. HCMV seronegative
transplant recipients with IFNγ secreting CD4+ T cells were also observed to have a lower
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risk of developing an HCMV viraemia after transplantation with a seropositive donor kidney
compared to those without such T cells [660]. It could therefore be possible that the sole
reliance on serology to test HCMV infectivity is not adequate, and this recipient had been
exposed to the virus prior to transplantation. Likewise, this could also be possible for the
other transplant patients who displayed IFNγ responses shortly after transplantation. The
detection of high frequency T cell responses so early before the peak of viral load could also
be the result of viral replication being confined to the donor organ. In this manner, HCMV
replicating in the kidney soon after transplantation would not be detected in the blood, which
was sampled here, and could thus result in the delivery of viral antigens to the draining lymph
nodes and the initiation of virus-specific T cell responses prior to detectable viraemia.
IFNγ secreting T cells were found to arise immediately post transplantation in response
to both HCMV lytic and latency-associated proteins. These positive IFNγ responses were
mostly maintained throughout the sampling period with a relative degree of fluctuation in
the frequencies of cytokine secreting cells detected. Generally, CD4+ and CD8+ T cells
secreting IFNγ in response to latency-associated proteins made up less than 1% of total CD3+
cells within individuals, although these did reach around 5% in some patients (197, 365, and
574). Patient 352 was the exception to this, where T cell frequencies were mostly between
1% and 16% of total CD3+ cells. Patient 352 had recurrent viraemia for the majority of the
sampled time points however, which could explain these high frequency T cell responses.
The frequencies of IFNγ secreting T cells responding to latency-associated ORFs following
primary infection were comparable to those observed from healthy donors, which were also
nearly entirely below 1% of total CD3+ cells (Mean=0.54, Std. deviation=0.73, Std. error of
mean=0.17, n=19) (data not shown). Additionally, these frequencies of IFNγ positive T cells
detected following primary infection are comparable to the frequencies of HCMV-specific
T cells reported in studies utilising tetramers or HCMV peptide/lysate stimulation and ICS
during primary infection [333, 373, 381, 391, 392, 400, 406]. The ability to generate IFNγ
responses to latency-associated ORF products following primary infection therefore does not
seem to be affected by immunosuppressive drug therapy. However, the data generated here do
not distinguish between CD4+ and CD8+ T cells. It is therefore possible that the frequencies
of CD4+ and CD8+ T cells specific to latency-associated ORFs in these immunosuppressed
transplant recipients could differ compared to healthy individuals.
IL-10 T cell responses were considerably less common and exhibited more dramatic
fluctuations than IFNγ responses following primary infection. No consistent IL-10 T cell
responses were detected to the latency-associated proteins during this initial period
following primary infection. Many donors did have IL-10 responses to gB early following
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transplantation, but the most consistent responses were found to US3 and pp71. The
detection of IL-10 T cell responses to US3 and pp71 so soon after transplantation, and the
consistency with which these were maintained over the subsequent weeks was surprising.
While T cells secreting IFNγ in response to US3 and pp71 have been reported previously
[288], analogous IL-10 responses have not. When testing a large HCMV seropositive donor
cohort composed of healthy individuals for CD4+ and CD8+ T cell responses to US3 and
pp71, high frequencies of IL-10, and IFNγ , secreting T cells were detected in a substantial
proportion of donors. These IL-10 secreting T cells were also mainly a separate population
from T cells secreting IFNγ . Age was not a factor influencing the frequencies of IL-10, or
IFNγ , secreting T cells responding to US3 or pp71 (data not shown), and it therefore appears
that these IL-10 responses are generated immediately following primary infection. While
expression of US3 and pp71 has been well characterised during lytic infection
[574, 692, 693], recent evidence suggests they could also be expressed during latent
infection [130, 604], although the expression of US3 detected by single-cell
RNA-sequencing could have originated from virus in the process of reactivating from
latency. Of note, the kidney transplant recipients were taking a range of immunosuppressive
drugs which could also have had an effect on the T cell responses detected. Further details
beyond which drugs each patient was prescribed, such as the duration of drug use, was not
available. However, despite the administration of these drugs, the consistent detection of
IL-10 secreting T cells to US3 and pp71 does illustrate that the absence of latency-associated
ORF specific responses was not the result of a defect in IL-10 secreting T cells caused by
immunosuppression.
The lack of T cells secreting IL-10 specific for latency-associated proteins following
primary infection suggests that these T cells could be generated as a result of longer term
viral carriage beyond the time points sampled here, or that they are not found in the peripheral
blood at such early stages after primary infection. It is therefore possible that IL-10 secreting
T cells are resident in certain tissue sites which are not accessible by sampling from the
peripheral blood. To support this idea, T cells secreting IL-10 specific to gB and pp65
have been detected in the mucosal tissue [621], and a recent study analysing multiple tissue
sites and peripheral blood from deceased organ donors found a heterogeneous distribution
of HCMV-specific CD8+ T cells across several tissues in individual donors, including the
bone marrow, lymph nodes, and lungs [398]. Additionally, the frequency of HCMV-specific
CD8+ T cells detected in the peripheral blood was not representative of their frequencies
in the tissues [398]. Such a discordance between HCMV-specific T cells in the peripheral
blood and in the tissues has also been reported in several studies carrying out a paired
analysis between a tissue site and the peripheral blood. One study using samples from
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kidney transplant recipients found pp65- and IE-specific CD8+ T cells to be less abundant in
lymph nodes, which also had fewer IFNγ+ CD8+ T cells, compared to the peripheral blood
[695]. A separate study utilising samples from lung transplant recipients however found
that pp65-specific IFNγ+ CD8+ T cell frequencies did not differ between peripheral blood
and lung mononuclear cells during the chronic phase of infection [380]. The frequencies of
pp65-specific IFNγ+ CD4+ T cells on the other hand were preferentially distributed in the
lung compared to the peripheral blood during chronic infection stages [380].
To begin to investigate the presence of T cells specific for HCMV latency-associated
proteins from tissue sites, samples from BMMNC were tested for T cell responses. The
bone marrow has been identified as an important site for the maintenance of memory T cells
[696–698], and several studies have examined HCMV-specific memory T cells at this site
[650, 699, 700]. In an initial experiment testing BMMNC responses to a range of HCMV
ORFs, IFNγ and IL-10 responses were detected. IFNγ secreting T cells were detected in
response to both lytic and latency-associated ORFs, including pp65 and IE1, which is in
agreement with previous studies [650, 699, 700]. Conversely, IL-10 responses were only
found in response to UL138 of the latency-associated ORFs, and these were at a very low
frequency. High frequencies of IL-10 secreting T cells were detected in response to US3 and
pp71, mirroring responses seen from PBMC.
A further preliminary experiment was carried out using paired BMMNC and PBMC
samples from one donor, enabling a test of CD4+ and CD8+ T cell HCMV ORF responses
between the two compartments. Considerable differences in the CD4+ and CD8+ T cells
responses were found between BMMNC and PBMC. The frequencies of CD4+ T cells
secreting IFNγ were found to be higher in BMMNC in response to nearly every ORF tested,
with the exception of LUNA. CD4+ T cells secreting IL-10 and CD8+ T cells secreting
IFNγ were more variable in their distribution, with responses to certain ORFs detected in
only one of the two compartments. However, CD8+ T cells secreting IL-10 were found in
response to every HCMV ORF tested in the bone marrow, where there were generally higher
frequencies of IL-10 secreting T cells compared to the peripheral blood. There were also
several ORF-specific responses from both CD4+ and CD8+ T cells that were only detected in
one of the two compartments, including CD4+ T cell IL-10 responses to UL111A, and CD8+
T cell IL-10 responses to US28. This preliminary evidence suggests that bone marrow could
be one reservoir site for IL-10 secreting HCMV-specific T cells, although further work will
have to be undertaken to determine if responses to certain latency-associated ORF products
are present in higher frequencies in the bone marrow compared to the peripheral blood, and
when during infection they appear.
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Comparisons between blood and bone marrow have examined T cells specific for lytic
HCMV ORFs such as pp65 and IE1 with somewhat conflicting results. One study found
similar frequencies of pp65-specific CD8+ T cells in both the bone marrow and peripheral
blood when examining tetramer positive CD8+ T cells [699]. In the same study however,
when assessing the frequencies of pp65-specific CD8+ T cells by IFNγ production following
peptide stimulation and ICS analysis, there were slightly lower frequencies of pp65-specific
CD8+ T cells in the bone marrow compared to the peripheral blood [699], which is in
agreement with the results presented here. Contrarily, a report using blood and bone marrow
samples from cancer patients found considerably fewer tetramer positive pp65-specific CD8+
T cells in the bone marrow than blood [700]. This study also reported finding fewer IFNγ
positive CD8+ T cells in the bone marrow compared to peripheral blood, in three donors,
following IE1 peptide stimulation and analysis by ICS [700], of which the opposite was
found here. In agreement with the data presented here, one study examining CD4+ T cells
found higher frequencies, as well as higher absolute numbers, of memory CD4+ T cells
specific for pp65 in the bone marrow after stimulation with pp65 protein and analysis by ICS
[650]. Additionally, considerably higher frequencies and absolute numbers of polyfunctional
CD4+ T cells secreting two or more of TNFα , IL-2, or IFNγ were also found resident in the
bone marrow compared to the blood [650]. As the experiments presented here were only
carried out on one donor, the inclusion of additional donors is required to be able to fully
compare the findings to previous research.
Within the three individuals tested, the presence of bone marrow derived T cells specific
to nearly every HCMV ORF examined was surprising. CD34+ progenitor cells, which
are one cellular site for HCMV latency, are also known to be resident in the bone marrow
[94]. The presence of T cells specific for the full array of lytic and latency-associated ORFs
in the bone marrow could therefore be indicative of considerable viral activity at this site,
where T cells might be required to control reactivating virus. An uncontrolled lytic infection
in the bone marrow could be extensively damaging, and the presence of so many HCMV-
specific T cells might be necessary to prevent this. Although these experiments were only
performed in two donors, the presence of high frequencies of IL-10 secreting T cells in the
bone marrow capable of responding to a broad array of ORFs, including IE1 and IE2, which
were not detected in the peripheral blood in paired samples, or at high frequencies in healthy
individuals (Section 3.2.7 and 4.2.4) [691], suggests a functional role for IL-10 at this site.
It is therefore plausible that IL-10 secretion from HCMV-specific T cells acts as a balance
against pro-inflammatory anti-viral responses, to prevent damaging immunopathology in the
bone marrow.
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These results are somewhat limited however by the lack of information on the donor
health and infection status at the time of sampling, and because the time points between the
sampling of BMMNC and PBMC were several months apart. As was shown in a previous
chapter (Sections 3.2.4, 4.2.2, and 4.2.5), fluctuations in detected T cell responses from
peripheral blood occur over time, which could result in an unrepresentative comparison
between the two compartments.
Although the conclusions that can be drawn from these data are limited given the small
sample size, differences in HCMV-specific responses between peripheral blood derived T
cells and bone marrow derived T cells were detected. These results provide the basis for
further experiments to be carried out in this area to determine if differences exist between
latency-associated ORF-specific bone marrow and PBMC T cell responses for example.
Furthermore, these results highlight the limitations of previous studies which only examined
T cell responses to lytic ORFs, such as pp65 or IE1, and therefore only provide a restricted
view of HCMV-specific T cell responses.

Chapter 6
In vitro Characterisation of
Latency-specific CD4+ T cells
6.1 Introduction
CD4+ T cells isolated from HCMV seropositive donors can recognise viral proteins expressed
during latency (Chapter 3) [501]. These CD4+ T cells were composed of two separate
populations, which either secreted IFNγ or IL-10 (Section 3.2.10). Previous work has
demonstrated that PBMC stimulated with UL138 ORF peptides can suppress CD4+ T cells
proliferation and that a subset of these UL138-specific CD4+ T cells express phenotypic
markers of Tregs [501]. These CD4+ T cells could therefore be involved in the prevention of
antiviral T cell responses during latency.
The aims of this chapter were to investigate in more detail the CD4+ T cells found to be
specific for the latency-associated proteins US28, UL111A, UL144, UL138, and LUNA, both
phenotypically and functionally. Comparing such CD4+ T cells specific for HCMV latency-
associated ORFs to those specific for lytic ORFs could reveal factors which prevent antiviral
responses during latency. To do this, CD4+ T cells were phenotypically characterised to
determine their memory sub-populations, in addition to assessing the expression of markers
associated with cytotoxicity. The effector functions of CD4+ T cells specific for latency-
associated HCMV ORFs was also examined by assessing the effects of the secretomes from
these cells on the proliferation of bystander CD4+ T cells and on the secretion of anti-viral
cytokines. The finding that CD4+ T cells secreting IFNγ in response to HCMV ORF peptide
pools were a separate sub-population from those secreting IL-10 led to the hypothesis that
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if these IL-10 secreting cells could be selectively removed, those secreting IFNγ should
be able to recognise and clear latently infected cells. Given that previous work has shown
that UL138-specific CD4+ express markers characteristic of Tregs [605], and these cells are
known producers of IL-10, selective removal of these cells was attempted to remove CD4+ T
cells expressing IL-10. Finally, an initial investigation into the peptide specificity of CD4+ T
cells specific for HCMV latency-associated ORFs was carried out with the aim of assessing
whether CD4+ T cells responding to the same individual peptide were composed of cells
secreting either IFNγ or IL-10, or IFNγ and IL-10 secreting cells together. Additionally, the
results of this peptide mapping could provide valuable information which could be used in
the design of an MHC class II tetramer.
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6.2 Results
6.2.1 Latency-specific CD4+ T cells secrete TGFβ in addition to IL-10
In addition to the previously described ability of UL138 and LUNA-specific CD4+ T cells to
secrete IL-10, it was also reported that these CD4+ T cells could secrete the
immunomodulatory cytokine TGFβ [501]. To determine if US28-, UL111A-, and
UL144-specific CD4+ T cells also secrete TGFβ , PBMC depleted of CD8+ cells were
stimulated with overlapping peptide pools spanning the ORFs of pp65, IE1, UL138, LUNA,
US28, UL111A, and UL144 for 48 hours. The resulting supernatants were evaluated for
TGFβ secretion by flow cytometry using a bead-based assay. TGFβ secretion was found to
vary in response to different ORFs between individuals. The responses to UL138 were either
very low or absent across the five donors tested (Figure 6.1). However, TGFβ was
consistently detected in response to the remaining latency-associated ORFs (Figure 6.1).
TGFβ secretion was consistently elevated in response to pp65, while IE1 responses were
more variable although they were also detected from every donor (Figure 6.1). TGFβ
secretion did not differ substantially in response to the lytic ORFs pp65 and IE1, compared
to the latency-associated ORFs tested, with TGFβ secretion in response to pp65 being
consistently raised (Figure 6.1). CD4+ T cells are therefore capable of secreting TGFβ in
response to HCMV ORFs, both to those expressed during lytic infection and those that are
latency-associated.
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Fig. 6.1 Detecting TGFβ secretion from CD4+ T cells in response to HCMV ORF
peptide pools PBMC from 5 HCMV seropositive donors were depleted of CD8+ cells
and stimulated with overlapping peptide pools spanning the ORFs of pp65, IE1, UL138,
LUNA, US28, UL111A, and UL144 for 48 hours. Following this, the supernatant was
harvested and the concentrations of total TGFβ assessed by flow cytometry. Samples were
run in duplicate and the total TGFβ present in the supernatant from unstimulated CD8+
depleted PBMC was deducted from all test samples. The lytic ORFs are illustrated with
black bars and the latency-associated ORFs with white bars.
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6.2.2 Phenotypic characterisation of latency-specific CD4+ T cells
HCMV-specific CD4+ T cells are reported to have direct effector functions such as cytokine
secretion (as shown in Section 3.2), and cytotoxicity [396, 401, 404, 501]. To investigate
the potential cytotoxic capacity of CD4+ T cells specific to latency-associated ORFs, the
expression of CD107a on CD4+ T cells following stimulation with overlapping peptide pools
spanning the HCMV ORFs gB, pp65, IE1, UL138, LUNA, US28, UL111A, and UL144
was determined. CD107a is a well-defined marker of degranulation and an indicator of
the cytotoxic potential of CD4+ T cells [404, 415]. In addition to CD107a, the levels of
expression of several granzymes (A, B, and K), and the expression of both CD107a and
granzymes together on CD4+ T cells was also determined.
HCMV-specific CD4+ T cells were identified through the expression of CD40L and
4-1BB [404, 701, 702] above the background level of expression on unstimulated CD4+ T
cells following peptide stimulation (Figure 6.2A). The expression of CD107a and granzymes
on CD4+ T cells with an ORF-specific response was then determined from 18 seropositive
donors. As has previously been described [393], a number of donors had CD4+ T cells
capable of degranulating in response to the lytic ORFs gB (7/14, 50%), pp65 (12/16, 75%),
and IE1 (5/16 31%) when stimulated ex vivo, although not all ORF-specific CD4+ T cells
possessed this ability, and the proportion of cells expressing CD107a was variable between
donors (Figure 6.2B). CD4+ T cell CD107a degranulation was also observed in response to
latency-associated ORFs. The number of donors with CD4+ T cells capable of degranulating
was highest in response to US28 (7/13 54%) and UL144 (6/13 46%), followed by LUNA
(4/13 31%) and UL111A (3/10, 30%), while none of the four donors with a UL138-specific
CD4+ T cell response had detectable CD107a upregulation (Figure 6.2B).
In general, CD4+ T cells expressing granzymes A, B, and K only were detected in
approximately one-third of donors who possessed an ORF-specific response, with the
exception of UL111A-specific CD4+ T cells which were found in 70% of such donors (7/10)
(Figure 6.2C). There were also donors with a small proportion of ORF-specific CD4+ T cells
that were positive for both CD107a and granzymes A, B, and K, which were found in
response to pp65 (7/15, 53%), gB (8/14, 57%), IE1 (9/16, 56%), UL144 (5/13, 38%), US28
(5/12, 42%), and LUNA (5/13, 38%) (Figure 6.2D). ORF-specific CD4+ T cells positive for
CD107a and granzyme expression in response to UL138 (1/4, 25%) and UL111A (2/10,
20%) were detected in one and two donors respectively (Figure 6.2D).
In addition to these effector functions, the memory phenotypes of CD4+ T cells specific
for proteins expressed during latency was also examined. Previous work has found that a
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subset of HCMV-specific CD4+ T cells possessed a differentiated memory cell phenotype,
where costimulatory molecules such as CD27 and CD28 were downregulated and there
was reexpression of CD45RA [390, 394, 396, 408]. To determine if the memory T cell
phenotypes differed between lytic- and latent-specific CD4+ T cells, cells were stimulated
with HCMV ORF peptide pools for 18 hours and then stained for expression of memory
markers. Antigen-specific CD4+ T cells were again determined by the upregulation of
CD40L and 4-1BB. The CD4+ T cells were grouped into four memory subsets based on
the expression of CD45RA and CD27 to give naive-like T cells (TNL) (CD27+ CD45RA+),
central memory T cells (TCM) (CD27+ CD45RA-), effector memory T cells (TEM) (CD27-
CD45RA-), and effector memory CD45RA-expressing T cells (TEMRA) (CD27- CD45RA+).
The typical strategy for gating the flow cytometry plots and a representative phenotype
from one donor are shown in Figure 6.3A. Data from 19 seropositive donors shows that
antigen-specific CD4+ T cells were predominantly TCM and TEM subsets, with a small
proportion expressing markers characteristic of (TEMRA) cells (Figure 6.3B). Despite CD4+
T cells specific for US28 and UL111A having slightly greater proportions of cells with a
naive-like phenotype, there was also no significant difference between CD4+ T cell memory
subsets specific for lytic ORFs and those specific for latency-associated ORFs. The data for
UL138-specific CD4+ T cells reflects the low number of individuals with a positive response.
CD4+ T cells specific for latency-associated ORF products therefore expressed markers
associated with cytotoxic potential, and were mainly composed of TCM and TEM memory
subsets, which did not differ significantly from CD4+ T cells specific to HCMV lytic ORFs.
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Fig. 6.2 Assessing the expression of CD107a and Granzymes A, B, and K on CD4+ T
cells specific to HCMV ORF peptide pools by flow cytometry. PBMC from 18 HCMV
seropositive donors were stimulated with overlapping peptide pools spanning the ORFs of
gB, pp65, IE1, UL138, LUNA, US28, UL111A, and UL144 for 18 hours, in the presence of
monensin. PBMC were then stained intracellularly for CD107a and the granzymes A, B, and
K. (A) The representative gating strategy to identify ORF-specific CD4+ T cells is shown
for UL144-specific CD4+ T cells from donor CMV305. Dead cells, CD14+ and CD19+
cells were first excluded, followed by doublets. Lymphocytes were then gated on by forward
scatter (FSCA) and side scatter (SSCA) and CD3+ cells identified. CD4+ and CD8+ cells
were then gated, followed by activated CD4+ T cells, identified as CD40L or 4-1BB positive
cells. CD4+ T cells with above background expression of CD40L or 4-1BB were considered
ORF-specific. The percentages of ORF-specific CD4+ T cells expressing (B) CD107a, (C)
granzymes A, B, or K, (D) or both CD107a and granzymes A, B, or K following ORF peptide
pool stimulation is shown.
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Fig. 6.3 Memory phenotypes of CD4+ T cells specific for HCMV antigens. PBMC
isolated from 19 HCMV seropositive donors were stimulated for 18 hours with HCMV
peptide pools spanning the ORFs of gB, pp65, IE1, UL138, LUNA, US28, UL111A, and
UL144, in the presence of monensin. Stimulated PBMC were then stained intracellularly. (A)
Representative gating strategy to identify the memory populations of CD4+ T cells specific
for IE1 from donor CMV324 is shown. Dead cells, CD14+ and CD19+ cells were first
excluded, followed by doublets. Lymphocytes were then gated on by FSCA and SSCA and
CD3+ cells identified. CD4+ and CD8+ cells were then gated, followed by activated CD4+ T
cells, identified by gating for CD40L or 4-1BB positive cells, and finally CD27 and CD45RA
to identify the memory phenotype. (B) The proportions of each CD4+ T cell memory
population responding to each ORF grouped by CD27 and CD45 expression. Naive-like
(TNL) (CD27+ CD45RA+), central memory (central memory (TCM) (CD27+ CD45RA-),
effector memory (TEM) (CD27- CD45RA-), and effector memory CD45RA-expressing T
cells (TEMRA) (CD27- CD45RA+).
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6.2.3 The secretome from latency-specific CD4+ T cells inhibits T cell
proliferation and secretion of antiviral cytokines
The production of IL-10 and TGFβ by latency-specific CD4+ T cells, which are cytokines
known to inhibit T cell proliferation and effector functions, could be affecting the ability
of anti-viral T cells to eliminate latently infected cells. Given that within individuals a
segregation of latency-specific CD4+ T cells into two populations was found, one which
produces the anti-viral cytokine IFNγ , and one which produces the immunosuppressive
cytokine IL-10 (Section 3.2.10), it was important to determine the overall effect of the
secretome from latency-specific CD4+ T cells on effector functions. To investigate a range
of effects the secretome from latency-specific CD4+ T cells could be having on other T cells,
a proliferation assay and a cytokine secretion inhibition assay were used.
In the first instance, the ability of T cells to proliferate following a polyclonal stimulus,
in the presence of CD4+ T cell secretomes, was assessed. PBMC were labelled with a
proliferation dye (CellTrace) and stimulated with anti-CD3/CD28/CD137 antibody coated
beads in the presence of supernatant derived from CD4+ T cells stimulated with US28 ORF
peptides. After five days, the proliferation of T cells was assessed by flow cytometry. The
proliferation assay was optimised so that the stimulus to proliferate was strong enough that
proliferation was observed robustly, but was not so potent as to prevent the inhibition from
recombinant IL-10. Proliferation was induced over a range of bead concentrations, before
a bead-to-cell ratio of 1:100 was chosen (Figure 6.4A). The ability of IL-10 to inhibit the
proliferation induced by this bead concentration was then confirmed and subsequently used
as a control in further experiments (Figure 6.4B). Using this assay, the supernatant derived
from US28-stimulated CD4+ T cells was found to inhibit the proliferation of both CD4+ and
CD8+ T cells by over 70% in comparison to anti-CD3/CD28/CD137 stimulated T cells only
(Figure 6.4C and D).
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Fig. 6.4 Assessing the proliferation of CD4+ T cells following incubation with
supernatant dervied from PBMC stimulated with US28 ORF peptides. (A) To
determine the concentration of polyclonal stimulus to use in the proliferation assays, PBMC
from one donor were stained with a proliferation dye then stimulated polyclonally with
Dynabeads® Human T-Activator CD3/CD28/CD137 at a range of concentrations. Following
a five day incubation, PBMC were phenoypted to determine the levels of proliferation of
CD4+ T cells. (B) The ability to inhibit this proliferation was confirmed using IL-10. A range
of IL-10 concentrations was utilised. PBMC were incubated in IL-10 prior to the addition
of the polyclonal stimulus before assessing proliferation after five days. PBMC from one
HCMV seropositive donor were stimulated with the US28 ORF peptide pool for 48 hours and
the supernatant was harvested. Separately isolated PBMC were stained with a proliferation
dye then incubated in this supernatant and stimulated polyclonally with Dynabeads® Human
T-Activator CD3/CD28/CD137 at a ratio of 1:100 beads per cell. IL-10 was used as a positive
control for inhibition at 2ng/ml. After five days, PBMC were analysed by flow cytometry for
the levels of proliferation of (C) CD4+ T cells and (D) CD8+ T cells.
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Development of the cytokine secretion inhibition assay
The ability of latency-specific CD4+ T cells secreting IL-10 and TGFβ to affect the
production of anti-viral cytokines from PBMC was then assessed using a cytokine secretion
inhibition assay. In this assay, PBMC were incubated in supernatant derived from HCMV
ORF peptide pool stimulated CD4+ T cells, before being stimulated with an anti-CD3/CD28
monoclonal antibody mix. The secretion of anti-viral IFNγ and TNFα was then quantified
by a flow cytometry based bead array. Initial experiments to develop this assay were carried
out using a mixture of recombinant IL-10 and TGFβ , in the place of CD4+ T cell
secretomes, at a range of concentrations. This positive control mixture of TGFβ and IL-10
was utilised to ensure that anti-CD3/CD28 antibody induced IFNγ and TNFα secretion from
PBMC could be inhibited. A range of IL-10 and TGFβ concentrations was tested, with all
showing strong inhibition of TNFα (Figure 6.5A) and IFNγ (Figure 6.5B) secretion. The
extent of the inhibition of anti-viral cytokine secretion can be illustrated by taking the
relative percentage of inhibition at every IL-10 and TGFβ concentration in comparison to
the cytokine secretion from the anti-CD3/CD28 antibody stimulated PBMC only. Doing so
for this donor showed that the secretion of IFNγ from PBMC was inhibited by
approximately 95% for all four IL-10 and TGFβ concentrations used compared to
anti-CD3/CD28 stimulated PBMC only (Figure 6.5C). The secretion of TNFα was also
highly inhibited, even at the lowest concentrations of IL-10 and TGFβ (Figure 6.5C).
A cohort of donor PBMC that could be used in subsequent experiments for these assays
was sought. The ability of TGFβ and IL-10 to inhibit IFNγ and TNFα secretion from
PBMC was therefore tested in several donors. Utilising a greater range of IL-10 and TGFβ
concentrations that extended lower than those used previously (Figure 6.5), donor CMV401
was found to exhibit a high level of inhibition of both TNFα and IFNγ secretion from
CD3/CD28 stimulated PBMC across the range of IL-10 and TGFβ concentrations tested
(Figure 6.6). The secretion of TNFα was consistently inhibited by around 70% at all
IL-10 and TGFβ concentrations, with IFNγ secretion found to be inhibited by between
approximately 65% and 75% at most concentrations (Figure 6.6A and C).
When carrying out the same analysis on additional donors, a donor specific variation
in the ability of IL-10 and TGFβ to inhibit the secretion of IFNγ and TNFα was observed
across the concentrations tested. For example, the inhibition of TNFα secretion from the
PBMC of donor CMV331 was low, even at the highest concentration of TGFβ and IL-10
(Figure 6.7A), where there was around a 20% inhibition (Figure 6.7C). Furthermore, at
concentrations of IL-10 and TGFβ below this, TNFα secretion actually increased above
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Fig. 6.5 IFNγ and TNFα production from PBMC following IL-10 and TGFβ treatment.
PBMC from one donor, CMV429, were incubated with media, or with combinations of
different IL-10 and TGFβ concentrations for 24 hours. The PBMC were then stimulated
with anti-CD3/CD28 monoclonal antibodies for 18 hours. Following this, the supernatants
were harvested and analysed for the secretion of (A) TNFα and (B) IFNγ by flow cytometry.
(C) The ability of different concentrations of IL-10 and TGFβ to inhibit cytokine secretion
was then expressed as a percentage of the TNFα and IFNγ secretion observed from the
anti-CD3/CD28 stimulated only control. Supernatant samples were tested in triplicate.
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Fig. 6.6 IL-10 and TGFβ inhibit the production of IFNγ and TNFα . PBMC from
donor CMV401 were incubated with media, or with combinations of different IL-10 and
TGFβ concentrations for 24 hours. The PBMC were then stimulated with anti-CD3/CD28
monoclonal antibodies for 18 hours. Following this, the supernatants were harvested
and analysed for the secretion of (A) TNFα and (B) IFNγ by flow cytometry. (C) The
ability of different concentrations of IL-10 and TGFβ to inhibit cytokine secretion was
then expressed as a percentage of the TNFα and IFNγ secretion observed from the anti-
CD3/CD28 stimulated only control. Supernatant samples were tested in triplicate. (D) The
concentrations of IL-10 and TGFβ used are shown in the table.
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that observed in the stimulation only control (Figure 6.7C). In contrast to the TNFα , IFNγ
secretion exhibited a 50% inhibition at the highest TGFβ and IL-10 concentration (Figure
6.7B and C).
Donor CMV426 showed near complete inhibition of TNFα secretion at the highest
concentration of IL-10 and TGFβ , which decreased consistently with decreasing
concentrations of IL-10 and TGFβ (Figure 6.8A and C). At the lowest concentrations, there
was a stimulatory effect of IL-10 and TGFβ on TNFα and production (Figure 6.8C), as seen
with donor CMV331 (Figure 6.7C). On the other hand, the inhibition of IFNγ secretion
remained elevated across all IL-10 and TGFβ concentrations, with around a 60% inhibition
observed at the lowest concentrations (Figure 6.8B and C).
The data from these four individuals revealed considerable variation between donors
in several characteristics that are important for the design of a reliable assay to detect the
inhibition of cytokine secretion. The inhibition of TNFα and IFNγ were differentially
affected by IL-10 and TGFβ in certain donors. Donor CMV331 for example exhibited
inhibition of IFNγ at many IL-10 and TGFβ concentrations where there was either no
inhibition of TNFα , or an observed increase in TNFα production (Figure 6.7). There was
also extensive variation in the TNFα and IFNγ secretion induced by the positive control mix
of anti-CD3/CD28 antibodies between donors. Additionally, the abilities of IL-10 and TGFβ
to inhibit TNFα and IFNγ differed dramatically between donors when comparing across the
same concentrations. Initially therefore, two donors were selected (CMV401 and CMV426)
for use in subsequent assays as TNFα and IFNγ secretion could be inhibited from their
PBMC by IL-10 and TGFβ , in addition to producing enough quantities of these cytokines to
give a wide range of inhibition.
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Fig. 6.7 IFNγ and TNFα production from PBMC following IL-10 and TGFβ treatment.
PBMC from donor CMV331 were incubated with media, or with combinations of different
IL-10 and TGFβ concentrations for 24 hours. The PBMC were then stimulated with anti-
CD3/CD28 monoclonal antibodies for 18 hours. Following this, the supernatants were
harvested and analysed for the secretion of (A) TNFα and (B) IFNγ by flow cytometry.
(C) The ability of different concentrations of IL-10 and TGFβ to inhibit cytokine secretion
was then expressed as a percentage of the TNFα and IFNγ secretion observed from the
anti-CD3/CD28 stimulated only control. Supernatant samples were tested in triplicate. (D)
The concentrations of IL-10 and TGFβ used are shown in the table.
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Fig. 6.8 IL-10 and TGFβ inhibit the production of IFNγ and TNFα . PBMC from
donor CMV426 were incubated with media, or with combinations of different IL-10 and
TGFβ concentrations for 24 hours. The PBMC were then stimulated with anti-CD3/CD28
monoclonal antibodies for 18 hours. Following this, the supernatants were harvested
and analysed for the secretion of (A) TNFα and (B) IFNγ by flow cytometry. (C) The
ability of different concentrations of IL-10 and TGFβ to inhibit cytokine secretion was
then expressed as a percentage of the TNFα and IFNγ secretion observed from the anti-
CD3/CD28 stimulated only control. Supernatant samples were tested in triplicate. (D) The
concentrations of IL-10 and TGFβ used are shown in the table.
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The secretome from latency-specific CD4+ T cells can inhibit the secretion of TNFα
and IFNγ from activated bystander T cells
The cytokine secretion inhibition assay was then used to investigate the ability of
supernatants from HCMV ORF stimulated CD4+ T cells to inhibit anti-viral cytokine
production (illustrated in Figure 6.9). Initially, PBMC from three HCMV seropositive
donors were depleted of CD8+ cells and stimulated with HCMV ORF peptide pools for 48
hours, and the levels of IL-10, IFNγ , and TNFα determined by a flow cytometry based bead
array (Figure 6.9A and Appendix B.1). Of note, IL-10 was only detected from CMV319
CD4+ T cell supernatants, and these were below 10pg/ml (Appendix B.1). The resulting
three sets of CD4+ T cell supernatants were then tested for their ability to inhibit the
secretion of IFNγ and TNFα from CD3/CD28 stimulated PBMC. Initially, these three sets
of CD4+ T cell ORF supernatants were tested for their abilities to inhibit cytokine secretion
from the PBMC of two non-autologous donors (CMV401 and CMV426). PBMC were
incubated in CD4+ T cell ORF supernatants for 24 hours before the addition of
anti-CD3/CD28 antibodies. The following day, the resulting CD3/CD28 stimulated
supernatants were analysed for the secretion of TNFα and IFNγ by a flow cytometry based
bead array (Figure 6.9C). Cytokine secretion in these test samples was compared to the
secretion observed from CD3/CD28 stimulated PBMC following incubation with
supernatant obtained from unstimulated CD4+ T cells. As a control, donor PBMC were left
incubated with supernatants for 42 hours without the addition of the anti-CD3/CD28
monoclonal antibody mix to determine the effect of the supernatants alone on cytokine
secretion (Figure 6.9B). Any IFNγ and TNFα secretion induced by the supernatant alone
(Appendix B.2 and B.3) was treated as background and deducted from the test values.
There were very few CD4+ T cell ORF supernatants that inhibited IFNγ and TNFα
secretion from CMV401 CD3/CD28 stimulated PBMC when comparing against the control
supernatant derived from unstimulated CD4+ T cells (Figure 6.10). The majority of CD4+ T
cell supernatants resulted in no change, or an increase, in IFNγ and TNFα secretion from
PBMC (Figure 6.10). CD4+ T cell supernatants derived from donor CMV324 did not have
any inhibitory effect on TNFα or IFNγ secretion on donor CMV401 PBMC, while there
were considerable increases in the secretion of these cytokines incubated with pp65 and
UL144 supernatants (Figure 6.10A and B, and 6.12C). The UL111A and UL144 stimulated
supernatants from donor CMV328 did have an inhibitory effect of around 50% on TNFα
secretion on PBMC from donor CMV401 (Figures 6.10C and 6.12A). Conversely, IFNγ
secretion was increased by incubation with all CMV328 CD4+ T cell ORF supernatants
(Figures 6.10D and 6.12A). The largest increase, of around double the IFNγ secretion of the
218 In vitro Characterisation of Latency-specific CD4+ T cells
Fig. 6.9 Representation of the stages in the cytokine secretion inhibition assay. (A)
PBMC depleted of CD8+ cells were stimulated with HCMV ORF peptide pools for 48 hours,
the supernatants harvested, and examined for IL-10, IFNγ , and TNFα secretion by a flow
cytometry based bead array. (B) PBMC were incubated in these HCMV ORF stimulated
CD4+ T cell supernatants for 24 hours, and as a measure of background cytokine secretion,
IFNγ and TNFα was quantified by a flow cytometry based bead array. (C) In test conditions,
a mix of anti-CD3 and anti-CD28 monoclonal antibodies (MAbs) were added to PBMC
following the incubation in (B), and 18 hours later the supernatants were harvested. IFNγ
and TNFα secretion was then determined by a flow cytometry based bead array.
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CD4+ T cell unstimulated supernatant control, was observed from the US28 ORF supernatant
(Figures 6.10D and 6.12A). Finally, there was only a small inhibitory effect on TNFα and
IFNγ secretion from donor CMV401 CD3/CD28 stimulated PBMC when incubated with
pp65 and UL144 CD4+ T cell supernatants from donor CMV319 (Figure 6.10E and F, and
6.12E). In contrast, there was an increase in IFNγ secretion from LUNA and US28 ORF
CD4+ T cell supernatant incubation, and an increase in TNFα following LUNA and UL111A
supernatant incubation (Figure 6.10E and F, 6.12E).
The same three sets of CD4+ T cell ORF stimulated supernatants were then tested on
CD3/CD28 stimulated PBMC from donor CMV426, highlighting considerable differences in
their effects on PBMC IFNγ and TNFα secretion between CMV401 and CMV426. None
of the CMV324 derived CD4+ T cell supernatants showed an inhibitory effect on CMV401
PBMC (Figure 6.10A and B, and 6.12C), but on CMV426 PBMC, all were able to mediate
inhibition of both IFNγ and TNFα secretion, excluding US28, and UL111A CD4+ T cell
supernatant on TNFα secretion (Figure 6.11A and B, and 6.12D). While UL111A and UL144
CD4+ T cell supernatants from donor CMV328 inhibited TNFα secretion from CMV401
CD3/CD28 stimulated PBMC (Figure 6.10C and 6.12A), these supernatants had a stimulatory
effect on CMV426 CD3/CD28 stimulated PBMC (Figure 6.11C and 6.12B). All of the CD4+
T cell ORF supernatants from CMV328 also increased IFNγ secretion from donor CMV426
PBMC to a much greater extent, reaching around 7.5 times higher than the unstimulated
control supernatant in several cases (Figure 6.11D and 6.12B). Similarly, differential abilities
of these supernatants to inhibit cytokine secretion between donors was observed for CMV319
supernatants. The pp65 and UL144 derived CD4+ T cell ORF supernatants showed a slight
inhibitory effect on IFNγ and TNFα secretion on donor CMV401 PBMC (Figure 6.10E and
F, and 6.12E), but this was not replicated for donor CMV426, where cytokine secretion was
actually increased (Figure 6.11E and F, and 6.12F). Inhibition was however observed from
CM426 PBMC for LUNA and US28 CD4+ T cell ORF supernatants (Figure 6.11E and F,
and 6.12F), which was not seen for donor CMV401 PBMC (Figure 6.10E and F, and 6.12E).
The discrepancies in cytokine secretion inhibition observed between PBMC from donors
CMV401 and CMV426 were considerable. It was hypothesised that this could be due to
the non-autologous nature of these experiments where CD4+ T cell supernatants were not
matched to the PBMC donor. Further work was therefore carried out using an autologous
system where supernatants were tested for their abilities to inhibit PBMC from the same
donor. CD4+ T cell supernatants were generated from one donor (CMV332) and assayed
for the presence of IL-10, IFNγ , and TNFα as before (Figure 6.9A and Appendix B.4), and
for the quantities of total TGFβ (Figure 6.1B). In the CD4+ T cell supernatants, IL-10 was
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Fig. 6.10 IFNγ and TNFα secretion by PBMC stimulated following incubation with
supernatant derived from CD4+ T cells stimulated with HCMV ORF peptide pools
PBMC from donor CMV401 were incubated with three sets of supernatant generated from
the HCMV seropositive donors CMV328, CMV324, and CMV319 for 24 hours. These
supernatants were derived from the stimulation of CMV328, CMV324, and CMV319 CD4+
T cells with overlapping HCMV ORF peptide pools spanning pp65, UL138, LUNA, US28,
UL111A, and UL144 ORFs, or media alone (Unstim), for 48 hours. Following this incubation,
PBMC were then stimulated with a mix of anti-CD3/CD28 monoclonal antibodies for 18
hours. Supernatants were then assayed for the secretion of (A, C, E) TNFα and (B, D, F)
IFNγ by flow cytometry in duplicate.
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Fig. 6.11 IFNγ and TNFα secretion by PBMC stimulated following incubation with
supernatant derived from CD4+ T cells stimulated with HCMV ORF peptide pools
PBMC from donor CMV426 were incubated with three sets of supernatant generated from
the HCMV seropositive donors CMV328, CMV324, and CMV319 for 24 hours. These
supernatants were derived from the stimulation of CMV328, CMV324, and CMV319 CD4+
T cells with overlapping HCMV ORF peptide pools spanning pp65, UL138, LUNA, US28,
UL111A, and UL144, or left unstimulated in media, for 48 hours. Following this incubation,
PBMC were then stimulated with a mix of anti-CD3/CD28 monoclonal antibodies for 18
hours. Supernatants were then assayed for the secretion of (A, C, E) TNFα and (B, D, F)
IFNγ by flow cytometry in duplicate.
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Fig. 6.12 Relative IFNγ and TNFα secretion by PBMC stimulated following incubation
with supernatant derived from CD4+ T cells stimulated with HCMV ORF peptide
pools PBMC from donors CMV401 and CMV426 were incubated with three sets of
supernatant generated from the HCMV seropositive donors CMV328, CMV324, and
CMV319 for 24 hours. These supernatants were derived from the stimulation of CMV328,
CMV324, and CMV319 CD4+ T cells with overlapping HCMV ORF peptide pools spanning
pp65, UL138, LUNA, US28, UL111A, and UL144, or left unstimulated in media, for 48
hours. Following this incubation, PBMC were then stimulated with a mix of anti-CD3/CD28
monoclonal antibodies. The next day, supernatants were assayed for the secretion of TNFα
and IFNγ by flow cytometry. Secretion of IFNγ and TNFα is displayed relative to the
secretion of these cytokines from PBMC incubated in CD4+ T cell unstimulated supernatant
and stimulated with anti-CD3/CD28 antibodies (shown with the dotted line).
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detected at very low levels, around 1pg/ml, in response to US28 from CMV332 (Appendix
B.4). Total TGFβ was also elevated in response to all HCMV ORFs, with the exception of
UL138 (Figure 6.1B). PBMC from donor CMV332 were then incubated with these CD4+ T
cell ORF supernatants for 42 hours to determine the background levels of IFNγ and TNFα
secretion when PBMC were not stimulated, and these quantities were deducted from the
cytokine secretion observed in the test conditions (Appendix B.4).
The autologous PBMC were then stimulated with anti-CD3/CD28 antibodies in the
presence of the CD4+ T cell supernatants. Inhibition of cytokine secretion was observed
from the majority of CD4+ T cell ORF supernatants, although there were differential effects
on TNFα and IFNγ secretion from several ORF pools. IFNγ secretion was inhibited by all
of the ORF supernatants tested except for the UL138 ORF stimulated supernatant (Figure
6.13A), suggesting this effect could be due to the presence of TGFβ in these CD4+ T cell
supernatants (Figure 6.1B). The greatest inhibition of IFNγ secretion was observed from
PBMC stimulated in the presence of supernatant from UL144 ORF stimulated CD4+ T cells,
reaching nearly 42% inhibition compared to the unstimulated supernatant (Figure 6.13A and
C). Low levels of IFNγ were detected in the pp65 ORF CD4+ T cell supernatant, while no
IFNγ was detected in the IE1 ORF CD4+ T cell supernatant (Appendix B.4). The TGFβ
present in both of these supernatants (Figure 6.1B) could therefore have been the mediator of
the IFNγ secretion from PBMC.
The effects of the CD4+ T cell ORF supernatants on TNFα secretion were more variable
in comparison to IFNγ secretion, as has been observed in previous experiments. The UL138,
LUNA, and UL111A CD4+ T cell ORF supernatants caused a low level of inhibition on
TNFα secretion from CD3/CD28 stimulated PBMC, while supernatants from pp65, IE1, and
US28 increased TNFα secretion, and the UL144 supernatant had no effect (Figure 6.13 B
and C).
In summary, the use of an autologous system for the cytokine secretion inhibition assay
has provided initial data showing that supernatant from HCMV-specific CD4+ T cells can
inhibit anti-viral cytokine production, although the extent of inhibition of TNFα secretion
was less than for IFNγ . Furthermore, certain CD4+ T cell ORF supernatants that inhibited
the secretion of IFNγ were found to increase secretion of TNFα from stimulated PBMC.
This inhibition was observed in the absence of elevated levels of IL-10 and could be mediated
by TGFβ .
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Fig. 6.13 IFNγ and TNFα secretion by PBMC stimulated following incubation with
supernatant derived from autologous CD4+ T cells stimulated with HCMV ORF
peptide pools CD4+ T cells from donor CMV332 were stimulated with overlapping HCMV
ORF peptide pools spanning pp65, UL138, LUNA, US28, UL111A, and UL144, or left
unstimulated in media (Unstim), for 48 hours. Autologous PBMC were then incubated
with these supernatants for 24 hours and then stimulated with a mix of anti-CD3/CD28
monoclonal antibodies. The next day, supernatants were assayed for the secretion of (A)
TNFα and (B) IFNγ by flow cytometry. (C) The secretion of TNFα (black bars) and IFNγ
(white bars) from PBMC following stimulation in ORF-specific supernatants relative to the
secretion of these cytokines from stimulation in the unstimulated supernatant.
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6.2.4 Assessing the ability of HCMV-specific CD4+ T cell secretomes
to inhibit CD8+ T cell control of viral spread
The secretome from CD4+ T cells stimulated with HCMV ORF peptide pools was then
investigated for their ability to inhibit CD8+ T cell control of an active lytic infection in
fibroblasts. As CD4+ T cells specific for HCMV latency-associated proteins secrete IL-10
and TGFβ , it was hypothesised that these immunosuppressive factors could reduce the
ability of CD8+ T cells to control HCMV lytic infection. To do this, a well described
viral dissemination assay was used [291]. Preliminary experiments were carried out using
autologous fibroblasts infected at low multiplicity of infection (MOI) with a Merlin virus
carrying a UL32-GFP tag. One day post infection, decreasing concentrations of CD8+ T cells
were added to the infected fibroblasts. The infected cells were then monitored for the spread
of virus over 10 days and the percentage of GFP-expressing fibroblasts determined by flow
cytometry. As expected, the control of HCMV spread was dependent on the effector-to-target
(E:T) ratio, where the greatest levels of control were seen at the highest E:T ratios, with a
gradual decline in control with decreasing E:T ratio observed (Figure 6.14). CD8+ T cells
were then incubated with recombinant IL-10 and TGFβ for two hours prior to their addition
onto the infected fibroblasts and the spread of the virus monitored as before. CD8+ T cells
treated with recombinant IL-10 and TGFβ were unable to control viral spread as well as
CD8+ T cells alone, although this effect was most pronounced at the lowest E:T ratio tested
(Figure 6.15). It is likely that the relatively weak inhibition of CD8+ T cell responses here
were due to the ability of this donor’s CD8+ T cells to overcome the effects of IL-10 and
TGFβ at a high E:T ratio.
CD4+ T cell secretomes generated from the stimulation of CD8+ cell depleted PBMC
with HCMV ORF peptide pools were then tested for their abilities to inhibit CD8+ T cell
mediated control of viral spread. As these secretomes could contain antiviral factors such as
IFNγ and TNFα , in addition to any inhibitory cytokines like IL-10 and TGFβ , they were
first tested for their ability to inhibit viral spread in isolation, in two donors. One day post
infection, fibroblasts were incubated with CD4+ T cell secretomes and were not removed for
the remainder of the assay. Several of the CD4+ T cell secretomes were able to inhibit viral
spread compared to the effect of fresh media and the secretome from unstimulated CD4+
T cells. Donor CMV301 displayed the greatest inhibition of viral spread from the pp65
and UL144 stimulated supernatants (Figure 6.16A). IE1, LUNA, and UL111A stimulated
supernatants also inhibited viral spread to a large extent, while UL138 and US28 stimulated
supernatants did not have an effect (Figure 6.16A). Likewise, many CD4+ T cell supernatants
from donor CMV305 had an inhibitory effect on viral spread in isolation. In particular,
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Fig. 6.14 In vitro spread of HCMV in the presence of CD8+ T cells Autologous dermal
fibroblasts from donor CMV307 were infected at low MOI with a Merlin-GFP virus. The
following day, CD8+ T cells isolated from the same donor by MACS were added at a range of
effector-to-target (E:T) ratios to the infected cells. The spread of the virus was then monitored
over 10 days and analysed for the percentage of GFP expressing fibroblasts by flow cytometry
compared to uninfected fibroblasts. The percentage of GFP expressing fibroblasts in test
conditions with added CD8+ T cells was normalised to the infected only control samples to
give a relative measure of infection.
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Fig. 6.15 In vitro spread of HCMV in the presence of CD8+ T cells treated with TGFβ
and IL-10 Autologous dermal fibroblasts from donor CMV307 were infected at low MOI
with a Merlin-GFP virus. The following day, CD8+ T cells isolated from the same donor
were incubated with a mix of 1.25ng/ml IL-10 and 0.5ng/ml TGFβ and added at a range of
effector-to-target (E:T) ratios to the infected cells. The spread of the virus was then monitored
over 10 days and analysed for the percentage of GFP expressing fibroblasts by flow cytometry
compared to uninfected fibroblasts. The percentage of GFP expressing fibroblasts in test
conditions with added CD8+ T cells was normalised to that in fibroblasts infected without
added CD8+ T cells to give a relative measure of infection.
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IE1, LUNA, UL111A, and UL144 stimulated supernatants, which inhibited virus spread
considerably (Figure 6.16B).
CD8+ T cells were then incubated for 18 hours in the donor-matched CD4+ T cell
secretomes before their addition to infected autologous fibroblasts. The CD8+ T cells were
washed prior to their addition onto lytically infected fibroblasts to remove the potentially
antiviral CD4+ T cell supernatants. When comparing the ability of CD8+ T cells to control
viral spread following incubation with ORF secretomes or with the control unstimulated
secretomes, no inhibitory effect was found for any of the ORF secretomes (Figure 6.17).
However, compared to CD8+ T cells alone, incubation with UL138 CD4+ T cell supernatant
resulted in a reduction in the ability of CD8+ T cells to control viral spread by nearly 25%
(Figure 6.17). It was thought that the inability of the CD4+ T cell secretomes to inhibit CD8+
T cells was due to the removal of the secretomes, and with it the removal of any inhibitory
cytokines. It could therefore be the case that these secretomes need to be present for the
duration of the assay to mediate inhibition.
Despite initial data showing IL-10 and TGFβ could inhibit the ability of CD8+ T cells
to control a lytic HCMV infection in fibroblasts, the same effect with HCMV latency-
associated ORF-specific CD4+ T cell supernatants could not be replicated. The factors
present in CD4+ T cell supernatants from two donors were unable to inhibit the ability of
CD8+ T cells to control viral spread in autologous fibroblasts following a 18 hour incubation
with the supernatants. Incubating infected fibroblasts with the CD4+ T cell supernatants
alone confirmed the presence of anti-viral factors that in many cases reduced viral spread
considerably.
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Fig. 6.16 In vitro spread of HCMV in the presence of CD4+ T cell secretomes
Autologous dermal fibroblasts from donors (A) CMV301 and (B) CMV305 were infected at
low MOI with a Merlin-GFP virus. The following day, infected fibroblasts were incubated
in supernatant derived from autologous CD4+ T cells left unstimulated for 48 hours, or
stimulated with overlapping peptide pools spanning the ORFs of IE1, pp65, UL138, LUNA,
US28, UL111A, and UL144 or with fresh media. The spread of the virus was then monitored
over 10 days and analysed for the percentage of GFP expressing fibroblasts by flow cytometry
compared to uninfected fibroblasts. The percentage of GFP expressing fibroblasts in test
conditions with added CD8+ T cells was normalised to the infected only control samples to
give a relative measure of infection.
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Fig. 6.17 In vitro spread of HCMV in the presence of CD8+ T cells pre-incubated with
CD4+ T cell secretomes Autologous dermal fibroblasts from donor CMV305 were infected
at low MOI with a Merlin-GFP virus. The same day, CD8+ T cells were isolated from the
donor and incubated for 18 hours in supernatant derived from this donor’s CD4+ T cells left
unstimulated for 48 hours, or stimulated with overlapping peptide pools spanning the ORFs
of IE1, UL138, LUNA, US28, UL111A, and UL144 or with fresh media. The following day,
CD8+ T cells were washed in fresh media were added at an effector-to-target (E:T) ratio of
2:1 to the infected fibroblasts. The spread of the virus was then monitored over 10 days and
analysed for the percentage of GFP expressing fibroblasts by flow cytometry compared to
uninfected fibroblasts. The percentage of GFP expressing fibroblasts in test conditions with
added CD8+ T cells was normalised to the infected only control samples to give a relative
measure of infection.
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6.2.5 Depletion of CD25+ expressing CD4+ T cells does not
consistently reduce the frequency of IL-10 secreting cells
The secretion of IL-10 is a well described function of Tregs. Tregs mediate their
immunosuppressive effects in part through IL-10 and to TGFβ secretion. Previous work
identified expression of phenoyptic markers associated with Tregs in a subset of LUNA- and
UL138-specific CD4+ T cells, which were absent from gB-specific CD4+ T cells [501].
Having also found extensive CD4+ T cell IL-10 responses to UL138, LUNA, US28, and
UL111A, it was hypothesised that these cells could be Tregs. The presence of two separate
populations of CD4+ T cells specific for the latency-associated HCMV ORFs, those
secreting IFNγ and those secreting IL-10, could enable the selective depletion of the IL-10
secreting CD4+ T cells if these cells could be identified phenotypically. Thus, if such IL-10
secreting cells are predominantly Tregs, their selective depletion could be an effective and
simple approach to remove IL-10 secreting CD4+ T cells and enable the CD4+ T cells that
secrete IFNγ , which might be more effective anti-viral cells, to predominate.
Tregs can be identified based on a number of different phenotypic markers. As has
been described, CD4+ T cells with low expression of CD127 and high expression of CD25
were found to express FoxP3 and have the characteristics of Tregs [482–484]. Therefore,
the elevated expression of the IL-2 receptor alpha chain (CD25) on Tregs could provide a
convenient target for their selective depletion. Indeed, previous work targeting Tregs by
CD25+ cell depletion led to an increase in IE1- and pp65-specific IFNγ secretion [494, 502].
The expression of FoxP3 by CD4+ T cells expressing high levels of CD25 was confirmed
using an intracellular staining procedure. The gating strategy to identity these cells is
shown in Figure 6.18. PBMC were stained and CD3+CD4+ cells identified following the
exclusion of doublets and gating for lymphocytes on forward and side scatter (Figure 6.18A).
The CD127loCD25hi population was then gated on and the expression of FoxP3 within
this population compared to the CD127hi expressing CD4+ T cells, confirming that FoxP3
expression was elevated on the CD127loCD25hi CD4+ T cells, which are therefore likely to
be Tregs (Figure 6.18B).
The depletion of CD25hi CD4+ T cells was then tested in an attempt to remove the
HCMV-specific IL-10 expressing CD4+ T cells. PBMC were either depleted of CD8+ cells
alone, or depleted of both CD8+ and CD25+ high expressing cells, by MACS to test the
CD4+ T cell responses with and without CD25hi cells. These depleted populations were
then stimulated with overlapping peptide pools spanning the ORFs of gB, pp65, IE1, UL138,
LUNA, US28, UL111A, and UL144 on dual IFNγ /IL-10 FluoroSpot plates. The frequencies
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Fig. 6.18 Identifying regulatory CD4+ T cells by FoxP3 expression PBMC from donor
CMV327 were phenotyped to identify Tregs by the markers CD127, CD25, and FoxP3.
(A) Doublets were first excluded, following by gating for lymphocytes by forward (FSC-A)
and side scatter (SSC-A). CD3+ cells and CD4+ cells were then gated on. (B) Tregs were
identified as CD127loCD25hi, and the expression of FoxP3 from this population confirmed
to be elevated (blue histogram) compared to other CD4+ T cells expressing CD127+ (red
histogram).
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of IFNγ and IL-10 secreting CD4+ T cells was then compared between the CD8+ depleted
and CD8+CD25hi depleted conditions. It might be expected that in addition to a decrease in
the frequency of IL-10 producing cells when CD25hi cells are depleted, there could also be an
increase in the frequency of IFNγ secreting cells, as they should occupy a higher proportion
of the total input cell number, and because of the decrease in immunosuppressive IL-10
secretion. CD25+ cell depletions were carried out on PBMC from six HCMV seropositive
donors.
The depletion of CD25hi cells was verified by flow cytometry to ensure that cells with
the highest expression of CD25+ had been depleted. Depleting CD25hi CD4+ T cells from
donor CMV319 (Figure 6.19A) resulted in a decrease in the frequency of IFNγ secreting
cells responding to pp65 and UL144, which were the only two ORFs responded to by
a high frequency of IFNγ secreting cells (Figure 6.19B). Following the same pattern, a
decrease in the frequency of IL-10 secreting cells was also observed for responses to pp65
and UL144 after CD25hi cell depletion (Figure 6.19C). Additionally, CD4+ T cells secreting
IL-10 in response to gB and US28 were also reduced following this depletion (Figure 6.19C).
Therefore, while the depletion of CD25hi cells in this donor did not remove all IL-10 secreting
CD4+ T cells, a proportion of ORF-specific CD4+ T cells secreting IL-10 were CD25hi.
Depletion of CD25hi cells from donor CMV321 (Figure 6.20A) resulted in a decrease
in the frequency of IFNγ secreting CD4+ T cells responding to UL144, but had no effect
on IFNγ responses to other ORFs (Figure 6.20B). As with donor CMV319, this decrease in
IFNγ secreting cells responding to UL144 following CD25hi cell depletion was also observed
for CD4+ T cells secreting IL-10 (Figure 6.20C). Therefore, approximately two-thirds of the
IL-10 secreting CD4+ T cell population responding to UL144 were CD25hi (Figure 6.20C).
However, this was not the case for IL-10 secreting CD4+ T cells responding to LUNA, which
were not appreciably changed following this depletion (Figure 6.20C).
Depletion of CD25hi cells (Figure 6.21A) from donor CMV328 resulted in an increase
in the frequency of IFNγ secreting CD4+ T cells for those responding to gB, pp65, and
US28 (Figure 6.21B), which was associated with a decrease in the frequencies of IL-10
secreting cells responding to gB and US28 (Figure 6.21B). However, a decrease in the
frequency of IFNγ secreting CD4+ T cells was observed for responses to IE1, UL111A,
and UL144 following CD25hi cell depletion (Figure 6.21B). No change was observed in the
IL-10 secreting CD4+ T cell frequencies responding to pp65, LUNA, and UL144 (Figure
6.21C). Therefore, depletion of CD25hi cells from this donor removed a minor proportion
of IL-10 secreting CD4+ T cells, and resulted in an increase in the frequencies of IFNγ
secreting CD4+ T cells, responding to gB and US28.
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Fig. 6.19 The frequency of IFNγ and IL-10 secreting CD4+ T cells and CD25hi depleted
CD4+ T cells from donor CMV319 following stimulation with HCMV ORF peptide
pools (A) PBMC from donor CMV319 were depleted of CD8+ cells and high expressors
of CD25 by MACS to remove Tregs. Pre-depletion and post-depletion cells were stained
for CD3, CD4, CD127, and CD25 to verify this depletion. PBMC depleted of CD8+ cells
or CD8+CD25hi cells were then stimulated with overlapping peptide pools spanning the
ORFs of gB, pp65, IE1, LUNA, UL144, UL138, UL111A, and US28 for 48 hours on dual
IFNγ /IL-10 FluoroSpot plates. The secretion of (B) IFNγ and (C) IL-10 was then stained for
and the number of positive spots enumerated by the automated cell counter and converted to
a spot forming unit (SFU) value per million cells. Each peptide pool was tested in triplicate
and the values from the number of background cells secreting cytokines in the unstimulated
wells was deducted from all test wells.
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Fig. 6.20 The frequency of IFNγ and IL-10 secreting CD4+ T cells and CD25hi depleted
CD4+ T cells from donor CMV321 following stimulated with HCMV ORF peptide
pools (A) PBMC from donor CMV321 were depleted of CD8+ cells and high expressors
of CD25 by MACS to remove Tregs. Pre-depletion and post-depletion cells were stained
for CD3, CD4, CD127, and CD25 to verify this depletion. PBMC depleted of CD8+ cells
or CD8+CD25hi cells were then stimulated with overlapping peptide pools spanning the
ORFs of gB, pp65, IE1, LUNA, UL144, UL138, UL111A, and US28 for 48 hours on dual
IFNγ /IL-10 FluoroSpot plates. The secretion of (B) IFNγ and (C) IL-10 was then stained for
and the number of positive spots enumerated by the automated cell counter and converted to
a spot forming unit (SFU) value per million cells. Each peptide pool was tested in triplicate
and the values from the number of background cells secreting cytokines in the unstimulated
wells was deducted from all test wells.
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Fig. 6.21 The frequency of IFNγ and IL-10 secreting CD4+ T cells and CD25hi depleted
CD4+ T cells from donor CMV328 following stimulated with HCMV ORF peptide
pools (A) PBMC from donor CMV328 were depleted of CD8+ cells and high expressors
of CD25 by MACS to remove Tregs. Pre-depletion and post-depletion cells were stained
for CD3, CD4, CD127, and CD25 to verify this depletion. PBMC depleted of CD8+ cells
or CD8+CD25hi cells were then stimulated with overlapping peptide pools spanning the
ORFs of gB, pp65, IE1, LUNA, UL144, UL138, UL111A, and US28 for 48 hours on dual
IFNγ /IL-10 FluoroSpot plates. The secretion of (B) IFNγ and (C) IL-10 was then stained for
and the number of positive spots enumerated by the automated cell counter and converted to
a spot forming unit (SFU) value per million cells. Each peptide pool was tested in triplicate
and the values from the number of background cells secreting cytokines in the unstimulated
wells was deducted from all test wells.
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There were a number of inconsistent changes following depletion of CD25hi cells from
donor CMV324 (Figure 6.22A). Very small increases in CD4+ T cells secreting IFNγ in
response to gB, LUNA, UL144, and UL111A were detected, while no changes were observed
for responses to pp65, and a small decrease was detected for the response to IE1 (Figure
6.22B). While no IL-10 secreting CD4+ T cells were detected in response to LUNA and
UL111A prior to CD25hi cell depletion, there was a considerable increase in IL-10 secreting
cells after this depletion (Figure 6.22B and C). A small decrease in IL-10 secreting CD4+ T
cells was observed in response to pp65 post depletion, and there was no change in responses
to gB and US28 (Figure 6.22C). CD25hi CD4+ T cells from donor CMV324 were therefore
not part of the IL-10 secreting population for responses to most ORFs.
To ensure that the IL-10 secreting CD4+ T cells thought to be Tregs were not contained
within the moderate and lower CD25+ expressing cells, a more comprehensive depletion
of the CD25+ population was carried out. To do this, a higher concentration of CD25
specific microbeads was used to deplete these cells. Two donors were tested in this way and
the depletion of CD25+ CD4+ T cells (Figure 6.23A) from donor CMV327 decreased the
frequencies of CD4+ T cells secreting IFNγ in response to gB, pp65, IE1, LUNA, and UL144
(Figure 6.23B). CD4+ T cells secreting IFNγ in response to US28 were increased however
(Figure 6.23B). The frequencies of IL-10 secreting CD4+ T cells were observed to decrease
for responses to gB, pp65, LUNA, UL144, and US28 following CD25+ cell depletion (Figure
6.23C). Of note, CD25+ cell depletion decreased the frequencies of both IFNγ and IL-10
secreting cells responding to gB, pp65, LUNA, and UL144, while for response to US28
this depletion increased IFNγ secreting cells and decreased IL-10 secreting cells (Figure
6.23B and C). An increase in IL-10 secreting cells was observed for responses to IE1 and
there was no change for responses to UL111A (Figure 6.23C). Although not the case for all
ORF-specific responses, CD25+ cells made up a considerable proportion of IL-10 secreting
CD4+ T cells in this individual.
Following CD25+ cell depletion, (Figure 6.24A), donor CMV323 had a decrease in
CD4+ T cells secreting IFNγ in response to UL144, while there was no such change for
responses to pp65 and US28 (Figure 6.24B). CD25+ cell depletion increased the frequencies
of CD4+ T cells secreting IL-10 in response to the majority of ORFs, including pp65, LUNA,
UL111A, and US28, while there was no change for responses to gB, and UL144 (Figure
6.24C). Therefore in this donor, CD25+ cells were not responsible for HCMV ORF-specific
IL-10 secretion.
Across the six donors tested, depletion of CD25 expressing cells had inconsistent effects
on the frequencies of IFNγ and IL-10 secreting CD4+ T cells. It is therefore likely that Tregs
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of this phenotype (CD4+CD127loCD25hi) are not the only CD4+ T cells secreting IL-10
in response to proteins expressed during HCMV latency, and the presence and size of this
population can depend on the individual and on the ORF-specific response.
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Fig. 6.22 The frequency of IFNγ and IL-10 secreting CD4+ T cells and CD25hi depleted
CD4+ T cells from donor CMV324 following stimulated with HCMV ORF peptide
pools (A) PBMC from donor CMV324 were depleted of CD8+ cells and high expressors
of CD25 by MACS to remove Tregs. Pre-depletion and post-depletion cells were stained
for CD3, CD4, CD127, and CD25 to verify this depletion. PBMC depleted of CD8+ cells
or CD8+CD25hi cells were then stimulated with overlapping peptide pools spanning the
ORFs of gB, pp65, IE1, LUNA, UL144, UL138, UL111A, and US28 for 48 hours on dual
IFNγ /IL-10 FluoroSpot plates. The secretion of (B) IFNγ and (C) IL-10 was then stained for
and the number of positive spots enumerated by the automated cell counter and converted to
a spot forming unit (SFU) value per million cells. Each peptide pool was tested in triplicate
and the values from the number of background cells secreting cytokines in the unstimulated
wells was deducted from all test wells.
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Fig. 6.23 The frequency of IFNγ and IL-10 secreting CD4+ T cells and CD25+ depleted
CD4+ T cells from donor CMV327 following stimulated with HCMV ORF peptide
pools (A) PBMC from donor CMV327 were depleted of CD8+ cells and moderate to
expressors of CD25+ by MACS to remove Tregs. Pre-depletion and post-depletion cells
were stained for CD3, CD4, CD127, and CD25 to verify this depletion. PBMC depleted
of CD8+ cells or CD8+CD25hi cells were then stimulated with overlapping peptide pools
spanning the ORFs of gB, pp65, IE1, LUNA, UL144, UL138, UL111A, and US28 for 48
hours on dual IFNγ/IL-10 FluoroSpot plates. The secretion of (B) IFNγ and (C) IL-10 was
then stained for and the number of positive spots enumerated by the automated cell counter
and converted to a spot forming unit (SFU) value per million cells. Each peptide pool was
tested in triplicate and the values from the number of background cells secreting cytokines in
the unstimulated wells was deducted from all test wells.
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Fig. 6.24 The frequency of IFNγ and IL-10 secreting CD4+ T cells and CD25+ depleted
CD4+ T cells from donor CMV323 following stimulated with HCMV ORF peptide
pools (A) PBMC from donor CMV323 were depleted of CD8+ cells and moderate to high
expressors of CD25 by MACS to remove Tregs. Pre-depletion and post-depletion cells were
stained for CD3, CD4, CD127, and CD25 to verify this depletion. PBMC depleted of CD8+
cells or CD8+CD25hi cells were then stimulated with overlapping peptide pools spanning the
ORFs of gB, pp65, IE1, LUNA, UL144, UL138, UL111A, and US28 for 48 hours on dual
IFNγ /IL-10 FluoroSpot plates. The secretion of (B) IFNγ and (C) IL-10 was then stained for
and the number of positive spots enumerated by the automated cell counter and converted to
a spot forming unit (SFU) value per million cells. Each peptide pool was tested in triplicate
and the values from the number of background cells secreting cytokines in the unstimulated
wells was deducted from all test wells.
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6.2.6 Characterisation of CD4+ T cell peptide specific cytokine
secretion
CD4+ T cells were found to either secrete IL-10 or IFNγ in response to HCMV ORF peptide
pools (Section 3.2.10). Whether CD4+ T cells specific to individual HCMV peptides were
composed entirely of one of these sub-population of cells, which secrete either IL-10 or
IFNγ , was investigated. By mapping CD4+ T cell responses to individual peptides, this could
also be useful in determining minimal peptide epitopes for the generation of MHC class II
tetramers. To begin characterising the specificity of the CD4+ T cell responses to latency-
associated HCMV ORFs, small peptide pools were used to stimulate CD8+ cell depleted
PBMC, and the frequencies of IFNγ and IL-10 secreting cells determined by FluoroSpot.
The peptide pools consisted of five individual overlapping peptides of 15 amino acids in
length spanning the ORFs of US28, LUNA, UL138, and UL111A. Two donors were tested
for their IFNγ and IL-10 responses to small peptide pools.
Donor CMV329 exhibited a number of responses to the small peptide pools (Figure
6.25). Although the responses to small LUNA, UL138, and UL111A peptide pools were
not very common in this donor, the CD4+ T cell responses did exhibit a mix of cytokine
responses. For example, CD4+ T cells responding to US28 pools 2 and 8 were exclusively
IL-10 secreting cells, while those responding to pool 9 were all IFNγ secreting (Figure
6.25A). A mix of IFNγ and IL-10 secreting cells responded to pools 3 and 6, although there
were many more cells secreting IL-10 in response to pool 6 (Figure 6.25A).
There were several pools that donor CMV324 had exclusive IFNγ responses to, such
as those to pool 1 and 7 of US28 (Figure 6.26A), pool 2 of LUNA (Figure 6.26B), pool 1
and 3 of UL138 (Figure 6.26C), and pool 4 of UL11A (Figure 6.26D). This donor did not
have CD4+ T cell responses to any small peptide pools that were composed entirely of IL-10
secreting cells. However, a small number of pools did elicit both IFNγ and IL-10 secreting
CD4+ T cells, including UL138 pool 2 and LUNA pool 1 (Figure 6.26C and B).
Therefore, several peptide pools were found that elicited a dominant IFNγ or IL-10 CD4+
T cell response, as well as a number that induced a combination of cells secreting both
cytokines. The individual 15 amino acid peptides from these peptide pools can subsequently
be tested individually to determine which 15 amino acid peptides are responded to.
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Fig. 6.25 Specificity of CD4+ T cells from donor CMV329 to small pools of latency-
associated ORF peptides. PBMC from donor CMV329 were depleted of CD8+ cells and
stimulated with pools composed of five individual overlapping peptides for 48 hours. These
small pools spanned the latency-associated ORFs of (A) US28, (B) LUNA, (C) UL138, and
(D) UL111A. IFNγ secretion was then stained for to give a number of positive spots that
were counted, and converted to spot forming units (SFU) per million cells. All samples were
run in triplicate and the frequencies of IFNγ positive cells was determined by subtracting
values in all test wells from the background number of positive cells in unstimulated well.
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Fig. 6.26 Specificity of CD4+ T cells from donor CMV324 to small pools of latency-
associated ORF peptides. PBMC from donor CMV324 were depleted of CD8+ cells and
stimulated with pools composed of five individual overlapping peptides for 48 hours. These
small pools spanned the latency-associated ORFs of (A) US28, (B) LUNA, (C) UL138, and
(D) UL111A. IFNγ secretion was then stained for to give a number of positive spots that
were counted, and converted to spot forming units (SFU) per million cells. All samples were
run in triplicate and the frequencies of IFNγ positive cells was determined by subtracting
values in all test wells from the background number of positive cells in unstimulated well.
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6.3 Discussion
6.3.1 CD4+ T cell functional and memory phenotype analysis
CD4+ T cells specific for HCMV latency-associated ORF products were further characterised
phenotypically and functionally by a range of methods. Having identified the ability of CD4+
T cells to secrete the immunosuppressive cytokine IL-10 in response to HCMV latency-
associated ORF products UL138, LUNA, US28, and UL111A, the secretion of TGFβ was
then examined. Previous work identified CD4+ T cells capable of secreting TGFβ following
UL138 and LUNA peptide pool stimulation, while this did not occur following gB peptide
pool stimulation [501]. The experiments carried out here have extended the HCMV ORFs
examined to include the additional latency-associated ORFs US28, UL111A, and UL144.
In these experiments, TGFβ was found to be produced by CD4+ T cells in response to all
latency-associated ORFs tested, with the exception of UL138 responses which were very
low or absent. Surprisingly, pp65 and IE1 peptide pool stimulated CD4+ T cells were also
capable of producing TGFβ .
TGFβ is a pleiotropic regulator of immune responses that has been shown to have a
number of effects on T cells. Immunomodulatory effects include the suppression of T
cell proliferation, Th1 cell differentiation, and IFNγ secretion, the promotion the iTreg
differentiation, and suppression of cytotoxic CD8+ T cell effector functions [487, 630, 703–
711]. TGFβ is also able to induce IL-10 expression via activation of the IL-10 promoter [712].
The effects of TGFβ have also been shown to be amplified by IL-10 and there is evidence
for the synergistic action of these cytokines on T cells [713]. Treatment of activated T cells
with IL-10 increases the expression of TGF receptor type-II and restores responsiveness to
TGFβ [710], while IL-10 is also thought to downregulate Th1 cytokines such as IFNγ and
IL-12 which would otherwise inhibit TGFβ secretion [714]. This evidence suggests that
because CD4+ T cells specific for lytic HCMV ORFs are predominantly IFNγ producers,
concomitant TGFβ production by these cells might not have as much of an inhibitory effect
in the absence of IL-10 and in the presence of Th1 cytokines such as IFNγ . The production
of TGFβ in addition to IL-10 by HCMV latency-associated ORF specific CD4+ T cells could
therefore be acting together to inhibit antiviral T cell responses.
HCMV-specific CD4+ T cells were examined for their cytotoxic potential to determine if
differences existed among T cells specific for latency-associated ORFs, and in comparison
to lytic ORF specific T cells. CD4+ T cells possessing direct anti-viral effector functions
such as cytotoxicity have been identified in HCMV infection in response to lytic ORFs
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including gB and pp65 [393, 401, 405, 715, 716], but a comparison with responses to latency-
associated ORFs has not been carried out previously. In agreement with reports showing
CD4+ T cell CD107a or granzyme expression in response to lytic ORFs such as gB, pp65,
and IE1 [393, 405, 715, 716], expression of these markers was also observed in response to
these ORFs, with degranulation in response to pp65 being particularly common. CD4+ T
cells were also capable of CD107a degranulation and granzyme expression in response to
latency-associated ORFs. CD107a expression was most commonly detected in response to
US28 and UL144, which were comparable to gB, and IE1 responses. CD4+ T cells were least
commonly detected in response to UL111A and UL138, although few donors had UL138-
specific CD4+ T cell responses that could be assessed. Whether these differences in the
expression of cytotoxic markers translates into a decreased ability to control HCMV infection
has not been examined, although it is interesting that UL138- and LUNA-specific CD4+ T
cells were shown to be dominated by IL-10 secreting T cells (Section 3.2.10). CD4+ T cells
specific for HCMV proteins expressed during latency therefore possess the potential to carry
out cytotoxic effector functions. This remains to be confirmed using a direct viral control
assay, such as the viral dissemination assay, to test the cytotoxic ability of latency-associated
ORF specific CD4+ T cells in the presence of virally encoded immunoevasins such as those
causing downregulation of MHC class II [127, 165, 581, 582, 717].
An analysis of the memory phenotypes of latency-associated ORF specific CD4+ T cells
was then carried out. In general, there were no differences in the CD4+ T cell memory
subsets of cells specific to lytic ORFs compared to latency-associated ORFs, although US28-
and UL111A-specific CD4+ T cells did display slightly higher proportions of cells with a
naive-like phenotype. The majority of HCMV ORF-specific CD4+ T cells were found to
express markers characteristic of TCM and TEM memory T cells. CD4+ memory T cells
which had re-expressed CD45RA were also detected, and these generally made up a small
proportion of ORF-specific cells, as has been reported previously [390, 715]. CD4+ TCM
cells were in many cases the dominant ORF-specific memory population. Several previous
studies performed using viral lysate or gB/pp65 peptide stimulation have described HCMV-
specific CD4+ T cells as mainly having an effector memory phenotype [379, 394, 404, 715].
This discrepancy could be due to the different methods for identifying HCMV-specific T
cells, as the expression of IFNγ was often used in these studies to do this, compared to the
expression of activation markers CD40L and/or 4-1BB as carried out here. Furthermore, one
recent study using HCMV peptide pools from lytic ORFs, including gB and pp65, identified
antigen-specific CD4+ T cells as those positive for CD40L and CD69 [393]. 4-1BB was
chosen over CD69 as a marker for activation in the work presented here as it was found to
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maintain higher levels of expression on CD4+ T cells for the duration of the assay (data not
shown).
An analysis of the memory phenotypes of CD4+ T cells specific for latency-associated
ORFs derived from tissue sites is also required as the results presented here were performed
on peripheral blood CD4+ T cells only. Differences in the proportions of CD4+ T cell memory
subsets between HCMV seronegative and seropositive individuals have been described in a
number of different tissues [398], but how the memory phenotypes of ORF-specific T cells in
tissues compared to peripheral blood remains to be determined. In one study, despite finding
CD4+ TEM and TEMRA cell subsets to be generally elevated in the bone marrow compared to
peripheral blood, no differences in the HCMV-specific TEM or TEMRA cell subsets between
the two compartments was detected [394].
Due to the low numbers of HCMV ORF-specific T cells in the peripheral blood, a very
large number of PBMC were required for these assays. Unfortunately, this meant it was
not possible to determine the expression of cytotoxic markers or the memory phenotypes of
IFNγ and IL-10 expressing CD4+ T cells, which was an original intention. IL-10 secreting
CD4+ T cells specific for latency-associated HCMV ORFs might show reduced expression
of markers associated with cytotoxic effector functions for example, and previous work
has shown minimal granzyme and perforin expression in naive-like and central memory
CD4+ T cells [394]. As the analysis of cytotoxic marker expression and memory phenotypes
were carried out on the entire population of CD4+ T cells deemed to be antigen-specific, it
is possible that delineating cytotoxic and memory phenotypes to IL-10 or IFNγ secreting
cells could reveal differences between lytic and latency-associated ORF specific CD4+ T
cells. Further work should seek to address these questions and could be vastly aided by the
generation of HLA class II-peptide tetramers specific to latency-associated ORF products, as
has been carried out for gB and pp65 [405].
6.3.2 CD4+ T cell functional analysis
HCMV-specific CD4+ T cells secreting IL-10 and TGFβ could be inhibiting antiviral T cell
responses. Several experiments were carried out examining the effects of the secretomes of
latent-specific CD4+ T cells on T cell effector functions. As two populations of CD4+ T
cells specific for latency-associated ORFs were identified, one secreting predominantly IFNγ
and one IL-10, it was not known if the secretomes containing a mixture of both cytokines
would be suppressive. Initially, the proliferation of CD4+ and CD8+ T cells stimulated
in the presence of CD4+ T cell secretomes was investigated. The secretome from US28
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peptide pool stimulated CD4+ T cells was found to inhibit the proliferation of both CD4+ and
CD8+ T cells by over 70%. This agrees with results from the secretome of UL138 peptide
stimulated CD4+ T cells, which were shown to inhibit CD4+ T cell proliferation [501].
CD4+ T cell secretomes were then examined for their ability to inhibit anti-viral cytokine
production. A cytokine secretion inhibition assay was designed and optimised to do this.
Using mismatched PBMC and CD4+ T cell supernatants derived from different donors was
found to result in considerable differences in cytokine secretion between different donor
PBMC incubated with the same supernatants. In an attempt to reduce this variability, matched
PBMC and CD4+ T cell secretomes were tested from one donor. Many of the ORF-specific
secretomes from this donor were able to inhibit cytokine secretion, although the inhibitory
effects were more pronounced for IFNγ compared to TNFα secretion. This inhibition could
have been mediated by TGFβ in isolation, as elevated levels of IL-10 were not detected in the
CD4+ T cell supernatants. Future experiments neutralising IL-10 and TGFβ could confirm
this. The results from optimisation experiments and from testing CD4+ T cell supernatants
with PBMC from mismatched donors highlighted the differential effects of IL-10 and TGFβ
on the inhibition of IFNγ and TNFα secretion in certain donors, and this could explain why
the inhibition of TNFα was minor in comparison to the inhibition of IFNγ .
This differential ability of CD4+ T cell supernatants to inhibit IFNγ and TNFα secretion
made it difficult to obtain a consistent system across donors. The donor-specific variation in
the abilities of IL-10 and TGFβ to inhibit PBMC secretion of IFNγ and TNFα , as well as
variation between donors in the levels of IFNγ and TNFα PBMC secreted when stimulated
with the same concentration of anti-CD3/CD28 antibody, also limited the reproducibility
of this assay. The inability of the flow cytometry based system to detect elevated secretion
of IL-10 was unexpected, especially as IL-10 secretion of peptide stimulated CD4+ T cells
was detected by both FluoroSpot and ELISA from donors CMV324 and CMV319 (Section
3.2.3 and 3.2.4). While it could be possible that fluctuations in the peripheral blood CD4+ T
cell frequencies as described in section 3.2.4 resulted in no IL-10 producing CD4+ T cells
being present at this time point, this seems unlikely to have occurred for all the supernatants
tested. The inhibition observed by CD4+ T cell supernatants from donor CMV332 could
therefore be due to the production of low levels of IL-10 not detected by the flow cytometry
based bead array. Additionally, when quantifying IL-10 secretion by ELISA (Section 3.2.3),
twice as many cells were stimulated with HCMV ORF peptides compared to experiments
here. It could also be the case that the inhibition mediated by CD4+ T cell was due to other
inhibitory factors that have not been sampled for. Further work in this area should attempt to
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measure IL-10 secretion in the supernatants by ELISA concurrently with the flow cytometry
based bead array.
The effect of CD4+ T cell secretomes on anti-viral CD8+ T cell control of a lytic HCMV
infection was then examined. It was hypothesised that the immunosuppressive cytokines in
the CD4+ T cell latency-associated ORF secretomes would inhibit the antiviral functions of
CD8+ T cells. Using an experimental model of lytic infection, the spread of a GFP-tagged
virus was measured following incubation with CD8+ T cells that had been incubated with
CD4+ T cell secretomes. While preliminary work indicated that CD8+ T cells incubated with
IL-10 and TGFβ had a reduced ability to control virus spread, this could not be replicated
with any of the ORF-specific CD4+ T cell supernatants. This could have been due to the
requirement to remove the CD4+ T cell supernatants before the addition of CD8+ T cells
to the infected fibroblasts, as these secretomes possessed antiviral activity alone. However,
the CD4+ T cell secretomes used in these assays were not analysed for their cytokine
content, and this should be done in future to quantify the levels of pro-inflammatory and
immunosuppressive cytokines.
These limited experiments have given an initial indication that the secretomes from CD4+
T cells specific for HCMV latency-associated ORF products are capable of inhibiting T cell
proliferation, the secretion of antiviral cytokines IFNγ and TNFα , and can control viral
dissemination in vitro. Further work should build on these experiments through repeating
them in additional donors and confirming the roles of IL-10 and TGFβ in these suppressive
effects through direct measurement and the use of neutralising antibodies where possible.
6.3.3 Depleting CD25hi cells to remove IL-10 secreting cells
The cytokines IL-10 and TGFβ have been shown to be secreted by Tregs as a potential
mechanism to inhibit immune activity [629, 718–726]. The characteristic transcription
factor FoxP3 is central to the function of Tregs [727] and many studies have shown the
presence of virus-specific FoxP3 expressing CD4+ T cells in HCMV infection [403, 502, 728].
Furthermore, previous work has shown that a subset of CD4+ T cells specific for UL138
and LUNA, but not gB, expressed FoxP3 [501]. While FoxP3 is the hallmark of Tregs,
its intracellular expression makes it unsuitable as a means to isolate or remove FoxP3+
cells. A number of cell surface markers have been used as surrogates to identify Tregs.
One such combination of markers identifies Tregs as CD4+CD127loCD25hi [483, 484, 729].
The constitutively high expression of CD25 on Tregs therefore provided a relatively simple
target to selectively deplete these cells. It was reasoned that because the latency-associated
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CD4+ T cells secreting IL-10 were a separate population from those secreting IFNγ (Section
3.2.10), removal of CD4+CD25+hi T cells would deplete the IL-10 producing cells and leave
the IFNγ secreting subset intact. If Tregs of this phenotype were the source of IL-10 then
their depletion might abrogate a source of immunosuppression on IFNγ secreting Th1 cells,
potentially enabling them to carry out more effective antiviral functions during latency.
Depletion of CD25+ cells has been utilised with some success to remove suppressive
regulatory populations [495, 730, 731]. In the context of HCMV, one study found that
depletion of CD25+ cells from PBMC resulted in an increase in the proportion of pp65-
specific CD8+ T cells secreting IFNγ [494]. Likewise, the depletion of CD25hi cells from
PBMC of kidney transplant patients with HCMV infection resulted in an increase in HCMV-
specific IFNγ secretion in those with recurring infection [502]. When testing this approach,
the depletion of CD4+CD25hi cells prior to stimulation with HCMV ORF peptide pools
did not consistently result in a decrease in the IL-10, or increase in IFNγ , secreting CD4+
T cell frequencies. This was also the case when depletion of moderate and lower CD25
expressing CD4+ T cells was carried out. In certain donors, CD25+ cell depletion was able
to reduce the frequencies of IL-10 secreting CD4+ T cells, but even this was found to vary
when comparing different ORF-specific responses within individuals. Therefore, in certain
donors, and in certain ORF-specific CD4+ T cell populations, CD25+ expressing cells, likely
to be Tregs, were a proportion of the IL-10 secreting CD4+ T cell population. CD25+ cell
depletion was also found to have varying effects on the ORF-specific IFNγ secreting CD4+
T cell populations, which often resulted in a decrease in this population. This could be due to
the removal of activated CD4+ T cells known to express CD25 [458, 732, 733]. Additionally,
certain resting memory CD4+ T cells that are Foxp3- have been shown to express intermediate
levels of CD25, which could also have been depleted [734, 735]. Although the majority of
late differentiated memory cells (CD28-GranzymeB+), which included the CD4+ T cells
secreting IFNγ in response to HCMV lysate, were found to be contained in the CD25-
population [734], it is possible that less differentiated memory CD4+ T cells specific to
HCMV also express intermediate levels of CD25. Given that depletion of CD25+ cells
did not consistently remove HCMV-specific IL-10 secreting CD4+ T cells, and also often
removed IFNγ secreting CD4+ T cells, which might be antiviral, this did not present a viable
strategy to target immunosuppressive T cell responses during latent HCMV infection.
As the population of IL-10 secreting CD4+ T cells that were CD25+ was found to be
variable within donors, it could be possible that these remaining IL-10 secreting cells are
part of a separate regulatory T cell population. Other potential regulatory T cell populations
that could be responsible for this IL-10 secretion include Tr1 cells. Tr1 cells do not typically
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express CD25 [528], and therefore would not have been depleted in these experiments. Tr1
cells express IL-10 and TGFβ , which are critical to their suppressive abilities, as well as
co-stimulatory markers such as ICOS, CD18, and LAG-3 [506–509, 512–515]. Expression of
these cell surface markers therefore provides potential targets which could be used to deplete
such cells. Assessing transcription factor expression and carrying out further phenotypic
characterisation of latency-associated ORF specific CD4+ T cells could also reveal differences
between the IL-10 and IFNγ secreting populations, and determine if IL-10 secreting cells
possess markers of Tr1 cells, thus enabling the targeting of IL-10 positive cells. The ability
to study latency-ORF specific CD4+ T cells without in vitro culture, which could alter their
phenotypes, would be highly useful. MHC class II-peptide tetramers provide this opportunity,
as have been synthesised to pp65 and gB [405].
6.3.4 CD4+ T cell peptide mapping
While designing an MHC class II tetramer specific to a latency-associated peptide was
beyond the scope of this work, small pools of five peptides from latency-associated ORFs
were used to stimulate CD4+ T cells to begin to map these T cells to a minimal peptide
epitope. In addition, this work provided an initial step in characterising the cytokine secretion
of single-peptide specific CD4+ T cells to begin to address the question of whether CD4+
T cells specific for a single ORF peptide secreted IFNγ or IL-10 in isolation, or whether
epitope-specific CD4+ T cell populations were composed of a combination of cytokine
secreting cells.
CD4+ T cells from three donors were stimulated with small pools of five peptides
spanning the ORFs of UL138, LUNA, US28, and UL111A. This revealed several pools
that elicited an IFNγ or IL-10 dominant response, as well as responses composed of both
cytokine secreting cells. Therefore, data from this initial work can be used to test CD4+ T
cell responses to the individual peptides that composed these pools, to determine peptide-
specificity and cytokine secretion.

Chapter 7
In vitro Characterisation of
Latency-specific CD8+ T cells
7.1 Introduction
In HCMV seropositive donors, the presence of high-frequency CD8+ T cell responses
against lytic HCMV proteins such as pp65 and IE1 are well established [287–290, 294]. The
ability of CD8+ T cells to recognise proteins expressed during latency has now also been
demonstrated (Chapter 4) [501, 691]. CD8+ T cells specific for lytic ORF products have been
well characterised by numerous groups showing these cells can have a distinct phenotypic
composition associated with T cell maturation, including downregulation of CD27 and CD28,
upregulation of CD57, and expression of effector molecules such as granzyme B and perforin
[287, 291, 292, 294, 295]. In addition, a population of HCMV-specific memory CD8+ T
cells can be defined by their reversion of the expression of CD45RA, which is associated with
naive T cells, from CD45RO, which is associated with memory T cells [291–293, 296, 297].
The memory phenotypes and cytotoxic potential of CD8+ T cells specific for HCMV
proteins expressed during latency have not been extensively studied. The aims of this chapter
were therefore to further characterise these CD8+ T cells, in an effort to reveal differences
between lytic ORF and latency-associated ORF specific T cells, and to begin to map their
peptide-specificities, which could inform the generation of MHC class I tetramers to enable
latency-specific CD8+ T cells to be isolated for further study.
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7.2 Results
7.2.1 Phenotypic characterisation of latency-specific CD8+ T cells
To investigate the cytotoxic potential of CD8+ T cells recognising HCMV latency-associated
ORFs, the expression of CD107a and granzymes A, B, and K was determined on CD8+ T
cells following overnight stimulation with overlapping peptide pools spanning the ORFs of
gB, pp65, IE1, UL138, LUNA, US28, UL111A, and UL144. Cytotoxic degranulation, and
subsequent surface expression of CD107a has been well documented for CD8+ T cells and is
an established marker for cytotoxicity [736].
Following peptide pool stimulation, HCMV-specific CD8+ T cells were identified by
gating for the expression of the activation markers CD69 and 4-1BB [702, 737] above
the expression observed on unstimulated CD8+ T cells (Figure 7.1A). The expression of
CD107a and granzymes A, B, and K were then determined on CD8+ T cells positive for
these markers (Figure 7.1A). The data from 18 HCMV seropositive donors shows that the
proportions of CD8+ T cells capable of degranulating in response to HCMV ORF peptide
pool stimulation were higher among ORF-specific CD8+ T cells (Figure 7.1B) compared
to ORF-specific CD4+ T cells (Figure 6.2B). Of the lytically-expressed ORFs, donors
had the highest percentages of CD8+ T cells specific for pp65 that expressed CD107a but
also the most number of donors with CD8+ T cells that showed any degranulation (17/18,
94%) (Figure 7.1B). The proportion of pp65-specific CD8+ T cells expressing CD107a
was significantly higher than gB- and UL111A-specific CD8+ T cells (Kruskal-Wallis with
Dunn’s multiple comparisons). Where donors had US28- and UL144-specific CD8+ T
cell responses, a proportion of these cells were always found to express CD107a, and the
proportion of US28-specific CD8+ T cells expressing CD107a was comparable to that of
pp65-specific CD8+ T cells (Figure 7.1B). UL111A- and UL138-specific CD8+ T cells
expressing CD107a were the least frequently observed, and fewer antigen-specific CD8+ T
cells expressed CD107a in comparison to other responses, although only three donors had
detectable UL138-specific CD8+ T cells (Figure 7.1B). Interestingly, CD4+ T cells specific
to UL111A and UL138 also displayed the lowest expression of CD107a (Figure 6.2B).
In general, there were lower proportions of antigen-specific CD8+ T cells positive for the
expression of granzymes A, B, and K alone compared to those expressing CD107a. CD8+ T
cells specific to gB had the highest expression of granzymes amongst responses to lytic ORFs
(Figure 7.1C). Interestingly, where pp65-specific CD8+ T cells expressing CD107a were
detected in 94% (17/18) of donors, expression of granzymes by pp65-specific CD8+ T cells
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Fig. 7.1 Assessing the expression of CD107a and granzymes A, B, and K on CD8+ T
cells in response to HCMV ORF peptide pools by flow cytometry. PBMC from 18
HCMV seropositive donors was stimulated with overlapping peptide pools spanning the ORFs
of gB, pp65, IE1, UL138, LUNA, US28, UL111A, and UL144 overnight, in the presence of
monensin. PBMC were then stained intracellularly for CD107a and the granzymes A, B, and
K. (A) The representative gating strategy to identify ORF-specific CD8+ T cells is shown
for LUNA-specific CD8+ T cells from donor CMV211. Dead cells, CD14+ and CD19+
cells were first excluded, followed by doublets. Lymphocytes were then gated on by forward
scatter (FSCA) and side scatter (SSCA) and CD3+ cells identified. CD4+ and CD8+ cells
were then gated, followed by activated CD8+ T cells, identified as CD69 or 4-1BB positive
cells. CD8+ T cells with above background expression of CD69 or 4-1BB were considered
ORF-specific. The percentages of ORF-specific CD8+ T cells expressing (B) CD107a, (C)
granzymes A, B, or K, (D) or both CD107a and granzymes A, B, or K following ORF peptide
pool stimulation is shown. Differences in CD107 and granzyme expression was assessed by
Freedman test with Dunn’s multiple comparisons with significant results set at p<0.05.
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was only detected in 20% (3/15) of donors (Figure 7.1C). The proportions of CD8+ T cells
expressing granzymes alone was also low on CD8+ T cells specific for latency-associated
ORFs but these cells could be detected in response to US28, LUNA, UL111A, and even
UL138, where no CD107a degranulation was detected (Figure 7.1C). No CD8+ T cells
specific to UL144 express granzymes in isolation (Figure 7.1C). CD8+ T cells expressing
both CD107a+ and granzymes was also determined. Low percentages of HCMV-specific
CD8+ T cells were found to express both CD107a and granzymes together in a subset of
individuals, with these cells tending to be make up higher proportions for CD8+ T cells
specific to the lytic ORFs gB, pp65, and IE1 (Figure 7.1D). Dual CD107a and granzyme
expressing CD8+ T cells were also identified in response to all latency-associated ORFs,
although these were less commonly detected than to lytic ORFs (Figure 7.1D).
The memory phenotypes of CD8+ T cells specific for proteins expressed during latency
was also examined. CD8+ T cells were stimulated with overlapping peptide pools and the
ORF-specific CD8+ T cells were grouped based on memory phenotypes as defined by the
expression of CD27 and CD45RA: naive-like (TNL) (CD27+ CD45RA+), central memory
(central memory (TCM) (CD27+ CD45RA-), effector memory (TEM) (CD27- CD45RA-),
and effector memory CD45RA-expressing T cells (TEMRA) (CD27- CD45RA+). The
representative gating strategy to identify these four memory subsets is shown in Figure 7.2A.
This phenotypic analysis was carried out on 17 HCMV seropositive donors. HCMV-specific
CD8+ T cells were found in each memory subset, although TEMRA cells tended to be the
dominant memory population, with the exception of gB- and UL144-specific CD8+ T cells,
which had a smaller proportion of TEMRA cells and larger TEM and/or TCM subset (Figure
7.2B). This is in contrast to the HCMV-specific CD4+ T cells, where TCM cells were the
largest memory subset (Figure 6.3B). On the whole, there were no significant differences in
memory subset composition between CD8+ T cells specific for lytic or latency-associated
proteins (Figure 7.2B). Unfortunately, only two donors possessed UL138-specific CD8+ T
cells with above background responses, so the memory composition of these cells could not
accurately be assessed.
In summary, CD8+ T cells specific for latency-associated ORF proteins express markers
consistent with the potential for cytotoxic activity. With the exception of pp65, there do not
appear to be large differences in expression of these cytotoxic markers between CD8+ T cells
specific for lytically-expressed ORFs gB and IE1, and latency-associated ORFs, especially
for US28-, LUNA-, and UL144-specific CD8+ T cells which were highly comparable in
CD107a expression. Likewise, no difference in the memory phenotypes of CD8+ T cells
specific for lytic proteins compared to latency-associated proteins was observed.
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Fig. 7.2 Memory phenotypes of CD8+ T cells specific for HCMV antigens. PBMC
isolated from 17 HCMV seropositive donors were stimulated overnight with HCMV
peptide pools spanning the ORFs of gB, pp65, IE1, UL138, LUNA, US28, UL111A, and
UL144, in the presence of monensin. Stimulated PBMC were then stained intracellularly.
(A) Representative flow cytometry dot plots the gating strategy to identify the memory
populations of CD8+ T cells is shown. Dead cells, CD14+ and CD19+ cells were first
excluded, followed by doublets. Lymphocytes were then gated on by FSCA and SSCA and
CD3+ cells identified. CD4+ and CD8+ cells were then gated, followed by activated CD8+ T
cells, identified by gating for CD69 or 4-1BB positive cells, and finally CD27 and CD45RA
to identify the memory phenotype. (B) The proportions of each CD8+ T cell memory
population responding to each ORF grouped by CD27 and CD45 expression. Naive-like
(TNL) (CD27+ CD45RA+), central memory (central memory (TCM) (CD27+ CD45RA-),
effector memory (TEM) (CD27- CD45RA-), and effector memory CD45RA-expressing T
cells (TEMRA) (CD27- CD45RA+).
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7.3 Characterisation of the peptide specificity of
US28-specific CD8+ T cells
In response to HCMV ORF peptide pools, CD8+ T cells capable of secreting IL-10 were
found to be a separate population to those secreting IFNγ (Section 4.2.7). However, whether
individual CD8+ T cell clones all secrete either IL-10 or IFNγ , or are a mix of IL-10 and
IFNγ secreting cells, remained an open question. To begin to address this, CD8+ T cells were
stimulated with individual overlapping peptides spanning the US28 ORF. In this manner,
the cytokine secretion from CD8+ T cells specific for individual US28 peptides could give
an indication of whether certain peptide responses were composed of one cytokine (IFNγ
or IL-10), or both. Additionally, this would act as an initial step in mapping CD8+ T cell
responses to a minimal US28 peptide epitope, which could be used in the design of an MHC
class I tetramer. The US28 ORF was focused on because in the vast majority of donors tested,
high frequency IFNγ and IL-10 CD8+ T cell responses were found to this ORF (Section
4.2.1 and 4.2.4). Furthermore, a number of donors were found to have CD8+ T cells specific
to US28 capable of upregulating CD107a (Figure 7.1B).
CD4+ cell depleted PBMC from four HCMV seropositive donors were stimulated with
individual 15 amino acid peptides spanning the US28 ORF. The frequencies of IFNγ and
IL-10 secreting CD8+ T cells was then determined in response to each peptide. The HLA
type of these four donors was also determined, which could enable mapping of distinct
peptide-specific responses to certain HLA types (Table 7.1).
Donor HLA Type
HLA-A HLA-B HLA-C
a b a b a b
CMV319 34 43 07 39 10 12
CMV320 01 32 14 27 08 03
CMV321 03 25 27 35 02 04
CMV324 01 24 07 37 06 07
Table 7.1 HLA typing of four HCMV seropositive donors.
Donor CMV324 CD8+ T cells were tested on three separate occasions for their responses
to individual US28 derived peptides. The first test of the CD8+ T cell responses from donor
CMV324 yielded only two peptides that elicited a relatively high frequency of CD8+ T cells
secreting IFNγ , peptides 18 and 58 (Figure 7.3A). In contrast, there were high frequency
IL-10 responses to many of the peptides tested, which also included peptides 18 and 58
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(Figure 7.3B). Additionally, there were many peptides that elicited only IL-10 secreting
CD8+ T cell responses, such as peptides 8, 9 and 38 (Figure 7.3).
A second test of this donor’s responses was undertaken a month later and several peptides
(7, 8, 11, 12, 16, 18, 30, 55, 57, and 58) that elicited high frequencies of cytokine secreting
CD8+ T cells in the first test (Figure 7.3) were selected and tested in duplicate. In addition,
peptides 31, 67, and 69 were tested in duplicate as negative controls because there were
either no CD8+ T cell responses to these peptides, or the responses were very low. In this
experiment, CD8+ T cell IFNγ responses were higher frequency, and much more prevalent
than those detected in the initial test (Figure 7.4A). The opposite was the case for the IL-10
responses. Although there were several clusters of two or three peptides overlapping that
elicited CD8+ T cell IL-10 responses, which could indicate that the T cell epitopes are
contained across the 5 amino acid overlap from adjacent 15 amino acid peptides, overall the
responses were less common and of lower frequency compared to the first test (Figure 7.4B).
There were also broad inconsistencies in the responses elicited by the peptides tested in
duplicate. Although the IFNγ responses to peptides 18 and 58 were only slightly lower than
the first test, responses to numerous other peptides far exceeded these responses, highlighting
the variability in responses over time. Moreover, none of the peptides selected because of the
high frequency CD8+ IL-10 T cell responses detected in the initial test elicited responses in
the second test (Figure 7.4B).
A further peptide screen was carried out on this donor’s CD8+ T cell responses. Peptides
18 and 58 again elicited IFNγ responses, and these were therefore the only peptides to do so
on all three tests (Figure 7.5A). There were several peptide-specific responses detected on
this third test that were also present on the second test (Figure 7.4) but absent from the first
(Figure 7.3). Similar frequencies of IFNγ secreting CD8+ T cells were found in response to
peptides 4, 21, 24, 33, 46, 50, 61, and 66 (Figure 7.5A).
Donor CMV319 CD8+ T cell responses were tested on two separate occasions.
Considerable differences in the frequencies of cytokine secreting cells were observed
between these two time points. Markedly lower frequencies of IFNγ secreting CD8+ T cells
were detected in response to individual US28 peptides on the first sampling point (Figure
7.6A) compared to the second (Figure 7.7A), with only one of the relatively high frequency
responses, to peptide 11, observed at both time points. This inconsistency was also detected
in IL-10 responses across the two time points, where none of the higher frequency IL-10
responses were observed on both occasions despite high frequency responses to peptide 8
and 11 at the first sampling time point (Figure 7.6B) and peptides 18, 51, 62, and 68 on the
second (Figure 7.7B).
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Experiment date: 10.5.17
Fig. 7.3 CD8+ T cell responses from donor CMV324 to individual peptides spanning
the US28 ORF. PBMC from donor CMV324 were depleted of CD4+ cells and stimulated
with individual 15 amino acid peptides spanning the ORF of US28 for 48 hours on dual
IFNγ /IL-10 FluoroSpot plates. (A) IFNγ and (B) IL-10 secretion was then stained for to give
a number of positive spots that were counted, and converted to spot forming units (SFU) per
million cells. The frequencies of positive cells was determined by subtracting values in all
test wells from the background number of positive cells in unstimulated well.
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Experiment date: 10.6.17
Fig. 7.4 CD8+ T cell responses from donor CMV324 to individual peptides spanning
the US28 ORF. PBMC from donor CMV324 were depleted of CD4+ cells and stimulated
with individual 15 amino acid peptides spanning the ORF of US28 for 48 hours on dual
IFNγ /IL-10 FluoroSpot plates. (A) IFNγ and (B) IL-10 secretion was then stained for to give
a number of positive spots that were counted, and converted to spot forming units (SFU)
per million cells. Peptides 7, 8, 11, 12, 16, 18, 30, 31, 55, 57, 58, 67, and 69 were tested in
duplicate. The frequencies of positive cells was determined by subtracting values in all test
wells from the background number of positive cells in unstimulated well.
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Experiment data: 16.9.17
Fig. 7.5 CD8+ T cell responses from donor CMV324 to individual peptides spanning
the US28 ORF. PBMC from donor CMV324 were depleted of CD4+ cells and stimulated
with individual 15 amino acid peptides spanning the ORF of US28 for 48 hours on dual
IFNγ /IL-10 FluoroSpot plates. (A) IFNγ and (B) IL-10 secretion was then stained for to give
a number of positive spots that were counted, and converted to spot forming units (SFU) per
million cells. The frequencies of positive cells was determined by subtracting values in all
test wells from the background number of positive cells in unstimulated well.
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Experiment date: 20.5.17
Fig. 7.6 CD8+ T cell responses from donor CMV319 to individual peptides spanning
the US28 ORF. PBMC from donor CMV319 were depleted of CD4+ cells and stimulated
with individual 15 amino acid peptides spanning the ORF of US28 for 48 hours on dual
IFNγ /IL-10 FluoroSpot plates. (A) IFNγ and (B) IL-10 secretion was then stained for to give
a number of positive spots that were counted, and converted to spot forming units (SFU) per
million cells. The frequencies of positive cells was determined by subtracting values in all
test wells from the background number of positive cells in unstimulated well.
264 In vitro Characterisation of Latency-specific CD8+ T cells
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69
0
25
50
75
100
125
150
175
200
225
Peptide
SF
U
/M
ill
io
n 
T 
ce
lls
CMV319 CD8+ T cells US28 peptides IFNγ
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69
0
100
200
300
400
500
600
Peptide
SF
U
/M
ill
io
n 
T 
ce
lls
CMV319 CD8+ T cells US28 peptides IL-10
A
B
Experiment date: 13.7.17
Fig. 7.7 CD8+ T cell responses from donor CMV319 to individual peptides spanning
the US28 ORF. PBMC from donor CMV319 were depleted of CD4+ cells and stimulated
with individual 15 amino acid peptides spanning the ORF of US28 for 48 hours on dual
IFNγ /IL-10 FluoroSpot plates. (A) IFNγ and (B) IL-10 secretion was then stained for to give
a number of positive spots that were counted, and converted to spot forming units (SFU) per
million cells. The frequencies of positive cells was determined by subtracting values in all
test wells from the background number of positive cells in unstimulated well.
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Donor CMV321 was sampled once. Several individual peptides elicited IFNγ secretion
from a moderate number of CD8+ T cells, with peptide 61 showing the greatest responses
(Figure 7.8A). IL-10 responses were composed of very high numbers of cytokine secreting
cells which were organised into clusters (Figure 7.8A). All the peptides which elicited
appreciable IFNγ responses also displayed high frequency IL-10 responses, including
peptides 12, 25, 29, 38, 49, and 61, while many peptides showed only IL-10 responses
(Figure 7.8).
Donor CMV320 was also sampled on only one occasion. Few peptides elicited an
IFNγ response, with only moderate frequencies of IFNγ secreting CD8+ T cells detected in
response to peptides 40, 57, and 58 (Figure 7.9A). No IL-10 secreting cells were detected in
response to any of the peptides tested (Figure 7.9B).
Testing individual CD8+ T cell responses to 15-mer peptides has highlighted several
peptides that elicited either an IFNγ or IL-10 response alone, or a combination of both
cytokine secreting cells. However, testing donors at multiple time points revealed that these
responses to individual peptides are often detected inconsistently.
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Fig. 7.8 CD8+ T cell responses from donor CMV321 to individual peptides spanning
the US28 ORF. PBMC from donor CMV321 were depleted of CD4+ cells and stimulated
with individual 15 amino acid peptides spanning the ORF of US28 for 48 hours on dual
IFNγ /IL-10 FluoroSpot plates. (A) IFNγ and (B) IL-10 secretion was then stained for to give
a number of positive spots that were counted, and converted to spot forming units (SFU) per
million cells. The frequencies of positive cells was determined by subtracting values in all
test wells from the background number of positive cells in unstimulated well.
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Fig. 7.9 CD8+ T cell responses from donor CMV320 to individual peptides spanning
the US28 ORF. PBMC from donor CMV320 were depleted of CD4+ cells and stimulated
with individual 15 amino acid peptides spanning the ORF of US28 for 48 hours on dual
IFNγ/IL-10 FluoroSpot plates. IFNγ secretion was then stained for to give a number of
positive spots that were counted, and converted to spot forming units (SFU) per million cells.
The frequencies of positive cells was determined by subtracting values in all test wells from
the background number of positive cells in unstimulated well.
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7.4 Discussion
CD8+ T cells specific for proteins expressed during latency were phenotypically characterised
to investigate differences in cytotoxic potential and memory phenotypes in comparison to
lytic ORF specific CD8+ T cells. As has been well documented, CD107a degranulation and
granzyme expression in response to proteins expressed during lytic infection, such as pp65
and IE1 was observed [304, 315, 316, 398, 738–740]. However, antigen-specific CD8+ T
cell CD107a expression was also detected in response to latency-associated ORFs, which
has not been previously described. The expression of CD107a and granzymes were found
to generally be similar between lytic and latency-associated ORF specific CD8+ T cells,
although pp65-specific CD8+ T cells did have significantly higher expression of CD107a
compared to gB- and UL111A-specific CD8+ T cells. Interestingly, a proportion of ORF-
specific CD8+ T cells that expressed CD107a was always detected in donors that possessed
UL144- and US28-specific CD8+ T cells. In addition, the high proportion of cells expressing
CD107a on US28-specific CD8+ T cells, which was comparable to that detected on pp65-
specific CD8+ T cells, was also observed for US28-specific CD4+ T cells (Section 6.2.2).
CD8+ T cells specific to latency-associated ORF products therefore possess the potential to
mediate cytotoxic responses. In addition, the memory T cell phenotypes of latency-associated
ORF specific CD8+ T cells did not differ substantially compared to lytic ORF specific T cells,
with large proportions of HCMV-specific CD8+ T cells occupying the TEMRA cell subset.
These results are in agreement with previous research carried out on responses to lytic ORFs
such as pp65 [287, 292, 294, 296, 301].
The potential of latency-associated ORF specific CD8+ T cells to mediate cytotoxic
responses raises questions as to why they are not effective against latently infected cells
in vivo. Whether this is due to inhibition mediated by suppressive cytokines released by
the virus, or by CD4+ and CD8+ T cells, requires investigation. The results presented here
are limited by the inability to determine the expression of cytotoxic and memory markers
on latent-specific CD8+ T cells that expressed IFNγ , IL-10, or neither cytokine, by ICS. It
was therefore not possible to examine whether latent-specific CD8+ T cells (defined here as
CD69+ and/or 4-1BB+) that were positive or negative for CD107a expressed IFNγ or IL-10,
due to the low frequency of IL-10 positive cells and insufficient number of acquired events.
These separate cytokine secreting populations could have different cytotoxic abilities and
could display different memory phenotypes to lytic ORF specific T cells, and this would
be important to determine given that responses to HCMV latency-associated ORFs are
composed of higher proportions of IL-10 secreting cells compared to lytic ORF-specific
responses (Section 4.2.7). As the results presented here represent the entire population of
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CD8+ T cells deemed to be antigen-specific, this information is lacking however. Future
work could approach this problem through the use of MHC class I tetramers. The use of
tetramers would enable the targeted sorting of CD8+ T cell specific to latency-associated
ORFs without the requirement to stimulate them. Whole populations of latency-associated
ORF specific CD8+ T cells could therefore be phenotyped and could also allow for more in
depth study, such as through single cell transcriptomics.
The inability of cytotoxic CD8+ T cells to target latently infected cells could also be
due to direct viral immune evasion. HCMV is known to interfere with antigen processing
and presentation, with the US2-US11 genomic region playing an important role in MHC
class I downregulation [571–574, 577, 741, 742], and these could also be active during latent
infection. The impact these genes have on MHC class I expression during latency is yet to be
fully established. Expression of the US2 and US3 genes, but not US11, have been reported
in an experimental model of latency [604], with recent RNA-sequencing analyses showing
detectable US2, and US11 [129], or US3 expression [130], although it is speculated that US3
expression was originating from virus in the process of reactivating to lytic infection. As
US3 is an IE gene, and can be detected from one hour post infection in lytically infected
fibroblasts, this explanation is plausible [743]. The cytotoxic capacities of CD8+ T cells
specific for latency-associated proteins expressed could be examined first using in vitro
viral dissemination assays to initially confirm they can prevent the spread of a lytic HCMV
infection. This is important because the use of overlapping peptide pool stimulation does
not account for the effects of virally encoded immune evasion molecules expressed during
infection, particularly those responsible for the downregulation of MHC class I molecules.
Differences between the cytotoxic and memory phenotypes of CD8+ T cells specific
for latency-associated ORFs compared to lytic ORFs could also be revealed if CD8+ T
cells derived from tissue sites are analysed. CD8+ T cells specific to HCMV are broadly
distributed across tissues in addition to the peripheral blood compartment [398]. A recent
study found the frequencies of CD8+ T cells specific for pp65, IE1, and pp50 epitopes
to be heterogeneously distributed across different tissue sites and peripheral blood within
individuals [398]. Interestingly, CD8+ T cells specific for varying epitopes of pp65 have been
shown to differ in functional capacities and memory phenotype [744]. Sampling from the
peripheral blood only might therefore not be representative of the CD8+ T cell responses to
HCMV latency-associated ORFs. In support of this, a comparison of HCMV-specific CD8+ T
cells between the lymph nodes and peripheral blood found both lower proportions of TEMRA
cells and granzyme B positive cells in the lymph nodes [695]. Additionally while two studies
examining pp65-specific CD8+ T cells between bone marrow and peripheral blood reported
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either no difference in frequencies [699], or a lower frequency in the bone marrow [700], the
bone marrow was found to be enriched for TCM cells [699]. However, an analysis of CD27,
CD28, and IL-7Rα expression on pp65-specific CD8+ T cells found similar phenotypes
between blood and lung T cells [745]. Differences between latency-associated and lytic
ORF specific CD8+ T cells might therefore be detected if certain tissue sites are enriched for
latency-associated ORF specific CD8+ T cells, or for CD8+ T cells specific to a particular
epitope within the latency-associated protein.
With a view towards the generation of an MHC class I tetramer, four donors were utilised
in the analysis of CD8+ T cell single-peptide responses to US28. As well as providing
initial data for the identification of a minimal CD8+ T cell peptide epitope, testing the
responses to individual peptides could provide an indication of whether CD8+ T cells specific
for a certain peptide are IL-10 or IFNγ producers only, or a mix of both. Across these
four donors, several peptides were found to elicit responses that were composed of either
entirely IFNγ or IL-10 secreting cells, or were a mixture of both. However, these responses
were found to be inconsistently detected in the donors sampled on multiple occasions. The
previously described results from the longitudinal sampling of CD4+ (Section 3.2.4) and
CD8+ (Section 4.2.2) T cells showing fluctuations in detected responses over time provide a
possible explanation for these results. Furthermore, the CD8+ T cell responses to individual
peptides might be expected to result in greater inconsistencies over time compared to whole
ORF responses as examined previously (Section 3.2.4 and 4.2.2). As with all T cell responses
being measured by FluoroSpot, it is also possible that the positive responses detected are
due to T cell cross-reactivity [658], necessitating the validation of positive responses. The
sampling of donors on multiple occasions might therefore be required to determine the
stability of peptide-specific responses, as shown for peptides 18 and 58 of US28 from donor
CMV324. Once peptides eliciting consistent responses are chosen, these can then be re-
synthesised to confirm the response, before mapping the minimal epitopes based on the CD8+
T cell responses to the overlapping peptides. This will enable a minimal peptide epitope to
be determined which can then be validated and used to synthesise an appropriate tetramer.
Chapter 8
Neutralising IL-10 and TGFβ to improve
T cell responses against latently infected
monocytes
8.1 Introduction
It has been demonstrated that cells latently infected with HCMV are capable of secreting
the immunosuppressive cytokines IL-10 and TGFβ , in addition to inducing secretion of
these cytokines from uninfected bystander cells [605]. Additionally, the expression of the
LAcmvIL-10 isoform of UL111A during latency is able to upregulate the transcription of
cellular IL-10 [164]. Investigations into the effect the secretome from latently infected
cells has on T cell effector function found it was able to inhibit CD4+ T cell production of
Th1 cytokines and CD4+ T cell mediated cytotoxicity [605]. These observations led to the
hypothesis that HCMV creates an immunosuppressive microenvironment during latency to
avoid recognition and clearance by T cells.
The findings from this research project, that CD4+ and CD8+ T cells specific for
latency-associated ORF products are capable of secreting IL-10, and TGFβ in the case of
CD4+ T cells, support such a hypothesis where immunosuppressive factors secreted into the
microenvironment of latently infected cells inhibit antiviral T cell responses during latency.
The observations that IL-10 secreting T cells were a separate sub-population to those
secreting IFNγ also raised the possibility of selectively targeting the suppressive population
in an attempt to boost Th1-type immune responses. However, efforts to deplete CD25+
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expressing cells which could be Tregs, in an attempt to target the ORF-specific IL-10
secreting CD4+ T cell population, were not able to consistently remove these cells. It was
therefore hypothesised that neutralising the immunosuppressive effects of IL-10 and TGFβ
could have the desired outcome of improving antiviral T cell responses against latently
infected cells. The aim of this chapter was therefore to determine if T cell responses could
be modulated to improve the clearance of latently infected cells by interfering with the
immunosuppressive factors IL-10 and TGFβ .
8.2 Results
8.2.1 The latency-associated secretome inhibits CD4+ T cell IFNγ
production in response to HCMV ORF peptide pools
The secretion of IL-10 and TGFβ into the cellular microenvironment by latently infected
cells, myeloid lineage bystander cells, and potentially latency-associated ORF specific T cells
could be preventing antiviral T cell responses during latency (Figure 8.1). Previous work
has shown that the secretome of latently infected CD34+ cells can inhibit the secretion of
Th1-associated cytokines [605]. To build on this, the inhibitory effects of the secretome from
latently infected cells on HCMV-specific T cell responses were examined. Initially, whether
CD4+ T cells exposed to IL-10 and TGFβ , prior to stimulation with HCMV peptides, would
result in a decrease in HCMV-specific IFNγ production was investigated. The IL-10 and
TGFβ were used as a proxy for the latent cell secretome. CD8+ cell depleted PBMC from
one donor were incubated with increasing concentrations of recombinant IL-10 and TGFβ
for two hours, then stimulated with HCMV ORF peptide pools. After incubation for 48
hours, the supernatants were analysed for IFNγ production by ELISA. CD4+ T cells that had
been pre-incubated with IL-10 and TGFβ were found to have reduced IFNγ production in
response to pp65 and US28, although for pp65 peptide stimulated cells, this was only at the
lowest IL-10 and TGFβ concentration (Figure 8.2). However, the concentrations of IL-10
and TGFβ tested were unable to mediate the inhibition of UL144-specific CD4+ T cell IFNγ
secretion (Figure 8.2)
The secretome of latently infected cells, which has been shown to contain the
immunosuppressive cytokines IL-10 and TGFβ [605], could therefore have a similar effect
on HCMV-specific CD4+ T cell IFNγ secretion. To test this, CD8+ cell depleted PBMC
from one donor were incubated with supernatants from latently infected CD14+ and CD34+
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Fig. 8.1 Model for inhibition of T cell responses during latency. Antiviral T cells specific
for proteins expressed during latency could be inhibited by LAcmvIL-10 secreted by latently
infected cells, the secretion of cellular IL-10 (cIL-10) and TGFβ by latently infected cells,
bystander myeloid cells, and latency-associated ORF specific CD4+ T cells, in addition to
cIL-10 secreted by latency-associated ORF specific CD8+ T cells [127, 165, 501, 605]
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cells (generated by Sarah Jackson) prior to HCMV ORF peptide stimulation. Analysing
IFNγ secretion by ELISA revealed that for this donor, ORF peptide pool stimulation resulted
in levels of IFNγ greater than the upper limit of detection in response to pp65 (not shown),
LUNA, and US28, while responses to UL111A were within the limits (Figure 8.3). CD4+ T
cells incubated with latent secretomes prior to peptide stimulation were found to have a
considerable reduction in IFNγ secretion for responses to LUNA, US28, and UL111A
(Figure 8.3).
8.2.2 Inhibition of IL-10 and TGFβ increases CD4+ T cell IFNγ
secretion in response to UL111A peptides
T cells responding to HCMV ORF peptide pools were found to be composed of distinct IFNγ
and IL-10 secreting sub-populations (Section 3.2.10 and 4.2.7). TGFβ secretion was also
detected from CD4+ T cells in response to HCMV ORFs. Whether the secretion of these
immunosuppressive cytokines from one sub-population of CD4+ T cell could be inhibiting
IFNγ secretion from the other was initially examined. CD4+ T cells from one donor were
stimulated with ORF peptide pools in the presence of anti-IL-10, anti-TGFβ , and anti-IL-10R
antibodies, or isotype control antibodies, and the secretion of IFNγ examined by ELISA.
The IFNγ secretion in response to pp65, LUNA, and US28 all exceeded the upper limits
of detection of the assay so were not included in the analysis. The addition of anti-IL-10,
anti-TGFβ and anti-IL-10R antibodies was found to increase IFNγ secretion in response to
UL111A compared to no treatment by approximately threefold, and by nearly twofold in
comparison to treatment with isotype control antibodies (Figure 8.4).
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Fig. 8.2 IFNγ secretion in response to HCMV latency-associated ORF peptides
following pre-incubation with IL-10 and TGFβ . CD8+ cell depleted PBMC were
incubated with increasing concentrations of IL-10 and TGFβ , or with media alone, for
two hours prior to the addition of HCMV ORF peptide pools spanning the ORFs of pp65,
UL138, LUNA, US28, UL144, and UL111A. After 48 hours, supernatants were harvested
and assessed for IFNγ secretion by ELISA in duplicate. Background IFNγ secretion from
unstimulated CD4+ T cells was deducted from test values.
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Fig. 8.3 IFNγ secretion in response to HCMV latency-associated ORF peptides
following pre-incubation with latency-associated secretome. CD8+ cell depleted PBMC
from donor CMV324 were incubated with the secretome harvested at day 14 from donor
CMV180308 CD14+ cells and CD34+ cells latently infected with the TB40e strain of
HCMV (white bars), or with media alone (black bars), for two hours prior to the addition
of HCMV ORF peptide pools spanning the ORFs of LUNA, US28, and UL111A. After 48
hours, supernatants were harvested and assessed for IFNγ secretion by ELISA in duplicate.
Background IFNγ secretion from unstimulated CD4+ T cells was deducted from test values.
The dashed line indicates the limit of detection of the assay.
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Fig. 8.4 IFNγ secretion in response to HCMV latency-associated ORF peptides in the
presence of neutralising IL-10 and TGFβ antibodies. CD8+ cell depleted PBMC were
incubated with media alone, or stimulated with HCMV ORF peptide pools spanning the
UL111A ORF, in the presence or absence of a cocktail of anti-IL-10 and anti-TGFβ , and anti-
IL-10 receptor antibodies at 5µg/ml, or a mix of IgG1 and IgG2b isotype control antibodies
at 5µg/ml. After 48 hours, supernatants were harvested and assessed for IFNγ secretion
by ELISA in duplicate. Background IFNγ secretion from unstimulated CD4+ T cells was
deducted from test values.
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8.2.3 Modulation of IL-10 and TGFβ during latency to improve T cell
recognition and clearance of infected cells
Prior work attempting to remove the CD4+ T cell population responsible for IL-10
production by CD25+ cell depletion was not consistently able to do so, as the size of the
CD25+ cell population secreting IL-10 varied between donors and between ORF-specific
CD4+ T cell populations. As this population could not be removed, the neutralisation of the
immunosuppressive activity of IL-10 and TGFβ was tested. From the work presented in this
thesis and by others, IL-10 and TGFβ are known to be expressed by HCMV
latency-associated ORF specific T cells, and cells in the latent microenvironment [501, 605].
Furthermore, IL-10 and TGFβ expressed by latently infected CD34+ cells was also
demonstrated to inhibit cytotoxic gB-specific CD4+ T cells [605]. An in vitro system was
utilised to examine the effects of IL-10 and TGFβ neutralisation on T cell killing of latently
infected cells.
Initially, CD14+ monocytes from an HCMV seropositive donor were latently infected
with TB40e-UL32-GFP for a period of 7 days to determine the optimal MOI for use in
subsequent experiments. A MOI of 1.25 was chosen as this produced high numbers of GFP+
cells at a lower concentration of virus (Figure 8.5A). Following this, the immunosuppressive
latent microenvironment was targeted by the addition of anti-IL-10 and anti-TGFβ
antibodies, before the addition of autologous CD3+ T cells isolated at high purity by MACS
(mean=92.9% CD3+ cells, Std. deviation=3.8, n=6) (data not shown). Following the
incubation of T cells with latently infected cells for three days with or without antibodies, T
cells were removed and monocytes were differentiated with GM-CSF and IL-4, followed by
LPS, to reactivate the latent virus, and the number of infected cells counted by microscopy
(Figure 8.5B). The cytotoxic effects of residual T cells that could not be removed prior to
reactivation were blocked by the addition of MHC class I and II antibodies. The selective
targeting of T cells was attempted through the use of cyclosporin A, but this was found to
reduce GFP expression in fibroblasts infected with TB40e-UL32-GFP at all concentrations
at 7 days post infection (Figure 8.6A), independently of cell death (Figure 8.6B). In this
manner, the effects of neutralising IL-10 and TGFβ on the ability of T cells to kill latently
infected cells was assessed compared to T cell killing with these cytokines present.
The addition of T cells to latently infected monocytes without antibodies was found to
reduce the number of infected cells by around 50%, compared to a 70% reduction when
T cells were added following IL-10 and TGFβ neutralisation (Figure 8.7). The addition
of isotype control antibodies prior to T cell addition was not found to have any additional
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Fig. 8.5 TB40e-UL32-GFP titration. CD14+ monocytes were latently infected over a range
of multiplicities of infection (MOI) with TB40e-UL32-GFP and incubated for five days in
96 well plates. To differentiate monocytes to dendritic cells (DCs), and reactivate latent
virus, latently infected cells were incubated with GM-CSF and IL-4 for five days and LPS
was added for 24 hours. (A) GFP positive DCs for each MOI were then counted under the
microscope. (B) A well of cells infected at an MOI of 1.25 is visualised. Each MOI was
tested in quadruplicate.
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Fig. 8.6 Effect of cyclosporin A on viral gene expression. Fibroblasts were infected with
TB40e-UL32-GFP at an MOI of 0.1 before the addition of cyclosporin A at a range of
concentrations. (A) Fibroblasts were harvested at 3 days (black line), and 7 days (grey bar)
post infection, and the percentages of GFP+ fibroblasts determined by flow cytometry. (B)
Cell death of fibroblasts at each cyclosporin A concentration was determined by Annexin V
staining and flow cytometry at 7 days post infection. Fibroblasts were tested in triplicate at
each cyclosporin A concentration.
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effect on latent monocyte killing over T cells alone (Figure 8.7). This experiment was then
repeated as above with the inclusion of conditions to test the effects of neutralising antibodies,
or their isotype controls, on latent viral carriage. In these additional conditions, latently
infected monocytes were incubated with anti-IL-10 and anti-TGFβ or IgG1 and IgG2b
isotype antibodies for 72 hours at 7 days post infection. As before, a decrease in the number
of GFP+ cells was observed, although by approximately 66%, following the addition of T
cells alone to latently infected monocytes (Figure 8.8). A comparable reduction in GFP+
cells was also observed on addition of anti-IL-10 and anti-TGFβ antibodies or their isotype
control antibodies in isolation, and on addition of isotype control antibodies together with
T cells (Figure 8.8). The addition of T cells following neutralisation of IL-10 and TGFβ
however did lead to a further reduction in GFP+ cell numbers of around 83% compared to
the addition of T cells to latent monocytes alone (Figure 8.8).
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Fig. 8.7 Effect of anti-IL-10 and anti-TGFβ antibodies on T cell killing of latently
infected monocytes. CD14+ monocytes were latently infected with TB40e-UL32-GFP at an
MOI of 1.25 for 7 days. Following this, anti-IL-10 and anti-TGFβ antibodies, or IgG1 and
IgG2b isotype antibodies were added for two hours prior to the addition of isolated CD3+
cells. CD3+ T cells were also added to latently infected cells without antibodies. T cells
were removed after 72 hours by PBS wash and replaced with media containing GM-CSF
and IL-4 to differentiate monocytes, in addition to anti-MHC class I and class II antibodies.
After 5 days, LPS was added and GFP+ cells counted after 2 days by microscopy. Each
experimental condition was carried out in triplicate.
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Fig. 8.8 Effect of anti-IL-10 and anti-TGFβ antibodies on T cell killing of latently
infected monocytes. CD14+ monocytes were latently infected with TGF40e-UL32-GFP at
an MOI of 1.25 for 7 days. Following this, anti-IL-10 and anti-TGFβ antibodies, or IgG1
and IgG2b isotype antibodies were added for two hours prior to the addition of isolated
CD3+ cells. CD3+ T cells or antibodies alone were also added to latently infected cells
in isolation. T cells were removed after 72 hours by PBS wash and replaced with media
containing GM-CSF and IL-4 to differentiate monocytes, in addition to anti-MHC class I
and class II antibodies. After 5 days, LPS was added and GFP+ cells counted after 2 days by
microscopy. Each experimental condition was carried out in triplicate.
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8.3 Discussion
The secretion of IL-10 and TGFβ by latently infected cells and uninfected bystander cells
[605], CD4+ T cells specific for HCMV latency-associated proteins [501], and IL-10
secretion by CD8+ T cells specific to latency-associated proteins, could be inhibiting
antiviral T cell responses during latency. To investigate the effects of the latent secretome on
CD4+ T cell responses to HCMV proteins expressed during latency, CD4+ T cells were
incubated in latent secretome prior to the addition of HCMV ORF peptide pools, and IFNγ
secretion was measured by ELISA. IFNγ secretion from CD4+ T cells incubated with latent
secretome was found to be inhibited in response to LUNA, US28, and UL111A, which is in
agreement with a previous study showing that CD4+ T cells given a polyclonal stimulus of
PHA in the presence of latent secretomes had reduced IFNγ secretion [605]. As the
experiment here was only carried out in one donor, who produced levels of IFNγ greater
than the upper limit of detection of this assay in response to LUNA and US28, it was not
possible to see the precise levels of inhibition for those responses. These results are also
limited by the use of latent secretomes without comparison to secretomes from mock
infected, and UV-inactivated virus infected, CD14+ and CD34+ cells. Future work should
seek to address this, and include neutralising antibodies to IL-10 and TGFβ , in addition to
vIL-10, to confirm these are the mediators of IFNγ secretion inhibition. Additionally, the
experiments should be repeated to investigate the inhibitory potential of latent secretomes on
CD8+ T cell IFNγ secretion. Finally, to confirm that the latent secretomes are not inducing
IFNγ secretion from another cell type, these experiments should be repeated using ICS to
confirm IFNγ production is originating from CD4+ T cells.
The inhibition of HCMV-specific CD4+ T cell IFNγ secretion mediated by latent
secretomes could also have been augmented by the IL-10 and TGFβ secretion from CD4+ T
cells. Given that two distinct sub-populations of T cells responding to HCMV
latency-associated ORF products were detected (Section 3.2.10 and 4.2.7), secreting either
IFNγ or IL-10, targeting inhibitory cytokines by neutralising antibodies could improve the
antiviral effector functions of the IFNγ secreting T cell population. An initial test was
carried out examining IFNγ secretion from CD4+ T cells treated with or without anti-IL-10,
anti-TGFβ , and anti-IL-10R antibodies in the presence of HCMV ORF peptides. Use of the
antibodies was found to increase IFNγ secretion in response to UL111A peptides, giving an
indication that the population of CD4+ T cells specific to HCMV latency-associated ORFs
that secreted IL-10 and TGFβ can suppress the IFNγ secreting population. In MCMV
infection, IL-10R blockade was associated with an increase in CD4+ T cells producing IFNγ
[626], and it would be interesting to examine whether targeting IL-10 and TGFβ results in
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an increase in the number of cells secreting IFNγ and/or an increase in the quantity of IFNγ
secreted per cell in response to HCMV peptides. As this was carried out in only one donor,
and IFNγ responses to LUNA and US28 were above the upper limit of detection of the
ELISA for all conditions, this experiment needs to be repeated to determine if this effect can
be observed for all ORF-specific IL-10 responses. Additionally, extending this analysis to
CD8+ T cells is important.
Having shown the inhibitory effects of latent secretomes on IFNγ secretion from CD4+
T cells stimulated with HCMV latency-associated peptides, and shown that treating CD4+
T cells with antibodies against IL-10, TGFβ , and the IL-10R increased IFNγ secretion
following HCMV peptide stimulation, these sources of inhibitory cytokines were then
targeted in the context of the latent microenvironment. The production of IL-10 and TGFβ
by latently infected cells has been shown to inhibit the cytotoxicity of gB-specific CD4+
T cells [605], providing a promising approach to assess the ability of T cells to eliminate
latently infected monocytes in the presence of IL-10 and TGFβ neutralising antibodies. This
approach has also been used in a cancer setting, where neutralisation of IL-10 and TGFβ
improved T cell cytotoxicity against tumour cells in mice [746].
In two experiments, T cells were added to latently infected monocytes, with and without
IL-10 and TGFβ neutralising antibodies, to examine whether T cell responses against
latently infected cells could be improved when the inhibitory effects of these cytokines
were abrogated. A considerable decrease in infected monocyte numbers was observed
following co-incubation with T cells alone. A previous study has also utilised a similar
in vitro latency system to approach T cell responses to latently infected cells. An histone
deacetylase inhibitor (MC1568) was used to transiently upregulate IE expression on latent
monocytes, making them susceptible to IE-specific T cells [120]. A reduction in infected
monocyte numbers was observed when such T cells were incubated with infected monocytes
alone, however, this was only about a 25% decrease [120] in comparison to the 50% and
66% decrease observed in experiments here. It was hypothesised that this could be due to the
virus preparation containing incoming lytic proteins such as gB and pp65, which could be
processed and presented by infected monocytes, in the absence of lytic gene expression, to
activate lytic-specific T cells. Future work could purify virus by sorbitol density gradients to
reduce this input of lytic proteins.
The addition of neutralising or isotype control antibodies alone was also found to reduce
the number of latently infected monocytes. Previous work has shown that latently infected
CD34+ cells treated with an anti-IL-10 antibody for seven days had increased levels of
apoptosis [606]. It might therefore be expected that the neutralisation of IL-10 might have
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the same effect on the survival of latently infected monocytes, but it was surprising to see that
treatment with isotype control antibodies resulted in a comparable decrease in virus-infected
cell numbers. However, it could be the case that the addition of anti-IL-10 antibody for seven
days is required to see this effect [606], compared to the three days tested here. Additionally,
in this previous experiment, an isotype control antibody was not used to compare the levels of
apoptosis between latent CD34+ cells treated with and without antibody [606]. Repeating the
experiment carried out here with a greater number of replicates is also important to determine
if this effect is reproducible.
In both experimental repeats, despite the large decrease in latently infected monocytes
observed when T cells were added in isolation, the addition of IL-10 and TGFβ neutralising
antibodies was found to give an additional level of monocyte-specific T cell killing, in
comparison to T cells added alone. Therefore, taking the results presented in this chapter as
a whole suggests that neutralising the suppressive effects of IL-10 and TGFβ will promote
the recognition and killing of latently infected cells.
Chapter 9
General Discussion
9.1 Discussion
The work presented in this thesis has provided novel insights into T cells specific for proteins
that are expressed during latent HCMV infection. Both CD4+ and CD8+ T cell responses to
the latency-associated ORFs UL138, LUNA, US28, UL111A, and UL144 were consistently
detected across a large donor cohort. CD4+ T cells, and surprisingly CD8+ T cells, from
HCMV seropositive donors were also capable of producing the immunosuppressive cytokine
IL-10 in response to HCMV ORF products, and these responses were generally more
prevalent to latency-associated ORFs. The IL-10 secreting T cells were found to be separate
sub-population than to those secreting IFNγ , and CD4+ T cells specific to latency-associated
ORFs inhibited proliferation and antiviral cytokine secretion. Taking the evidence presented
here in combination with previous research [501, 605], suggests that HCMV infection
manipulates that antiviral T cell response to a more suppressive phenotype, which could be
aiding the ability of the virus to persist during latency.
Alongside IL-10 secreting T cells specific for latently expressed HCMV proteins,
latent-specific IFNγ secreting T cells were also detected together with latent-specific T cells
expressing markers associated with cytotoxicity. Such T cells could therefore represent a
population of antiviral T cells that are capable of eliminating latently infected cells but are
being inhibited from doing so. The inhibition of these T cells could be in part mediated by
the populations of IL-10 secreting CD4+ and CD8+ T cells, which, by secreting
immunosuppressive cytokines alongside latently infected cells and their bystander cells,
prevent antiviral T cells from targeting latently infected cells. Indeed, when IL-10 and TGFβ
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were targeted with neutralising antibodies, both IFNγ secretion from CD4+ T cells, and T
cell killing of latently infected cells were increased, highlighting the ability of these
suppressive cytokines to modulate the interactions between antiviral T cells and latently
infected cells for the benefit of viral persistence.
Given these observed increases in antiviral T cell functions following the neutralisation of
IL-10 and TGFβ , future work should also aim to identify and target the latent-specific T cell
populations responsible for immunosuppressive cytokine secretion, as Tregs were found to
only represent a proportion of this population. Further work targeting the immunosuppressive
cytokines directly to improve T cell recognition and clearance of latently infected cells
should also be undertaken. The initial results from two experiments showing an increase in T
cell killing of latently infected cells following the addition of IL-10 and TGFβ neutralising
antibodies emphasise the potential for such an intervention to reduce latent viral loads.
Whether targetting the microenvironment in this manner represents an effective therapeutic
option will require considerable experimental investigation in the future.
To improve on the in vitro system utilised in these experiments, virus could be purified by
sorbitol density gradients to reduce the input of lytic proteins on infection, and thus reduce T
cell killing of latently infected cells when T cells are added in isolation. Additionally, the use
of T cell lines specific to single or multiple latency-associated proteins could result in a lower
background level of infected monocyte killing. Virus preparations could also be titrated on
CD14+ monocytes from each donor prior to testing them, to provide a more accurate MOI
for infection. Similarly, such titrations could be carried out for the differentiation stimuli,
with GM-CSF and IL-4, M-CSF and IL-1β , and PMA, by titrating these on each donor’s
infected monocytes to determine which is most effective.
The use of TB40e-UL32-GFP virus was a also limitation due to the time required for
GFP expression to occur [611]. As UL32 is a late gene, GFP was usually detected at around
three days post differentiation of latently infected monocytes. To improve on this, initial
experiments were carried out using a TB40e-IE2-YFP virus with PMA as the reactivation
stimulus (Appendix C.1), as this provided a much quicker system for detecting infected
cells, given that YFP expression occurs from IE time points. However, this virus is missing
the US2-US6 genomic region [612], and future research should seek to generate a repaired
IE reporter virus with these genes intact. Finally, follow-up investigations could examine
the effect of IL-10 and TGFβ neutralisation on T cell killing in the context of a naturally
latent infection. Although such an approach has its difficulties, it has been used previously to
examine T cell responses to latently infected monocytes [120], and doing so could eliminate
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the problem of introducing lytic viral proteins on infection, which was encountered in this
experimental latency system.
The potential to identify immunosuppressive cytokine secreting latent-specific T cell
populations could also enable those secreting pro-inflammatory cytokines, that might be
antiviral during latency, to be identified. This could then enable an adoptive T cell therapy
approach to be taken if the T cells capable of targeting latently infected cells could be isolated
reliably and expanded ex vivo prior to infusion. Numerous studies have shown successes in
such an approach, in both HSCT and solid organ transplantation settings, to restore HCMV
immune responses, reduce viral load, and thus reduce the risk of HCMV disease [382, 747–
751]. An increased understanding of the distinct IL-10 and IFNγ producing latency-specific
T cell populations might therefore enable antiviral T cells to be expanded based on certain
HCMV-derived peptides or TCRs. The expanded T cells capable of targetting latently infected
cells, or strategies to target inhibitory T cells, could then be used in the immunosuppressed
transplant setting to reduce latent viral load and improve clinical outcomes. The need
to develop new therapeutic options to combat HCMV is especially important given the
limitations of antivirals and vaccines. Given the emergence of resistance, novel therapeutics
could alleviate the reliance on currently available drugs and prolong their effectiveness
[752]. The lack of an effective vaccine to HCMV capable of conferring protection to naive
individuals, and protecting against superinfection and reactivation in infected individuals, is
also an issue, and one that could also be partially addressed through developing the means to
target latently infected cells.
Several questions remain unanswered regarding the phenotypes and capabilities of the
IFNγ and IL-10 secreting populations of T cells. Phenotypic analysis indicated that T cells
specific for latency-associated ORFs possessed cytotoxic potential and did not differ in
memory phenotype composition from lytic-ORF specific T cells. The ICS techniques used in
this work however could not delineate the cytotoxic potential and memory phenotypes of
these two separate populations, and thus it is not known whether IFNγ secreting T cells differ
from IL-10 secreting T cells in these aspects. Moreover, in initial examinations, a proportion
of latent-specific CD4+ T cells secreting IL-10 expressed CD25, and could thus be Tregs, but
further characterisation of surface markers and transcription factor expression of these cells
could help determine whether these cells fit into a defined T helper cell subset. Likewise, the
widespread IL-10 secreting CD8+ T cells found in response to the latency-associated ORFs
should be examined in more detail with similar analyses, especially by determining if these
cells can secrete TGFβ . To address these issues, future research could make use of MHC
class I and II tetramers. The use of tetramers will allow for the sorting of epitope specific T
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cells, which will enable in-depth phenotypic characterisation, such as via single cell RNA
sequencing and transcription factor expression analysis [334, 337, 405, 753, 754]. In addition,
through the use of tetramers, T cells can be sorted to high purity for use in downstream
functional assays as well as grown out as lines. Further phenotypic characterisation of IL-10
secreting T cells could reveal markers that are differentially expressed compared to IFNγ
secreting T cells. Doing so could then enable the selective depletion of IL-10 secreting T
cells to both elucidate their role during infection and to remove suppression on antiviral T
cell responses during latency.
With a view towards generating tetramers, I carried out the initial mapping of CD4+
and CD8+ T cell responses to minimal peptide epitopes. For CD8+ T cells this highlighted
several 15mer peptides able to elicit either sole IFNγ and IL-10 responses, or in several cases
separate populations of cells secreting both cytokines to the same peptide. Knowledge of
the cytokine secretion of single peptide-specific T cells can give an initial indication as to
whether the IFNγ and IL-10 secreting T cell clones diverged from the same parent cell, but
this can be confirmed by TCR sequencing once tetramers have been made. Having mapped
responses to individual peptides, these peptides could also be used to stimulate T cells and
generate specific clonal lines, which could enable the expansion of peptide-specific IL-10
or IFNγ secreting T cells. This could provide a relatively simple way of determining if
CD4+ and CD8+ T cells specific to certain latency-associated ORF products are cytotoxic.
Additionally, using an in vitro latency system, expanded latent-specific IFNγ secreting T
cells could be tested for their ability to clear a latent infection. However, the manipulations
required to expand T cells could impact on their functional capacity and phenotypes so it
would be advantageous to use tetramers to sort cells for phenotyping and functional assays
without manipulation.
The unexpected findings that IL-10 secreting CD8+ T cells specific to latent proteins
were present and so widespread could be indicative of an additional axis by which HCMV
interferes with antiviral immunity during latency to aid viral persistence. CD8+ T cell-
derived IL-10 could act together with IL-10 and TGFβ produced by latently infected cells
and their bystander cells, and by latent-specific CD4+ T cells to inhibit pro-inflammatory
latent-specific antiviral T cells. While experiments were carried out showing the ability of
latency-associated ORF specific CD4+ T cell secretomes to inhibit secretion of antiviral
cytokines, future work should also examine the effects of CD8+ T cell secretomes on
antiviral T cell functions, as this could represent another key part of the inhibitory latent
microenvironment. Investigations into the relative importance of CD4+ versus CD8+ T cell
derived inhibitory factors on latent carriage could also be undertaken. Furthermore, the
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experiments carried out on CD4+ T cell secretomes should be extended to additional donors
to validate the inhibition of IFNγ and TNFα by supernatants, as well as to investigate the
differential inhibitory effects on these cytokines supernatants can have.
The generation of these IL-10 secreting CD4+ and CD8+ T cells was investigated at the
point of primary HCMV infection. To do this, samples from patients undergoing kidney
transplantation were utilised, where blood had been collected over a number of time points
before and after seroconversion. Although T cells secreting IFNγ were observed immediately
following transplantation, IL-10 secreting T cells were not detected consistently to latency-
associated ORF products. Surprisingly, T cells secreting IL-10 could be detected in response
to the lytic proteins US3 and pp71 soon after transplantation and these responses were
maintained. It is therefore possible that IL-10 secreting T cells specific to latency-associated
proteins are generated following longer term viral carriage, perhaps influenced by T cell
activation in the established latent microenvironment which contains immunosuppressive
cytokines [506, 755, 756]. It could also be possible that IL-10 secreting latent-specific T
cells are generated immediately following primary infection, but they are not present in
the blood at such early stages. Initial experiments were then carried out on paired bone
marrow and peripheral blood T cells to begin to address whether T cells secreting IL-10
were preferentially localised to tissue sites rather than peripheral blood. Differences in the
localisation of ORF-specific IFNγ and IL-10 secreting latent-specific T cells were found
between the blood and bone marrow, with IL-10 secreting T cells found to be enriched in the
bone marrow for many ORF-specific responses. The enrichment of IL-10 secreting T cells
in the bone marrow could be indicative of a functional role for these immunosuppressive
cells at this site, such as the prevention of immunopathology caused by the pro-inflammatory
T cells which were also present. Further work should seek to address this question as the
results could have implications for the feasibility of any intervention that targets inhibitory
cytokines or cells at this site.
Initial additional experiments should include more donors, and test paired tissue/blood
samples that have been isolated from the same time points to validate the findings presented
here. T cells should also be sampled from additional tissues to enable a greater degree of
comparison between sites, especially from tissues serving as potential entry routes during
transmission, such as oral and lung. In MCMV infection, for example, CD4+ and CD8+
TRM cells are induced in the salivary gland, of which the CD8+ T cells provided immediate
protection against re-infection [460]. Furthermore, future research could attempt to determine
the phenotypes of HCMV-specific T cells found in the bone marrow and other tissue sites.
Phenotyping of such T cells to identify if they are truly resident memory T cells, using well
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defined markers such as CD69 and CD103 [465], and detecting IL-10 production from these
cells, will be important in elucidating the role of virally induced immunomodulation, and
the role of HCMV-specific T cells, at these sites. Building on the research presented here,
further work is therefore required to increase our understanding of the immunobiology of
HCMV, which could inform attempts to target the virus and lead to the ability to remove
latently infected cells in a clinical setting.
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Fig. A.1 Analysis of the magnitudes of CD4+ T cell IFNγ responses to 8 HCMV ORF peptide
pools correlated with donor age after donors have been separated by sex. CD8+ depleted PBMC
from 91 seropositive donors were stimulated with HCMV ORF peptide pools for 48 hours on dual
IFNγ/IL-10 FluoroSpot plates and the frequencies of CD4+ T cells secreting IFNγ within each
seropositive donor enumerated and converted to Spot Forming Units (SFU)/106 cells. The SFU/106
cells of IFNγ secreting CD4+ T cells is shown against donor age for responses to (A) gB, (B) pp65, (C)
IE1, (D) UL138, (E) LUNA, (F) US28, (G) UL111A, and (H) UL144 with male responses illustrated
by the filled triangles (▲) and female responses with open circles (◦). The correlation (Spearman rs
values and p values shown on each graph), and line of best fit are shown. Spearman rank correlation
analysis of these responses indicates that CD4+ IFNγ T cell responses to (F) US28 from male donors
significantly decrease with donor age (rs = -0.3454, P = 0.0313).
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Fig. A.2 Analysis of the magnitudes of CD4+ T cell IL-10 responses to 8 HCMV ORF peptide
pools correlated with donor age after donors have been separated by sex. CD8+ depleted PBMC
from 68 seropositive donors were stimulated with HCMV ORF peptide pools for 48 hours on dual
IFNγ/IL-10 FluoroSpot plates and the frequencies of CD4+ T cells secreting IL-10 within each
seropositive donor enumerated and converted to Spot Forming Units (SFU)/106 cells. The SFU/106
cells of IL-10 secreting CD4+ T cells is shown against donor age for responses to (A) gB, (B) pp65,
(C) IE1, (D) UL138, (E) LUNA, (F) US28, (G) UL111A, and (H) UL144 with male responses
illustrated by the filled triangles (▲) and female responses with open circles (◦). The correlation
(Spearman rs values and p values shown on each graph), and line of best fit are shown. There were
significant negative correlations in male donors between the magnitude of CD4+ T cells secreting
IL-10 and age in response to (C) IE1 (rs = -0.3941, P = 0.0232), (D) UL138 (rs = -0.4553, P = 0.0078),
and (G) UL111A (rs = -0.3498, P = 0.0460) by Spearman rank correlation analysis.
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Fig. A.3 Analysis of the magnitudes of CD8+ T cell IFNγ responses to 8 HCMV ORF peptide
pools correlated with donor age after donors have been separated by sex. CD4+ depleted PBMC
from 91 seropositive donors were stimulated with HCMV ORF peptide pools for 48 hours on dual
IFNγ/IL-10 FluoroSpot plates and the frequencies of CD8+ T cells secreting IFNγ within each
seropositive donor enumerated and converted to Spot Forming Units (SFU)/106 cells. The SFU/106
cells of IFNγ secreting CD4+ T cells is shown against donor age for responses to (A) gB, (B) pp65,
(C) IE1, (D) UL138, (E) LUNA, (F) US28, (G) UL111A, and (H) UL144 with male responses
illustrated by the filled triangles (▲) and female responses with open circles (◦). The correlation
(Spearman rs values and p values shown on each graph), and line of best fit are shown. A significant
negative correlation between the frequency of IFNγ secreting CD8+ T cells and increasing donor age
in response to (D) UL138 in male donors was observed (Spearman rs = -0.3805, P = 0.0169).
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Fig. A.4 Analysis of the magnitudes of CD8+ T cell IL-10 responses to 8 HCMV ORF peptide
pools correlated with donor age after donors have been separated by sex. CD4+ depleted PBMC
from 45 seropositive donors were stimulated with HCMV ORF peptide pools for 48 hours on dual
IFNγ/IL-10 FluoroSpot plates and the frequencies of CD8+ T cells secreting IFNγ within each
seropositive donor enumerated and converted to Spot Forming Units (SFU)/106 cells. The SFU/106
cells of IFNγ secreting CD4+ T cells is shown against donor age for responses to (A) gB, (B) pp65, (C)
IE1, (D) UL138, (E) LUNA, (F) US28, (G) UL111A, and (H) UL144 with male responses illustrated
by the filled triangles (▲) and female responses with open circles (◦). The correlation (Spearman rs
values and p values shown on each graph), and line of best fit are shown. There was a significant
negative correlation between CD8+ T cell IL-10 responses and increasing donor age in response to
(B) pp65 in male donors (Spearman rs = -0.5288, P = 0.0055).
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Fig. B.1 Secretion of IFNγ , TNFα , and IL-10 from CD4+ T cells stimulated with
HCMV ORF peptide pools (A) PBMC depleted of CD8+ cells from donors CMV324,
CMV328, and CMV319 were stimulated with overlapping HCMV ORF peptide pools
spanning pp65, UL138, LUNA, US28, UL111A, and UL144, or left unstimulated (Unstim)
in media, for 48 hours. Following this incubation, supernatants were harvested and assayed
for the secretion of (B, D, F) TNFα , (C, E, G) IFNγ , and (H) IL-10 by flow cytometry.
Samples were tested in duplicate.
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Fig. B.2 IFNγ and TNFα secretion by PBMC following incubation with supernatant
derived from CD4+ T cells stimulated with HCMV ORF peptide pools (A) PBMC
depleted of CD8+ cells from donors CMV328, CMV324, and CMV319 were stimulated with
overlapping HCMV ORF peptide pools spanning pp65, UL138, LUNA, US28, UL111A,
and UL144, or left unstimulated (Unstim) in media, for 42 hours. Following this incubation,
the supernatants were harvested. PBMC from donors CMV401 were then incubated in these
supernatants for 36 hours and assayed for the secretion of (B, D, F) TNFα and (C, E, G)
IFNγ . Samples were tested in duplicate.
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Fig. B.3 IFNγ and TNFα secretion by PBMC following incubation with supernatant
derived from CD4+ T cells stimulated with HCMV ORF peptide pools PBMC depleted
of CD8+ cells from donors CMV328, CMV324, and CMV319 were stimulated with
overlapping HCMV ORF peptide pools spanning pp65, UL138, LUNA, US28, UL111A,
and UL144, or left unstimulated (Unstim) in media, for 42 hours. Following this incubation,
the supernatants were harvested. PBMC from donors CMV426 were then incubated in these
supernatants for 36 hours and assayed for the secretion of (A, C, E) TNFα and (B, D, F)
IFNγ . Samples were tested in duplicate.
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Fig. B.4 IFNγ and TNFα secretion by PBMC following incubation with supernatant
derived from CD4+ T cells stimulated with HCMV ORF peptide pools PBMC depleted
of CD8+ cells from donor CMV332 were stimulated with overlapping HCMV ORF peptide
pools spanning pp65, UL138, LUNA, US28, UL111A, and UL144, or left unstimulated
(Unstim) in media, for 48 hours. Following this incubation, the supernatants were harvested
and assessed for the secretion of (A) TNFα , (B) IFNγ , and (IL-10) by a flow cytometry
based bead array. PBMC from donor CMV332 were then incubated in these supernatants
for 36 hours and assayed for the secretion of (D) TNFα , (E) IFNγ , and (F) IL-10 by a flow
cytometry based bead array. Samples were tested in duplicate.

Appendix C
Latent infection of monocytes with
TB40e-UL32-GFP virus
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Fig. C.1 Reactivation of HCMV following PMA treatment. CD14+ monocytes were
latently infected with TB40e-IE2-YFP for a period of 4 or 8 days before the addition of
20ng/ml Phorbol 12-myristate 13-acetate (PMA) for 48 hours. Infected monocytes were also
left untreated. YFP+ cells were then examined by microscopy.

Appendix D
Donor data
Donor ID Age Sex
HCMV
Serostatus
Donor ID Age Sex
HCMV
Serostatus
CMV324 23 Male Positive ARIA014 67 Male Positive
CMV323 24 Male Positive ARIA034 67 Male Positive
ARIA133 29 Male Positive ARIA002 68 Male Positive
CMV321 32 Male Positive ARIA067 68 Male Positive
ARIA126 33 Male Positive ARIA086 70 Male Positive
ARIA063 36 Male Positive ARIA127 71 Male Positive
ARIA148 37 Male Positive ARIA012 72 Male Positive
ARIA146 38 Male Positive ARIA124 72 Male Positive
ARIA150 38 Male Positive ARIA139 72 Male Positive
ARIA161 38 Male Positive ARIA123 73 Male Positive
CMV319 39 Male Positive ARIA120 74 Male Positive
ARIA147 39 Male Positive ARIA121 74 Male Positive
ARIA039 40 Male Positive ARIA122 74 Male Positive
ARIA152 40 Male Positive ARIA128 74 Male Positive
ARIA046 43 Male Positive ARIA142 75 Male Positive
CMV307 43 Male Positive ARIA140 76 Male Positive
ARIA005 46 Male Positive ARIA160 38 Male Negative
ARIA062 48 Male Positive ARIA125 38 Male Negative
ARIA044 52 Male Positive ARIA049 40 Male Negative
ARIA069 53 Male Positive ARIA087 45 Male Negative
ARIA061 55 Male Positive ARIA149 51 Male Negative
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Donor ID Age Sex
HCMV
Serostatus
Donor ID Age Sex
HCMV
Serostatus
ARIA137 56 Male Positive ARIA075 55 Male Negative
ARIA132 58 Male Positive ARIA053 68 Male Negative
ARIA141 58 Male Positive ARIA020 71 Male Negative
ARIA158 58 Male Positive ARIA155 72 Male Negative
CMV301 59 Male Positive ARIA023 72 Male Negative
ARIA065 62 Male Positive ARIA118 78 Male Negative
ARIA151 64 Male Positive ARIA024 65 Female Positive
ARIA017 27 Female Positive ARIA025 65 Female Positive
ARIA032 27 Female Positive ARIA003 66 Female Positive
ARIA088 27 Female Positive ARIA031 66 Female Positive
ARIA145 28 Female Positive ARIA064 66 Female Positive
ARIA043 29 Female Positive ARIA016 67 Female Positive
ARIA144 32 Female Positive ARIA019 67 Female Positive
ARIA045 33 Female Positive ARIA042 67 Female Positive
ARIA055 33 Female Positive ARIA033 68 Female Positive
ARIA131 35 Female Positive ARIA013 69 Female Positive
ARIA119 36 Female Positive ARIA018 69 Female Positive
ARIA072 37 Female Positive ARIA037 69 Female Positive
ARIA130 38 Female Positive ARIA073 69 Female Positive
ARIA006 39 Female Positive ARIA028 70 Female Positive
ARIA066 39 Female Positive ARIA035 70 Female Positive
ARIA081 39 Female Positive ARIA054 70 Female Positive
ARIA089 39 Female Positive ARIA079 70 Female Positive
ARIA091 39 Female Positive ARIA071 71 Female Positive
ARIA047 40 Female Positive ARIA011 73 Female Positive
ARIA134 40 Female Positive ARIA138 73 Female Positive
ARIA052 42 Female Positive ARIA143 73 Female Positive
ARIA076 49 Female Positive ARIA051 74 Female Positive
ARIA026 50 Female Positive ARIA070 74 Female Positive
ARIA084 50 Female Positive ARIA136 74 Female Positive
ARIA080 51 Female Positive ARIA159 29 Female Negative
ARIA004 54 Female Positive ARIA040 32 Female Negative
ARIA010 54 Female Positive ARIA030 37 Female Negative
ARIA021 54 Female Positive ARIA068 39 Female Negative
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Donor ID Age Sex
HCMV
Serostatus
Donor ID Age Sex
HCMV
Serostatus
ARIA029 54 Female Positive ARIA082 48 Female Negative
ARIA078 54 Female Positive ARIA036 48 Female Negative
ARIA015 55 Female Positive ARIA154 48 Female Negative
CMV320 57 Female Positive ARIA083 58 Female Negative
ARIA008 60 Female Positive ARIA007 60 Female Negative
ARIA074 60 Female Positive ARIA056 66 Female Negative
ARIA048 62 Female Positive ARIA156 73 Female Negative
ARIA022 63 Female Positive ARIA157 73 Female Negative
ARIA085 64 Female Positive ARIA038 75 Female Negative
Table D.1 Donor data. Serum from 128 healthy donors was tested for HCMV serostatus by
CMV IgG ELISA and grouped according to age and sex.
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Peptide library sequences
E.1 UL138
Peptide
Number
Peptide
Sequence
Peptide
Number
Peptide
Sequence
1 MDDLPLNVGLPIIGV 17 RFSERPDEILVRWEE
2 LNVGLPIIGVMLVLI 18 PDEILVRWEEVSSQC
3 PIIGVMLVLIVAILC 19 VRWEEVSSQCSYASS
4 MLVLIVAILCYLAYH 20 VSSQCSYASSRITDR
5 VAILCYLAYHWHDTF 21 SYASSRITDRRVGSS
6 YLAYHWHDTFKLVRM 22 RITDRRVGSSSSSSV
7 WHDTFKLVRMFLSYR 23 RVGSSSSSSVHVASQ
8 KLVRMFLSYRWLIRC 24 SSSSVHVASQRNSVP
9 FLSYRWLIRCCELYG 25 HVASQRNSVPPPDMA
10 WLIRCCELYGEYERR 26 RNSVPPPDMAVTAPL
11 CELYGEYERRFADLS 27 PPDMAVTAPLTDVDL
12 EYERRFADLSSLGLG 28 VTAPLTDVDLLKPVT
13 FADLSSLGLGAVRRE 29 TDVDLLKPVTGSATQ
14 SLGLGAVRRESDRRY 30 LKPVTGSATQFTTVA
15 AVRRESDRRYRFSER 31 GSATQFTTVAMVHYH
16 SDRRYRFSERPDEIL 32 QFTTVAMVHYHQEYT
Table E.1 Amino acid sequences of individual overlapping 15mer peptides spanning the
predicted UL138 ORF
E.2 LUNA 379
E.2 LUNA
Peptide
Number
Peptide
Sequence
Peptide
Number
Peptide
Sequence
1 MTSVRAPLLPLRRLC 14 SSSSVGGNPGDCGRN
2 APLLPLRRLCPVRIS 15 GGNPGDCGRNSETAP
3 LRRLCPVRISARDSP 16 DCGRNSETAPRMTLL
4 PVRISARDSPAWVSE 17 SETAPRMTLLRGKRP
5 ARDSPAWVSESSSPL 18 RMTLLRGKRPARSCT
6 AWVSESSSPLASSKP 19 RGKRPARSCTWGRLI
7 SSSPLASSKPANMAS 20 ARSCTWGRLILSGLP
8 ASSKPANMASDRGVG 21 WGRLILSGLPGVRVQ
9 ANMASDRGVGVGVEE 22 LSGLPGVRVQNPRRK
10 DRGVGVGVEERSSSS 23 GVRVQNPRRKKWMRP
11 VGVEERSSSSSSSSS 24 NPRRKKWMRPSGCRC
12 RSSSSSSSSSSSSSV 25 RRKKWMRPSGCRCSK
13 SSSSSSSSSVGGNPG
Table E.2 Amino acid sequences of individual overlapping 15mer peptides spanning the
predicted LUNA ORF
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E.3 US28
Peptide
Number
Peptide
Sequence
Peptide
Number
Peptide
Sequence
1 MTPTTTTAELTTEFD 36 DYDYLEVSYPIILNV
2 TTAELTTEFDYDEDA 37 EVSYPIILNVELMLG
3 TTEFDYDEDATPCVF 38 IILNVELMLGAFVIP
4 YDEDATPCVFTDVLN 39 ELMLGAFVIPLSVIS
5 TPCVFTDVLNQSKPV 40 AFVIPLSVISYCYYR
6 TDVLNQSKPVTLFLY 41 LSVISYCYYRISRIV
7 QSKPVTLFLYGVVFL 42 YCYYRISRIVAVSQS
8 TLFLYGVVFLFGSIG 43 ISRIVAVSQSRHKGR
9 GVVFLFGSIGNFLVI 44 AVSQSRHKGRIVRVL
10 FGSIGNFLVIFTITW 45 RHKGRIVRVLIAVVL
11 NFLVIFTITWRRRIQ 46 IVRVLIAVVLVFIIF
12 FTITWRRRIQCSGDV 47 IAVVLVFIIFWLPYH
13 RRRIQCSGDVYFINL 48 VFIIFWLPYHLTLFV
14 CSGDVYFINLAAADL 49 WLPYHLTLFVDTLKL
15 YFINLAAADLLFVCT 50 LTLFVDTLKLLKWIS
16 AAADLLFVCTLPLWM 51 DTLKLLKWISSSCEF
17 LFVCTLPLWMQYLLD 52 LKWISSSCEFERSLK
18 LPLWMQYLLDHNSLA 53 SSCEFERSLKRALIL
19 QYLLDHNSLASVPCT 54 ERSLKRALILTESLA
20 HNSLASVPCTLLTAC 55 RALILTESLAFCHCC
21 SVPCTLLTACFYVAM 56 TESLAFCHCCLNPLL
22 LLTACFYVAMFASLC 57 FCHCCLNPLLYVFVG
23 FYVAMFASLCFITEI 58 LNPLLYVFVGTKFRQ
24 FASLCFITEIALDRY 59 YVFVGTKFRQELHCL
25 FITEIALDRYYAIVY 60 TKFRQELHCLLAEFR
26 ALDRYYAIVYMRYRP 61 ELHCLLAEFRQRLFS
27 YAIVYMRYRPVKQAC 62 LAEFRQRLFSRDVSW
28 MRYRPVKQACLFSIF 63 QRLFSRDVSWYHSMS
29 VKQACLFSIFWWIFA 64 RDVSWYHSMSFSRRG
30 LFSIFWWIFAVIIAI 65 YHSMSFSRRGSPSRR
E.3 US28 381
31 WWIFAVIIAIPHFMV 66 FSRRGSPSRRETSSD
32 VIIAIPHFMVVTKKD 67 SPSRRETSSDTLSDE
33 PHFMVVTKKDNQCMT 68 ETSSDTLSDEVCRVS
34 VTKKDNQCMTDYDYL 69 DTLSDEVCRVSQIIP
35 NQCMTDYDYLEVSYP
Table E.3 Amino acid sequences of individual overlapping 15mer peptides spanning the
predicted US28 ORF
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E.4 UL111A
Peptide
Number
Peptide
Sequence
Peptide
Number
Peptide
Sequence
1 MLSVMVSSSLVLIVF 19 RYLEIVFPAGDHVYP
2 VSSSLVLIVFFLGAS 20 VFPAGDHVYPGLKTE
3 VLIVFFLGASEEAKP 21 DHVYPGLKTELHSMR
4 FLGASEEAKPATTTT 22 GLKTELHSMRSTLES
5 EEAKPATTTTIKNTK 23 LHSMRSTLESIYKDM
6 ATTTTIKNTKPQCRP 24 STLESIYKDMRQCPL
7 IKNTKPQCRPEDYAT 25 IYKDMRQCPLLGCGD
8 PQCRPEDYATRLQDL 26 RQCPLLGCGDKSVIS
9 EDYATRLQDLRVTFH 27 LGCGDKSVISRLSQE
10 RLQDLRVTFHRVKPT 28 KSVISRLSQEAERKS
11 RVTFHRVKPTLQRED 29 RLSQEAERKSDNGTR
12 RVKPTLQREDDYSVW 30 AERKSDNGTRKGLSE
13 LQREDDYSVWLDGTV 31 DNGTRKGLSELDTLF
14 DYSVWLDGTVVKGCW 32 KGLSELDTLFSRLEE
15 LDGTVVKGCWGCSVM 33 LDTLFSRLEEYLHSR
16 VKGCWGCSVMDWLLR 34 DTLFSRLEEYLHSRK
17 GCSVMDWLLRRYLEI 35 RQCVSVSVAALSAQR
18 DWLLRRYLEIVFPAG
Table E.4 Amino acid sequences of individual overlapping 15mer peptides spanning the
predicted UL111A ORF
E.5 UL144 383
E.5 UL144
Peptide
Number
Peptide
Sequence
Peptide
Number
Peptide
Sequence
1 MKPLVMLICFGVILL 43 SGLYNCTNCTECNDT
2 MKPLVMLILLSMLLA 44 TGLYNCTNCTQCNDT
3 MKPLIMLICFAVILL 45 CTDCTQCNVTQVMIR
4 MLICFGVILLQLGVT 46 CTNCTECNDTEVTIR
5 MLILLSMLLACIGKT 47 CTNCTQCNDTQITVR
6 MLICFGVFLLQLGGS 48 QCNVTQVMIRNCTST
7 GVILLQLGVTKVCQ OH 49 ECNDTEVTIRNCTST
8 SMLLACIGKTEICKP 50 QCNDTQITVRNCTST
9 GVFLLQLGGSKMCKP 51 QVMIRNCTSTNNTVC
10 QLGVTKVCQHNEVQL 52 EVTIRNCTSTNNTVC
11 CIGKTEICKPEEVQL 53 QITVRNCTSTNNTIC
12 QLGGSKMCKPDEVKL 54 NCTSTNNTVCAPKN OH
13 KVCQHNEVQLGNECC 55 NCTSTNNTVCASKNY
14 EICKPEEVQLGNQCC 56 NCTSTNNTICASKN OH
15 KMCKPDEVKLGNQCC 57 NNTVCAPKNHTYFST
16 NEVQLGNECCPPCGL 58 NNTVCASKNYTSFSV
17 EEVQLGNQCCPPCKQ 59 NNTICASKNHTSFSS
18 DEVKLGNQCCPPCGS 60 APKNHTYFSTPGVQ OH
19 GNECCPPCGLGQRVT 61 ASKNYTSLSVPGVQ OH
20 GNQCCPPCKQGYRVT 62 ASKNYTSFSISGVQ OH
21 PPCGLGQRVTKVCTE 63 ASKNHTSFSSPGVQ OH
22 PPCKQGYRVTGQCTQ 64 TYFSTPGVQHHKQRQ
23 PPCGSGQRVTKVCTD 65 TSLSVPGVQHHKQRQ
24 GQRVTKVCTERTSVT 66 PGVQHHKQRQQNHTA
25 GYRVTGQCTQYTSTT 67 PGVQHHKQRQNHTA
26 GQRVTKVCTDYTSVT 68 HKQRQQNHTAHITVK
27 GQKVTKVCTEISGIT 69 HKQRQNHTAHVTVK
28 KVCTERTSVTCTPCP 70 QNHTAHITVKQGKSG
29 GQCTQYTSTTCTLCP 71 NHTAHVTVKQGKSG
30 KVCTDYTSVTCTPCP 72 QNHTAHVTVKQRKSG
31 KVCTEISGITCTLCP 73 HITVKQGKSGRHTLA
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32 RTSVTCTPCPNGTYV 74 HVTVKQGKSGRHTLA
33 YTSTTCTLCPNGTYV 75 HVTVKQRKSGRHTLA
34 YTSVTCTPCPNGTYV 76 QGKSGRHTLAWLSLF
35 ISGITCTLCPNGTYL 77 RHTLAWLSLFIFLVG
36 CTPCPNGTYVSGLYN 78 WLSLFIFLVGIILLI
37 CTLCPNGTYVSGLYN 79 IFLVGIILLILYLIA
38 CTLCPNGTYLTGLYN 80 IILLILYLIAAYRSE
39 NGTYVSGLYNCTDCT 81 LYLIAAYRSERCQQC
40 NGTYVSGLYNCTNCT 82 AYRSERCQQCCSIGK
41 NGTYLTGLYNCTNCT 83 RCQQCCSIGKIFYRT
42 SGLYNCTDCTQCNVT 84 CSIGKIFYRTL
Table E.5 Amino acid sequences of individual overlapping 15mer peptides spanning the
predicted UL144 ORF
E.6 gB 385
E.6 gB
Peptide
Number
Peptide
Sequence
Peptide
Number
Peptide
Sequence
1 MESRIWCLVVCVNLC 91 LNITHRTRRSTSDNN
2 WCLVVCVNLCIVCLG 92 RTRRSTSDNNTTHLS
3 CVNLCIVCLGAAVSS 93 TSDNNTTHLSSMESV
4 IVCLGAAVSSSSTSH 94 TTHLSSMESVHNLVY
5 AAVSSSSTSHATSST 95 SMESVHNLVYAQLQF
6 SSTSHATSSTHNGSH 96 HNLVYAQLQFTYDTL
7 ATSSTHNGSHTSRTT 97 AQLQFTYDTLRGYIN
8 HNGSHTSRTTSAQTR 98 TYDTLRGYINRALAQ
9 TSRTTSAQTRSVYSQ 99 RGYINRALAQIAEAW
10 SAQTRSVYSQHVTSS 100 RALAQIAEAWCVDQR
11 SVYSQHVTSSEAVSH 101 IAEAWCVDQRRTLEV
12 HVTSSEAVSHRANET 102 CVDQRRTLEVFKELS
13 EAVSHRANETIYNTT 103 RTLEVFKELSKINPS
14 RANETIYNTTLKYGD 104 FKELSKINPSAILSA
15 IYNTTLKYGDVVGVN 105 KINPSAILSAIYNKP
16 LKYGDVVGVNTTKYP 106 AILSAIYNKPIAARF
17 VVGVNTTKYPYRVCS 107 IYNKPIAARFMGDVL
18 TTKYPYRVCSMAQGT 108 IAARFMGDVLGLASC
19 YRVCSMAQGTDLIRF 109 MGDVLGLASCVTINQ
20 MAQGTDLIRFERNII 110 GLASCVTINQTSVKV
21 DLIRFERNIICTSMK 111 VTINQTSVKVLRDMN
22 ERNIICTSMKPINED 112 TSVKVLRDMNVKESP
23 CTSMKPINEDLDEGI 113 LRDMNVKESPGRCYS
24 PINEDLDEGIMVVYK 114 VKESPGRCYSRPVVI
25 LDEGIMVVYKRNIVA 115 GRCYSRPVVIFNFAN
26 MVVYKRNIVAHTFKV 116 RPVVIFNFANSSYVQ
27 RNIVAHTFKVRVYQK 117 FNFANSSYVQYGQLG
28 HTFKVRVYQKVLTFR 118 SSYVQYGQLGEDNEI
29 RVYQKVLTFRRSYAY 119 YGQLGEDNEILLGNH
30 VLTFRRSYAYIYTTY 120 EDNEILLGNHRTEEC
31 RSYAYIYTTYLLGSN 121 LLGNHRTEECQLPSL
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32 IYTTYLLGSNTEYVA 122 RTEECQLPSLKIFIA
33 LLGSNTEYVAPPMWE 123 QLPSLKIFIAGNSAY
34 TEYVAPPMWEIHHIN 124 KIFIAGNSAYEYVDY
35 PPMWEIHHINKFAQC 125 GNSAYEYVDYLFKRM
36 IHHINKFAQCYSSYS 126 EYVDYLFKRMIDLSS
37 KFAQCYSSYSRVIGG 127 LFKRMIDLSSISTVD
38 YSSYSRVIGGTVFVA 128 IDLSSISTVDSMIAL
39 RVIGGTVFVAYHRDS 129 ISTVDSMIALDIDPL
40 TVFVAYHRDSYENKT 130 SMIALDIDPLENTDF
41 YHRDSYENKTMQLIP 131 DIDPLENTDFRVLEL
42 YENKTMQLIPDDYSN 132 ENTDFRVLELYSQKE
43 MQLIPDDYSNTHSTR 133 RVLELYSQKELRSSN
44 DDYSNTHSTRYVTVK 134 YSQKELRSSNVFDLE
45 THSTRYVTVKDQWHS 135 LRSSNVFDLEEIMRE
46 YVTVKDQWHSRGSTW 136 VFDLEEIMREFNSYK
47 DQWHSRGSTWLYRET 137 EIMREFNSYKQRVKY
48 RGSTWLYRETCNLNC 138 FNSYKQRVKYVEDKV
49 LYRETCNLNCMLTIT 139 QRVKYVEDKVVDPLP
50 CNLNCMLTITTARSK 140 VEDKVVDPLPPYLKG
51 MLTITTARSKYPYHF 141 VDPLPPYLKGLDDLM
52 TARSKYPYHFFATST 142 PYLKGLDDLMSGLGA
53 YPYHFFATSTGDVVY 143 LDDLMSGLGAAGKAV
54 FATSTGDVVYISPFY 144 SGLGAAGKAVGVAIG
55 GDVVYISPFYNGTNR 145 AGKAVGVAIGAVGGA
56 ISPFYNGTNRNASYF 146 GVAIGAVGGAVASVV
57 NGTNRNASYFGENAD 147 AVGGAVASVVEGVAT
58 NASYFGENADKFFIF 148 VASVVEGVATFLKNP
59 GENADKFFIFPNYTI 149 EGVATFLKNPFGAFT
60 KFFIFPNYTIVSDFG 150 FLKNPFGAFTIILVA
61 PNYTIVSDFGRPNAA 151 FGAFTIILVAIAVVI
62 VSDFGRPNAAPETHR 152 IILVAIAVVIITYLI
63 RPNAAPETHRLVAFL 153 IAVVIITYLIYTRQR
64 PETHRLVAFLERADS 154 ITYLIYTRQRRLCTQ
65 LVAFLERADSVISWD 155 YTRQRRLCTQPLQNL
66 ERADSVISWDIQDEK 156 RLCTQPLQNLFPYLV
67 VISWDIQDEKNVTCQ 157 PLQNLFPYLVSADGT
E.6 gB 387
68 IQDEKNVTCQLTFWE 158 FPYLVSADGTTVTSG
69 NVTCQLTFWEASERT 159 SADGTTVTSGSTKDT
70 LTFWEASERTIRSEA 160 TVTSGSTKDTSLQAP
71 ASERTIRSEAEDSYH 161 STKDTSLQAPPSYEE
72 IRSEAEDSYHFSSAK 162 SLQAPPSYEESVYNS
73 EDSYHFSSAKMTATF 163 PSYEESVYNSGRKGP
74 FSSAKMTATFLSKKQ 164 SVYNSGRKGPGPPSS
75 MTATFLSKKQEVNMS 165 GRKGPGPPSSDASTA
76 LSKKQEVNMSDSALD 166 GPPSSDASTAAPPYT
77 EVNMSDSALDCVRDE 167 DASTAAPPYTNEQAY
78 DSALDCVRDEAINKL 168 APPYTNEQAYQMLLA
79 CVRDEAINKLQQIFN 169 NEQAYQMLLALARLD
80 AINKLQQIFNTSYNQ 170 QMLLALARLDAEQRA
81 QQIFNTSYNQTYEKY 171 LARLDAEQRAQQNGT
82 TSYNQTYEKYGNVSV 172 AEQRAQQNGTDSLDG
83 TYEKYGNVSVFETSG 173 QQNGTDSLDGQTGTQ
84 GNVSVFETSGGLVVF 174 DSLDGQTGTQDKGQK
85 FETSGGLVVFWQGIK 175 QTGTQDKGQKPNLLD
86 GLVVFWQGIKQKSLV 176 DKGQKPNLLDRLRHR
87 WQGIKQKSLVELERL 177 PNLLDRLRHRKNGYR
88 QKSLVELERLANRSS 178 RLRHRKNGYRHLKDS
89 ELERLANRSSLNITH 179 KNGYRHLKDSDEEEN
90 ANRSSLNITHRTRRS 180 NGYRHLKDSDEEENV
Table E.6 Amino acid sequences of individual overlapping 15mer peptides spanning the
predicted gB ORF
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E.7 pp65
Peptide
Number
Peptide
Sequence
Peptide
Number
Peptide
Sequence
1 MESRGRRCPEMISVL 57 IIKPGKISHIMLDVA
2 RRCPEMISVLGPISG 58 KISHIMLDVAFTSHE
3 MISVLGPISGHVLKA 59 MLDVAFTSHEHFGLL
4 GPISGHVLKAVFSRG 60 FTSHEHFGLLCPKSI
5 HVLKAVFSRGDTPVL 61 HFGLLCPKSIPGLSI
6 VFSRGDTPVLPHETR 62 CPKSIPGLSISGNLL
7 DTPVLPHETRLLQTG 63 PGLSISGNLLMNGQQ
8 PHETRLLQTGIHVRV 64 SGNLLMNGQQIFLEV
9 LLQTGIHVRVSQPSL 65 MNGQQIFLEVQAIRE
10 IHVRVSQPSLILVSQ 66 IFLEVQAIRETVELR
11 SQPSLILVSQYTPDS 67 QAIRETVELRQYDPV
12 ILVSQYTPDSTPCHR 68 TVELRQYDPVAALFF
13 YTPDSTPCHRGDNQL 69 QYDPVAALFFFDIDL
14 TPCHRGDNQLQVQHT 70 AALFFFDIDLLLQRG
15 GDNQLQVQHTYFTGS 71 FDIDLLLQRGPQYSE
16 QVQHTYFTGSEVENV 72 LLQRGPQYSEHPTFT
17 YFTGSEVENVSVNV OH 73 PQYSEHPTFTSQYRI
18 EVENVSVNVHNPTGR 74 HPTFTSQYRIQGKLE
19 SVNVHNPTGRSICPS 75 SQYRIQGKLEYRHTW
20 NPTGRSICPSQEPMS 76 QGKLEYRHTWDRHDE
21 SICPSQEPMSIYVYA 77 YRHTWDRHDEGAAQG
22 QEPMSIYVYALPLKM 78 DRHDEGAAQGDDDVW
23 IYVYALPLKMLNIPS 79 GAAQGDDDVWTSGSD
24 LPLKMLNIPSINVH OH 80 DDDVWTSGSDSDEEL
25 LNIPSINVHHYPSAA 81 TSGSDSDEELVTTER
26 INVHHYPSAAERKHR 82 SDEELVTTERKTPRV
27 YPSAAERKHRHLPVA 83 VTTERKTPRVTGGGA
28 ERKHRHLPVADAVI OH 84 KTPRVTGGGAMAGAS
29 HLPVADAVIHASGKQ 85 TGGGAMAGASTSAGR
30 DAVIHASGKQMWQAR 86 MAGASTSAGRKRKSA
31 ASGKQMWQARLTVSG 87 TSAGRKRKSASSATA
E.7 pp65 389
32 MWQARLTVSGLAWTR 88 KRKSASSATACTSGV
33 LTVSGLAWTRQQNQW 89 SSATACTSGVMTRGR
34 LAWTRQQNQWKEPDV 90 CTSGVMTRGRLKAES
35 QQNQWKEPDVYYTSA 91 MTRGRLKAESTVAPE
36 KEPDVYYTSAFVFPT 92 LKAESTVAPEEDTDE
37 YYTSAFVFPTKDVAL 93 TVAPEEDTDEDSDNE
38 FVFPTKDVALRHVVC 94 EDTDEDSDNEIHNPA
39 KDVALRHVVCAHELV 95 DSDNEIHNPAVFTWP
40 RHVVCAHELVCSMEN 96 IHNPAVFTWPPWQAG
41 AHELVCSMENTRATK 97 VFTWPPWQAGILARN
42 CSMENTRATKMQVIG 98 PWQAGILARNLVPMV
43 TRATKMQVIGDQYVK 99 ILARNLVPMVATVQG
44 MQVIGDQYVKVYLES 100 LVPMVATVQGQNLKY
45 DQYVKVYLESFCEDV 101 ATVQGQNLKYQEFFW
46 VYLESFCEDVPSGKL 102 QNLKYQEFFWDANDI
47 FCEDVPSGKLFMHVT 103 QEFFWDANDIYRIFA
48 PSGKLFMHVTLGSDV 104 DANDIYRIFAELEGV
49 FMHVTLGSDVEEDLT 105 YRIFAELEGVWQPAA
50 LGSDVEEDLTMTRNP 106 ELEGVWQPAAQPKRR
51 EEDLTMTRNPQPFMR 107 WQPAAQPKRRRHRQD
52 MTRNPQPFMRPHERN 108 QPKRRRHRQDALPGP
53 QPFMRPHERNGFTVL 109 RHRQDALPGPCIAST
54 PHERNGFTVLCPKNM 110 ALPGPCIASTPKKHR
55 GFTVLCPKNMIIKPG 111 LPGPCIASTPKKHRG
56 CPKNMIIKPGKISHI
Table E.7 Amino acid sequences of individual overlapping 15mer peptides spanning the
predicted pp65 ORF
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Peptide
Number
Peptide
Sequence
Peptide
Number
Peptide
Sequence
1 CNENPEKDVLAELVK 42 TCVETMCNEYKVTSD
2 EKDVLAELVKQIKVR 43 MCNEYKVTSDACMMT
3 AELVKQIKVRVDMVR 44 KVTSDACMMTMYGGI
4 QIKVRVDMVRHRIKE 45 ACMMTMYGGISLLSE
5 VDMVRHRIKEHMLKK 46 MYGGISLLSEFCRVL
6 HRIKEHMLKKYTQTE 47 SLLSEFCRVLCCYVL
7 HMLKKYTQTEEKFTG 48 FCRVLCCYVLEETSV
8 YTQTEEKFTGAFNMM 49 CCYVLEETSVMLAKR
9 EKFTGAFNMMGGCLQ 50 EETSVMLAKRPLITK
10 AFNMMGGCLQNALDI 51 MLAKRPLITKPEVIS
11 GGCLQNALDILDKVH 52 PLITKPEVISVMKRR
12 NALDILDKVHEPFEE 53 PEVISVMKRRIEEIC
13 LDKVHEPFEEMKCIG 54 VMKRRIEEICMKVFA
14 EPFEEMKCIGLTMQS 55 IEEICMKVFAQYILG
15 MKCIGLTMQSMYENY 56 MKVFAQYILGADPLR
16 LTMQSMYENYIVPED 57 QYILGADPLRVCSPS
17 MYENYIVPEDKREMW 58 ADPLRVCSPSVDDLR
18 IVPEDKREMWMACIK 59 VCSPSVDDLRAIAEE
19 KREMWMACIKELHDV 60 VDDLRAIAEESDEEE
20 MACIKELHDVSKGAA 61 AIAEESDEEEAIVAY
21 ELHDVSKGAANKLGG 62 SDEEEAIVAYTLATA
22 SKGAANKLGGALQAK 63 AIVAYTLATAGVSSS
23 NKLGGALQAKARAKK 64 TLATAGVSSSDSLVS
24 ALQAKARAKKDELRR 65 GVSSSDSLVSPPESP
25 ARAKKDELRRKMMYM 66 DSLVSPPESPVPATI
26 DELRRKMMYMCYRNI 67 PPESPVPATIPLSSV
27 KMMYMCYRNIEFFTK 68 VPATIPLSSVIVAEN
28 CYRNIEFFTKNSAFP 69 PLSSVIVAENSDQEE
29 EFFTKNSAFPKTTNG 70 IVAENSDQEESEQSD
30 NSAFPKTTNGCSQAM 71 SDQEESEQSDEEEEE
31 KTTNGCSQAMAALQN 72 SEQSDEEEEEGAQEE
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32 CSQAMAALQNLPQCS 73 EEEEEGAQEEREDTV
33 AALQNLPQCSPDEIM 74 GAQEEREDTVSVKSE
34 LPQCSPDEIMAYAQK 75 REDTVSVKSEPVSEI
35 PDEIMAYAQKIFKIL 76 SVKSEPVSEIEEVAP
36 AYAQKIFKILDEERD 77 PVSEIEEVAPEEEED
37 IFKILDEERDKVLTH 78 EEVAPEEEEDGAEEP
38 DEERDKVLTHIDHIF 79 EEEEDGAEEPTASGG
39 KVLTHIDHIFMDILT 80 GAEEPTASGGKSTHP
40 IDHIFMDILTTCVET 81 TASGGKSTHPMVTRS
41 MDILTTCVETMCNEY 82 KSTHPMVTRSKADQ
Table E.8 Amino acid sequences of individual overlapping 15mer peptides spanning the
predicted UL123 (IE1) ORF
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Peptide
Number
Peptide
Sequence
Peptide
Number
Peptide
Sequence
1 MESSAKRKMDPDNPD 58 GASVTSSHHGRGGFG
2 KRKMDPDNPDEGPSS 59 SSHHGRGGFGGAASS
3 PDNPDEGPSSKVPRP 60 RGGFGGAASSSLLSC
4 EGPSSKVPRPETPVT 61 GAASSSLLSCGHQSS
5 KVPRPETPVTKATTF 62 SLLSCGHQSSGGAST
6 ETPVTKATTFLQTML 63 GHQSSGGASTGPRKK
7 KATTFLQTMLRKEVN 64 GGASTGPRKKKSKRI
8 LQTMLRKEVNSQLSL 65 GPRKKKSKRISELDN
9 RKEVNSQLSLGDPLF 66 KSKRISELDNEKVRN
10 SQLSLGDPLFPELAE 67 SELDNEKVRNIMKDK
11 GDPLFPELAEESLKT 68 EKVRNIMKDKNTPFC
12 PELAEESLKTFEQVT 69 IMKDKNTPFCTPNVQ
13 ESLKTFEQVTEDCNE 70 NTPFCTPNVQTRRGR
14 FEQVTEDCNENPEKD 71 TPNVQTRRGRVKIDE
15 EDCNENPEKDVLAEL 72 TRRGRVKIDEVSRMF
16 NPEKDVLAELGDILA 73 VKIDEVSRMFRNTNR
17 VLAELGDILAQAVNH 74 VSRMFRNTNRSLEYK
18 GDILAQAVNHAGIDS 75 RNTNRSLEYKNLPFT
19 QAVNHAGIDSSSTGP 76 SLEYKNLPFTIPSMH
20 AGIDSSSTGPTLTTH 77 NLPFTIPSMHQVLDE
21 SSTGPTLTTHSCSVS 78 IPSMHQVLDEAIKAC
22 TLTTHSCSVSSAPLN 79 QVLDEAIKACKTMQV
23 SCSVSSAPLNKPTPT 80 AIKACKTMQVNNKGI
24 SAPLNKPTPTSVAVT 81 KTMQVNNKGIQIIYT
25 KPTPTSVAVTNTPLP 82 NNKGIQIIYTRNHEV
26 SVAVTNTPLPGASAT 83 QIIYTRNHEVKSEVD
27 NTPLPGASATPELSP 84 RNHEVKSEVDAVRCR
28 GASATPELSPRKKPR 85 KSEVDAVRCRLGTMC
29 PELSPRKKPRKTTRP 86 AVRCRLGTMCNLALS
30 RKKPRKTTRPFKVII 87 LGTMCNLALSTPFLM
31 KTTRPFKVIIKPPVP 88 NLALSTPFLMEHTMP
E.9 IE2 393
32 FKVIIKPPVPPAPIM 89 TPFLMEHTMPVTHPP
33 KPPVPPAPIMLPLIK 90 EHTMPVTHPPEVAQR
34 PAPIMLPLIKQEDIK 91 VTHPPEVAQRTADAC
35 LPLIKQEDIKPEPDF 92 EVAQRTADACNEGVK
36 QEDIKPEPDFTIQYR 93 TADACNEGVKAAWSL
37 PEPDFTIQYRNKIID 94 NEGVKAAWSLKELHTH
38 TIQYRNKIIDTAGCI 95 AAWSLKELHTHQLCP
39 NKIIDTAGCIVISDS 96 KELHTHQLCPRSSDY
40 TAGCIVISDSEEEQG 97 HQLCPRSSDYRNMII
41 VISDSEEEQGEEVET 98 RSSDYRNMIIHAATP
42 EEEQGEEVETRGATA 99 RNMIIHAATPVDLLG
43 EEVETRGATASSPST 100 HAATPVDLLGALNLC
44 RGATASSPSTGSGTP 101 VDLLGALNLCLPLMQ
45 SSPSTGSGTPRVTSP 102 ALNLCLPLMQKFPKQ
46 GSGTPRVTSPTHPLS 103 LPLMQKFPKQVMVRI
47 RVTSPTHPLSQMNHP 104 KFPKQVMVRIFSTNQ
48 THPLSQMNHPPLPDP 105 VMVRIFSTNQGGFML
49 QMNHPPLPDPLGRPD 106 FSTNQGGFMLPIYET
50 PLPDPLGRPDEDSSS 107 GGFMLPIYETAAKAY
51 PLGRPDEDSSSSSSS 108 PIYETAAKAYAVGQF
52 EDSSSSSSSSCSSAS 109 AAKAYAVGQFEQPTE
53 SSSSSCSSASDSESE 110 AVGQFEQPTETPPED
54 CSSASDSESESEEMK 111 EQPTETPPEDLDTLS
55 DSESESEEMKCSSGG 112 TPPEDLDTLSLAIEA
56 SEEMKCSSGGGASVT 113 LDTLSLAIEAAIQDL
57 CSSGGGASVTSSHHG 114 LAIEAAIQDLRNKSQ
Table E.9 Amino acid sequences of individual overlapping 15mer peptides spanning the
predicted UL122 (IE2) ORF
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E.10 US3
Peptide
Number
Peptide
Sequence
Peptide
Number
Peptide
Sequence
1 MKPVLVLAILAVLFL 19 VLAILAVLFLRLADS
2 AVLFLRLADSVPRPL 20 RLADSVPRPLDVVVS
3 VPRPLDVVVSEIRSA 21 DVVVSEIRSAHFRVE
4 EIRSAHFRVEENQCW 22 HFRVEENQCWFHMGM
5 ENQCWFHMGMLYFKG 23 FHMGMLYFKGRMSGN
6 LYFKGRMSGNFTEKH 24 RMSGNFTEKHFVNVG
7 FTEKHFVNVGIVSQS 25 FVNVGIVSQSYMDRL
8 IVSQSYMDRLQVSGE 26 YMDRLQVSGEQYHHD
9 QVSGEQYHHDERGAY 27 QYHHDERGAYFEWNI
10 ERGAYFEWNIGGHPV 28 FEWNIGGHPVTHTVD
11 GGHPVTHTVDMVDIT 29 THTVDMVDITLSTRW
12 MVDITLSTRWGDPKK 30 LSTRWGDPKKYAACV
13 GDPKKYAACVPQVRM 31 YAACVPQVRMDYSSQ
14 PQVRMDYSSQTINWY 32 DYSSQTINWYLQRSM
15 TINWYLQRSMRDDNW 33 LQRSMRDDNWGLLFR
16 RDDNWGLLFRTLLVY 34 GLLFRTLLVYLFSLV
17 TLLVYLFSLVVLVLL 35 LFSLVVLVLLTVGVS
18 VLVLLTVGVSARLRF 36 LVLLTVGVSARLRFI
Table E.10 Amino acid sequences of individual overlapping 15mer peptides spanning the
predicted US3 ORF
E.11 pp71 395
E.11 pp71
Peptide
Number
Peptide
Sequence
Peptide
Number
Peptide
Sequence
1 MSQASSSPGEGPSSE 56 RRLPDNGFQLLIPKS
2 SSPGEGPSSEAAAIS 57 NGFQLLIPKSFTLTR
3 GPSSEAAAISEAEAA 58 LIPKSFTLTRIHPEY
4 AAAISEAEAASGSFG 59 FTLTRIHPEYIVQIQ
5 EAEAASGSFGRLHCQ 60 IHPEYIVQIQNAFET
6 SGSFGRLHCQVLRLI 61 IVQIQNAFETNQTHD
7 RLHCQVLRLITNVEG 62 NAFETNQTHDTIFFP
8 VLRLITNVEGGSLEA 63 NQTHDTIFFPENIPG
9 TNVEGGSLEAGRLRL 64 TIFFPENIPGVSIEA
10 GSLEAGRLRLLDLRT 65 ENIPGVSIEAGPLPD
11 GRLRLLDLRTNIEVS 66 VSIEAGPLPDRVRIT
12 LDLRTNIEVSRPSVL 67 GPLPDRVRITLRVTL
13 NIEVSRPSVLCCFQE 68 RVRITLRVTLTGDQA
14 RPSVLCCFQENKSPH 69 LRVTLTGDQAVHLEH
15 CCFQENKSPHDTVDL 70 TGDQAVHLEHRQPLG
16 NKSPHDTVDLTDLNI 71 VHLEHRQPLGRIHFF
17 DTVDLTDLNIKGRCV 72 RQPLGRIHFFRRGFW
18 TDLNIKGRCVVGEQD 73 RIHFFRRGFWTLTPG
19 KGRCVVGEQDRLLVD 74 RRGFWTLTPGKPDKI
20 VGEQDRLLVDLNNFG 75 TLTPGKPDKIKRPQV
21 RLLVDLNNFGPRRLT 76 KPDKIKRPQVQLRAG
22 LNNFGPRRLTPGSEN 77 KRPQVQLRAGLFPRS
23 PRRLTPGSENNTVSV 78 QLRAGLFPRSNVMRG
24 PGSENNTVSVLAFAL 79 LFPRSNVMRGAVSEF
25 NTVSVLAFALPLDRV 80 NVMRGAVSEFLPQSP
26 LAFALPLDRVPVSGL 81 AVSEFLPQSPGLPPT
27 PLDRVPVSGLHLFQS 82 LPQSPGLPPTEEEEE
28 PVSGLHLFQSQRRGG 83 GLPPTEEEEEEEEED
29 HLFQSQRRGGEENRP 84 EEEEEEEEEDDEDDL
30 QRRGGEENRPRMEAR 85 EEEEDDEDDLSSTPTP
31 EENRPRMEARAIIRR 86 DEDDLSSTPTPTPLS
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32 RMEARAIIRRTAHHW 87 SSTPTPTPLSEAMFA
33 AIIRRTAHHWAVRLT 88 PTPLSEAMFAGFEEA
34 TAHHWAVRLTVTPNW 89 EAMFAGFEEASGDED
35 AVRLTVTPNWRRRTD 90 GFEEASGDEDSDTQA
36 VTPNWRRRTDSSLEA 91 SGDEDSDTQAGLSPA
37 RRRTDSSLEAGQIFV 92 SDTQAGLSPALILTG
38 SSLEAGQIFVSQFAF 93 GLSPALILTGQRRRS
39 GQIFVSQFAFRAGAI 94 LILTGQRRRSGNNGA
40 SQFAFRAGAIPLTLV 95 QRRRSGNNGALTLVI
41 RAGAIPLTLVDALEQ 96 GNNGALTLVIPSWHV
42 PLTLVDALEQLACSD 97 LTLVIPSWHVFASLD
43 DALEQLACSDPNTYI 98 PSWHVFASLDDLVPL
44 LACSDPNTYIHKTET 99 FASLDDLVPLTVSVQ
45 PNTYIHKTETDERGQ 100 DLVPLTVSVQHAALR
46 HKTETDERGQWIMLF 101 TVSVQHAALRPTSYL
47 DERGQWIMLFLHHDS 102 HAALRPTSYLRSDMD
48 WIMLFLHHDSPHPPT 103 PTSYLRSDMDGDVRT
49 LHHDSPHPPTSVFLH 104 RSDMDGDVRTAADIS
50 PHPPTSVFLHFSVYT 105 GDVRTAADISSTLRS
51 SVFLHFSVYTHRAEV 106 AADISSTLRSVPAPR
52 FSVYTHRAEVVARHN 107 STLRSVPAPRPSPIS
53 HRAEVVARHNPYPHL 108 VPAPRPSPISTASTS
54 VARHNPYPHLRRLPD 109 PSPISTASTSSTPRS
55 PYPHLRRLPDNGFQL 110 STASTSSTPRSRPRI
Table E.11 Amino acid sequences of individual overlapping 15mer peptides spanning the
predicted pp71 ORF
